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Abstract 
Classically, the emergence of resistance to protease inhibitors (PIs) in HIV-1 requires the 
stepwise accumulation of primary and compensatory mutations in the viral protease (PR). In 
addition, it was demonstrated that mutations occurring on one of the natural substrates of the 
PR, Gag, could behave as compensatory mutations in the presence of certain primary PR 
mutations. Furthermore, mutations on the Gag could account for resistance to PIs when 
appeared in isolation. So far, most studies assessing the effect of Gag mutations on resistance 
to PIs have focused on two cleavage sites (CS), namely P7/P1 and P1/P6. However, data on 
the remaining CS and non-cleavage sites is scarce. 
In my PhD studies, I developed and optimized an assay for the amplification and sequencing 
of HIV-1 Gag and PR genes in order to characterize mutations occurring in patients failing 
PI-based therapy. Initially, I performed a cross-sectional analysis by comparing the Gag and 
protease sequences from PI-experienced patients and PI-naïve subjects. A number of Gag 
mutations associated with PI-selective pressure were determined, which were not restricted to 
P7/P1 and P1/P6 CSs, but present throughout the Gag. Subsequently, I conducted a 
longitudinal analysis of patients failing a PI-based regimen, which confirmed that under PI-
selective pressure the entire Gag evolved along with the PR and that changes were most 
prominent at P2/P7, P7/P1 and P1/P6 CSs and in the P17 protein outside CSs. Finally, I 
performed phenotypic characterization of PI susceptibility and replicative capacity studies on 
patient’s viruses and side-directed mutants. As a result of these investigations I found that the 
evolution of Gag in patients on unsuccessful PI therapy led to increased levels of PI 
resistance and improved viral replicative capacity. Specifically, I characterized two novel CS 
mutations (P17/P24: Y132F, and P2/P7: T375A) that conferred resistance in the context of a 
wild type backbone. 
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1 Chapter one: general introduction 
1.1 History of the discovery of HIV-1 
On 5
th
 June 1981, the Centers for Disease Control and Prevention (CDC) published a report 
of Pneumocystis carinii pneumonia in five previously healthy young homosexual men in Los 
Angeles, two of whom had died (CDC Weekly 1982a; CDC Weekly 1982b; CDC Weekly 
1982c). Examination of the patients showed a marked reduction in cellular immune response 
as a common denominator. Owing to the media influence, the disease was originally dubbed 
Gay-related immune deficiency (GRID). Similar cases were soon reported in Western 
European countries, all of which were characterized by a profound depression of cell-
mediated immunity and the presence of opportunistic infections and rare malignancies 
previously described only in severely immunocompromised patients. These new cases were 
not restricted to men who have sex with men (MSM), but affected other population groups, 
such as blood transfusion patients and injecting drug users. In 1982, the CDC introduced the 
term acquired immune deficiency syndrome (AIDS) to describe this newly recognized entity.  
 
In January 1983, a potential causative agent was isolated at the Pasteur institute in France by 
Luc Montagnier and colleagues from cultured T lymphocytes derived from a patient with 
cervical lymphadenopathy, a sign that was considered a precursor of AIDS. The new 
retrovirus was named lymphadenopathy-associated virus (LAV), but no proof of causality 
with AIDS was established at this time (Barre-Sinoussi, 1983). In May 1984, Robert Gallo’s 
group compiled sufficient evidence to convince the medical and scientific communities that 
the new virus, which was renamed human T-lymphotropic virus type III (HTLV-III), was the 
etiological agent for the emerging AIDS epidemic (Popovic et al, 1984). In August 1984, Jay 
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levy confirmed Gallo’s findings by reporting they had isolated a retrovirus designated ARV 
for AIDS-associated retrovirus, in 22 patients with AIDS (Levy et al, 1984).  
 
In February 1985, sequencing of the entire genome from LAV, HTLV-III and ARV viruses 
demonstrated that they were variants of the same virus (Ratner et al, 1985). In 1986, the 
Committee on the Taxonomy of Viruses proposed the name human immunodeficiency virus 
(HIV) to designate the causative agent of AIDS. On the same year, a second retrovirus was 
isolated from West African patients hospitalized at a Lisbon hospital (Clavel et al, 1986), 
who had a clinical picture compatible with AIDS but no detectable antibodies against HIV. 
This new virus was called human immunodeficiency virus type 2 (HIV-2), and the original 
HIV was renamed as human immunodeficiency virus type 1 (HIV-1).   
 
For the discovery of the infectious agent currently known as HIV-1, Luc Montagnier and 
Francoise Barré-Sinoussi from the Pasteur Institute were awarded the Nobel Prize in 
Physiology or Medicine in 2008. 
 
1.2 HIV-1 origin and diversity  
HIV-1 is classified in four groups, named M (major), N (non-M, non-O), O (outlier) and P, 
each of which arose from an independent zoonotic transmission from non-human primates 
infected with simian immunodeficiency virus (SIV) to humans in Central and West Africa. 
Human infections probably occurred through cutaneous or mucous membrane exposure to 
infected ape blood/body fluids during activities such as hunting or butchering of primates. 
HIV-1 groups M and N originated from two different lineages of SIVcpzPtt that infected 
common chimpanzees (Pan troglodytes troglodytes) inhabiting southeastern and south-
- 3 - 
 
central Cameroon, respectively (Corbet et al, 2000; Gao et al, 1999; Keele et al, 2006). HIV-1 
groups O and P are related to SIVgor found in gorillas (Gorilla gorilla) living in Cameroon, 
although SIVgor itself is supposed to be derived from an ancestor of a divergent SIVcpz lineage 
acquired by cross-species infection from sympatric chimpanzees (Plantier et al, 2009 and Van 
Heuverswyn et al, 2006). 
 
The timing of cross-species transmissions varies according to particular HIV-1 groups. HIV-1 
group M appears to be the oldest lineage in humans with an estimated time to the most recent 
common ancestor around 1908 (range 1884-1924). The estimated times of the most recent 
common ancestors of HIV-1 groups O and N are 1920 (1890-1940) and 1963 (1948-1977), 
respectively (Korber et al, 2000; Wertheim et al, 2009). The time of origin of HIV-1 group P 
is unknown as only two different sequences are available, precluding relevant phylogenetic 
analysis.   
 
The current global diversity of HIV-1 is the result of the interaction of several elements, 
namely the intrinsically high genetic variation of the virus, the selection and evolution of 
viral strains within the host and the different patterns of propagation of viral strains.  
 
HIV has a huge intrinsic genetic variability. The lack of 3’-5’ exonuclease activity 
(proofreading activity) of the reverse transcriptase enzyme introduces 0.2-2 substitutions per 
genome per replication cycle (Darke et al, 1993; Roberts et al, 1988). In addition, relatively 
large insertions and deletions are common occurrences in the viral genome. These high rates 
of mutation in conjunction with high rates of virus replication (10
10
-10
12
 virions per day) (Ho 
et al, 1995) result in the rapid generation of genetically diverse viral populations within each 
individual, where viral sequences can differ by up to 10%. Moreover, further genetic 
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variability occurs due to a high recombination rate (7-30 recombination events per genome 
per replication cycle) (Jetzt et al, 2000) when two or more different strains simultaneously 
infect an individual.  
The enormous genetic diversity of HIV-1 is subject to intra-host evolutionary selective 
pressures. Among them, the action of the immune system plays a crucial role in shaping the 
structure of the viral population. Despite the variability of the HIV-1 genome, only 10%  
undergoes positive selective pressure. The regions affected are those that define critical 
residues in host-pathogen interaction, half of which are mapped to CTL epitopes located in 
the Gag protein. The importance of the host immune response in driving viral diversity and 
evolution was clearly showed by Draenert and colleagues in a study of monozygotic twins 
infected with the same viral strain (Draenert et al, 2006). They found that the initial CD8+ T 
cell response targeted 17 epitopes, 15 of which were identical in each twin. Three years post- 
infection, four responses had declined in both twins, three of which showed mutations at the 
same Gag residues. Similarly, the antibody responses cross-neutralized the other twin’s virus 
and also showed similar evolutionary changes in the envelope gene. These results illustrated a 
considerable concordance in cellular and humoral immune response and HIV-1 evolution in 
the same genomic environment.  
 
In addition to adaptive immune response, mammalian cells express a number of proteins 
whose function is to suppress viral replication. These have been termed restriction factors and 
provide an initial line of defense against infection as a component of, or even preceding, 
innate antiviral responses. The most extensively described host restriction factors include the 
apolipoprotein B messenger RNA (mRNA)-editing enzyme catalytic polypeptide-like 3 
(APOBEC 3) family of proteins, and in particular APOBEC3G, the tetherin/bone marrow 
stromal cell antigen 2 (BST2)/CD317 termed tetherin, and the tripartite-motif-containing 5α 
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(TRIM5α).  APOBEC3G is a member of a family of vertebrate proteins with polynucleotide 
cytidine deaminase activity; its action interferes with reverse transcription by inducing 
numerous deoxycytidine to deoxyuridine mutations on the nascent proviral negative strand, 
which ultimately results in guanosine-to-adenosine hypermutation at hot spots within the 
proviral DNA, thus rendering the provirus defective. Its action is counteracted by HIV-1 vif 
protein, which binds APOBEC3G inducing its proteosomal degradation. TRIM5α is a 
cytoplasmic protein, whose mechanism of action is unknown, but it has been demonstrated 
that binds to the viral capsid precipitating its degradation soon after entry and ultimately 
blocking reverse transcription. Tetherin is a transmembrane protein that is incorporated into 
the lipid envelope of the HIV-1 particle and causes virions to remain trapped at the surface of 
the infected cells hindering its dissemination. The HIV-1 Vpu protein antagonizes tetherin 
action by an uncertain mechanism (Neil et al, 2008). In general, host restriction factors are 
poor inhibitors of retrovirus that are found naturally in the same host species, but are often 
active against retroviruses that are found in other species and therefore these proteins are 
important determinants of host range and cross species transmission. In addition, in order to 
establish infection a host-pathogen co-evolution is required and consequently, host restriction 
factors are important determinants of viral evolution. For instance, it has been proposed that 
APOBEC action is not completely abolished by HIV-1 vif and that it can induce infrequent 
mutations (as opposed to hypermutation) which may be benefitial to the virus in terms of 
immune escape or drug resistance and consequently, APOBEC3 appears to be an important 
contributor to viral diversity and evolution (Wood et al, 2009; Kim et al, 2010 and Sadler et 
al, 2010).  
 
 Furthermore, exogenous pressures, such as anti-retroviral therapy, further delineate the 
nature of quasispecies present in single individuals.  
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The patterns of dissemination of HIV-1 groups are substantially different. Whereas groups N, 
O and P have not spread significantly beyond Central and West Africa, group M is 
responsible for the HIV pandemic as the vast majority (>95%) of viral strains distributed 
worldwide belong to this group.   
 
HIV-1 group M is highly heterogeneous on the basis of phylogenetic analysis. Currently, it is 
divided into nine subtypes or clades (A, B, C, D, F, G, H, J, K) (Geretti, 2006), which show 
an average intersubtype genetic variability of 15% for the gag gene and 20% for the env gene 
(Geretti 2006; Robertson et al, 2000). Moreover, some subtypes are subdivided in sub-
subtypes (Geretti, 2006), as is the case for clades A and F, which are separated into A1 and 
A2 and F1 and F2, respectively. In addition, full-length genome sequencing has revealed the 
existence of intersubtype recombinants, which are classified either as unique recombinant 
forms (URFs) or circulating recombinant forms (CRFs). URFs represent recombinant viruses 
that have been only identified in a single individual or an epidemiologically linked cluster 
without evidence of epidemic spread, whereas CRFs are recombinant viruses that have been 
identified in at least three epidemiologically unlinked individuals (Geretti, 2006; Thomson 
and Najera, 2005). CRFs are labeled with numbers in order of discovery followed by the 
letters of the two parental subtypes in alphabetical order (e.g., CRF03_AB) In addition, the 
extension “cpx”, for complex, is given if the CRF consists of contributions from three or 
more subtypes. At present, a total of 51 CRFs have been described, which constitute around 
20% of all HIV infections worldwide (Hemelaar et al, 2012).  
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1.3 HIV-1 epidemiology 
1.3.1 Global distribution of HIV 
Currently, HIV-1 accounts for more than 30 million infections worldwide. Group M viruses 
constitute the pandemic form of HIV representing over 95% of all HIV-1 infections and has 
been found in virtually every country on the globe. By contrast, the contribution of HIV-1 
groups O, N and P to the pandemic is negligible as these clades have remained confined to 
specific countries in West and Central Africa. Group O viruses have not spread significantly 
beyond Cameroon, Gabon and Equatorial Guinea, and represent less than 1% of global HIV-
1 infections. Group N infections have been only detected in 13 individuals from Cameroon, 
whereas group P viruses have so far only been identified in two Cameroonians from 
Yaounde.   
 
The different group M subtypes and recombinant forms have distinct global distribution 
patterns (Hemelaar et al, 2012). All HIV-1 group M subtypes and a high proportion of URFs 
and CRFs are present in West Central Africa, the potential epicentre of the global HIV 
epidemic. However, in other regions usually one or two genetic forms are predominant, fact 
that responds to a founder effect whereby the earliest genetic form successfully introduced 
within a population establishes itself as predominant and gains an initial advantage over other 
genetic forms arriving later. Nonetheless, this situation is not static and replacement of 
established genetic variants can occur. The best example is possibly the case occurred in 
Thailand were the initially introduced subtype B was replaced by CRF01-AE a year later. 
Similarly, an increase in non-B subtype infections has been reported in several Western 
European countries, mainly among native individuals. 
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On a global scale, subtype C is the most successful of the HIV-1 M lineages (48%) 
(Hemelaar et al, 2012), followed by subtypes A (12%) and B (11%). The most abundant CRF 
is CRF02_AG, which accounts for 8% of global HIV-1 infections. Other subtypes and 
recombinant forms represent individually less than 5% of the global total.  
 
Regarding subtype distribution, subtype C is highly prevalent in Southern Africa countries, 
India and Ethiopia and also circulates as a minor form in Brazil and Russia (Geretti, 2006). 
Subtype A viruses are predominant in East and West Africa as well as in Eastern Europe and 
Central Asia (Thomson and Najera, 2005). Subtype B predominates in the Americas, Western 
Europe, the Middle East and North Africa. However, the prevalence of non-B subtype 
infections in high-income countries of North America and Western Europe has increased as a 
consequence of the influx of immigrant population from Africa and Asia (Fox et al, 2010). 
With regard to CRFs, CRF02-AG is highly prevalent in West Africa (Takebe et al, 2004), 
whereas CRF01-AE is the major genetic variant in South and East Asia (Thomson and 
Najera, 2005), where it has replaced subtype B as the predominant form.   
 
Other less prevalent subtypes and CRFs are more locally distributed. For example, subtype D 
is mainly found in East Africa, subtype F is predominant in Romania, subtype G is mainly 
spread across West and Central Africa, with the highest prevalence in Nigeria but it is also 
found in Portugal and northwest Spain (Thomson and Najera, 2005), and CRF12_BF widely 
circulates in Argentina. In addition, URFs also feature in the HIV epidemic. A diversity of 
URFs have been reported in areas such as DR Congo, Tanzania, Argentina, Cuba and Galicia 
(Thomson and Najera, 2005).  
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1.3.2 Current status of the HIV pandemic 
Since the pandemic began in 1981, the cumulative total of individuals infected with HIV 
ascends to 60 millions, 25 millions of whom have since died (UNAIDS 2010). At the end of 
2009, the Joint United Nations Programme on HIV/AIDS (UNAIDS) estimated that there 
were 33.3 million [31.4-35.3] people living with HIV infection, that 2.6 million [2.3-2.8] 
people became newly infected with the virus during 2009 and that there were 1.8 million 
[1.6-2.1] AIDS-related deaths in the same year (UNAIDS 2010).   
 
Worldwide, the rates of annual new infections have been steadily declining since 1997, the 
year in which the epidemic peaked. Between 2001 and 2009, a more than 25% reduction in 
HIV incidence was documented in 33 countries, 22 of which were located in sub-Saharan 
Africa, the global region bearing the highest HIV prevalence. In spite of the number of new 
infections falling in most parts of the world, the number of people living with HIV has 
continued to rise due to a significant reduction in AIDS-related deaths as a consequence of 
expanded access to antiretroviral therapy.   
 
Sub-Saharan Africa is the global region with the highest HIV prevalence (67.5%). The HIV 
burden is unevenly distributed, with countries in southern Africa most severely affected 
(South Africa, Zambia, Zimbabwe, Malawi, Mozambique, Namibia, Botswana, Lesotho, 
Swaziland). In particular, South Africa, which had an estimated 5.6 million [5.4-5.8] infected 
people in 2009, remains the largest epidemic in the world. Although the rate of new 
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infections in sub-Saharan Africa decreased from 2.2 million in 2001 to 1.8 million in 2009, 
the number of people living with HIV has steadily risen during this period reaching a total of 
22.5 million [20.9-24.2] at the end of 2009, figure which corresponds to 68% of the global 
total. Importantly, women account for 60% of infections. The main transmission modes are 
unprotected sexual intercourse and perinatal infection. In regard to AIDS-related mortality, 
sub-Saharan Africa continues to be the most important contributor worldwide, with an 
estimated 1.3 million [1.1-1.5] deaths ascribable to the epidemic during 2009, which equals 
to 72% of the global total.    
South and East Asia is second to sub-Saharan Africa in terms of HIV prevalence (14.3%), 
with an estimated 4.9 million [4.5-5.5] infected people at the end of 2009. The HIV epidemic 
in this global region is largely stable as the previous figure is similar to the one from 2004. 
Between 2001 and 2009, the HIV incidence has fallen by more than 25% in India, Nepal and 
Thailand, remained stable in Malaysia and Sri Lanka, but increased by more than 25% in 
Bangladesh and Philippines. The HIV burden is mainly concentrated in intravenous drug 
users, sex workers and their clients and homosexual men.   
 
The Eastern Europe-Central Asia global region deserves special merit as the number of 
people living with HIV has more than doubled since 2001 and reached an estimated total of 
1.4 million [1.3-1.6] in 2009. The HIV incidence has increased in several countries in this 
region such as Armenia, Georgia, Kazakhstan, Kyrgyzstan, Tajikistan, The Russian 
Federation and Ukraine. However, The Russian Federation and Ukraine account for almost 
90% of newly reported HIV diagnoses. The HIV epidemics is mainly concentrated among 
intravenous drug users and their sexual partners, which is leading to an increase of the 
proportion of HIV infected women, and sex workers and their clients (Mathers et al, 2008). 
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The Middle East and North Africa global region shows a similar trend to Eastern Europe-
Central Asia global region as the number of people living with HIV has leapt from an 
estimated 180,000 (150,000-200,00) in 2001 to an estimated 460,000 (400,000-530,000) in 
2009. In addition, the HIV incidence has more than doubled and AIDS-related deaths have 
more than tripled during this period. However, reliable data of the epidemic in these regions 
are still scarce, hindering proper data analysis. 
 
The HIV epidemic in the North America and Western-Central Europe global region appear to 
have stabilized as the rates of annual new HIV infections have remained constant for at least 
the past five years. However, the number of people living with HIV has steadily risen 
between 2001 and 2009 reaching a total of 2.3 million [20.9-2.7] at the end of 2009. 
Unprotected sex between men continues to dominate patterns of HIV transmission in these 
areas. However, injecting drug use and unprotected heterosexual paid sex are also important, 
especially in Mexico and parts of Southern Europe. Worth of mention is the increasing role 
played by immigrants from countries with generalized epidemics, as they represented almost 
17% of people newly infected with HIV in Europe during 2007. 
 
The HIV epidemics in other global regions, including Central and South America, the 
Caribbean and Oceania are either stable or declining. In South and Central America, about 
one third of all people living with HIV live in Brazil and most of the epidemic is concentrated 
in this region in and around networks of MSM. Injecting drug use has been the other main 
route of transmission, especially in the southern cone of South America. In the Caribbean, 
unprotected heterosexual sex is believed to be the main mode of transmission in this region 
and the burden of HIV varies considerably between countries, the exceptionally low 
prevalence of Cuba (0.1%) contrast with a 3.1% adult HIV prevalence in the Bahamas. The 
- 12 - 
 
Caribbean remains the only region, besides sub-Saharan Africa, where women outnumber 
men among people living with HIV. The HIV epidemic in Oceania is small, the largest and 
the only one generalized is in Papua New Guinea. The HIV epidemic is mainly driven by 
sexual transmission. Unprotected heterosexual intercourse is the main mode of transmission 
in Papua New Guinea, while unprotected sex between men predominates in the smaller 
Pacific countries and those of Australia and New Zealand. 
 
1.3.3 The status of the HIV epidemic in the UK 
To date, 120,000 people have been diagnosed with HIV in the UK, of whom 27,000 have 
developed AIDS and more than 20,000 have died. An estimated number of 91,500 (85,400-
99,000) people were living with HIV in the UK at the end of 2010, of whom approximately a 
quarter were unaware of their infection (HIV in UK 2011 report). Most individuals acquired 
their infection heterosexually [47,000 (43,900-50,400)] and through sex between men 
[40,100 (35,300-46,700)], whereas a minority [2,300 (1,900-2,700)] were injecting drug 
users.   
 
A total of 6,660 individuals (4,510 men and 2,150 women) were diagnosed with HIV 
infection during 2010. An estimated 50% (3,350) of newly diagnosed individuals acquired 
their infection heterosexually. Most of these individuals were black Africans who acquired 
the infection abroad, mainly in sub-Saharan Africa. However, 33% of heterosexually 
acquired infections occurred within the UK.  An estimated 45% (3,000) of new HIV 
diagnoses resulted from sex between men. Most of these individuals (81%) acquired the 
infection in the UK, were of white ethnicity and two thirds were born in the UK. While the 
number of HIV diagnoses among people infected heterosexually has declined, new diagnoses 
among MSM have reached an all-time high. The number of new infections among people 
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who inject drugs remains low (2.5%), mostly due to early and effectual harm-reduction 
programmes. No case of HIV acquisition through blood transfusion has been documented in 
the UK since 2002.  
 
Concerning subtype and CRFs distribution, subtype B continues to be the most common 
subtype among MSM, however an increase of non-B subtypes among this population has 
been reported with subtypes C, and A followed by CRF01-AE and CRF02-AG recombinant 
being the most common subtypes found, indicating that risk-group segregation of HIV-1 
clades is becoming less distinct (Fox et al, 2010).   
 
 
 
1.4 HIV-1 virion characteristics 
HIV-1 is a member of the Lentivirus genus in the family of Retroviridae (Ratner et al, 1985; 
Wain-Hobson et al, 1985). The HIV-1 virion is spherical in morphology and measures 
between 100 and 150 nm in diameter. 
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1.5 HIV-1 genome and proteins 
The HIV-1 genome is approximately 9.2 kb in length. The sequence is flanked by the two 
long terminal repeats (LTRs). The 5’ LTR contains the enhancer/promoter sequence for viral 
transcription and the 3’ LTR contains the polyadenylation signal.  The viral genome contains 
nine open reading frames (ORFs). From 5’ to 3’ it comprises the gag gene, which encodes the 
virion structural components; the pol gene, which encodes the viral enzymes and the env 
gene, which encodes the envelope glycoproteins. The HIV-1 genome contains six additional 
genes: tat and rev which code for two regulatory proteins and vif, vpr, nef and vpu which 
encode four accessory peptides.  
 
Figure 1.3 Genome organization of HIV-1 (adapted from Sierra-Aragon, 2008).  
 
 
The three primary HIV-1 translation products (Gag, pol and env) are initially synthesized as 
polyprotein precursors, which are subsequently processed by viral or cellular proteases into 
mature proteins. The Gag precursor is cleaved by the viral protease into the matrix (P17), 
capsid (P24), nucleocapsid (P7) and p6 proteins as well as two small spacer peptides P1 and 
P2 (Henderson et al, 1992; Mervis et al, 1988).  The P17 protein is located along the inner 
leaflet of the viral lipid envelope, where it directs the incorporation of the envelope 
glycoproteins into the forming virion (Dorfman et al, 1994). The P24 protein assembles to 
form the conical core of the virion. The P7 is an RNA binding protein responsible for 
packaging of the genomic RNA into the virion (Gorelick et al, 1990). The p6 protein appears 
to be important for viral budding (Accola et al, 2000).  Autocatalysis of the Gag-Pol 
precursor give rise to the retroviral enzymes: the protease (PR), which is an homodimeric 
protein that is required for the formation of fully mature and infectious viral particles; the 
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reverse transcriptase (RT), which provides both the RT activity, that allows RNA-dependent 
RNA polymerization and the RNase H activity, that allows the specific degradation of RNA 
in RNA-DNA duplexes; and the integrase (IN) which mediates the integration of the viral 
DNA into the chromosome of the host cell (Farnet et al, 1996). Finally, proteolytic digestion 
of the envelope glycoprotein (gp160) by cellular serine proteases leads to surface (gp120) and 
transmembrane (gp41) subunits (Willey et al, 1988). The remaining six HIV-1 encoded 
proteins (Vif, Vpr, Tat, Rev, Vpu and Nef) are the primary translation products of spliced 
mRNA.  The tat protein is a trans-activating protein that enhances the rate of viral 
transcription and permits synthesis of full-length transcripts to occur (Laspia et al, 1990; 
Marciniak et al, 1990).  The rev protein mediates the transport of single spliced and unspliced 
viral RNAs from the nucleus to the cytoplasm (Emerman et al, 1989; Malim et al, 1989). The 
vif protein acts late in the viral life cycle to facilitate virus release and infectivity, it interacts 
with the cellular proteins APOBEC3F and APOBEC3G inducing their degradation by 
proteosomes. In the absence of vif the APOBEC proteins are incorporated into virions where 
they deaminate cytidine to uridine in the minus strand of the forming cDNA leading to 
inactivating hypermutation in the HIV-1 genome. Consequently, Vif is required for 
production of infectious virions (Malim et al 2008; Henriet et al, 2009). The vpr protein is 
involved in infectivity, apoptosis, cell cycle control, viral transcription and nuclear import of 
the pre-integration complex (Romani and Engelbrecht, 2009). The nef protein modulates both 
cellular signal transduction and membrane trafficking. It plays a role in downregulation of 
CD4 and class I major histocompatibility complex (MHC) from the cell surface preventing 
immune recognition of infected cells (Garcia et al, 1991). Finally, the vpu protein enhances 
the release of virions from infected cells (Klimkait et al, 1990; Nomaguchi et al, 2008) and 
degrades CD4 during virus production preventing and inhibitory effect on infectivity of 
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progeny virions that occur when the viral receptor interacts with the viral envelope (Levesque 
et al, 2003).  
 
 
1.6  The HIV-1 replication cycle 
The entire replication cycle of HIV-1, which is completed in approximately 24 hours 
(Perelson et al, 1996), comprises a series of sequential steps which are shown in figure 1.4 
and reviewed below.  
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Figure 1.4 Replication cycle of HIV-1 
 
The HIV-1 replication cycle begins with the binding of viral envelope surface glycoprotein (gp120) to the cell surface CD4 receptor and CCR5 or CXCR4 
chemokine coreceptors. This is followed by fusion, entry and uncoating of the conical viral core. Reverse transcription converts the single-stranded viral RNA 
genome into a double-stranded DNA copy. The preintegration complex (PIC) of viral and cellular proteins and proviral DNA is transported to the nucleus, 
followed by integration into the host chromosomal DNA. Next, the integrated viral DNA is transcribed by cellular RNA Pol II forming spliced and unspliced 
mRNA templates used for translational synthesis of the accessory factors and polyproteins (Gag and Gag-Pol) encoding structural proteins and functional 
enzymes. Viral RNA, polyproteins, and envelope localize to the inner face of the plasma membrane where they are packaged into assembling viral particles. 
Finally, progeny virions bud from the cell surface as immature particles and acquire infectious capacity by proteolysis-induced morphological maturation.  
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1.6.1 Viral entry 
Initially, the virion adsorbs to the target cell (i.e., T helper lymphocytes, macrophages and 
some populations of dendritic cells) through the interaction of the viral envelope protein 
(env) or human cell membrane proteins present on the viral envelope with a number of 
several attachment factors displayed on the target cell membrane (e.g., heparan sulfate 
proteoglycans, α4β7 integrin), which in turn brings the viral receptor (i.e., CD4 molecule) 
and co-receptor (i.e., CC or CXC family of chemokine receptors) in close proximity to env, 
thus increasing the efficiency of infection. Subsequent binding of the gp120 subunit of env to 
the CD4 molecule causes rearrangements in the V1/V2 loops followed by the V3 loop and 
leads to the formation of a bridging sheet composed of two double stranded β sheets that are 
spatially separated in the unliganded state. These conformational changes in gp120 enable its 
binding to the co-receptor molecule (Sattentau et al, 1991; Wu et al, 1996). Two major co-
receptor molecules, the α-chemokine receptor CXCR4 and the β-chemokine receptor CCR5, 
have been identified. Although a number of other chemokine receptors can act as co-
receptors for HIV-1 entry in cultured cells (Berger et al, 1999), there is no compelling 
evidence that they play an important role in vivo. HIV-1 strains can be classified based on 
their co-receptor usage preference, which is mainly determined by the base sequence of the 
V3 loop. R5-tropic strains are those that employ CCR5, X4-tropic strains those that use 
CXCR4 and dual-tropic strains those that can employ both co-receptors (Berger et al, 1998). 
The importance of viral co-receptors for HIV-1 infection was demonstrated by the discovery 
of a 32 base-pair deletion in CCR5, termed CCR5∆32, which has an allelic frequency of 10% 
in Caucasians. This mutation results in a truncated CCR5 protein that is not expressed on the 
cell membrane, but retained in the endoplasmic reticulum. Homozygosity for this 
polymorphism confers profound resistance to HIV-1 infection as homozygous individuals are 
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only rarely infected despite persistent high risk behavior (Paxton et al, 1996; Samson et al, 
1996). Co-receptor binding induces the exposure of a hydrophobic fusion peptide in the 
amino-terminal ectodomain of gp41, which inserts into the cell membrane. This allows the 
fusion peptide of each gp41 in the trimer to fold at an angle bringing the amino and carboxy-
terminal helical regions from each gp41 subunit together to form a six helix bundle, which in 
turn brings the viral and cellular lipid bilayers into close apposition, resulting in the formation 
of a fusion pore (Melikyan et al, 2000) through which the viral contents are delivered into the 
cytoplasm. 
 
1.6.2 Uncoating 
Uncoating is defined as the loss of viral capsid that occurs within the cytoplasm of the 
infected cell after the virion enters the cell and before the viral genome penetrates the 
nucleus. It is an obligatory step in the HIV life cycle that accompanies the transition between 
reverse transcription complexes (RTCs), in which reverse transcription occurs, and pre-
integration complexes (PICs), which are able to integrate into the host genome. HIV-1 enters 
the nucleus through a nuclear pore which diameter falls behind that of the viral capsid. 
Consequently, uncoating should occur at some point after viral entry and before nuclear 
import. Nevertheless, the exact time and location of the event remains unclear. Recent studies 
suggest that uncoating occurs gradually, possibly in response to both cellular and viral 
signals. Among cellular factors are found:  Cyclophilin A (CypA), which has been seen to 
bind the capsid and assist uncoating (Javanbakht, et al 2007), prolyl isomerases pin 1 (Pin1) 
which specifically recognised phosphorilated serine-proline residues in the viral capsid and 
promotes uncoating as demonstrated by the linked between dysfunctional uncoating and 
depletion of pin1 in cell targets (Misumi et al, 2010) and also cellular factors present in non-
resting cells as it has been demonstrated that uncoating requires cell activation (Auewarakul 
- 20 - 
 
et al, 2005).  Viral factors such as the integrase protein that appears to be required to maintain 
the interaction between CypA and capsid (Briones et al, 2010) as well as the complexion of 
reverse transcription and formation of the central DNA flap seems also to play a crucial role 
in HIV-1 uncoating (Arhel et al, 2007).  
 
1.6.3 Reverse transcription 
Reverse transcription is the process whereby the single-stranded RNA viral genome is 
converted into a linear double-stranded DNA that is the substrate for integration into the host 
genome. The enzyme that performs this action is the HIV-1 reverse transcriptase (RT), which 
has two activities: (a) DNA polymerase that can copy either RNA or DNA templates and (b) 
RNase H that degrades RNA from DNA-RNA duplexes.  
 
Reverse transcription commences with the binding of the host tRNA
Lys3
 to a complementary 
sequence located approximately 180 nucleotides from the 5’ end of the viral genome called 
the primer binding site (PBS). The RT initiates the synthesis of the minus strand DNA from 
the 3’ end of the tRNA and proceeds towards the 5’ end of the viral genome sequentially 
copying the U5 and R sequences. The RNase H activity of the RT removes the U5 and R 
RNA sequences from the RNA-DNA structure, exposing the newly synthesized minus DNA 
strand. As a result of the degradation of RNA-DNA hybrid, the minus DNA strand is exposed 
facilitating the annealing between the newly synthesized R DNA sequence and a 
complementary R RNA sequence present at the 3’ end of the RNA genome, which in turn 
leads to the transfer of the minus DNA strand to the direct repeat at the 3’ end of the RNA 
genome. After this transfer, the RT continues to elongate the minus DNA strand towards the 
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PBS located at the 5’ end of the RNA genome. As DNA synthesis proceeds, so does RNase H 
degradation. In HIV-1, there are two short purine rich sequences, known as polypurine tracts 
(PPT), which are resistant to the RNase H activity and serve as primers for the synthesis of 
the plus DNA strand. The PPT located adjacent to the 3’ end of the viral genome is essential 
for viral replication, whereas the PPT located near the middle of the viral genome increases 
the ability of the virus to complete the plus DNA strand, but is not essential. The RT initiates 
the synthesis of the plus DNA strand from the PPT adjacent to the 3’ end of the viral genome 
and proceeds towards the 5’ end of the minus DNA strand sequentially copying the U3, R, 
U5 sequences, but also the first 18 nucleotides of tRNA
Lys3
. Afterwards, the tRNA is partially 
removed by the RNaseH activity, exposing the PBS sequence in the 3’ end of the plus DNA 
strand and facilitating its pairing with the complementary PBS sequence located at the 3’ end 
of the minus DNA strand and consequently leading to a second translocation event. Extension 
of plus and minus DNA strands by the RT leads to the synthesis of the complete double-
stranded linear viral DNA, which is longer than the viral genome as each end is flanked by a 
long terminal repeat (LTR) containing the U3-R-U5 sequence. Plus-strand synthesis 
terminates at the end of the minus strand at a sequence known as central termination signal 
(CTS) (Charneu et al, 1994). The position of the central PPT upstream of the CTS results in 
the displacement of approximately 100 nucleotides of plus-strand DNA and the formation of 
a central triplex DNA structure termed central DNA flap which appears to have a role in 
translocation of the viral DNA into to the nucleus (Zennou et al, 2000) and that is 
subsequently eliminated by the cellular enzyme flap endonucelase I (FEN1).  
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1.6.4 Intracellular transport and nuclear entry  
Prior to integration, the viral cDNA is translocated into the nucleus as part of a large 
nucleoprotein complex, the pre-integration complex (PIC), which contains both viral (i.e., 
P17, P24, RT, integrase and Vpr) (Farnet et al, 1991; Miller et al, 1997) and cellular proteins. 
 
HIV-1 and other lentiviruses have the unusual ability of infecting non-dividing cells, which 
implies that the PIC must enter the nucleus through an intact nuclear membrane. In contrast, 
other retroviruses require the disintegration of the nuclear membrane during mitosis to gain 
access to the nuclear components. The exact mechanism by which HIV-1 enters into the 
nucleus remains to be established (Fassati 2006). Over the years, a plethora of viral 
determinants involved in viral translocation through the nuclear pore have been proposed, 
including several components of the PIC, such as  matrix (P17), capsid (P24) and integrase 
proteins, as well as a triple stranded DNA structure known as the flap. Nuclear import of the 
PIC is mainly directed by nuclear location signals (NLS) present in the above mentioned viral 
proteins. Thus, both P17 and integrase proteins are recognised by the NLS-binding site 
present on the importin α protein. This binding triggers the interaction between importin α 
and β proteins, which in turn targets the PIC to the nuclear pore by attachment to 
nucleoporins (Nitahara-Kasahara, et al, 2007; Görlich et al, 1996). Although Vpr does not 
contain a NLS, it has been shown to promote the translocation of the PIC by tethering to the 
nuclear pore in a manner analogous to the importin α/β family (Gallay et al, 1996; Vodicka, 
et al 1998). In addition, the three-stranded DNA flap structure generated at the central 
polypurine tract also appears to contribute to the nuclear import of the PIC as a ten-fold 
reduction in the efficiency of this process was documented in its absence (Zennou et al, 
2000). 
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However, the latest evidence suggests that the capsid protein (P24) is the main viral 
determinant of nuclear import and point mutations in this protein selectively impair viral 
entry into the nucleus. In addition, genome-wide screens studies have identified several host 
nuclear pore proteins that HIV-1 can utilize to gain access to the nucleus; among them are  
transportin 3 (product of the TNPO3 gene) and Nup358 (product of RANBP2 gene)  and P24 
is  responsible for controlling the virus interaction with such host factors (Brass et al, 2008 
and Lee et al, 2010).  
 
1.6.5 Integration 
Once in the nucleus, the next and second distinguishing feature of the HIV-1 replication cycle 
is the integration of a copy of the viral cDNA into a cellular chromosome. The integrated 
viral cDNA, termed provirus, serves as the template for the synthesis of viral RNAs, which 
may either be translated into viral proteins or act as genomic RNA in progeny virions. In 
addition, the proviral DNA is replicated along with cellular DNA during cycles of cell 
division and is maintained as part of the host genome for the lifetime of the infected cell. 
Integration of the viral cDNA into a cellular chromosome is catalyzed by the integrase and 
proceeds in a series of coordinated events. Firstly, the integrase catalyses the removal of two 
nucleotides from each 3’ terminus of the linear viral cDNA leading to a pre-integration 
substrate with 3’-recessed ends that always terminate with the conserved CA-3´ sequence.  In 
the next step, the integrase catalyses a strand transfer reaction where the cellular DNA is 
cleaved at the integration site and the newly-generated 3’ ends of the viral cDNA are 
covalently bound to the 5´ends of the cellular DNA. Finally, proviral formation is completed 
by cellular enzymes that remove two unpaired bases at the 5´ends of the viral cDNA, fill in 
the single-strand gaps between viral and cellular DNA and ligate the 5´ends of viral DNA to 
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the cellular DNA (Delelis et al, 2008; Jegede et al, 2008). Although viral DNA can integrate 
into any sequence in the host, it has been shown to preferentially target actively transcribed 
regions in order to promote efficient gene expression (Marshall et al, 2007). Cell proteins, 
primarily the transcription activator factor LEDGF/p75, appear to boost the efficiency of 
integration and mediate targeting to active transcription units. LEDGF/p75 contains a 
chromatin-binding region, which comprises a PWWP domain at the amino terminus and a 
pair A/T hook domains, and a carboxy-terminal domain that bounds tightly to IN. This 
protein binds simultaneously to the integrase and chromatin at active transcription units, thus 
directing integration to these locations.   
 
1.6.6 Gene expression 
Control of gene expression of the HIV-1 provirus is exerted by both cis and trans-acting viral 
elements, which orchestrate complex interactions with the cellular transcription, splicing and 
RNA export and translation apparatus. 
 
Transcription is positively regulated both at initiation and elongation stages. The U3 region 
located within the 5’-LTR contains two important elements that stimulate transcription 
initiation: an extremely efficient promoter, which is capable of supporting even higher levels 
of transcription than the adenovirus major late promoter or the CMV immediate early 
promoter, and an enhancer that contains two NF-κB binding motifs, which facilitate 
transcription initiation by removing chromatin restrictions near the promoter through the 
recruitment of histone acetyltransferases. The Tat protein up-regulates transcription 
elongation by binding simultaneously to a transactivating-responsive region (TAR) present in 
the 5’ end of nascent viral RNA and to the positive transcriptional elongation factor (pTEFb) 
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components CDK9 kinase and cyclin T1. These interactions trigger a complex set of 
phosphorylation reactions that stimulate transcription elongation by inactivating negative 
elongation factors, such as NELF and DSIF, and by enhancing RNA polymerase II 
processivity (Dingwall et al, 1990).  
 
Depending on the degree of splicing, viral transcripts produced during the replication cycle 
are classified into three categories: completely spliced mRNAs that encode the viral proteins 
Tat, Rev and Nef, incompletely spliced mRNAs that code for Env, Vif, Vpr and Vpu and full-
length unspliced transcripts, which act both as the virion genomic RNA and the mRNA for 
the Gag/Gag-Pro-Pol polyproteins. The efficiency of splicing is regulated by the intrinsic 
strength of 5’ and 3’ splice sites and the presence of cis-acting elements, such as splicing 
enhancers and silencers.  Immediately after infection, the synthesis of completely spliced 
mRNAs is predominant. These mRNAs are exported to the cytoplasm via a constitutive 
endogenous pathway used by cellular mRNAs and translated to yield Tat, Rev and Nef 
proteins. The Rev protein dictates the fate of incompletely spliced and unspliced viral RNA 
transcripts. When Rev levels are below a specific threshold these RNAs are either spliced or 
degraded in the nucleus. However, when Rev levels exceed the threshold, these intron-
containing viral RNAs are exported to the cytoplasm due to the interaction of Rev with an 
elongated stem-loop structure of 351 nt, termed the Rev-responsive element (RRE), present 
on these viral transcripts. The binding of Rev to the RRE induces its own polymerization and 
triggers the interaction with a protein of the nuclear pore complex, the karyopherin family 
member Crm1, which in a GTP-dependent process translocates the viral RNA species into the 
cytoplasm. As the infection proceeds, incompletely spliced mRNAs and full-length unspliced 
transcripts are increasingly exported to the cytoplasm (Groom et al, 2009). 
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Translation is regulated by frameshifting, in which specific cis-acting sequences in the RNA 
cause a reading frame change during translation. For example, the production of Gag-Pro-Pol 
precursor during the translation of full-length unspliced transcripts occurs as a consequence 
of a -1 shift in the Gag translational reading frame. This frameshift occurs 5% of the time and 
results in the production of one Gag-Pro-Pol precursor for every 20 Gag precursors 
synthesized.  
    
 
1.6.7 Assembly, budding and maturation  
During assembly, viral and cellular components are packaged at nucleation sites leading to 
the formation of immature virions. Gag polyprotein is largely responsible for viral assembly 
and its expression is sufficient for the formation of non-infectious spherical viral-like 
particles. Gag, which is translated from full-length unspliced RNA transcripts in cytoplasmic 
polysomes, is composed by folded domains separated by flexible linker regions that display 
HIV-1 protease cleavage sites (CSs) (Figure 1.5).  
 
 
 
Figure 1.5 Gag polyprotein domains and protease cleavage sites. 
 
The majority of Gag traffics in the cytoplasm as soluble monomers or dimers in an auto-
inhibited conformation. However, a minor proportion is found complexed with dimers of 
genomic RNA forming ribonucleoprotein complexes (RNPs). RNPs genesis requires 
dimerization of genomic RNAs, which occurs in the cytoplasm by virtue of the non-covalent 
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binding at the dimer initiation sites located within the 5’UTR, followed by the interaction of 
Gag with genomic RNA dimers, where two retroviral zinc motifs within the P7 domain of 
Gag recognize highly-organized structures in the 5’UTR. In particular, the ψ sequence, which 
is located in the 5’ LTR region spanning the major splice donor and the Gag initiation codon, 
plays a central role in this process and is required for efficient genome packaging (Berkowitz 
et al, 1996).  
 
Nucleation sites are plasma membrane lipid rafts that are enriched in sphingomyelin, 
cholesterol and plasmalogen-PE and display an increase in saturated fatty acids compared 
with the cell plasma membrane. Targeting of Gag and RNPs to nucleation sites is mediated 
by a multipartite membrane-binding signal located within the P17 domain, which consists of 
a myristic acid covalently attached to the N-terminal Gly in the P17 protein and a patch of 
basic residues. Binding of the P17 domain to the inner leaflet lipid phosphatidyl inositol (4, 
5) biphosphate exposes the myristoyl group stably anchoring Gag/RNPs to the plasma 
membrane. In addition, electrostatic interactions between the stretch of basic residues and 
acidic phospholipids on the inner leaflet of the lipid rafts reinforce membrane docking 
(Hermida-Matsumoto and Resh, 1999; Zhou et al, 1994). The initial presence of RNPs at 
nucleation sites is important for effective virion assembly. The interaction of newly-arrived 
Gag monomers or dimers with RNPs through their CA domains converts the auto-inhibited 
conformation into one that is optimal for Gag polymerization. Multimerization of Gag 
through its P24-P2 region leads to the formation of an immature lattice, in which membrane-
bound Gag molecules are extended and oriented radially with the carboxy-terminal end 
facing the interior of the particle. During viral assembly, apart from Gag and 
ribonucleoprotein complexes, other viral components are also incorporated into the immature 
viral particle. The Gag-Pro-Pol polyprotein, which is translated in the cytosolic polysomes, is 
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incorporated via the same mechanism as Gag/RNPs.  The Env protein is translated in ER-
associated ribosomes and then travels through the constitutive cellular secretory pathway 
where it is glycosylated, olygomerized into trimeric complexes, cleaved by furin to form 
transmembrane (gp41) and surface (gp120) subunits and transported to the plasma membrane 
via vesicular transport. The long intracellular tail of gp41 helps to sort the protein into 
nucleation sites and interacts with the P17 domain of Gag to promote Env virion 
incorporation. Other viral proteins, such as Vpr, Vif or Nef are incorporated into the 
immature viral particle by virtue of its interaction with the carboy-terminal P6 domain of 
Gag. In addition, a number of cellular components have been shown to be packaged into the 
viral particles. The host tRNA
Lys3
 is recognized by an 18 base-pair sequence (PBS) located 
within the 5’ LTR. In addition, host proteins, such as ICAM-1, HLA-II, actin, cyclophilin A, 
are incorporated into the virion either passively or by interaction with Gag. The involvement 
of these human proteins in viral biology is not well established in the majority of cases.    
 
During budding the immature virion is released from the plasma membrane. The process is 
largely mediated through interactions between P6 protein and the cellular ESCRT 
(endosomal sorting complexes required for transport) machinery. The ESCRT apparatus 
usually catalyzes membrane fission reactions that release vesicles into endosomal 
multivesicular bodies.  
 
The carboxy-terminus of Gag (P6) contains two short sequence motifs (i.e., late assembly 
domains) that recruit and bind to early-acting ESCRT factors (Katzman et al, 2002). The 
highly conserved PTAP motif located near the amino terminus of P6 (Huang et al, 1995) 
binds to the TSG101 component of the ESCRT-I complex, whereas the YPXL motif located 
downstream of the PTAP motif interacts with the ESCRT-III binding partner ALIX (Usami, 
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et al 2009; Roxrud et al, 2010; Bieniasz et al, 2009; Strack et al, 2003 and VerPlank et al, 
2001). These interactions result in the recruitment of the ESCRT-III proteins of the CHMP 1, 
2 and 4 families, which promote closure of the virion neck, and VPS4 ATPases, which 
complete the fission reaction by hydrolyzing ATP. As a result of these actions the immature 
viral particle is released from the plasma membrane.  
 
During maturation, the immature virion experiences dramatic morphological changes and 
becomes infectious.  Maturation begins concomitant with or immediately after budding and is 
driven by the HIV-1 protease cleavage of Gag and Gag-Pro-Pol polyproteins (Kaplan et al, 
1993). Construction of mutant virus lacking the viral PR clearly indicated that the proteolytic 
processing of these polyproteins is required for restructuring of the virion in a fully mature 
and infectious form (Kohl et al, 1988; Peng et al, 1989).  
 
HIV-1 PR is an aspartyl protease with extensive sequence homology to cellular counterparts, 
such as pepsin and renin. Like other aspartic acid proteases, HIV-1 PR uses two aspartic acid 
side chains within a characteristic Asp-Thr-Gly motif to activate a water molecule that 
catalyses the hydrolysis of the peptide bond. In contrast to cellular proteases, the holoenzyme 
is a dimer of two identical subunits, each containing 99 amino acid residues (Tozser et al, 
2003). As revealed by crystallographic studies, the active site is located in the interior of a 
long cleft present at the dimer interface and is stabilized by non-covalent interactions 
between Asp-Thr-Gly motifs and four-stranded mixed β sheets created by the amino and 
carboxy termini of each subunit. The active site contains two catalytic aspartic acid residues 
(Asp-25 and Asp-25’), each contributed by a different subunit (Oroszlan et al, 1990;  
Wlodawer et al, 1993). Substrate access to the active site is regulated by two flexible flaps 
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that undergo dramatic movements to allow entry of substrates and exit of products.  The 
structure of the HIV-1 PR is shown in figure 1.6.  
 
 
HIV-1 PR binds substrates asymmetrically in an extended anti-parallel β-sheet conformation. 
Three to four amino acids (P4 to P1 and P1’ to P3’) located on either side of the cleavable 
peptide bond (P1↓P1’) participate in binding to the substrate cavity of the protease. Substrate 
specificity studies (Pettit et al, 1991; Poorman et al, 1991; Billich et al, 1988; Griffiths,  et al, 
1992; Tomasseli et al, 1994; Tozser et al, 1992; Loeb et al, 1989) have reached a series of 
conclusions: P1 and P1’ are usually large hydrophobic residues, P1 never contains a β-
branched aliphatic side chain, P2 and P2’ are typically hydrophobic or small polar residues, 
and P4, P3 and P3’ can accommodate a variety of residues. However, as Gag and Gag-Pro-
Pol cleavage sites vary considerably in amino acid sequence, it has been postulated that the 
enzyme appears to recognize the shape of the substrate rather than its specific sequence 
(Prabu-Jeyabalan et al, 2000; Prabu-Jeyabalan et al, 2002). 
  
The Gag-Pro-Pol polyprotein contains three inactive viral enzymes: protease, reverse 
transcriptase and integrase. The molecular mechanisms that lead to activation and regulation 
of HIV-1 protease are unclear, but these processes must be tightly regulated, so that the Gag 
polyprotein is not cleaved before assembly and budding.  Experimental findings have 
suggested that dimerization of Gag-Pro-Pol polyproteins during assembly at nucleation sites 
is required for initial activation (Franke et al, 1994; Gamble et al, 1997; Gatlin et al, 1998) 
and an aggregation model has been proposed to explain how this may be regulated. However, 
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other factors such as drop in pH or an influx of Ca
2+
 ions associated with virion release, may 
contribute to activation (Skalka, 1989; Vogt, 1996). The partially active HIV-1 PR within the 
Gag-Pro-Pol dimer appears to be responsible for the initial autocatalysis of Gag-Pro-Pol 
through intra-molecular mechanisms (Pettit et al, 2004; Tessmer and Krausslich, 1998). 
Primary processing occurs at the P2↓P7 junction (Pettit et al, 2004) and is followed by 
secondary and tertiary processing of the transframe region (TFR or P6) at TFR↓P6pol and 
P6
pol↓PR, respectively (Phylip et al, 1995). Based on these studies, these initial processing 
events give rise to p121, p114 and p107 early intermediates as a consequence of cleavage at 
P2↓P7, TFP↓P6pol and P6pol↓PR CSs, respectively. Since the TFR negatively regulates PR 
function, its removal is concomitant with the appearance of an elevated enzymatic activity 
characteristic of a mature PR (Louis et al, 1991). Subsequent cleavage events occur by inter-
molecular mechanisms and liberate the structural and functional enzymes of the Gag and Pol 
regions, respectively (Wondrak et al, 1996). There is little information available concerning 
the sequence of events in processing CSs in HIV-1 pol. Studies support that RT↓IN is 
processed first and is followed by PR↓RT and the by RTP51↓RTP66 (Tozser et al, 1991). 
However, a simultaneous processing of all pol CSs resulting in the concurrent release of PR, 
IN and both RT subunits (P66 and P51) cannot be excluded. As a consequence of the entire 
autocatalytic process, three fully active protease, reverse transcriptase and integrase are 
produced (Craven et al, 1991; Swanstrom and Wills, 1997; Xiang et al, 1997; Gross et al, 
2000). 
 
The Gag polyprotein contains four structural proteins, matrix (P17), capsid (P24), 
nucleocapsid (P7) and P6, and two smaller spacer peptides P2 and P1 located between 
P24/P7 and P7/P6, respectively (Orozslan et al, 1990). Gag is cleaved by the HIV-1 protease 
- 32 - 
 
at five different sites (CS). The order of cleavage is highly conserved and is mainly regulated 
by the intrinsic susceptibility of each site to proteolysis (Tozser et al, 1997). These cleavage 
sites are classified into three groups according to their rate of processing: rapid (P2 / P7), 
intermediate (P1 / P6, P17 / P24) and slow (P7 / P1, P24 / P2) (Pettit et al, 1994). Cleavage at 
each site appears to occur independently (Pettit et al, 1994) and appears to perform a different 
function. Primary processing occurs at P2 / P7 and gives rise to P43 (P17-P24-P2) and P14 
(P7-P1-P6) intermediates. This cleavage is conducive to the activation of the Env protein. 
Secondary processing involves cleavage at P1 / P6 shortly followed by cleavage at P17 / P24 
and leads to P17, P6, and P8 (P7-P1) and P25 (P24-P2) intermediates. Finally, tertiary 
cleavage at P7 / P1 followed by P24 / P2 gives rise to P7, P1, P24 and P2 final products. 
These cleavages lead to the condensation and stabilization of the dimeric RNA genome and 
the assembly of the conical capsid. The dramatic rearrangement of the internal virion 
components triggered by Gag proteolytic processing is essential for the production of viable 
infectious virus particles (Kaplan et al, 1993, Pettit et al, 1994, Swanstrom and Wills, 1997; 
Xiang et al, 1997 and Vogt, 1996). 
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Figure 1.7 Schematic representation of the genomic and polyprotein organization of HIV-1. 
 The upper diagram represents the 9.8 kb provirus genome. The lower diagram represents the HIV-1 
Gag and Gag-Pol polyprotein precursors. The proteins encoded in pol are synthesized at a frequency 
of 5-10% by a -1 translational frameshift of the unspliced genomic mRNA template to yield Gag-Pol. 
At the stage of virion budding and release, Gag and Gag-Pol polyproteins are proteolytically cleaved 
at domain boundaries by the viral protease to release their constitutive protein species and complete 
the maturation process. The location of these protease cleavage sites are indicated by the vertical 
arrows. Primary (1), secondary (2), tertiary (3), and quaternary (4) cleavage events are numbered 
accordingly. Gag polyproteins are processed into matrix (MA, p17), capsid (CA, p24), nucleocapsid 
(NC, p7), p6
gag 
and two spacer proteins p2 and p1. Processing of Gag-Pol polyproteins additionally 
yields the transframe region proteins (TFP and p6
pol
), protease (PR, p10), reverse transcriptase (RT, 
p66/51) which contains an RNase H (RNH) domain in its larger subunit, and integrase (IN, p32). The 
HXB2 amino acid sequence for each cleavage site in HIV-1 Gag and Gag-pol precursor is indicated in 
the table below, the scissile amide bond is indicated by the vertical arrow (↓). 
 
1.7 Antiretroviral drugs and mechanisms of resistance 
Currently, there are 24 antiretrovirals (ARVs) approved by the US Food and Drug 
Administration (FDA) for the treatment of HIV-1 infection (Table 1.1). They are classified 
into six classes: nucleo(s)tide reverse transcriptase inhibitors (NRTIs), non-nucleoside 
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reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors (FIs), 
integrase inhibitors (INIs) and co-receptor antagonists (CCR5 antagonists). All, except for the 
CCR5 antagonists, target essential viral proteins-reverse transcriptase (NRTIs and NNRTIs); 
protease (PIs), transmembrane protein gp41 (FIs) and integrase (INIs). The CCR5 antagonist, 
by contrast, is unique among the ARVs in that it targets the host cell chemokine co-receptor 
CCR5 rather than a viral protein. All ARVs act by inhibiting some of the steps of the viral 
replication: FIs and CCR5 antagonists inhibit viral entry; NRTIs and NNRTIs inhibit reverse 
transcription; PIs inhibit the proteolytic processing of Gag and Gag-Pro-Pol polyproteins and 
INIs inhibit the integration of the viral DNA into the host cell chromosome.  
 
A common feature derived from the use of ARVs, regardless of its class, is the emergence 
and selection of resistant HIV-1 variants. As a general rule, resistance is conferred by 
punctual and well-characterized mutations in the target gene. In general, the main drivers of 
the development of drug resistance are the high level of virus production reaching up to 10
9
-
10
12
 virus particles per day in untreated patients (Perelson et al, 1996) and the high error rate 
during reverse transcription, the RT introduces an average of one or two mutations for each 
viral genome transcribed (Bebenek et al, 1989; Ji and Loeb, 1992). These two characteristics 
combined ensure that patients have a complex and diverse mixture of viral strains termed 
“quasispecies”, each differing by one or two mutations. Within the quasispecies certain 
strains dominate. This represents an equilibrium between escape from selective pressure, 
such as immune system or drug therapy, and preserved ability to replicate and infect. 
Consequently, variants with reduced susceptibility to ARVs are usually found in the viral 
population before treatment, but are present at low frequency due to impaired fitness when 
compared to the wild-type strain.  If any of these variants confers a selective advantage to the 
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virus, such as decreased drug susceptibility, it will become dominant. Emergence of 
resistance will therefore only occur in patients who have ongoing viral replication in the 
presence of levels of ARVs that are insufficient to completely abolish viral replication but 
sufficient to exert a positive selective pressure on variants with decreased susceptibility. The 
main scenario conducive to emergence of drug resistance is in patients with suboptimal 
adherence to treatment. However, others circumstances, such as drug interactions, may also 
lead to sub-therapeutical drug levels and as a result to the development of drug resistance.  
Many studies have demonstrated that toxicity and side effects are closely associated with 
adherence to antiretroviral therapy. For instance, in the ICONA study group, patients 
receiving indinavir-and-ritonavir containing HAART had a higher chance of discontinuing 
therapy because of toxicity (21%) compared to treatment failure (10%) (D’arminio Monforte, 
et al, 2000). The development of new, more potent and safer antiretroviral therapies has 
reduced HAART-related toxicity. However, unfortunately no drug is entirely devoid of 
secondary effects. Of the NRTIs, tenofovir can cause renal toxic effects and potentially 
osteopaenia. Abacavir can cause an increased risk of cardiovascular disease and is also 
associated with a serious hypersensitivity reaction, particularly in HLA-B5701 positive 
patients. Many of the once popular thymidine analogues, especially stavudine, are currently 
known to cause profound long-term and probably irreversible side-effects, such as 
lipoatrophy. Among the NNRTIs, efavirenz is reported to be teratogenic and has also 
substantial short-term CNS toxic effects. Neviripine can cause severe liver disease and 
hypersensitivity reactions, particularly in patients starting therapy with high CD4 T-cell 
counts. Regarding integrase inhibitors, raltegravir appears to be safe, well tolerated and 
highly effective, but long-term safety data are still missing. Concerning protease inhibitors, 
most of them increase plasma lipid concentrations and consequently increase cardiovascular 
risk; in addition, many have clinically relevant drug interactions, usually when boosted with 
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low dose ritonavir. Furthermore, most PIs are associated with gastrointestinal disturbances. 
Atazanavir also increases the plasma concentration of unconjugated bilirubin, occasionally 
causing reversible jaundice. The CCR5 inhibitor maraviroc is generally well tolerated and has 
no known short or long-term side effects. However, by contrast with all other antiretrovirals, 
CCR5 inhibitors bind a host target and consequently there are concerns about its long term 
risk. Lastly, the fusion inhibitor Enfuvirtide is poorly tolerated because of the need for 
injection twice daily, which is often associated with local pain.  
 
Strict adherence is required to achieve and maintain viral suppression. Suboptimal drug 
exposure can result in the rapid development of drug resistance. This is especially true for 
drugs with low genetic barrier to resistance, which are commonly part of some of the most 
popular first-line regimens, and include NRTIs (e.g., lamivudine or emtricitabine), NNRTIs 
(e.g., efavirenz and nevirapine) and INIs (e.g., raltegravir). By contrast, PIs have a higher 
genetic barrier to the development of resistance and consequently long-term exposure is 
generally required before resistance emerges. In general, it is believed that PIs are more 
forgiving in terms of non-adherence. The management of HAART side effects is of pivotal 
importance in the management of HIV-infection. Most treatment modifications of first line 
HAART are related to toxic effects (Elzi et al, 2010). Similarly, it has been reported that 
nearly all first regimen virological failure can be attributed to either non-adherence or pre-
existing drug resistance (Paredes et al, 2010). Consequently, virological failure should trigger 
a thorough review of potential causes for non-adherence including drug side-effects, search 
for other drugs that can be affecting absorption or metabolism and because resistance 
selection may have occurred, a resistance genotype should also be obtained.  
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Resistance to ARVs in an individual is not only the result of failure to therapy, but can be due 
to interpersonal transmission of resistant strains.  Importantly, due to the integration of the 
HIV-1 viral genome into the host cell chromosome during replication, all major quasispecies 
that have ever been generated within a patient will be archived and replication will favour the 
form that is fittest under current conditions. However, if conditions change, previously 
archived variants can rapidly re-emerge.    
 
The mechanisms of resistance differ for ARVs as it does their genetic barrier to resistance 
defined by the ease of emergence of resistance, which is a function of the number of 
mutations required to abrogate drug activity. The highest barrier to resistance is observed for 
ritonavir boosted PIs (PI/r), as the phenotypic impact of individual mutations is generally 
low. By contrast, the lowest genetic barrier to resistance is documented for first generation 
NNRTIs, such as efavirenz (EFV) and nevirapine (NVP), as a single mutation is sufficient to 
confer complete resistance to the drugs.    
 
Below, we describe the mechanism of action and resistance of each class of ARVs: 
 
 
    1.7.1 Fusion inhibitors 
Emfuvirtide (T-20) is the only fusion inhibitor currently available in the market. As 
previously discussed, the entry of the HIV-1 virus into the target cell is a multi-step process 
that involves attachment, co-receptor binding and fusion of the viral envelope and the cell 
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membrane. T-20 binds the heptad repeat region 1 (HR1) region in the HIV-1 trans-membrane 
protein gp41 preventing the formation of the six helical bundle and consequently blocking the 
fusion between the lipid bilayer of the virus and that of the host cell. 
 
Resistance to T-20 is the consequence of mutations in the HR1 region.  The first three 
substitutions associated with resistance were described in amino acids 36-38 (Derdeyn et al. 
2000, 2001 and Rimsky et al, 1998). It was demonstrated that amino acid position 36 played 
a relevant role in the fusogenic activity of HIV-1 envelope and certain mutations at this 
residue were associated with increased fusion kinetics, leading to resistance to the drug. On 
completion of clinical trials in HIV-1 infected patients, the region conferring T-20 resistance 
was expanded to include amino acid positions 36-45 (Lu et al, 2004; Wei et al, 2002).    
 
1.7.2 Co-receptor antagonists 
Maraviroc is so far the sole co-receptor antagonist licensed for the treatment of HIV-1 
infection (Macarthur and Novak, 2008). It is a noncompetitive allosteric antagonist of CCR5 
(Dorr et al, 2005; Watson et al, 2005) that binds the CCR5 co-receptor and prompts a 
conformational change that ultimately prevents the interaction between CCR5 and the V3 
crown of the surface glycoprotein gp120 (Watson et al, 2005; Dragic et al, 2000) and 
consequently the entry of the virus into the target cell. Maraviroc binds the CCR5 co-receptor 
but not the closely related CCR2 chemokine or CXCR4 receptors (Dorr et al, 2005). As a 
result, maraviroc selectively inhibits the entry of R5-tropic HIV-1 strains into cells, but not 
that of X4-tropic viruses. Since maraviroc dose not compete with the binding of chemokines 
to CCR5 it is not expected to affect cellular signaling via CCR5 (Dorr et al, 2005).  
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Different pathways of resistance to maraviroc have been reported. A first mechanism of 
resistance involves the use of the co-receptor CXCR4 for entry into the host cell.  This 
requires a change in HIV-1 tropism, which can be acquired by two possible mechanisms: the 
first is through the de novo acquisition of mutations in the env gene, which allow the use of 
the CXCR4 co-receptor (truly co-receptor switch), and the second involves the outgrowth of 
a pre-existing population of CXCR4-using variants. A number of studies have suggested that 
the outgrowth of CXCR4-using variants is the most common mechanism of resistance 
(Westby et al, 2006; Kuhmann and Moore, 2005). Another potential mechanism of resistance 
is the emergence of mutations in the gp120 envelope protein, primarily in the V3 loop, which 
will increase the affinity of the protein for the inhibitor-free co-receptor, consequently 
favouring the binding of the virus versus. the antagonist. In addition, mutations in the V3 
loop may enable the virus to bind the inhibitor-bound receptor (Westby M, 2007a). Given the 
extensive variability of the HIV-1 envelope, the patterns of mutations emerging as a 
consequence of maraviroc selective pressure may considerably differ among patients and as a 
result the genotypic predictors of this mechanism of resistance have yet to be clearly 
identified (Westby et al, 2007b).    
 
 
 
 1.7.3 Reverse transcriptase inhibitors 
Inhibition of the reverse transcriptase constitutes the cornerstone of most antiretroviral 
regimens. Two different classes of drugs are grouped within the reverse transcriptase 
inhibitors: nucleos(t)ide reverse transcriptase inhibitors (NRTIs) and nonnucleos(t)ide reverse 
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transcriptase inhibitors (NNRTIs). Although, both classes target the reverse transcription step 
by inhibiting the activity of the viral reverse transcriptase enzyme, the mechanism of action 
differed between the two classes. 
 
1.7.3.1 NRTIs 
NRTIs are competitive inhibitors of the DNA polymerase activity of the RT.  Structurally, 
NRTIs are nucleos(t)ide analogues that lack the 3’-hydroxy group, which once incorporated 
into the growing DNA chain caused premature chain termination (Parker et al, 1991, El et al; 
2007;  Zdanowicz, 2006). There are currently eight NRTIs, comprising seven nucleosides 
analogues: zidovudine (ZDV), stavudine (d4T), zalcitabine (ddC), didadosine (ddI), 
lamivudine (3TC), abacavir (ABC) and emtricitabine (FTC) and one nucleotide analogue: 
tenofovir (TDF). ZDV was in fact the first antiretroviral approved for the treatment of HIV-1 
infection in 1987 and since then NRTIs has formed the backbone of antiretroviral therapy.  
 
NRTIs are pro-drugs that require phosphorylation (bi-phosphorylation for nucleotide 
analogues and tri-phosphorylation for nucleoside analogues). Tissue-dependant cellular 
kinase activity determines the levels of drug effectiveness (Gao et al, 1993). In addition, 
NRTIs that rely on the same phosphorylation pathway, as it is the case for ZDV and d4T, can 
show antagonism when administered in combination (Havlir et al, 2000).  
 
Resistance to NRTIs is the result of the emergence of amino acids changes in the RT enzyme. 
These changes could be sequential additions (e.g; for ZDV resistance), insertions, or single 
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amino acid substitutions (e.g; for 3TC resistance). RT mutations confer resistance to NRTIs 
by two possible mechanisms: the first, which is termed NRTI excision, involves and ATP-
dependent pyrophosphorolysis that leads to the selective removal of the NRTIs from the 3’-
end of the nascent DNA chain and as a result to reversal of the chain termination (Arion et al, 
1998; Boyer et al, 2001; Meyer et al, 1999). Mutations that cause resistance by this 
mechanism are the thymidine analogue mutations (TAMs), which include a group of amino 
acids changes selected by ZDV and d4T, such as M41L, D67N, K70R, T215Y/F and 
K219E/Q (Bacheler et al, 2001; Boucher et al, 1992; Harrigan et al, 1996; Kellam et al, 
1992). Emergence of TAMs by NRTI-selective pressure occurs by two different pathways: 
TAM-1, which includes mutations M41L, L210W, T215Y and occasionally D67N, and 
TAM-2, which includes D67N, K70R, T215F and K219Q/E. The TAM-1 pathway is 
associated with greater level of ZDV resistance and NRTI cross resistance than the TAM-2 
pathway (Marcelin et al, 2005; Miller, 2004; Hu et al, 2006).  TAMs emerge in sequential 
order and their accumulation over time leads to increasing levels of resistance, mainly to 
ZDV and d4T but also ABC, ddI and TDF.  
 
The second mechanism of NRTI resistance involves the prevention of NRTI incorporation 
into the nascent DNA chain. Mutations associated with this mechanism of resistance are 
M184V/I, K65R, K70E, L74V and Q151M.  The M184V/I mutations are selected by 3TC or 
FTC-containing regimens and associated with high level resistance to both drugs. The 
mutation is located close to the RT active site and causes steric hindrance that hampers the 
incorporation of the NRTI (Sarafianos et al, 1999). The K65R mutation is selected by TDF, 
ABC and ddI and decreases susceptibility to all NRTIs except for ZDV. The mutation 
favours the incorporation of the natural dNTP substrate over the drug (Deval et al, 2004; 
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White et al, 2006). K70E mutation is primarily associated with resistance to TDF by 
prompting a decrease in the incorporation of the inhibitor (Sluis-Cremer et al, 2007). The 
L74V mutation is selected by ddI and ABC conferring resistance to both drugs; the mutation 
alters the rate of incorporation of ddI and also favours the incorporation of natural dNTP over 
ABC (Deval et al, 2004; Winters et al, 1997).  Finally, the Q151M mutation is part of multi-
drug resistance mutation complex (MDR) along with amino acid changes, such as F116Y, 
F77L, V75I and A62V. These mutations are typically selected by drug combinations 
including ZDV and ddI and confer resistance to all NRTIs, albeit less so to 3TC and TDF 
(Sluis-Cremet et al, 2000). The Q151M mutation interacts with the nitrogen base of the dNTP 
resulting in the altered recognition and reduced incorporation of the NRTI (Sluis-Cremer et 
al, 2000).     
 
In addition to the two classic mechanisms of resistance to NRTIs described above, a growing 
body of evidence has emerged indicating a role in resistance to this drug class for mutations 
in the connection and the RNase H domains. These mutations have been demonstrated to 
increase resistance to ZDV by altering the balance between NRTI excision and RNase H 
activity. Specifically, the mutations reduce the RNase H activity of the RT enzyme allowing 
more time for the enzyme to excise ZDV from the terminated DNA chain. Mutations in the 
connection domain conferring resistance to ZDV are E312Q, G335C/D, N348I, A360I/V, 
A371V, V365I, A376S (Nikolenko et al, 2007; viks-Frankenberry et al, 2007; Viks-
Frankenberry et al, 2008 and Yap et al, 2007) and mutations located in the RNase H domain 
that also contribute to ZDV resistance include H539N, D549N and Q509L (Brehm et al, 
2007; Brehm et al, 2008 and Nikolenko et al, 2005).   
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1.7.3.2 NNRTIs 
Currently, there are five NNRTIs licensed for the treatment of HIV-1 infection. They are 
classified as first generation, which include delavirdine (DLV), efavirenz (EFV) and 
nevirapine (NVP) and second generation, which comprise etravirine (ETV) and rilpivirine 
(RPV). They are allosteric noncompetitive inhibitors of the RT.  
 
All NNRTIs exert their action by binding to the HIV-1 RT in a hydrophobic pocket termed 
the non-nucleoside inhibitor binding pocket with a common butterfly-like binding mode 
(Kohlstaedt et al, 1992; Ding et al, 1995). The non-nucleoside binding pocket, which exists 
only in the presence of the NNRTI and is not opened in the unliganded enzyme, consists of 
hydrophobic residues Y181, Y188, F227, W229 and Y232 and hydrophylic residues, such as 
K101, K103, S105, D192 and E224 in the p66 subunit of the RT and E138 in the P51 subunit 
of the enzyme.  The NNRTI-binding pocket is close but distinct from the active site and the 
dNTP binding site of the enzyme and as a consequence it does not prevent the binding of 
either the dNTP or the RNA template to the RT, but it brings a conformational change that 
impairs its catalytic activity. The main difference between first and second generation 
NNRTIs lies in that the former are rather inflexible and their binding to the RT is severely 
impaired as a consequence of key mutations in the enzyme. By contrast, second generation 
NNRTIs are much more flexible and consequently can rapidly adapt to changes in the drug 
binding pocket (Andries 2004; Rodriguez-Barrios et al, 2005).     
 
High level resistance to NNRTIs generally results from the rapid acquisition of single amino 
acid substitutions located directly in the NNRTI-binding pocket (Tantillo et al, 1994) and as a 
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result hamper the binding of the inhibitor. Mutations that confer NNRTI resistance cluster in 
two regions of the HIV-1 RT enzyme: regions adjacent to codons 180-188 and 100-110 
(Nunberg et al, 1991; Larder, 1992 and Larder, 1995). Mutations associated with high level 
resistance to first generation NNRTIs (NVP, EFV and DLV) are K103N, Y181C, G190A/S, 
Y188L and V106A/M (Wainberg et al, 2003). Other mutations, such as L100I, K101E/P, 
A98G, V108I, V179D/E, P225H, M230L and K238T/N, cause low level resistance to first 
generation NNRTIs and they usually occur in combination with the major NNRTI-resistance-
associated mutations described above and act synergistically to reduce NVP, EFV and DLV 
susceptibility (Pelemans et al, 1998; Bacheler et al, 2001; Rhee et al, 2006).  In general, 
resistance mutations are shared between the three first generation NNRTIs, but exceptions are 
G190A and Y181C, which are frequently selected by NVP-containing regimens but rarely 
emerge under EFV-selective pressure. By contrast, K103N is by far the most frequently 
selected mutation by EFV. While K103N and G190A cause high level resistance to all the 
three agents, Y181C causes high level resistance to NVP and DLV, but only intermediate 
resistance to EFV (Casado et al, 2000). However, results of treatment with EFV in patients 
who developed the mutation after NVP-failure has been disappointing (Lecossier et al, 2005) 
and consequently patients who develop resistance after treatment with any of the three first 
generations NNRTIs cannot be successfully treated with another of these agents (Delaugerre 
et al, 2001).  
 
Second generation NNRTIs (ETV and RPV) have a higher genetic barrier to resistance than 
first generation NNRTIs as accumulation of several mutations is required before significant 
reduction in susceptibility to the drugs is observed (Seminari et al, 2008). This finding can be 
explained by the fact that these drugs can bind the RT enzyme in different conformations and 
- 45 - 
 
as a result can rapidly adapt to changes in the NNRTI-binding pocket created as a 
consequence of specific resistance mutations. In general, it is considered that complete 
resistance to ETV requires accumulation of several of the following mutations V90I, A98G, 
L100I, K101E/P, V106I, E138A/G/K/Q, V179D/F/T, Y181C/I/V and G190A/SA and 
M230L. However, studies have shown that mutations at codons 100, 101 and 181 have a 
greater impact on clinical response to ETV compared to other mutations (Haddad et al, 2010). 
A total of 15 mutations have been associated with reduced susceptibility to RPV including 
K101E/P, E138A/G/K/Q/R, V179L, Y181C/I/V, H221Y, F227C and M230L, of them E138K 
is the most frequently found in patients failing RPV therapy (Rimsky et al, 2012; Haddad et 
al, 2011).  
1.7.4 Protease inhibitors 
There are currently nine protease inhibitors (PIs) licensed for the treatment of HIV-1 
infection: saquinavir (SQV), ritonavir (RTV), indinavir (IDV), nelfinavir (NFV), amprenavir 
(APV), lopinavir (LPV), atazanavir (ATV), tipranavir (TPV) and darunavir (DRV).  All of 
them are competitive inhibitors that bind to the active site of the viral PR with high affinity 
and by doing so they prevent the binding of its natural substrate Gag. As a consequence, PIs 
inhibit the catalytic processing of the Gag and Gag-Pro-Pol polyprotein into their mature 
components rendering the released virus immature and non-infectious. (Flexner, 1998; Patick 
and Potts, 1998). 
 
PIs are designed as analogues of the cleavage sites found in the natural substrate Gag of the 
HIV-1 PR in which the scissile bond has been replaced by a non-cleavable, transition-state 
motif. All of them, except for TPV, are peptidomimetic inhibitors and therefore they contain 
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a hydroxyethilene core, which shares structural similarity with the tetrahedral intermediate 
formed during the hydrolytic cleavage of a peptide bond of the natural substrate (Randolph 
and Degoy, 2004).  By contrast TPV, contains a dihydropyrone ring as a central scaffold, 
which directly interacts with the flap region of the HIV-1 PR and is structurally unrelated to 
the tetrahedral intermediate (Chrusciel and Strobach 2004). This unique binding motif and 
structure of TPV has been reported to increase flexibility allowing the drug to adjust to amino 
acid changes in the active site of the viral PR (Larder et al, 2000; Turner et al, 1998).  
 
Due to the vital role that HIV-1 PR plays in the viral life cycle and its small size, it was 
initially believed that resistance to PIs would be infrequent during treatment. However, the 
protease gene has shown great plasticity with mutations detected in 49 of the 99 amino acids 
of the HIV-1 protease and more than 20 substitutions associated with resistance to PIs (Shafer 
et al, 2000). Emergence of PI resistance requires the stepwise accumulation of primary 
mutations (major mutations) and secondary mutations (minor, compensatory or accessory 
mutations) (Molla et al, 1996), where each inhibitor usually selects for signature primary 
mutations and a characteristic pattern of secondary mutations. Thus, multiple substitutions 
are required for the development of complete PI resistance while maintaining effective virus 
replication and maturation. In general, primary resistance mutations are located near the 
active site of the PR at positions involved in inhibitor and substrate binding, some of these 
are: D30N, G48V, I50V, V82A, and I84V. Often, these mutations have a deleterious effect 
on the replication capacity of the resistant virus (Nijhuis et al, 2001; Quinones-Mateu, 2001) 
and such negative effect can be alleviated by the emergence of secondary mutations in the 
PR. These amino acid changes are generally outside the substrate-binding cavity of the 
enzyme and promote adaptation to the primary changes observed in the protease and 
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compensate at least partially the impairment of HIV-1 replication (Eastman et al, 1998; Ho et 
al, 1994; Mammano et al, 2000 and Nijhuis et al, 1999). Importantly, early studies 
demonstrated that in addition to mutations in the PR, changes located within the substrate 
(Gag) Cleavage sites are also selected in the context of PI resistance (Clavel et al, 2000; 
Doyon et al, 1996; Miller 2001; Nijhuis et al, 2001; Zhang et al, 1997), these mutations have 
been classified as compensatory mutations similarly to secondary mutations selected in the 
PR. Primary mutations directly affect the binding of the inhibitor to the protease and by doing 
this, they confer resistance to the drug. By contrast, the mechanisms in place for secondary 
mutations located both in the PR and in its natural substrate Gag is more difficult to elucidate. 
It has been propose that certain secondary PR mutations may alter the active site of the 
enzyme to adapt to the changes introduced by the active site primary mutations. Similarly, it 
has been proposed that mutations at cleavage sites provide better substrates for the mutated 
protease, which partially compensate for the loss of viral fitness displayed by the PI-resistant 
virus (Clavel et al, 2000; Doyon et al, 1996; Mammano et al, 2000; Nijhuis et al, 2001 and 
Zennou et al, 1998). However, other studies have shown that in certain instances Gag 
cleavage site mutations compensate for the replicative capacity of PI-resistant viruses without 
increasing the rate of cleavage compared to the wild type virus, suggesting that secondary 
mutations in Gag may exert their action through a variety of mechanism (Mammano et al, 
2000). Regardless of the mechanism of action, a common characteristic of secondary 
mutations in the PR and Gag is that they do not confer significant levels of PI resistance on 
their own by they are required along with primary PI resistance in order to achieve high level 
resistance to the inhibitors.  
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The advent of the first PIs (SQV, RTV, IDV, and NFV) in the early 1990s was a landmark 
breakthrough in the treatment of HIV-1 infection. They made possible the dual class triple 
combination therapy that became known as highly active antiretroviral therapy (HAART). 
HAART not only reduced HIV-1 RNA plasma levels below the level of quantification in 
most patients (Gulick et al, 1997; Hammer et al, 1997) but also significantly slowed the 
progression of HIV disease compared with single or dual therapy (Hammer et al, 1997) and 
as a result it was established as standard of care in all HIV-1 infected patients. However, the 
clinical utility of early PIs was restricted by their low bioavailability and large pill burden 
which ultimately reduced adherence and limited long-term viral inhibition. Furthermore, 
failure to first generation PI-containing therapy often resulted in the development of high 
levels of PI resistance due to the accumulation of mutations in amino acids generally located 
in the PR active site, D30, G48, I50, V82, I84V, but also occasionally at non-active site 
residues such as M46 and L90M. Despite each PI selecting for a characteristic pattern of 
mutations, cross-resistance was common among first generation PIs as all of them occupy a 
similar space in the HIV-1 PR.  
 
The next major development in the treatment of HIV-1 came when it was observed that RTV 
was a strong inhibitor of the CYP34A isoenzyme, which is the main responsible for the 
catabolism of PIs and consequently co-administration of most PIs with low dose RTV boost 
the exposure of the PI allowing flexible dosing including once daily dose. In addition, when 
boosted with RTV, PIs became more effective against PI-resistant viruses by increasing the 
drug plasma levels and consequently requiring higher levels of resistance to completely 
abrogate drug activity (Condra et al, 1996).  Subsequently, novel PIs were developed which 
were specifically designed to be active against PI-resistant viruses. While first generation PIs 
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fixed exactly within the active site of the PR and were designed with large hydrophobic 
groups to maximize hydrophobic interactions with the HIV-1 PR, novel PIs were developed 
to fix in the substrate-binding region. In addition, smaller hydrophobic groups were 
introduced in novel PIs so that the affinity for the inhibitor was not so dramatically affected 
by mutations in the active site as well as introducing additional polar interaction with main 
chain atoms which cannot be easily altered by mutations and which provided the inhibitor 
with enough flexibility as to adapt to changes in the PR active site. The first PI conceived 
with this approach was APV, this drug was developed to fit predominantly within the 
substrate envelope (King et al, 2004) and its mutational profile was distinct to the first 
generation PIs (SQV, RTV and IDV) providing evidence that inhibitors with greater 
resemblance to the natural substrate will be less affected by mutations selected by first 
generation PIs. Following the same structural approach, more recently DRV was developed 
which provide additional interactions with the active site protein backbone which, by contrast 
with the rest of the PR, is extraordinarily conserved. By introducing additional interactions, 
DRV provides an impressive resistance profile necessitating up to six active site mutations in 
the PR before the activity of the drug is completely abolished.  
It was soon thought that alternative mechanisms may assist the virus to evade the drug 
selective pressure. Indeed, it was demonstrated that viral strains resistant to DRV were 
selected in vitro. These resistant viruses exhibited changes in the Gag CS P7/P1 in the 
absence of any other changes in the HIV-1 genome, and when introduced in a reference 
strain, it was demonstrated that such variants conferred 10 fold resistance to the PI (Nijhuis et 
al, 2007). This was the first evidence that Gag CS mutations could cause resistance by 
themselves independently of their role as compensatory mutations. Since them, a few studies 
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have pointed to the role of Gag mutations, not only at CS but also beyond, in resistance to the 
drugs (Parry et al, 2009; Gupta et al, 2010). 
 
1.7.5 Integrase inhibitors 
Raltegravir (RAL) is the only INI currently licensed for the treatment of HIV-1 infection. It is 
an analogue of the diketo acid class compounds and as a result it shares their β-hydroxy-
ketone structural motif (Hazuda et al, 2000; Pommier et al, 2005). As previously specified, 
the process of integration is catalysed by the viral integrase and is a multistep mechanism that 
comprises the formation of a pre-integration complex; its nuclear importation; the 3’-
processing of the DNA molecule; and strand transfer reaction that results in the attachment of 
viral and cellular DNA.  To exert its action, the HIV-1 integrase requires the presence of 
divalent cations, such as Mg
2+
 or Mn
2+, 
in its active site. Raltegravir is an inhibitor of the 
strand transfer event in the integrase process (Hazuda et al, 2000) which, as other diketo-acid 
compounds, possesses metal-chelating functions. Its mechanism of action is not completely 
understood. However, it is reported that it binds tightly to the active site of the viral integrase 
and its chelating properties result in the sequestration of the metal ions present in the active 
site that are crucial for HIV-1 IN function.    
 
Resistance to Raltegravir is associated with mutations pointed directly to the catalytic site of the 
HIV-1 integrase enzyme (Pommier et al, 2005) and emerge in at least three different genetic 
pathways defined by a major mutation at Q148H/K/R, N155H and less often Y143R/H/C and one 
or more minor mutations which further increase the level of resistance to the inhibitor and/or 
compensate for the decreased fitness often associated with the presence of major mutations 
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(Delelis et al, 2010; Marinello et al, 2008; Kobayashi et al, 2008). The Q148 amino acid is a 
critical part of the active site of the integrase.  Not surprisingly, mutations at this codon reduce 
the susceptibility to raltegravir, but also markedly impair enzyme function. The replication defect 
associated with the presence of the signature raltegravir mutation Q148 H/K/R is frequently 
rescued by the compensatory mutations G140S and to a lesser extend E138E/K (Fransen et al, 
2009; Delelis et al, 2010). The second most common pathway of raltegravir resistance includes 
the major mutation N155H, which lies at the base of the catalytic site of the HIV1- integrase 
interacting with active site residues and directly interfering in enzyme metal binding (McColl et 
al, 2010). The N155H mutation reduces raltegravir susceptibility without affecting the replicative 
capacity to the extent of mutations at codon 148. The E92Q minor mutation is frequently found in 
combination with N115H and in this context further contribute to resistance to the INI, but it does 
not rescue the replicative capacity of the mutant virus (Fransen et al, 2009). Finally, the third 
pathway of resistance, which is much less common, comprises the mutation Y143R/C. 
Raltegravir interacts with Y143 residue during binding to the integrase inhibitor and consequently 
mutations at this site removes this favourable interaction causing resistance to the drug (Hare et 
al, 2010 and Delelelis et al, 2010). The T97A minor mutation is commonly seen with Y143R/C 
and significantly increases raltegravir resistance (Reuman et al, 2010;  Fransen et al, 2009).     
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Table 1.1 Antiretrovirals approved for HIV-1 treatment. 
Abbreviations:   NRTIs = nucleoside/nucleotide reverse transcriptase inhibitors; NNRTIs = non-nucleoside/nucleotide 
reverse transcriptase inhibitors; PIs = protease inhibitors; FIs = fusion inhibitor; INIs = integrase inhibitor; RT = 
reverse transcriptase; PR = protease; IN = integrase.  
Name (Abbreviation) Key mutations implicated in resistance 
NRTIs 
Zidovudine (ZDV) RT: M41L, D67N, K70R, L210W, T215YF, K219EQ 
Stavudine (d4T) RT: M41L, K65R D67N, K70R, L210W, T215YF, K219EQ 
Lamivudine (3TC) RT: K65R, M184VI 
Abacavir (ABC) RT: K65R, L74V, Y115F, M184V 
Didadosine (ddI) RT: K65R, L74V 
Emtricitabine (FTC) RT: K65R, M184VI 
Tenofovir (TDF) RT: K65R, K70E 
NNRTIs 
Nevirapine (NVP) RT: L100I, K101P, K103NS, V106AM, V108I, Y181CI, Y188CLH, G190A 
Delaviridine (DLV) RT: L100I, K101P, K103NS, V106AM, V108I, Y181CI, Y188CLH, G190A 
Efavirenz (EFV) RT: L100I, K101P, K103NS, V106M, V108I, Y181CI, Y188L, G190AS, P225H 
Etravirine (ETV) RT: V90I, A98G, L100I, K101EHP, V106I, E138AGKQ, V179DFT, Y181CIV, G190AS, M230L 
Rilpivirine (RPV) RT: K101EP, E138AGKQR, V179L, Y181CIV, H221Y, F227C, M230IL 
PIs 
Saquinavir (SQV) PR: L10IRV, L24I, G48V, I54VL, I62V, A71VT, G73S, V77I, V82AFTS, I84V, L90M 
Ritonavir (RTV) PR: L10FIRV, K20MR, V32I, L33F, M36I, M46IL, I54LV, A71VT, V77I, V82AFT, I84V, L90M 
Indinavir (IDV) PR: L10IRV, K20MR, L24I, V32I, M36I, M46IL, I54V, A71VT, G73SA, L76V, V77I, V83AFT, I84V, 
L90M 
Nelfinavir (NFV) PR: L10FI, D30N, M36I, M46IL, A71VT, V77I, V82AFTS, I84V, N88DS, L90M 
FosAmprenavir  (fAPV) PR: L10FIRV, V32I, M46IL, I47V, I50V, I54LVM, G73S, L76V, V82AFST, I84V, L90M 
Lopinavir (LPV) PR: L10FIRV, K20MR, L24I, V32I, L33F, M46IL, I47AV, I50V, F53L, I54ALMTSV, L63P, A71TV, 
G73S, L76V, V82AFTS, I84V, L90M 
Atazanavir (ATV) PR: L10CFIV, G16E, K20IMRTV, L24I, V332I, L33FIV, E34Q, M35ILV, M46IL, G48V, I50L, F53LY, 
I54ALMVT, D60E, I62V, A71ILTV, G73ACST, V82AFIT, I84V, I85V, N88S, L90M, I93LM 
Tipranavir (TPV) PR: L10V, L33F, M36ILV, K43T, M46L, I47V, I54AMV, Q58E, H69KR, T74P, V82LT, N83D, I84V, 
L89IMV 
Darunavir (DRV) PR: V11I, V32I, L33F, I47V, I50V, I54LM, T74P, L76V, I84V, L89V 
FIs 
Emfuvirtide (T20) Gp41: G36DS, I37V, V38AEM, Q39R, Q40H, N42T, N43D 
INIs 
Raltegravir (RAL) IN: E92Q, Y143CHR, Q148HKR, N155H 
Co-receptor antagonists 
Maraviroc (MVC) There are not specific mutations described. 
- 53 - 
 
1.8 Resistance testing 
The development of drug resistance is an important factor leading to treatment failure 
(Alcorn and Faruki, 2000). Consequently, major guidelines recommend the use of resistance 
testing at the time of treatment failure in order to decide the optimal regimen (US Department 
of Health and Human Services guidelines, 2010; Hirsh et al, 2008; The British HIV 
Association guidelines, 2012). Several randomized studies have demonstrated that this 
practice leads to superior virological response (Durant et al, 1999; Baxter et al, 2000; Cohen 
et al, 2002).  There are two main types of resistance testing: genotypic and phenotypic. 
Although both approaches are appropriate to evaluate drug resistance in the context of 
treatment failure, genotypic testing is preferred in clinical practice due to its faster turnaround 
time and simplicity.  
  
To perform genotypic resistance testing, the viral RNA is isolated from plasma, the genomic 
region of interest (HIV-1 RT, PR, IN, Env) is amplified by RT-PCR and the amplicon is 
sequenced by the Sanger method. This sequencing method uses dideoxynucleotides 
(ddNTPs), which lack the 3’ hydroxyl group required for the formation of a phosphodiester 
bond between two nucleotides and consequently they act as chain terminators. Briefly, the 
amplicon is denatured and a primer annealed to one of the template strands. The four 
deoxynucleotides triphosphate (dNTPs) are added together with the four ddNTPs, each 
marked with a different colour dye, at a 100:1 ratio. As the DNA polymerase polymerizes, 
dNTPs are added to the growing chain. However, on occasion a ddNTP rather than a dNTP is 
incorporated resulting in a chain terminating event. Chain of different lengths are produced 
and detected via fluorescence.  
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Direct sequencing from amplicons is known as viral population sequencing, and generates a 
consensus nucleotide sequence from the patient’s most prevalent viral quasispecies, which is 
further translated into its corresponding amino acid sequence. Point mutations are identified 
by alignment with a reference wild-type strain sequence, typically HXB2, and those variants 
with known effects on drug resistance are scored in the interpretation. Several online 
genotypic interpretation systems are available, which translate a specific mutation pattern into 
the predicted level of susceptibility. The three most commonly employed in clinical practice 
are ANRS, Rega and Stanford HIV db (Frentz et al, 2010).     
 
To perform phenotypic testing, in its initial format the isolation of patient’s virus and PBMCs 
were required. These were subsequently cultivated for 2-8 weeks in the presence of 
increasing concentrations of drugs and the readout was generally the production of P24 in the 
supernatant. This method has the advantage of incorporating both cells and virus from the 
patient, thus mimicking “in vivo” conditions closely. However, this approach had major 
disadvantages, particularly the long time required to complete the assay. In addition, due to 
biological variations, reproducibility was also a problem (Schmidt et al, 2002; Japour et al, 
1993).  As a result, simpler phenotypic resistance testing methods based on recombinant virus 
techniques were developed. The initial steps are the same as for genotypic testing and 
involved the isolation of the patient’s RNA and the amplification of the gene of interest, 
typically RT, PR and/or IN. In phenotypic tests, the amplified gene is then transferred into a 
laboratory strain of HIV that lacks the gene of interest, producing a recombinant virus. This 
mosaic virus contains patient-derived sequences that can be tested for drug susceptibility in 
two possible formats; these are:  
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 Single cycle phenotypic assay: this method is based on a single round of infection. 
The assay uses restriction, digestion and ligation to clone the patient’s HIV genomic 
region of interest into an HIV expression vector that lacks this region, to form 
Resistance Test Vectors (RTVs). The RTVs are replication defective as they are 
deprived of the envelope gene. Cells are co-transfected with three plasmids:  the 
resistance test vector, which contains the patient’s derived sequences, a reporter 
vector, which contains the HIV packaging sequence and also expresses luciferase that 
is employed as a marker of virus production, and a vector expressing the vesicular 
stomatitis G protein, which provides the envelope to the pseudovirus,.  Following 
exposure to increasing drug concentrations, the amount of pseudotyped virus is 
measured by quantifying the amount of luciferase production. Single cycle assays also 
provide a measure of the replicative capacity of the virus, which is defined by its 
ability to replicate in the absence of drugs and reported as a proportion (%) of the 
replication observed with wild-type virus.  
 
 Multiple cycle phenotypic assay: In this format the tested virus undergoes multiple 
rounds of infection. The assay uses homologous recombination in cell culture to insert 
the HIV genomic region of interest into a molecular HIV-1 clone, usually HXB2, 
which lacks the same region. This yields infectious recombinant viral particles 
capable of multiple rounds of replication. The virus is grown in the presence of 
increasing drug concentrations and replication is measured by expression of a reporter 
gene such as 3-(4, 5-dimethylthiazol)-2, 5-diphenyltetrazolium bromide (MTT).  
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The main advantage of multiple cycle assays is that the virus undergoes multiple rounds of 
infection and as a result mimics more closely “in vivo” conditions. However, these types of 
assays are time consuming, processing requires high level of containment, and retain the 
potential that the virus may mutate during passages. By contrast, single cycle phenotypic 
testing can typically be performed within a week and the results obtained are generally highly 
reproducible. In addition, the format of the assay eliminates the possibility of selection of 
viral populations that may not accurately represent the original virus and therefore may be the 
method of choice when the effect of specific mutations needs to be characterized. Regardless 
of the format of phenotypic assay employed, both assays report drug susceptibility results as 
a fold change for each drug, which is determined by the ratio of the IC50 (the concentration of 
a drug that is required for 50% viral inhibition) from the patient’s chimeric virus divided by 
the IC50 of a wild-type reference virus.  The interpretation of phenotypic tests is based on 
defined cut-offs. The technical cut off is generated by measuring the variation seen with 
repeat testing of the same samples and provides a measurement of the reproducibility of the 
system. The biological cut off (BCO) represents the phenotypic variability observed within 
treatment naïve patients and provides a measurement of the normal variation in fold changes 
observed in wild type viruses. The clinical cut off (CCO) represents the value that 
discriminates between treatment responders and non-responders among treatment 
experienced patients. Two clinical cut-offs are defined for each drug:  the lower cutoff 
(CCO1) would define when the susceptibility begins to decline, but the drug still has partial 
activity, and the upper cutoff (CCO2) represents the fold change at which all drug activity is 
lost.  From a clinical perspective, clinical cut-offs provide the most useful information, but if 
these clinical cutoffs have not been defined for a given drug, then biological cutoffs are 
applied.  
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Both standard phenotypic and genotypic resistance testing have limitations. Firstly, they are 
unable to detect minority variants, which are present at frequencies below 20%. Alternative 
methods capable of detecting low frequency variants include allele specific PCR (Charpentier 
et al, 2004), single genome analysis (Palmer et al, 2005) and ultra-deep sequencing assays 
(Wang et al, 2007). The allele specific PCR employs genetic probes to detect specific 
resistance mutations. It can detect mutations at frequencies between 0.5-1 % depending on 
the specific mutation. In single genome analysis, the complementary viral DNA is 
synthesized from the patient’s plasma and diluted to one copy; then each viral copy is 
amplified and sequenced. Finally, Ultra-deep sequencing uses large scale parallel 
pyrosequencing and is able to detect viral quasispecies present at very low levels. The role of 
minority variants in failure of antiretroviral remains to be elucidated. In drug naïve patients, 
studies have shown an association between the presence of minority drug resistant variants 
and subsequent virological failure, particularly when NNRTI-based regimens are 
administered (Johnson et al, 2008a; Metzner et al, 2009 and Geretti et al, 2009). However, 
definitive cut-offs remain to be established. There is likely a threshold above which minority 
variants will lead to therapy failure and this threshold will depend on the barrier to resistance 
of the affected drug, the antiviral activity of other drugs in the regimen as well as patient’s 
characteristics, such as baseline viral load and adherence patterns. Another important 
restriction of current phenotypic and genotypic resistance testing methods is that they do not 
include the entire viral sequence. As a result, there may be important mutations outside the 
standard area of interest that will be missed by these techniques. For instance, to evaluate 
resistance to RTIs, the connection and RNase H domains are not routinely sequenced or 
included in the recombinant viruses used for phenotypic assays. Mutations in these areas have 
been reported to be selected by NRTI therapy and increase the level of resistance to these 
drugs (Nikolenko et al, 2007). Similarly, most phenotypic and genotypic tests only include 
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the PR region of HIV-1, those that include regions of Gag,  the main substrate for protease, 
are restricted to the two CS located at the C-terminal site (P7/P1/P6). However, mutations in 
Gag outside this region have been recently demonstrated to contribute to resistance to PIs 
(Parry et al, 2009). Importantly, mutations in the RNase H and connection domains have been 
reported to emerge in the context of multiple TAMs. Therefore, their presence in already 
highly resistant virus questions its clinical utility. However, mutations in Gag have been 
found to confer resistance in the absence of typical PI-resistance-associated mutations 
(Nijhuis et al, 2007; Gupta et al, 2010).  
 
1.9 Viral fitness and replicative capacity  
The term “viral fitness” refers to the ability of a virus to replicate and produce a progeny in a 
given environment (Domingo et al, 1997a). There are two stages to describe the evolution of 
viral fitness whilst on therapy. The first stage is characterised by the selection of primary, 
also referred to as major, resistance mutations resulting in viruses that not only have reduced 
drug susceptibility but often an impaired replicative capacity relative to the wild type virus. 
During the second stage, additional mutations arise that alone do not confer drug resistance 
but in combination with the primary mutations enhance the replicative capacity of the virus. 
These mutations are known as accessory mutations or also termed minor or secondary 
mutations (Nijhuis et al, 1999). It can be said that the natural evolution of HIV under drug 
pressure is towards increasing levels of resistance, cross-resistance and fitness. There are 
different modes for the assessment of viral fitness and these methods can be broadly 
classified as in vivo and in vitro methods. In vivo methods assess viral fitness by comparing 
the amount of wild type and mutant virus detected in “in vivo” populations (Devereux et al, 
2001).  These methods closely mimic the natural setting of the natural host. However, the 
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entire individual offers a variety of cell types and microenvironments to the infecting HIV-1 
with conflicting selective pressure and consequently, in vivo methods are difficult to 
extrapolate to different situations.   
 
In vitro methods employ HIV-1 isolates or more frequently recombinant viruses and can be 
very useful as models for determining the effect of drug resistant variants on replication in a 
fixed environment. There are several methods for the evaluation of viral fitness in vitro. In 
general, they are all grouped into two main categories: monoinfection assays (or viral growth 
kinetics) and growth competition experiments. In monoinfection assays, the replicative 
capacity of different HIV isolates or recombinant viruses is tested individually and measured 
by measuring the amount of specific viral proteins, usually P24, or the activity of viral 
enzyme, such as RT.  Virus replicative capacity can also be measured in monoinfection 
assays by using a reporter gene, such as luciferase, in a single cycle assay (Dykes and 
Demeter, 2007) and comparing luciferase production by a mutant virus and WT reference 
virus.   
 
In growth competition experiments, two phenotypically distinguishable viruses are mixed at 
similar or different proportions and the outgrowth of one of the population is measured 
(Domingo et al, 1997a;  Domingo and Holland et al, 1997b). By doing this, the fitness of both 
viral strains can be directly compared as two viral populations in cell culture compete with 
each other until one outgrows the other one. In general, cells are infected with the mixture of 
viruses and after several passages, the proportion of both viruses is measured and compared 
with their proportions in the initial mixture (Holland et al, 1991 and Domingo et al, 1997a).  
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Overall, growth competition experiments are more accurate and sensitive for the 
determination of small differences in fitness than monoinfection assays.  The single cycle 
assay offers a fast and reproducible method to measure the replicative capacity of mutant 
virus that can be compared and expressed as a percentage of that observed for a WT reference 
strain. As it is a monoinfection assay, it cannot accurately determined small differences in 
replicative capacity. However, it can be of use for the characterization of novel mutations 
since growth competition experiments increase the potential for mutations to occur in the 
different passages and divert form the population of interest.  
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2 Chapter two: materials and methods 
2.1 Materials 
2.1.1 Bacteria 
 TOP10: F- mcrA Δ (mrr-hsdRMS-mcrBC) Φ80lacZΔM15 ΔlacΧ74 recA1 araD139 
Δ (ara-leu) 7697 galU galK rpsL (StrR) endA1 nupG. 
 HB101: F-, thi-1, hsdS20 (rB-, mB-), supE44, recA13, ara-14, leuB6, proA2, lacY1, 
galK2, rpsL20 (str
r
), xyl-5, mtl-1.  
 XL1 blue supercompetent cells: recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac 
[F´ proAB lacI
q
ZΔM15 Tn10 (Tetr)]. 
 
2.1.2 Mammalian cell lines 
Human Embryonic Kidney 293 cells (HEK 293 Cells): HEK 293 cells were generated in the 
70s by transformation of cultures of normal human embryonic kidney cells with sheared 
adenovirus 5 DNA (Graham FL, et al, 1977).  
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2.1.3 Bacterial culture media 
Luria-Bertani (LB) broth: 10 g tryptone, 5 g of yeast extract, 10 g NaCl and deionised water 
to a final volume of 1 litre. Ampicillin was added at a concentration of 50 mg/ml.  
 
 LB agar plates: LB medium was prepared as indicated above and 15g/l of agar was 
added before autoclaving and supplemented with 50 mg/ml of ampicillin after 
autoclaving.  
 LB agar X-Gal plates: ampicillin-containing LB agar plates were prepared as above 
and spread with 40 µl of 40 mg/ml X-gal 10 minutes before use.  
 Super Optimal Broth with catabolite repression (SOC): SOC medium was purchased 
from Invitrogene and contained 20 g tryptone, 5 g yeast extract, 10 mM NaCl, 2.5 
mM KCl, 10 mM MgCl2 and 20 mM glucose.  
 NZY+ broth: 10 g of NZ amine (casein hydrolysate), 5 g of yeast extract, 5 g of NaCl, 
12.5 ml of 1M MgCl2, 12.5 ml of 1M MgSO4, 10 ml of 2M glucose and deionised 
water to a final volume of 1 litre. The pH was adjusted to 7.5 using NaOH.  
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2.1.4 Cell culture media 
Cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) (GIBCO, Invitrogene, 
Paisley, UK) supplemented with 100 U/ml of penicillin, 100 mg/ml of streptomycin and 15% 
of Fetal Calf Serum (FCS) (Biosera, UK).  
 
Cell transfection was conducted in Opti-MEM® Reduced Serum Medium with GlutaMAX 
(Opti-MEM) (GIBCO, Invitrogene, Paisley, UK).  
 
2.1.5 Transfection reagent 
FuGENE® 6 Transfection Reagent (Roche Diagnostics, US), which is a proprietary blend of 
lipids and other components, was employed for cell transfection.   
 
2.1.6 Antiretrovirals 
Protease inhibitors (PIs): Amprenavir (APV), Atazanavir (ATV), Darunavir (DRV), Indinavir 
(IDV), Lopinavir (LPV) and Saquinavir (SQV). All antiretrovirals were obtained through the 
AIDS Research and Reference Program, Division of AIDS, NIAID, NIH.  
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2.1.7 Primers 
 Sequences for the primers employed in the study are detailed in tables 2.1 to 2.4. 
 
2.1.8 Vectors 
 P8.9NSX: it is a modified form of Gag-Pro-Pol expression plasmid pCMV-∆R8.2 
(Naldini et al, 1996). The vector encodes HIV-1 Gag-pol and the virulence genes (vif, 
vpu and nef); accessory genes (Rev and Tat) as well as env gene have been deleted. In 
addition, the vector contains numerous restriction sites such as NotI site upstream of 
Gag, ApaI and SpeI sites within Gag and XmaI in the integrase allowing foreign Gag-
PR and RT sequences to be cloned. We further modified the P8.9NSX vector to allow 
the independent cloning of external full-length Gag and PR genes.  Modifications 
were performed by SDM and consisted of introduction of a BglII site at the end of 
Gag and beginning of PR and a BamHI site at the end of the protease. In addition, an 
additional BglII and a BamHI present in the vector downstream of RT were blocked 
by “in vitro” mutagenesis so that the final sequence contains a unique NotI site 
upstream of Gag, a unique BglII at the end of Gag and beginning of PR and a unique 
BamHI at the end of the PR. Upon completion of the “in vitro” mutagenesis, the HIV 
backbone sequence of the P8.9NSX vector was confirmed by sanger sequencing and 
the presence of the restriction sites by digestion with the corresponding restriction 
endonucleases.     
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 pCSFLW: it is a modified form of the pHR-SIN-CSGW vector in which the gene 
encoding green fluorescent protein has been replaced with firefly luciferase (FL) 
(Demaison et al, 2002). Therefore, as pHR-SIN-CSGW, pCSFLW  is a self-
inactivating vector (SIN vector) in which the U3 region of the 5’ LTR of HIV has 
been replaced with the CMV promoter and that has a deletion in the U3 region of the 
3’ LTR which includes segments encoding the enhancer and promoter functions. The 
deletion will be transferred to the 5’LTR after reverse transcription and as a result the 
transcriptional unit from the LTRs in the provirus is eliminated providing a SIN 
vector. The pCSFLW encoded firefly luciferase which is employed as the reporter 
gene in the drug susceptibility and replicative capacity assays and also contains the 
HIV packaging sequence.  
 
 PMDG: it expressed the Vesicular estomatitis virus G envelope protein under 
regulation of the CMV promoter and is used for the pseudotyping of the HIV and 
luciferase expressing vectors.  
 
 PCR2.1®TOPO: it is a commercial vector (Invitrogene, Pasley, UK) which is 
supplied linearized with a 3’-thymidine (T) overhang and Topoisomerase covalently 
bound to the vector.  This vector was employed for TA cloning of PCR products 
which would be used for clonal analysis of samples which did not render interpretable 
population sequencing results or in which clonal analysis was required for the study 
of linkage of mutations.      
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 PGEM8.9: this vector was obtained by cloning the P8.9NSX HIV backbone 
containing restriction sites into the commercial vector PgemEasyTvector (Promega, 
UK). PGEM8.9 was employed as a template for SDMs.   
 
2.2 Methods 
2.2.1 Patients, samples and sequences 
 In the validation of the HIV-1 Gag and protease (Gag-PR) amplification and 
sequencing assay, we employed plasma samples from patients attending the HIV services at 
Royal Free Hospital (RFH). The Virology Department at Royal Free Hospital holds a 
database in which all HIV-1 infected patients that attend the hospital for drug resistance 
testing have their pol gene sequences and genotypic profile entered. The database also 
contains information on treatment status, treatment regimen, plasma HIV-1 RNA load and 
HIV-1 subtype. In 2011, the database contained approximately 10000 pol sequences. Plasma 
samples were selected representing a wide range of HIV-1 subtypes and circulating 
recombinant forms (CRFs).  
 
 In the cross-sectional comparison of PI-naïve and PI-experienced patients, we 
included patients from different cohorts in order to increase the number of sequences 
analyzed. Firstly, we selected both PI-naïve and PI-experienced patients from the RFH (n= 
52 and n=50, respectively). Secondly, we analyzed sequences from PI-experienced patients 
attending the Cologne University Hospital (n = 128). Lastly, we included PI-experienced 
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patients from the MaxCmin 1, MaxCmin2 and COLATE clinical trials (n = 13).  . In 
addition, we also downloaded 148 drug-naïve Gag-PR sequences from the HIV Los Alamos 
Database.  In total, we compared 200 PI-naïve and 191 PI-experienced sequences. All 
sequences obtained from PI-experienced patients contained at least one major PR resistance 
mutations and all sequences were retrieved from subjects with long lasting subtype B HIV-1 
infection (i.e.; 3-10 years).    
 
 
 In  the longitudinal analysis of Gag-PR in patients failing PI-based regimens as well 
as for the assessment of the effect of Gag mutations on PI susceptibility and replicative 
capacity (RC), we  selected patients from the MaxCmin1, MaxCmin2 or COLATE trials, 
who had matched pre-treatment and treatment failure plasma samples. In addition, we also 
studied patients from the HIV services at Royal Free Hospital who had long term on-going 
viraemia while on PI-based regimen and showed evidence of PR evolution on their routine 
HIV resistance genotypic tests.   
 
2.2.2 General molecular biology techniques 
Standard molecular biology techniques as described in Molecular Cloning: a Laboratory 
Manual, (Maniatis et al, 1986) were used throughout.  
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2.2.2.1 RNA extraction 
We employed Qiagen QIAamp Viral RNA Kit (Qiagen, Crawley, UK) and EasyMag 
automated extractor (Nuclisens, Biomerieux, Boxtel, Netherlands) for manual and semi-
automated RNA extraction, respectively. Both methods are based on the nucleic acid 
extraction protocol developed by Boom and colleagues (Boom et al, 1990) which employed 
the lysing and nuclease-inactivating properties of the chaotropic agent guanidinium 
thiocynate together with the nucleic acid-binding properties of silica particles in the presence 
of this agent. One millilitre of plasma was centrifugated for 1 hour at 4°C to concentrate the 
virus. The supernatant was then removed and the pellet re-suspended to a final volume of 280 
µl. The re-suspended pellet was employed for nucleic acid extraction with either Qiagen 
QIAamp Viral RNA Kit (Qiagen, Crawley, UK) if the plasma HIV viral load was below 
1,000 copies/ml or the automated extractor EasyMag (Nuclisens, Biomerieux, Boxtel, 
Netherlands) if the HIV plasma viral load was above that threshold. In both cases nucleic acid 
extraction was performed following the manufacturer’s instructions.   
 
2.2.2.2 Amplification of HIV-1 Gag-protease region 
A RT-nested PCR protocol was designed for reverse transcription followed by specific 
amplification of full-length Gag-PR. Primers employed for amplification are shown in table 
2.1. Three different commercial Kits were evaluated for amplification of the HIV-1 Gag-PR 
region. Two of the methods performed reverse transcription and amplification in a single tube 
followed by a second PCR round on the initial PCR product: Qiagen one step RT-PCR 
Kit/Qiagen HotStar®Taq DNA polymerase Kit (Qiagen, Crawley, UK), namely Qiagen Gag-
PR amplification protocol and Invitrogene SuperScript®III One-Step RT-PCR System/ 
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Platinum® Taq DNA polymerase HF Kit (Invitrogene, UK), namely Invitrogene Gag-PR 
amplification protocol. The third method (AccuScript™ High Fidelity (HF) PCR/ PfuUltra 
HF DNA Polymerase) (Stratagene, Netherlands), namely Stratagene Gag-PR amplification 
protocol, separates both reverse transcription and both rounds of amplification in three 
independent steps.  
 
 Qiagen incorporates non-proofreading enzymes for both reverse transcription and 
amplification. Invitrogene system uses a blend of proof-reading and non-proofreading 
enzymes for reverse transcription and PCR. In addition, the reverse transcriptase included in 
Invitrogene system displayed a reduced RNase H activity facilitating complete synthesis of 
cDNA strands. Lastly, Stratagene kits contained proof-reading enzymes for both reverse 
transcription and amplification.  
 
The three systems were optimized and the selection of one or another method for 
amplification will depend on the specific purpose i.e.: population sequencing vs. clonal 
analysis. 
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2.2.2.2.1 Qiagen Gag-protease amplification protocol 
One step RT-PCR: 
 Prepare master mix containing: 1 x Qiagen RT-PCR buffer, 400 µM dNTPs, 0.4 µM 
of forward and reverse primers and 2.5 Units of Qiagen RT/PCR enzyme mix.  
 Add 40 µl of the above mix to 10 µl of RNA extract. 
 Perform RT-PCR as follows: 
 
 
 
2
nd 
round PCR: 
 Prepare master mix containing: 1 x Qiagen PCR buffer, 400 µM dNTPs, 0.4 µM of 
forward and reverse primers and 2 Units of Qiagen Hotstar Taq DNA polymerase.  
 Add 48 µl of the above mix to 2 µl of 1st round PCR product. 
 Perform PCR as follows: 
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2.2.2.2.2 Invitrogene Gag-protease amplification protocol: 
One step RT-PCR: 
 Prepare master mix containing: 1 x Invitrogene buffer supplemented with 1.2 Mm 
Mg
2+
 and 200 µM dNTPs, 0.4 µM of forward and reverse primers and 2 Units of 
RT/PCR enzyme mix.  
 Add 40 µl of the above mix to 10 µl of RNA extract. 
 Perform RT-PCR as follows: 
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2
nd 
round PCR: 
 Prepare master mix containing: 1 x Invitrogene PCR buffer, 1.5 mM Mg2+ , 200 µM 
dNTPs, 0.4 µM of forward and reverse primers and 2.5 Units of Platinum Taq HF Taq 
DNA polymerase.  
 Add 48 µl of the above mix to 2 µl of 1st round PCR product. 
 Perform PCR as follows: 
 
 
 
2.2.2.2.3 Stratagene Gag-protease amplification protocol: 
Reverse transcription (RT): 
 Prepare master mix containing: 1 x AccuSript RT buffer, 10 Mm Dithiothreitol 
(DTT),   1mM dNTPs, 2µM of outer reverse primers and 20 Units of RNase 
inhibitors.  
 Add 39 µl of the above mix to 10 µl of RNA extract 
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 Incubate the above mix at 65°C for 5 minutes and subsequently cool down reaction to 
room temperature.  
 Add 2 units of AccuScript RT enzyme 
 Perform RT for 1 hour at 42°C.  
 
1
st
 round PCR:  
 Prepare master mix containing: 1 x Pfu Ultra HF buffer  containing 2 mM Mg2+ , 200 
µM dNTPs, 0.4 µM of forward and reverse primers and 2.5 Units of Pfu Ultra HF 
DNA polymerase.  
 Add 45 µl of the above mix to 5 µl of cDNA 
 Perform PCR as follows: 
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2
nd
 round PCR:  
 Prepare master mix containing: 1 x Pfu Ultra HF buffer , 4 mM Mg2+ , 200 µM 
dNTPs, 0.4 µM of forward and reverse primers and 2.5 Units of Pfu Ultra HF DNA 
polymerase.  
 Add 48 µl of the above mix to 2 µl of 1st round PCR product. 
 Perform PCR as follows: 
 
 
 
2.2.2.3 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to confirm the correct size of the PCR product. 1.5 g of 
agarose was dissolved in TAE buffer in a microwave and once cooled; 10mg/ml ethidium 
bromide was added. PCR products were mixed with 5X loading dye and loaded onto the gel 
with a DNA mass ladder. Gels were run for approximately 1-2 hours at 100 volts, depending 
on the size of the band expected. All gels were visualised using a UV transilluminator 
(Biorad, Hertfordshire, UK). 
 
- 75 - 
 
2.2.2.4 Purification of PCR products 
PCR products were visualised using ethidium bromide staining and agarose gel 
electrophoresis. Products of the expected size were either excised and purified using the 
QIAQuick Gel Extraction Kit (Qiagen, Crawley, UK) if the PCR product was going to be 
subsequently cloned,  or directly purified from the PCR mixed using the QIAQuick PCR 
Purification kit (Qiagen, Crawley, UK). Both purification methods were performed in 
accordance with the manufacturer’s instructions. Briefly, the PCR product was added to the 
buffer containing the chaotropic agent guanidine thiocyanate and bound to the silica 
membrane in the QIAquick spin column through centrifugation for 1 minute at 13,000rpm. 
Impurities and contaminants were removed through washing with an ethanol containing 
buffer and DNA was eluted into a low salt and pH containing buffer. If gel excision was 
employed, the gel slice was previously dissolved in 3 volumes of buffer QG and subsequently 
the DNA purified as indicated above for a PCR product.  
 
2.2.2.5 A-tailing 
To enable efficient TA cloning of products generated with high fidelity polymerases, such as 
those incorporated into Invitrogene or Stratagene systems, purified PCR products were added 
to a mix of 250 uM dATP, 10Xbuffer containing 2.5 mM MgCl2, and 2.5 units of Amplitaq 
Gold Polymerase. The mix was heated to 95
o
C for 10 minutes followed by 20 minutes at 
72
o
C. 
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2.2.2.6 PCR TA cloning into pCR®2.1-TOPO 
The TOPO TA cloning kit (Invitrogen, Paisley, UK) was used to clone the HIV Gag-PR 
genes. TOPO TA cloning uses Topoisomerase I to ligate the PCR product with the vector. All 
PCR products produced with conventional Taq polymerases contain a deoxyadenosine (A) 
overhang to the 3’end, as a consequence of the non-template-dependent terminal transferase 
displayed by the enzymes. In the case that proof-reading enzymes were employed for PCR, 
the A-overhang was incorporated into the PCR product by the A-tailing procedure described 
above. The linearized vector supplied in the kit (pCR®2.1-TOPO) has a deoxythimidine (T) 
overhang. Ligation will occur between A-overhang in the PCR product and T-overhang in the 
vector.  A number of cloning reaction, varying amount of PCR products and incubation 
times, were set-up in order to identify the optimal condition for the cloning of HIV-1 Gag-PR 
genes into the pCR®2.1-TOPO vector. Final ligation reaction consisted of: 4 µl PCR product, 
1 µl salt solution and 1 µl pCR®2.1-TOPO vector. Ligation reactions were incubated at room 
temperature for 30 minutes and then placed on ice ready for transformation. 50 µl of TOP10 
E. coli cells were transformed with 2 µl of the ligation reaction. Transformation was carried 
out by incubating cells and ligation reaction for 30 minutes on ice followed by heat shock at 
42ºC for 45 seconds and cooled on ice for 2 minutes. 250 µl of SOC medium (Invitrogen, 
Paisley, UK) was added to the cells and incubated in a 37ºC orbital shaker for 1 hour. Cells 
were then plated onto LB agar plates containing 50 mg/ml ampicillin and 40 mg/ml of X-Gal 
and incubated overnight at 37ºC.  
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2.2.2.7 Plasmid DNA purification 
2.2.2.7.1 Minipreps 
Plasmid DNA was extracted from bacterial cells using the QIAPrep Spin Mini-prep Kit 
(Qiagen, Crawley, UK) in accordance with the manufacturer’s instructions. Briefly, a single 
transformed E. coli colony was inoculated into 3 mls of LB broth containing 50 mg/ml 
ampicillin and incubated overnight at 37°C in an orbital shaker. 2mls of the overnight culture 
were employed the following day for plasmid DNA  extraction. Bacterial cells were 
resuspended and lysed under alkaline conditions. The lysate was then neutralised with acetic 
acid and bound to the silica membrane of the QIAprep spin column through centrifugation for 
1 minute at 13,000rpm. Remaining impurities were washed away using an ethanol based 
buffer. The plasmid DNA was then eluted under low salt conditions into RNase-free water. 
 
2.2.2.8 DNA quantification 
The quality and quantity of plasmid DNA extracted was assessed by UV-Vis-
Spectophotometry using 1 µl of mini-prep and a NanoDrop® ND-1000 UV-Vis 
Spectrophotometer (NanoDrop).  
 
PCR products were also quantified by visualization using Ethidium bromide (Invitrogene) 
staining and agarose gel electrophoresis of a 5 µl aliquot of purified DNA with a DNA 
molecular marker.   
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2.2.2.9 EcoRI restriction digest 
The introduced PCR product is flanked by EcoRI restriction sites in the pCR®2.1-TOPO 
vector. Therefore, digestion of the plasmids with EcoRI restriction endonuclease will release 
the PCR product and allow us to identify clones harbouring the expected insert. To this 
purpose, 5 µl of mini-prep were digested with 1µl EcoRI (Invitrogen, Paisley, UK), 2µl 
buffer containing 1 mM MgCl2, and 12µl RNase free water. Digests were incubated for 1 
hour at 37ºC and visualised using ethidium bromide staining and agarose gel electrophoresis. 
Positive clones were identified as those harbouring the correctly sized inserts. 
 
2.2.2.10 DNA sequencing 
All DNA was sequenced using Sanger methodology. Primers employed for Gag-PR 
sequencing are shown in table 2.2.  Purified PCR products or Plasmids identified as 
containing the PCR insert were diluted to a concentration of around 20 ng/µl and sequenced 
using the BigDye Sequencing mix v3.1. Sequencing reaction contained 8 µl of PCR product 
or plasmid, 0.5 µM of the selected primer and nuclease-free water to a final volume of 20 µl.  
A total of 8 to 10 primers were required for full-length Gag-PR sequencing. Primers were 
employed in different combinations depending on the specific sample. Sequencing PCR 
conditions were as follows, 25 cycles of 96°C for 10 seconds, 50°C for 5 seconds and 60°C 
for 4 minutes and a hold at 4°C. Sequencing reactions were purified by precipitating the DNA 
with 52 µl of a mix containing 50 µl of 100% ethanol (EtOH) and 2 µl of 3M sodium acetate 
followed by a washing step with 150 µl of 70% EtOH. Purified sequencing reactions were 
then run on a 3730-Avant Genetic Analyzer (Applied Biosystems, UK) and the obtained 
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sequence analysed employing Sequence analysis version 5.0, Seqscape version 6.0 and Mega 
Molecular Evolutionary Genetic Analysis software version 4.0 programmes.  
 
2.2.2.11 Site-directed mutagenesis 
Site directed mutagenesis was carried out using Quickchange Multi/Site Directed 
Mutagenesis Kit (Stratagene, Cheshire, UK) to insert desired mutations. All primer 
combinations were designed specifically to incorporate the desired mutation and are shown in 
table 2.3. 50 ng plasmid and 125 ng of the primers containing the required mutation were 
used in the following PCR, 16 cycles of 95°C for 30 seconds, 90°C for 30 seconds, 55°C for 
1 minute, 72°C for 2 minutes and a hold at 4°C. In order to degrade the parental DNA 
plasmid, the PCR product was incubated at 37ºC for at least one hour with the restriction 
enzyme Dpn1. 50 µl of XL1-blue supercompetent cells were then transformed with 2 µl of 
Dpn-digested DNA. Transformation was carried out by incubating cells and ligation reaction 
for 30 minutes on ice followed by heat shock at 42ºC for 30 seconds and cooled the reaction 
on ice for 2 minutes. 500 µl of NZY
+
 broth were added to the cells and incubated in a 37ºC 
orbital shaker for 1 hour. Cells were then plated onto LB agar plates containing 50 mg/ml 
ampicillin and incubated overnight at 37ºC. The following days, a number of colonies were 
selected for screening for the presence of the correct mutation. Plasmidic DNA was extracted 
with QIAPrep Spin Miniprep Kit (Qiagen, Crawley, UK) as described in section 2.2.2.7.1 and 
the presence of the correct mutations was confirmed by sequencing the full Gag-PR region 
using Sanger sequencing as previously described in section 2.2.2.10. 
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2.2.3 General tissue culture techniques 
All cells and pseudo-virus cultures were grown in humidified 37°C incubators with 5% CO2 
in varying volumes and passaged as required.  
 
2.2.3.1 Cell thawing 
HEK-293 cells were removed from liquid nitrogen and thawed rapidly at 37°C. Cells were 
added to 10 ml of pre-heated DMEM media (GIBCO, Invitrogene, Pasley, UK) supplemented 
with 100 U/ml penicillin, 100 µg/ml streptomycin (GIBCO, Invitrogene, Pasley, UK) and 
10% FCS (Biosera, UK). The cells were subsequently pelleted at 325g for 5 minutes, washed 
once in 10 ml of DMEM media and re-suspended in 15 ml of DMEM media in 10 cm dishes. 
The following day the media was replaced with fresh media.  
 
2.2.3.2 Cell passaging 
HEK-293 cells were maintained in DMEM media (GIBCO, Invitrogene, Pasley, UK) 
supplemented with 10% FCS (Biosera, UK), 100 U/ml of penicillin and 100 µg/ml 
streptomycin (GIBO, Invitrogene, Pasley, UK). Cells were washed with phosphate buffered 
saline (PBS) [137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2H(PO)4, 1.4 mM KH2(PO)4], 
incubated with 2 ml of trypsin-EDTA (Gibco, Invitrogene, Pasley, UK) until the cells were 
detached from the dish. Cells were then pelleted at 325g for 5 minutes, the tripsine removed 
and the cells re-suspended in fresh DMEM media. Cells were split 1:4 to 1:8, depending on 
the cell density and rate of growth, two or three times a week and grown in 5% CO2 at 37°C. 
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2.2.3.3 Cell freezing 
HEK-293 cells were centrifugated at 325g for 5 minutes and re-suspended at 1x 10
7
cells/ml 
in 40% DMEM media, 50% FCS and 10% dimethyl sulphoxide (DMSO, Sigma, UK). Cells 
were then aliquoted into cryovials (Nunc, USA) and gradually cooled to -80°C in an 
isopropanol-containing cryo-container (Nalgene, USA) before being transferred to liquid 
nitrogene.   
 
2.2.4 Single cycle assay related techniques 
2.2.4.1 Generation of resistance test vectors 
RTVs were generated by cloning patient related Gag and/or PR sequences into the P8.9NSX 
HIV expression vector. The P8.9NSX was provided by Professor Pillay’s group and was 
further modified to facilitate the cloning of patients’ Gag, PR or Gag-PR sequences. 
Modification consisted of “in vitro” side-directed mutagenesis leading to introduction of two 
restriction sites and the blocking of other two restriction sites in order to generate unique sites 
at the beginning and end of Gag and protease genes allowing the cloning of these two genes 
either simultaneously or independently. After mutagenesis, the sequence of the P8.9NSX 
HIV backbone was confirmed by Sanger sequencing and the presence of the restriction sites 
verified by digestion with the corresponding restriction endonucleases. Primers employed for 
vector modification by SDM are shown in table 2.4.  
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The generation of RTVs comprised the following steps: 
1. Introduction of appropriate restriction sites in patient’s samples: the introduction of 
restriction sites in patient’s samples was accomplished by amplification employing 
Invitrogene protocol and modified nested PCR primers (sequences are shown in table 
2.5).  Modified primers were designed with restriction sites in their 5’ regions. 
Different restriction sites were including in the forward and reverse primers 
generating a PCR product whose termini now carry restriction sites that can be used 
for directional cloning.  
 
2. Purification of PCR product containing restriction sites: Once the restriction site-
containing PCR product was generated, this was purified to eliminate the excess of 
primers, dNTPs and DNA polymerase from the amplified product before digestion 
with restriction endonucleases. PCR products were purified with QIAQuick PCR 
purification Kit (Qiagen, Crawley, UK) as indicated in section 2.2.2.4.  
 
 
3. Digestion with restriction endonucleases: the purified PCR fragment and the 
PGEM8.9 vector were subsequently digested with appropriate restriction enzymes and 
the digested products were separated by agarose gel electrophoresis and visualized 
using ethidium bromide staining.  The right size digested PCR product and vector 
were then gel extracted using QIAQuick Gel Extraction Kit as indicated in section 
2.2.2.4.  
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Three different digestion protocols were optimized depending on whether Gag, PR or 
Gag-PR was going to be cloned into the P8.9NSX vector: 
 
 Gag Cloning: vector and patient sample were digested with NotI and BglII. 
Digestion reaction contained:  1 µg of DNA, 2 µl of 1:10 Bovine Serum Albumin (BSA), 
5 units of NotI and BglII to a final volume of 20 µl of NE Buffer 3. Digestion proceeded 
at 37°C for 2 hours after which 2 more units of NotI were added and the reaction 
incubated for two further hours.      
 PR Cloning: vector and patient sample were digested with BglII and BamHI. 
Digestion reaction contained: 1 µg of DNA, 2 µl of 1:10 BSA, 5 units of BglII and 
BamHI to a final volume of 20 µl of NEBuffer 3. Digestion proceeded for 2 hours at 
37°C.  
 Gag-PR cloning:  vector and patient sample were digested with NotI and 
BamHI. Digestion reaction contained:  1 µg of DNA, 2 µl of 1:10 BSA, 5 units of NotI 
and BamHI to a final volume of 20 µl of NE Buffer 3. Digestion proceeded at 37°C for 2 
hours after which 2 more units of NotI were added and the reaction incubated for two 
additional hours.      
 
 
4. Cloning: the digested PCR product and PGEM8.9 vector were ligated together using 
Rapid Ligation Kit (Roche Diagnostics, USA) according to the manufacturer’s 
instructions. Previous to ligation the digested PGEMP8.9 vector was treated with 
shrimp alkaline phosphatase (Roche Diagnostics, USA) to prevent self-ligation. A 
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typical ligation reaction contained vector: insert molar ratio 1:3 in a final volume of 
21 µl and total DNA content of 200 ng.  
 
5. Transformation of E.coli HB101 cells: Ligated products were purified employing 
QIAQUICK PCR purification Kit (Qiagen, Crawley, UK) to eliminate excess 
restriction endonucleases and transformed into E.coli HB101 cells. Transformation 
was carried out by incubating cells and ligation reaction for 30 minutes on ice 
followed by heat shock at 42ºC for 45 seconds and cooled on ice for 2 minutes. 250 µl 
of SOC medium (Invitrogen, Paisley, UK) was added to the cells and incubated in a 
37ºC orbital shaker for 1 hour. Cells were then plated onto LB agar plates containing 
50 mg/ml ampicillin and incubated overnight at 37ºC.  
 
 
6. Miniprep: Plasmid DNA was extracted from bacterial cells using the QIAPrep Spin 
Mini-prep Kit (Qiagen, Crawley, UK) as indicated in section 2.2.2.7.1.  
 
7. Sequencing: The miniprep containing the plasmid DNA was subsequently sequenced 
with HIV specific primers to verify the successful cloning of patient’s sample into 
pGEMP8.9. 
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8. SDM: The plasmid containing ligated PGEMP8.9 and patient’s Gag, PR or Gag-PR 
sequences could be employed as a template for SDM in case modified patient’s 
sequences or modified wild type HIV sequences were required. 
 
9. Transfer of Patient’s sample from PGEM8.9 to the HIV expression vector P8.9NSX: 
patient’s Gag, PR or Gag-PR sequences or modified sequences for these genes were 
transferred from PGEMP8.9 vector to the HIV expressing vector (P8.9NSX) by 
digestion of both plasmids with appropriate restriction endonuclease, ligated together 
using rapid Ligation Kit (Roche Diagnostics, US) and transformed into E. coli HB101 
cells as described above.  Upon sequencing of the HIV backbone of the P8.9NSX 
vector using HIV specific primers in order to confirm successful cloning of patient 
backbone into the P8.9NSX vector, the RTVs are ready to be employed in drug 
susceptibility and RC experiments.  
 
2.2.4.2 Generation of pseudotyped viruses 
Pseudotyped viruses were produced by transient transfection of HEK 293-T cells with three 
plasmids: RTV containing patient’ related Gag and/or protease sequences or wild type HIV; 
pCSFLW containing the HIV packaging sequencing and the luciferase encoding gene and 
PMDG expressing vesicular estomatitis G protein. Briefly, HEK 293-T cells were seeded so 
that 10 cm dishes were just sub-confluent on the day of transfection. 18 µl of FuGENE-6 
(Roche Diagnostics, US) was added to 200 µl of Opti-MEM medium (Invitrogene). 1.5 µg of 
pCSFLW, 1 µg of PMDG and 1 µg of P8.9NSX HIV Gag-pol expression vector were made 
up to 15 µl of TE buffer and added to the Fu-GENE-6 and Opti-MEM mixture. The 
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transfection mixture was incubated for 30 minutes at room temperature before being added 
dropwise to the sub-confluent HEK 293-T cells in 8 ml of fresh DMEM medium 
(Invitrogene) supplemented with 10% FCS (Biosera, UK), 100 U/ml penicillin and 100 µg/ml 
streptomycin (Invitrogene). HEK 293-T cells and transfection mixture were incubated 
overnight at 37°C and 5% CO2. The following day, the cell culture medium was replaced for 
fresh medium. The pseudovirus containing supernatants were either directly employed in 
drug susceptibility assays or harvested at 48 and 72 hours, filtered with a 0.45 µm filter to 
eliminate cell debris and stored at -80°C in 1ml aliquots for subsequent applications.   
 
2.2.4.3 Protease inhibitor susceptibility assay 
Pseudovirus stocks used for PI susceptibility testing were obtained by co-trasfecting HEK 
293 T cells with RTV, pCSFLW and PMDG plasmids as described above. The cells were 
tripsinized approximately 16 hours after transfection and distributed into 96-well plates 
containing serial dilutions spanning and empirical determined range for each PI (between 
1000 nm -0.005 nm). Pseudoviral stocks generated in the presence of PIs were harvested at 
around 48 hours after transfection and employed to infect fresh HEK 293 T cell cultures in 
96-well plates in the absence of drug. Replication was monitored by measuring luciferase 
expression in infected target cells at approximately 48 hours after infection. Luciferase 
expression was measured using Steady Glo and a Glomax Luminometer (both Promega). 
Data were analyzed by plotting the percent inhibition of luciferase activity versus. log10 drug 
concentration. The percent inhibition was derived as follows: [1-(luciferase activity in the 
presence of drug-background)/ (luciferase activity in the absence of drug-background)] x 100. 
Mean percent inhibition for each drug concentration was determined from independent 
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replicates and the deviation standard calculated.  Inhibition curves, defined by the four-
parametric sigmoidal function f(x) = a- [b/ (1+(x/c)
d
], were fit to the data by nonlinear least-
squares and used to calculate the drug concentration required to inhibit virus replication by 
50% (IC50). The fold change (FC) in drug susceptibility is determined by comparing the IC50 
for the tested virus to the IC50 of the WT reference virus (P8.9NSX) which contains the PR 
and RT sequences of the NL4-3 strain of HIV-1. All analysis was performed employing 
GraphPad PRISM version 5.  
 
2.2.4.4 Replicative capacity assay 
Pseudovirus stocks are prepared by co-transfecting HEK 293T cells with RTVs, pCSFLW 
and PMDG plasmids as described above. Cells and transfection mix are incubated for 48 
hours in DMEM medium supplemented with 10% FCS, 100 U/ml penicillin and 100 µg/ml 
streptomycin. The medium will be replaced with fresh medium every 24 hours. Pseudo-virus 
supernatant will be filtered with a 0.45 µm filter to eliminate cell debris and 100 µl will be 
employed to infect fresh HEK 293T cells in 96 well plates. Thus, pseudo-virus containing 
supernatant will be titrated along the HEK 293- cells-containing 96 well plates. Replication 
will be monitored by measuring luciferase expression 48 hours after infection. Luciferase 
activity was determined with steady Glo and a Glomax Luminometer (both Promega) and 
expressed relative to the wild type reference virus (P8.9NSX). The relative light luciferase 
units (RLU) were plotted against both µl of virus supernatant and the ng of P24 produced by 
virus supernatants and the mean luciferase activity calculated by using at least four values 
within the linear range. Replicative capacity (RC) of the tested virus would be directly related 
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to the luciferase activity displayed and would be expressed as a percent of the WT reference 
virus (P8.9NSX) to which a 100% RC value would be assigned.    
 
2.2.4.5 P24 ELISA 
In order to correct for potential transfection efficiency, the relative luciferase units produced 
by RTVs were expressed normalized by ng of P24 protein. P24 protein in pseudovirus 
supernatant was measured by employing a twin-site sandwich Enzyme-linked 
immunosorbent assay (ELISA). The ELISA was performed with reagents supplied by Aalto 
Bioreagents LTd. Briefly, 96 well plates were coating with Anti-HIV-1-p24 Gag by adding 
100 µl per well of affinity purified sheep anti-HIV-1-p24 Gag (D7320, Aalto bio Reagenst 
Ltd) reconstituted in water at 1 mg/ml. Plates were incubated overnight at room temperature. 
The following day the plate is washed twice with 200 µl of TBS buffer. P24 antigen is 
captured from the pseudo-virus containing supernatant which is previously inactivated by 
treated with Empigen zwitterionic detergent (Sigma Aldrich) at a final concentration of 1% 
per volume and incubated at 56ºC for 30 minutes. Serial dilutions of pseudo-virus 
supernatants are made in TBS/Empigen and 100 µl of the dilutions added to the Anti-HIV-
p24-Gag-coated well and incubated for 3 hours at room temperature. Unbound p24 was 
washed away with 2 x 200µl of TBS. Bound p24 was detected by using alkalin- phosphatase- 
conjugated anti-HIV-1-p24 mouse monoclonal antibody (BC 1071-AP, Aalto Bio Reagenst) 
and the AMPAK ELISA amplification system. The HIV-1 p24 assay was calibrated using 
known amounts of a purified recombinant p24 protein (AG6054, Aalto Bio Reagenst). The 
calibration curved was obtained by plotting the optical density (OD) at 492 nm against the 
known amount of recombinant p24 protein. Comparison of OD displayed by pseudo-viral 
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supernatants with that of calibrators allowed us to determine the amount of p24 in pseudo-
virus containing supernatants.         
 
Table 2.1 Primers employed for the amplification of HIV-1 Gag and protease genes 
 
Primer 
name
a
 
Sequence 5’-3’ Positionb Description 
GagFout GTT GTG TGA CTC TGG TAA CTA 
GAG ATC CCT CAGA 
570-603 Forward outer primer 
GagBout TCC TAA TTG AAC YTC CCA RAA 
GTC YTG AGT TC 
2797-2828 Reverse outer primer 
GagFin TCT CTA GCA GTG GCG CCC GAA 
CAG 
626-649 Forward inner primer 
 
GagBin 
 
GGC CAT TGT TTA ACC TTT GGD 
CCA TCC 
 
2597-2623 
 
Reverse inner primer 
GagFin2 AAA TCT CTA GCA GTG GCG CCC 
GAACAG 
623-649 Forward inner primer 
GagBin2 TGG MCC AAA RGT TAA ACA RTG 
GC 
2600-2622 Reverse inner primer 
a
GagFin and GagBin were employed as default inner primers in the nested PCR protocol. GagFin2 
and GagRin2 were used when the default primers failed.  
b
Primer position is relative to HXB2 (GenBank accession number K03455).   
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Table 2.2 Primers employed for the sequencing of HIV-1 Gag and protease genes 
Primer 
name 
Sequence 5’-3’ Positiona Direction 
G00* GACTAGCGGAGGCTAGAAG 764-782 Forward  
G50* CACAGCAAGCAGCAGCTG 1133-1150 Reverse  
G70* ATGAGGAAGCTGCAGAATGGG 1406-1426 Forward 
G01* AGGGGTCGTTGCCAAAGA 2281-2264 Reverse  
G05* TGTTGGCTCTGGTCTGCTCT 2157-2138 Reverse  
G35* CATGCTGTCATCATTTCTTCTA 1838-1817 Reverse  
G45* TTGGACCAACAAGGTTTCTGTC 1761-1740 Reverse  
Ana1 GGG CCA TCC ATT CCT GGC TT 2602-2586 Reverse  
Ana2 CAG AGC CAA CAG CCC CAC CAG 2147-2167 Forward  
Ana3 ATC KTT CYA GCT CCC TGC TTG 916-899 Reverse 
Ana4 GCC ATA TCR CCT AGA ACY TT 1228-1244 Forward  
Ana5 GGG ATT AAA YAA AAT AGT AAG 1593-1612 Forward  
Ana6 TAG AAG RAA TGA TGA MAG 1820-1834 Forward  
Ana7 ATA ATC CAC CTA TCC CAG 1547-1561 Forward  
Ana8 GAC ACC AAR GAA GCY TTA 1078-1092 Forward  
G85* TGC ACT ATA GGG TAA TTT TG 1193-1173 Reverse  
Ana9 GAT AGG GGG AAT TGG AGG TTT 
TAT CAA AGT 
2390-2419 Forward  
Ana10 ATG TTG ACA GGT GTA GGT CCT 
ACT AAT ACT GTC C 
2503-2470 Reverse  
Primers G00, G50, G70, G01, G35, G45 and G85 had been previously published (Sanders-Buel, 
1995). 
a
Primer position is relative to HXB2 (GenBank accession number K03455).   
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Table 2.3 Primers employed for Site-directed mutagenesis (SDM) 
Primer 
name 
Sequence 5’-3’ Description 
Y132F-F CAGGTCAGCCAAAATTTCCCTATAGTGCAGACC Forward primer for 
introduction of 
Y132F  
Y132F-R GTTCTGCACTATAGGGAAATTTTGGCTGACCTG Reverse primer for 
introduction of 
Y132F 
T375A-F CAAATCCAGCTGCCATAATGATACAGAAAGGC Forward primer for 
introduction of 
T375A 
T375A-R GCCTTTCTGTATCATTATGGCAGCTGGATTTG Reverse primer for 
introduction of 
T375A 
∆T375A-F CCAAGTAACAAATCCAGCTACCATAATGATACAGAAAGGC Forward primer for 
reversion of T375A 
∆T375A-R GCCTTTCTGTATCATTATGGTAGCTGGGTTTGTTACTTGG Reverse primer for 
reversion of T375A 
V82I-F CTTAGATCATTATATAATACAATAGCAACCCTCTATTGTGTG Forward primer for 
introduction of 
V82I 
V82I-R CACACAATAGAGGGTTGCTATTGTATTATATAATGATCTAAG Reverse primer for 
introduction of 
V82I 
A115I-F CAAAAGTAAGAAAAAAGTACAGCAAGCAGCAGCTGACAC Forward primer for 
introduction of 
A115I 
A115I-R GTGTCAGCTGCTGCTTGCTGTACTTTTTTCTTACTTTTG Reverse primer for 
introduction of 
A115I 
A120S-F CACAGCAAGCAGCAGTTGACACAGGACACAG Forward primer for 
introduction of 
A120S 
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A120S-R CTGTGTCCTGTGTCAACTGCTGCTTGCTGTG Reverse primer for 
introduction of 
A120S 
I437V-F GCTAATTTTTTAGGGAAGGTCTGGCCTTCCCACAAGGG Forward primer for 
introduction of 
I437V 
I437V-R CCCTTGTGGGAAGGCCAGACCTTCCCTAAAAAATTAGC Reverse primer for 
introduction of 
I437V 
Y441H-F GAAGATCTGGCCTTCCCACAAGGGAAGGCCAG Forward primer for 
introduction of 
Y441H 
 
Y441H-R CTGGCCTTCCCTTGTGGGAAGGCCAGATCTTC Reverse primer for 
introduction of 
Y441H 
G443E-F GATCTGGCCTTCCTACAAGGGGAGGCCAGGGAATTTTTTTCAG Forward primer for 
introduction of 
G443E 
G443E-R CTGAAAAAAATTCCCTGGCCTCCCCTTGTAGGAAGGCCAGATC Reverse  primer for 
introduction of 
G443E 
∆Y132F-F CAGGTCAGCCAAAATTACCCTATAGTGCAGAAC Forward primer for 
reversion of Y132F 
∆Y132F-R GTTCTGCACTATAGGGTAATTTTGGCTGACCTG Reverse primer for 
reversion of Y132F 
∆L449F-F GGCCAGGGAATTTTCTTCAGAGCAGCC Forward primer for 
reversion of L449F 
∆L449F-R GGTCTGCTCTGAAGAAAATTCCCTGGCC Reverse primer for 
reversion of L449F 
∆A431V-F CTGAGAGACAGGCTAATTTTTTAGGGAAGATCTG Forward primer for 
reversion of A431V 
∆A431V-R CAGATCTTCCCTAAAAAATTAGCCTGTCTGTCTCAG Reverse primer for 
reversion of A431V 
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Table 2.4 Primers employed for modification of P8.9NSX vector by SDM 
Primer 
name 
Sequence 5’-3’ Description 
BglII-F TCTCTTTGGCAGCGCTTCCCTCAGAT Forward primer for 
introduction of 
BglII restriction site 
BglII-R CGCTGCCAAAGAGAGGTCTGAGGGAAG Reverse primer for 
introduction of 
BglII restriction site 
BamHI-F CCAGGTATGGATCCCCCAAAAGTTAAACAATGGCC Forward primer for 
introduction of 
BamHI restriction 
site 
BamHI-R 
 
GGCCATTGTTTAACTTTTGGGGGATCCATACCTGG Reverse primer for 
introduction of 
BamHI restriction 
site 
∆BglII-F CTAATTTTTTAGGGAGACCTGGCCTTCCCGAAGG Forward primer for 
blocking BglII 
restriction site 
∆BglII-R CCTTGTGGGAAGGCCAGGTCTTCCCTAAAAAATTAG Reverse primer for 
blocking BglII 
restriction site 
∆BamHI-F CATTCGATTAGTGAACGGGTCCTTGGCACTTATCTG Forward primer for 
blocking BamHI 
restriction site 
∆BamHI-R CAGATAAGTGCCAAGGACCCGTTCACTAATCGAATG Reverse primer for 
blocking BamHI 
restriction site 
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Table 2.5 Primers employed for the introduction of appropriate restriction sites 
a
Primer position is relative to HXB2 (GenBank accession number K03455).   
The above primers are employed for nested amplification of patient’s samples in preparation for 
cloning into the P8.9NSX  HIV-1 expression vector. Cloning of Gag gene will require amplification 
with GagF-NotI and GagB-BglII, cloning of PR gene will require amplification with PRF-BglII and 
PRB-BamHI and cloning of both Gag and PR simultaneously will require amplification with GagF-
NotI and PRB-BamHI.  Restriction sites are shown in bold.  
 
 
 
 
Primer 
name 
Sequence 5’-3’ Positiona Description 
GagF-NotI  TCTCTAGCGGGCCGCGCAGTGGCGCCCGAACAG 626-649 Forward primer for 
introduction of 
NotI site at the 
beginning of Gag 
gene 
GagB-
BglII 
GGCCATAGATCTTGTTTAACYTTTGGDCCATCC 2597-2629 Reverse primer for 
introduction of 
BglII site at the 
end of Gag gene 
PRF-BglII CCCAGATCTCACCAGAAGAGAGCTTC 2159-2178 Forward primer for 
introduction of 
BglII at the 
beginning of PR 
gene.  
PRB-
BamHI 
 
GGGGGATCTCCATCCATTCCTGGCTT 2585-2604 Reverse primer for 
introduction of 
BamHI at the end 
of PR gene. 
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3 Chapter three: development and optimization of 
an assay for the amplification and sequencing of 
full-length HIV-1 Gag and protease genes 
3.1 Introduction 
Since the discovery of HIV as the causative agent of acquired immunodeficiency syndrome 
(AIDS), research efforts have led to the development and clinical use of several drugs aimed 
at inhibiting the viral replication cycle at particular critical stages. Six classes of antiretroviral 
drugs are currently approved that target the fusion between viral and cellular membranes, the 
reverse transcription of viral RNA into cDNA, the integration of viral DNA into the host 
genome and the maturation of  newly synthesized virions.  
 
In 1996-1998, the combination of three antiretroviral drugs, which is known as highly active 
antiretroviral therapy (HAART), revolutionized the care of patients infected with HIV 
leading to a dramatic decrease in mortality and morbidity. However, inadequate treatment 
(e.g., lack of complete adherence to therapy or insufficient potency of some regimens) may 
produce incomplete viral suppression, which often results in the appearance of viral 
resistance and as a consequence in therapy failure.  
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The clinical relevance of HIV drug resistance is well established. The emergence of 
resistance to first-line HAART might not only facilitate failure to subsequent line of therapy 
due to cross resistance, but is also associated with an increased risk of death, particularly if all 
three major classes of drugs (nucleoside or nucleotide reverse transcriptase inhibitors 
(NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors 
(PIs)) are involved (Hogg et al, 2006; Zaccarelli et al, 2005). In most cases, resistance arises 
from genetic mutations affecting the viral protein targeted by the antiretroviral drug. As a 
consequence, detection of resistance in clinical practice is usually achieved by sequencing the 
targeted gene, commonly reverse transcriptase (RT) or protease (PR), followed by the 
identification of resistance-associated mutations (RAMs).  
 
The classic mechanism of resistance to PIs features the stepwise accumulation of 
substitutions in the viral protease (Croteau et al, 1997; Johnson et al, 2008b and Nijhuis et al, 
1999). The first amino acids changes observed during PI exposure often involve the 
substrate-binding cleft of the viral enzyme. The mutations that encode these amino acid 
changes, termed primary mutations, are responsible for the resistance of the virus to PIs. 
However, these mutations also have a deleterious effect in the replication capacity of the 
virus as they code for a protease that displays a reduced cleaving activity. Long-term 
exposure to a non-suppressive PI-containing regimen may lead to the selection of 
compensatory mutations, whose principal role is to re-establish the original replication 
capacity of the wild type (WT) virus. Several compensatory mutations have been described, 
mainly within the protease itself (Eastman et al, 1998; Ho et al, 1994; Mammano et al, 2000; 
Molla et al, 1996; Nijhuis et al, 2001 and Quinones-Mateu and Arts, 2001;), but also in its 
natural substrate, the Gag gene (Clavel et al, 2000; Doyon et al, 1996; Miller et al, 2001; 
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Nijhuis et al, 2001 and Zhang et al, 1997). Most reports have identified the Gag C-terminal 
cleavage sites (CS) P7/P1 and P1/P6 as major mutation hot spots (Doyon et al, 1996; Malet et 
al, 2007; Nijhuis et al, 2007; Verheyen et al, 2006 and Zhang et al 1997). However, this 
observation may be biased as most studies have only targeted these cleavage sites. In fact, 
there have been anecdotal reports that describe mutations at other CS or even outside the CS 
areas in association with exposure to PIs (Gatanaga et al, 2002), which imply that such 
regions may also have a role in the development of PI resistance. Moreover, some groups 
have suggested that mutations in Gag outside CSs could be responsible for primary resistance 
to PIs (Gupta et al, 2010; Nijhuis et al, 2007 and Parry et al 2009). Taken together, these 
observations suggest that resistance to the PIs may be underestimated in routine clinical 
practice since only primary mutations in the protease are searched for. 
 
The objective of the study presented in this chapter was to develop an assay for the co-
amplification and sequencing of full-length HIV-1 Gag and protease genes in order to 
evaluate the contribution of Gag mutations to drug susceptibility and viral fitness, and 
investigate linkage between Gag and protease mutations in patients failing PI-based therapy. 
More specifically, this encompassed: 1) the design and selection of PCR and sequencing 
primers; 2) the optimization of the PCR reaction for full-length HIV-1 Gag and protease 
genes and 3) sequencing optimization for full-length HIV-1 Gag and protease genes.   
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3.2 Methods 
3.2.1 Samples 
Plasma samples derived from HIV-1 infected patients attending the HIV services at the Royal 
Free Hospital were used for this study. The HIV-1 subtype was determined by submitting 
polymerase (pol) sequences to the NCBI HIV-1 genotyping tool. The plasma HIV-1 RNA 
load (“viral load”) was measured with the RealTime HIV-1 assay (Abbott Molecular, USA).  
A selection of samples representing a wide range of HIV-1 subtypes and circulating 
recombinant forms (CRFs) was employed for the study.  
 
3.2.2 Primers 
A total of 1,400 HIV-1 sequences from all available group M subtypes and CRFs were 
downloaded from the Los Alamos National Laboratory Database (www.hiv.lanl.gov) and 
aligned using Mega Molecular Evolutionary Genetic Analysis software version 4.0. 
Sequences that were relatively well conserved across different subtypes and close to the Gag 
and protease region of interest (Gag-Pr) were selected for primer design. PCR and sequencing 
primers were constructed employing Oligo software V7.0 and synthesized by Invitrogene 
(Invitrogene, UK).  
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3.2.3 RNA extraction 
One milliliter of plasma was centrifuged at 25,000 g for one hour at 4°C to concentrate the 
virus. The supernatant was then removed and the pellet re-suspended to a final volume of 280 
µl. The re-suspended pellet was used for nucleic acid extraction; two extraction methods 
were employed according to the manufacturer’s instructions, the manual QIAamp Viral RNA 
MiniKit (Qiagen, Germany) and the semi-automated EasyMag (Nuclisens, France). 
Finally, the RNA was eluted into 55µl of buffer and stored at -80°C. The performance of the 
assay with both extraction methodologies was compared.  
 
3.2.4 Amplification of Gag-protease region 
A reverse-transcription-nested (rt-nested) PCR protocol was designed for the amplification of 
the HIV-1 Gag-Pr region. The procedure was divided in two stages:  
 
Stage 1 encompassed two sequential reactions, an initial reverse transcription of the viral 
RNA into cDNA followed by a PCR reaction leading to the generation of a 2.2Kb DNA 
fragment; the Qiagen one-step RT-PCR kit (Qiagen, Germany) used for this purpose contains 
Omniscript® / Sensiscript® reverse transcritptase and HotStar® Taq DNA polymerase.  
 
Stage 2 comprised a PCR reaction on the 2.2 Kb DNA fragment which led to the production 
of a 2.0 Kb DNA fragment. This stage was carried out using the HotStar® Taq DNA 
polymerase kit (Qiagen, Germany).  
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All experiments were initially performed following the manufacturer’s instructions. 
However, subsequent modifications to different parameters affecting the development of 
reverse transcription and nested PCR reactions, such as annealing temperature, concentration 
of Magnesium [Mg
2+
], concentration of desoxiribonucleotides [dNTPs],  concentration of 
primers [primers], type of reverse transcriptase (AccuScript reverse transcriptase (Stratagene, 
Netherlands), SuperScript® III reverse transcriptase (Invitrogene, UK) and type of DNA 
polymerase (Pfu Ultra DNA polymerase (Stratagene, Netherlands), Platinum®TaqDNA 
Polymerase HF(Invitrogene, UK) were tested in order to optimize the yield. 
 
The optimized reverse transcriptase-nested PCR protocol was validated with a variety of 
HIV-1 group M and CRFs.  
 
3.2.5 Sequencing of the Gag-protease region 
PCR products were purified using Microcon YM-100 centrifugal filters units (Millipore, UK) 
according to the manufacturer’s instructions. Population sequencing was performed using the 
ABI PRISM BigDye Terminator v3.1 ready reaction cycle sequencing kit and reactions were 
run on an ABI3100 Genetic analyzer. 
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3.2.6 Cloning of PCR products  
Clonal analysis was performed on samples were population sequencing was not conclusive. 
For this purpose, the 2.0 Kb PCR product encompassing the sequence of the HIV-1 Gag-Pr 
region was cloned into a plasmid vector (PCR2.1) using the TOPO TA Cloning Kit 
(Invitrogene, UK). Positive clones, identified as those harbouring inserts of the correct size 
after restriction enzyme digestion, were isolated and sequenced as previously described. 
 
3.2.7 Sequence analysis 
Sequences were analyzed using Sequence analysis version 5.0, Seqscape version 6.0 and 
Mega Molecular Evolutionary Genetic Analysis software version 4.0 programmes. 
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3.3 Results 
3.3.1 Primers 
Multiple sets of potential primers for amplification and sequencing were obtained by OLIGO 
software and their characteristics were examined in order to choose the most suitable pairs. 
Selection criteria included:   
 GC content >50%. 
 No obvious tendency to form secondary structures.  
 No complementary regions between primers of the set.   
 Lack of homology with other sequences on either strand of the HIV-1 genome. 
 Difference in melting temperature between forward and reverse primers < 5°C.  
  
The region targeted by forward amplification primers was located within the 5’LTR region, 
which is present upstream of the Gag gene. As this sequence was relatively conserved across 
different HIV-1 strains only a single set of primers was designed for each of the reactions 
comprising the nested PCR. By contrast, no conserved region located downstream of Gag and 
protease genes was identified, so reverse amplification primers, consisted of a mixture of 
several primers whose sequences differ at certain positions (i.e., degenerated primers), were 
constructed. 
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We selected the following sets of primers for the amplification of HIV-1 Gag-Pr by nested 
PCR: 
 A sole set of outer primers derived from an alignment of all group M HIV-1 subtypes 
and CRFs.  
 Two sets of inner primers: a main set that was chosen based on an alignment 
constructed with the most prevalent subtypes found in the Royal Free Hospital 
population (i.e., subtypes B, C, A, D and CRF02) and an accessory set that was 
obtained from an alignment of all other group M HIV-1 subtypes and CRFs and was 
employed when the main set of primers did not render a PCR product.  
 
Similarly, we designed several primers for sequencing purposes. A total of 18 primers were 
employed in different combinations, usually 8 to 10, in order to obtain a full-length Gag-Pr 
sequence. The location of the primers and the amplicon length for each set of amplification 
primers are indicated in Figure 3.1. Primer sequences for amplification and sequencing are 
given in chapter 2, tables 2.1 and 2.2, respectively.  
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Figure 3.1 Location of amplification primers in HIV-1. 
 The length of the amplicons for different sets of primers is indicated.   
 
3.3.2 Reverse transcription and amplification of Gag-protease 
region 
The Qiagen one-step RT-PCR kit was used for reverse transcription of viral RNA and first 
PCR run. The kit consisted of a single enzyme mix, which contained Omniscript® and 
Sensiscript® reverse transcriptase and HotStar® Taq DNA polymerase.  
 
The initial experiment was conducted under the conditions recommended by the 
manufacturer: 1X buffer containing 2.5 mM of Mg
2+
, 400 µM of each dNTP, 0.6 µM of both 
forward and reverse primers and 2.5 units of RT-PCR enzyme mix. Reverse transcription 
occurred for 30 minutes at 50°C. By heating at 95°C for 15 minutes, the reverse transcriptase 
was inactivated and simultaneously the DNA polymerase was activated. Subsequent PCR 
cycling conditions included a denaturation step of 2 minutes at 95°C; 40 cycles of 15 seconds 
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at 95°C; 30 seconds at the annealing temperature calculated by OLIGO software for the set of 
primers (56°C) and 2 minutes and 30 seconds extension at 68°C and followed by a final 
extension step of 10 minutes at 68°C.   
 
The experiment included HIV-1 positive (subtype B) and negative controls. The positive 
control was diluted at different concentrations prior to extraction.  
 
The results of these preliminary experiments are shown in figure 3.2. Successful 
amplification was demonstrated by visualization of a 2.2 Kb PCR product on an agarose gel 
electrophoresis. A patent band of the expected size was present when viral loads were 
between 3,000 and 100,000 copies/ml. A very faint band could be appreciated at viral loads 
around 1,000 copies/ml. No amplification was detected when the viral load was 500 
copies/ml.  However, strong non-specific amplification was evident on the agarose gel at all 
tested viral loads.  
 
As amplification of the target was achieved, the primer pair employed was considered 
appropriate. However, it was deemed that the sensitivity and specificity of the method should 
undergo further optimization. Parameters considered for optimization included PCR cycling 
conditions, particularly annealing temperature as well as Mg
2+,
 dNTPs and primer 
concentrations.  
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Figure 3.2 Agarose gel electrophoresis following RT and amplification of HIV-1 Gag-pr region. 
The band numbers from 1 to 10 on the gel correspond to different viral load of the dilutions tested : 
1(negative control); 2 (100,000 cp/ml); 3 (50,000 cp/ml); 4 (25,000 cp/ml); 5 (12,500 cp/ml); 6 
(10,000 cp/ml); 7 (5,000 cp/ml); 8 (3,000 cp/ml);9 (1,000 cp/ml); 10 (500 cp/ml) and M correspond to 
low DNA Mass ladder (Invitrogene, UK). 
 
3.3.2.1 Optimization of annealing temperature 
Optimization of the annealing temperature started by calculating the melting temperature 
(Tm) for the primer-template pairs with the OLIGO software v7.0. As recommended for most 
PCR applications, the annealing temperature (Ta) was preliminarily set 5°C below the 
calculated Tm, which was 57°C. The optimal Ta was finally determined by performing 
temperature gradient PCR studies within the range 52-62°C, employing Qiagen one Step RT-
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PCR system. This was achieved by programming a 10°C gradient and setting the Ta to 57°C. 
Other PCR parameters such as [Mg
2+
]
,
 [dNTPs], primers and target concentrations remained 
constant. Results are presented in Figure 3.3.  
 
The amplification of the desired target (2.2 Kb product) was successful when the annealing 
temperature was between 55°C and 60°C, but strong non-specific reactivity was detected on the 
agarose gel. Below 55°C only non-specific amplification was observed. At annealing 
temperatures above 60°C there was no evidence of amplification on the agarose gel. The 
strongest amplification of the target was observed at 57 °C; therefore, this annealing temperature 
was maintained constant on subsequent experiments, while other parameters were modified for 
further optimization.   
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Figure 3.3 Agarose gel electrophoresis of the temperature gradient PCR experiments.  
A subtype B HIV-1 positive control of 20,000 copies/ml was extracted manually with 
QiaAmp Viral RNA extraction kit and subjected to a temperature gradient PCR with Qiagen 
one step RT-PCR. Band M correspond to Low DNA Mass ladder (Invitrogene, UK) and the 
different annealing temperatures tested are shown.   
 
3.3.2.2 Optimization of magnesium concentration 
The optimal [Mg
2+
] was determined empirically by setting a series of experiments between 
0.5 and 5.0 mM of Mg
2+
. Results are shown in figure 3.4. As demonstrated in the agarose gel 
electrophoresis, a minimum [Mg
2+
] of 2.5 mM was required in order to achieve amplification 
of the target. Above this concentration, a faint band of the expected size was visualized on the 
gel and specificity and sensitivity of the PCR protocol did not significantly change within the 
range 2.5- 5 mM [Mg
2+
]. Because an increase in the [Mg
2+
] may have a detrimental effect on 
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the fidelity of the Taq DNA polymerase and because no difference in sensitivity and 
specificity of the PCR reaction was detected above 2.5mM of the cation, we considered this 
concentration appropriate for further experiments and no adjustment of [Mg
2+
] and [dNTPs] 
with respect to those recommended by the manufacturer were judged necessary.    
 
 
 
Figure 3.4 Agarose gel electrophoresis of [Mg
2+
] titration experiments.   
Optimization was carried out with a subtype B HIV-1 positive control of 20,000 copies/ml and 
Qiagen one step RT-PCR system. 400 µM of each dNTPs was included in all reactions. Band number 
from 1 to 10 correspond to 10 different PCR reactions with Mg
2+
 concentrations of (1) 0.5 mM; (2)1.0 
mM; (3) 1.5 mM; (4) 2.0 mM; (5) 2.5 mM; (6) 3.0 mM; (7) 3.5 mM; (8) 4.0 mM; (9) 4.5 mM and 
(10) 5.0mM, respectively. Band M correspond to low DNA Mass ladder (Invitrogene, UK).    
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3.3.2.3 Optimization of primer concentrations 
Most PCR applications give suitable results with primer concentrations within 0.1-1.0 µM.  
The use of the lowest concentrations of primers favours specific amplification and generally 
requires at least 30 cycles of amplification for a 1Kb segment. Longer templates, however, 
necessitate higher primer concentrations, which can result in mispriming and ultimately non-
specific amplification. The Qiagen system recommends employing specific primers at a 0.6 
µM concentration. Primer titration experiments were carried out in order to assess the optimal 
primer concentration. According to the agarose gel electrophoresis presented in figure 3.5, a 
0.4 µM concentration of primers seems to be sufficient for amplification. At lower 
concentrations, no PCR product was detectable on the gel. By contrast, increasing primer 
concentrations led to substantial non-specific reactivity. Because keeping primer 
concentrations low is likely to have a positive effect on PCR specificity as well as fidelity, we 
decided to select the lowest concentration of primers at which amplification of the target was 
visible on agarose gel electrophoresis;(0.4 µM); this concentration was used in subsequent 
experiments.       
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Figure 3.5 Agarose gel electrophoresis of primer titration experiments.  
Amplification was performed after manual extraction with QiaAmp Viral RNA extraction Kit 
(Qiagen) of a HIV-1 subtype B positive control, employing Qiagen one step RT-PCR system. Primer 
concentrations between 0.1 µM and 1mM were tested and the band numbers from 1 to 10 on the gel 
correspond to the different primer concentrations: 1 (0.1µM); 2 (0.2µM); 3 (0.3µM); 4 (0.4µM); 5 
(0.5µM); 6 (0.6µM); 7 (0.7µM); 8 (0.8µM); 9 (0.9µM) and 10 (1mM) and band M corresponds to low 
DNA Mass ladder (Invitrogene, UK).  
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3.3.2.4 Touchdown and nested PCRs 
Previous experiments demonstrated that using the Qiagen one-step RT-PCR with the selected 
set of primers successfully generated a 2.2 Kb product comprising HIV-1 gag and protease 
genes. However, there were two main drawbacks to the procedure: 
 Weak detection of target band on agarose gel electrophoresis, even after optimization 
of the RT-PCR conditions. 
  Variable amount of non-specific reactivity.    
Two strategies were envisaged to correct these defects: 
 
1) Touchdown PCR 
Touchdown PCR may be used to reduce non-specific amplification. A high annealing 
temperature is maintained during the initial PCR cycles favouring specific priming, but is 
decreased as the reaction progresses in order to facilitate amplification. This ensures initial 
selective generation of the target amplicon, so that it will be in a favorable position to 
outcompete any lagging PCR product during the remaining cycles. To this end, the first 3 
PCR cycles were set at an annealing temperature of 60°C, which was the maximum annealing 
temperature at which we observed amplification in the temperature gradient PCR 
experiments, whereas the remaining 37 PCR cycles were maintained at the previously 
determined optimal Ta of 57°C.  
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2) Nested PCR 
Nested PCR may be used to increase both specificity and sensitivity. Nested PCR is expected 
to reduce contamination in the PCR product resulting from amplification of unexpected 
primer binding sites. It is highly unlikely that any unwanted PCR products contain binding 
sites for both set of primers, ensuring that the product from this second PCR run has little 
contamination from unwanted PCR products of primer dimers, hairpirins and alternative 
primer targeted sequences. In addition, by conducting a second run of amplification, the 
sensitivity of the target amplification is also expected to increase. Therefore, a volume of two 
µl of the first PCR run product was subjected to an additional PCR run with the designed 
inner set of primers.  Hotstar Taq DNA polymerase (Qiagen, Germany) was employed and 
we maintained the [Mg
2+
]
, 
[dNTPs] and primer concentrations determined for the first PCR 
run. The optimal annealing temperature for the inner PCR primers was calculated by 
oligosoftware and confirmed by setting temperature gradient experiments as previously 
described. Final cycling conditions consisted of a denaturation step of 2 minutes at 95°C; 3 
cycles of 15 seconds at 95 °C, 30 seconds at 60°C and 2 minutes and 30 seconds at 68°C 
followed by 27 cycles of 15 seconds at 95°C, 30 seconds at the primer annealing temperature 
(55°C) and 2 minutes and 30 seconds at 68 °C and a final extension step of 10 minutes at 
68°C.   
 
Results can be seen in Figure 3.6. Touchdown and nested PCRs significantly reduced non-
specific amplification and increased the sensitivity of the amplification reaction as 
demonstrated by the presence of distinct bands of the expected size (2.0 Kb) for all viral load 
levels tested (500-100,000  copies/ml). 
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Figure 3.6 Agarose gel electrophoresis of nested and touchdown PCR.  
Amplification was performed after manual extraction with QiaAmp Viral RNA extraction Kit 
(Qiagen) of a HIV-1 subtype B positive control. The RNA extract was subjected to reverse 
transcription and 1
st
 run PCR and 2 µl of the 1
st
 run PCR product was subjected to a second PCR. The 
eight bands presented on the gel correspond to the Mass ladder (M) and positive control at 
concentrations 100,000 cp/ml (1); 50,000 cp/ml (2); 25,000 (3); 10,000 cp/ml (4); 3,000 cp/ml (5); 
1,000 cp/ml (6) and 500 cp/ml (7), respectively.  
 
3.3.3 Evaluation of the RT-nested PCR protocol  
RT-nested PCR conditions were as depicted in detail in section 2.2.2.2.1 of chapter 2 and 
briefly summarized below:  
 
 Concentration of reagents, primers and enzyme for RT-PCR:  1 X Qiagen RT-PCR 
buffer, 400 µM dNTPs, 0.4 µM forward and reverse primers (GagFout, GagBout), 
10µL of RNA extract and 2.5 Units of Qiagen RT/PCR enzyme mix.  
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 RT-PCR conditions: temperature and time:   
o Reverse transcription of viral RNA into cDNA: 30 minutes at 50°C. 
o Inactivation of reverse transcriptase and activation of DNA polymerase: 15 
minutes at 95°C 
o 1st PCR run:  2 minutes at 95°C; 3x { 15 seconds at 95°C, 30 seconds at 60°C 
and 2:30 minutes at 68°C}; 37x {15 seconds at 95°C, 30 seconds at 57°C, 2:30 
minutes at 68°C} and 10 minutes at 68°C. 
 
 Concentration of reagents, primers and enzyme for 2nd  PCR run : 2µ of 1st run PCR 
product, 1X Qiagen PCR buffer, 400 µM dNTPs, 0.4 µM forward and reverse primers 
(GagFin, GagBin) and 2 units of Qiagen Hotstar Taq polymerase. 
 2nd PCR run conditions:  2 minutes at 95°C; 3x {15 seconds at 95°C, 30 seconds at 
60°C, 2:30 minutes at 68°C}; 27x {15 seconds at 95°C, 30 seconds at 55°C, 2:30 
minutes at 68°C} and 10 minutes at 68°C. 
 
The optimized RT-nested PCR protocol was tested against a panel of different HIV-1 group 
M subtypes and CRFs. The limit of detection for each subtype was determined by performing 
serial dilutions. The results of the evaluation are summarized in table 3.1. Amplification of 
HIV-1 Gag and protease genes was achieved in 21/28 (75%) samples. The majority of these 
samples (16/21, 76%) were amplifiable at viral load levels ≤ 1,000 copies/ml. However, 5 
samples (1 HIV-1 subtype G; 2 CRF02; 1 CRF14 and 1 CRF06) required viral loads > 1,000 
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copies/ml in order to attain amplification. Samples that failed to amplify included 3 HIV-1 
subtype G; 1 subtype J; 2 Complex mosaic HIV-1 sequences and 1 CRF13.  
 
Amplification using an accessory set of inner primers (GagFin2 and GagBin2) was attempted 
in samples that did not amplify at all, or that did not amplify at viral loads below 1,000 
copies/ml. All of the samples amplified (Figure 3.7) and serial dilutions of these samples 
demonstrated amplification at viral loads below 1,000 copies/ml for all them (Table 3.2).  
Sample Subtype Viral load 
(copies/mL) 
Last dilution positive by 
PCR  
(viral load copies/mL) 
First dilution negative  
by PCR  
(viral load copies/mL) 
B-1 B 123,237 1:200 (600) 1:400 (300) 
B-2 B 200,237 1:400 (500) 1:800 (250) 
B-3 B 1,075 1:2 (500) 1:4 (250) 
C -1 C 130,307 1:200 (650) 1: 400 (300) 
C-2 C 61,595 1:800 (750) 1:1600 (350) 
C-3 C 16,000 1:200 (800) 1:400 (400) 
D-1 D 46,168 1:200 (500) 1:400 (250) 
D-2 D 10,015 1:20 (500) 1:40 (250) 
D-3 D 867 1:1 (867) 1:2 (435) 
A-1 A 9,000 1:16 (600) 1:32 (300) 
A-2 A 26,579 1:40 (750) 1:80 (350) 
A-3 A 138,783 1: 200 (700) 1:400 (350) 
G-1 G 1,236 PCR FAILED  
G-2 G 714,852 1:100 (7000) 1:200 (3500) 
G-3 G 7,550 PCR FAILED  
G-4 G 604,206 PCR FAILED  
F-1 F 24,737 1:100 (300) 1:200 (150) 
J-1 J 218,794 PCR FAILED  
CRF02-1 CRF02 11,346 1:1 (10,000) 1:2 (5,000) 
CRF02-2 CRF02 16,500 1:20 (800) 1:40 (400) 
CRF02-3 CRF02 76,000 1:2 (35,000) 1:4 (19,000) 
CRF01-1 CRF01 6,831 1:8 (850) 1:16 (425) 
Cpx-1 Complex 22,000 1:20 (1,000) 1:40 (500) 
Cpx-2 Complex 14,523 PCR FAILED  
Cpx-3 Complex 9,354 PCR FAILED  
CRF13-1 CRF13 824 PCR FAILED  
CRF14-1 CRF14 102,675 1:20 (5,000) 1:40 (2,500) 
CRF06-1 CRF06 93,980 1:40 (2,000) 1:80 (1,000) 
Table 3.1 Evaluation of the RT-nested PCR protocol (1).  
The subtype and viral loads of 28 HIV-1 plasma samples employed in the evaluation are shown. Samples were manually 
extracted using QiaAmp Viral RNA extraction Kit (Qiagen). Undiluted samples were initially amplified with the optimized 
RT-nested PCR protocol. Positive samples were subsequently diluted before extraction and amplification to estimate the 
limit of detection of the assay. 
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Figure 3.7 Agarose gel electrophoresis of RT-nested PCR.  
Amplification of 12 plasma samples that failed to amplify with the initial set of selected primers was 
performed with the optimized RT-nested PCR protocol employing an accessory set of inner primers 
(GagFin2, GagBin2). Bands number from 1 to 12 represent different genotypes and viral loads: (1) G, 
1,236 cp/ml;  (2) G, 7,550 cp/ml; (3) G, 604,206 cp/ml; (4) J, 218,794 cp/ml; (5) Cpx, 14,523 cp/ml; 
(6) Cpx, 9,354 cp/ml; (7)CRF13, 824 cp/ml; (8) G, 1,236 cp/ml; (9) CRF02, 1,546 cp/ml; (10) 
CRF02, 76,000 cp/ml; (11) CRF14, 102,675 cp/ml; (12) CRF06, 93,980 cp/ml and band M refers to 
the low DNA mass ladder (Invitrogene).  
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Sample Subtype Viral load 
(copies/mL) 
Last dilution positive 
by PCR  
(viral load copies/mL) 
First dilution negative  
by PCR  
(viral load copies/mL) 
G-1 G 1,236 1:2 (618) 1:4 (309) 
G-2 G 714,852 1:800 (875) 1:1600 (440) 
G-3 G 7,550 1:10 (750) 1:20 (375) 
G-4 G 604,206 1: 800 (750) 1:1600 (375) 
J-1 J 218,794 1:200 (1,090) 1:400 (545) 
CRF02-1 CRF02 11,346 1:10 (1,134)     1;20 (567) 
CRF02-3 CRF02 76,000 1:100 (760) 1:200 (380) 
Cpx-2 Complex 14,523 1:20 (726) 1:40 (363) 
Cpx-3 Complex 9,354 1:10 (935) 1:20 (467) 
CRF13-1 CRF13 824 1:1 (824) 1:2 (412) 
CRF14-1 CRF14 102,675 1:100 (1,026) 1:200 (513) 
CRF06-1 CRF06 93,980 1:100 (940) 1:200 (470) 
Table 3.2 Evaluation of RT-nested PCR protocol (2).  
The subtypes and viral loads of the 12 samples amplified with a second set of inner PCR primers 
(GagFin2, GagBin2) are shown. Samples were manually extracted with QiaAmp viral RNA extraction 
kit. Undiluted samples were initially amplified and positive samples were subsequently diluted before 
extraction and amplification to estimate the limit of detection.    
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3.3.4 Evaluation of the amplification protocol with proofreading 
enzymes 
Both the reverse transcriptase and Taq DNA polymerase employed for amplification of HIV-
1 Gag and protease genes lack proofreading activity (3’-5’exonuclease activity) and as a 
consequence they may not be appropriate for applications where fidelity is paramount. We 
evaluated the performance of the amplification method with alternative polymerase enzymes. 
After extensive literature review, we selected AccuScript™ High Fidelity (HF) RT-PCR plus 
PfuUltra HF DNA Polymerase (Stratagene) and SuperScript III one-step RT-PCR plus 
Platinum®TaqDNA Polymerase HF (Invitrogene). The Stratagene kit separates reverse 
transcription and PCR reactions in two different steps: it employs proofreading enzymes for 
both reverse transcription (AccuScript) and PCR (pfuUltra DNA polymerase).  RNA was 
reverse transcribed into cDNA using the following conditions: 1X AccuScript RT buffer; 10 
mM DTT; 1mM dNTPs, 20 Units of RNAse inhibitors and 2 µM of outer reverse primer. 
Primers and template are incubated at 65°C for 1 hour time after which the reaction is cooled 
to room temperature, 2 Units of AccuScript RT enzyme are then added and reverse 
transcription occurs at 42°C for 1 hour. The resulting cDNA is then subjected to nested PCR 
using the same cycling conditions as for Qiagen. The optimal [Mg
2+
], [dNTPs] and primer 
concentrations were determined by running titration experiments as previously described.  
 
The final conditions were : 1
st
 run PCR mix including: 1x Pfu Ultra HF buffer containing 
2mM of Mg
2+
; 200 µM dNTPs; 0.4 µM of forward and reverse primers and 2.5 units of Pfu 
Ultra DNA polymerase. 2 µl of the 1
st
 run PCR was subjected to a second PCR with 1X Pfu 
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Ultra HF buffer; 200 µM dNTPs; 0.4 µM of forward and reverse primers, additional Mg
2+ 
was required up to 4mM in the final mix and 2.5 Units of Pfu Ultra DNA polymerase.   
 
The Invitrogene kit performs reverse transcriptase and PCR in a single step but in contrast to 
Qiagen, it employs a mix of a proofreading reverse transcriptase (Pfu) and non-proofreading 
DNA polymerase (Taq). Cycling conditions for rt-nested PCR were those previously established 
with Qiagen. As before, optimal [Mg2+], [dNTPs] and primers for Invitrogene system were 
determined by performing titration experiments. The final conditions for amplification of Gag 
and protease with Invitrogene were: RT-PCR mix included 1X Invitrogene buffer containing 1.2 
mM Mg2+ and 200 µM dNTPs; 0.4 µM of forward and reverse primer and 2 unit of RT-PCR 
enzyme mix. 2µl of the resulting PCR product was subjected to nested PCR with Platinum Taq 
DNA polymerase (Invitrogene, UK). Nested PCR mix contained 1x PCR buffer, 1.5 mM of 
Mg2+, 200µM of dNTPs, 0.4µM of forward and reverse primers and 2.5 unit of Platinum Taq HF 
DNA polymerase.  
 
For a more detailed explanation about reverse transcription and nested PCR protocols (Qiagen, 
Stratagene and Invitrogene), please refer to section 2.2.2.2 in chapter 2. 
Ten plasma samples from patients infected with HIV-1 subtypes B (n=2), C (n=2), D (n=2), A 
(n=2), CRF02 (n=2) were diluted to achieve a final viral load concentration of 10,000 copies/ml 
and amplified according to the conditions specified in the three protocols (Qiagen, Invitrogene 
and Stratagen).  
 
- 121 - 
 
The agarose gel electrophoresis of the 10 plasma samples amplified with the three systems is 
presented in figure 3.8. The Qiagen and Invitrogene protocols amplified 10/10 (100%) samples, 
although bands were in general fainter when the Invitrogene kit was employed. By contrast 4/10 
(40%) samples failed to amplify when the Stratagene kit was utilized. 
 
Figure 3.8 Agarose gel electrophoresis of nested PCR with Qiagen, Stratagene and Invitrogene 
kits.  
Ten plasma samples (subtype B, n=2; C, n=2; D, n=2; A, n=2, CRF02, n=2) were tested with the three 
protocols, which differed in the reverse transcriptase and polymerase enzymes employed. Samples 
were diluted to a HIV-1 RNA load of 10,000 copies/ml and manually extracted with QiaAmp Viral 
RNA extraction Kit (Qiagen) before amplification. Band M correspond to low DNA mass ladder 
(Invitrogene) and bands from 1-10 represents subtypes B (1, 2); C (3, 4); D (5, 6); A (7, 8) and CRF02 
(9, 10), respectively. 
 
3.3.5 Manual vs. automated extraction 
Plasma samples of subtypes A, B, C and CRF02 were diluted to achieve a viral load of 3,000, 
1,000 and 500 copies/ml prior to extraction. Extraction was carried out using either a manual 
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(QiaAmp viral RNA extraction Kit (Qiagen,) or a semi-automated (Nuclisens EasyMag 
(France)) method. As shown in the agarose gel electrophoresis presented on figure 3.9, all 
samples extracted with QiaAmp viral RNA MiniKit amplified successfully. However, by 
using semi-automated extraction most samples with viral load of 1,000 and 500 copies/ml 
failed to amplify by PCR. The manual extraction method incorporates carrier-RNA that 
facilitates efficient RNA extraction. In addition, in the manual extraction, samples are 
previously concentrated by centrifugation at 25,000g at 4°C. Including the centrifugation step 
before semi-automated extraction may also increase the sensitivity of amplification as 
demonstrated by visualization of a band on agarose gel electrophoresis at a viral load of 1,000 
copies/ml in all  samples  and in 2/4 (50%) of samples with 500 copies/ml.  
 
 
Figure 3.9 Agarose gel electrophoresis of nested PCR after manual, automated or modified 
automated extraction.  
Four samples (subtype A, B, C, CRF02,) were diluted to a viral load of 3,000 1,000 and 500 copies/ml 
before being extracted manually (QiaAmp Viral RNA extraction kit, Qiagen) or with a semi-
automated extractor (EasyMag, Nuclisens). EasyMag* included a high speed centrifugation for 1 hour 
at 4 °C prior to extraction. Band M corresponds to low DNA mass ladder (Invitrogene) and bands 
from 1 to 3 represents samples with viral load levels of 3,000 copies/ml; 1,000 copies/ml and 500 
copies/ml, respectively.  
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3.3.6 Sequencing results 
Twenty-eight plasma samples belonging to different group M subtypes and CRFs (B, n=3; C, 
n=3; A, n=3; D, n=3; G, n=4; F, n=1; J, n=1; CRF02, n=3; CRF01, n=1; Cpx, n=3; CRF13, 
n=1; CRF14, n=1 and CRF06, n=1) were amplified by nested PCR using the Qiagen rt-nested 
PCR protocol and subsequently sequenced. In addition, 5 samples (subtypes B, n=2; C, n=2 
and D, n=1) were amplified in parallel with Stratagene and Invitrogene kits prior to 
sequencing in order to assess to what extent the use of a non-proofreading enzyme (Qiagen), 
a proofreading enzyme (Stratagene) or a mix of both affected the  sequencing results. 
Different combinations of sequencing primers were used in order to achieve full-length Gag-
PR sequencing. Population sequencing was achieved in 17/28 (61%) samples. The remaining 
11 samples produced non-interpretable sequences by population sequencing in P7 (2/11); P6 
and P7 (1/11); P6 and P17 (2/11); P6, P7 and P17 (6/11) and clonal analysis was required to 
obtain full-length Gag-PR sequencing.  The primers employed for each sample are detailed in 
Figure 3.10.  
 
The analysis of amino acid sequences showed no variation between the different DNA 
polymerases in the 17 samples analysed by population sequencing.  
 
Clonal analysis of 11 samples demonstrated higher genetic variability in the regions where 
population sequencing was inconclusive compared with other regions of Gag and protease. 
Thus, mean inter-clone nucleotide variability was between 0.4-3.01 % in P17; 0.05-0.14% in 
P24; 0.71-8.51% in P7 and 0.08-5.96 in P6 (Table 3.4).  
- 124 - 
 
 
One of the samples requiring clonal analysis was amplified by the Qiagen, Invitrogene and 
Stratagene protocols. No significant difference was observed in the pattern of nucleotide 
variations regardless of the amplification protocol used. The most predominant nucleotide 
changes detected in Gag were A-to-G (23.8%) and G-to-A (16.25%) transitions, followed by T-
to-C (15.14%) and C-to-T (13.89%) transitions. Transitions occurred around three times more 
frequently than transversions. Similarly, no significant difference was observed in the percentage 
of nucleotide variations among clones obtained after amplification with the three different 
protocols (Table 3.3). 
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Figure 3.10 Primers employed for full-length Gag and protease sequencing.  
A total of 28 plasma samples representing different subtypes and CRFs underwent population 
sequencing after manual extraction with QiaAmp Viral RNA extraction kit and amplification by 
nested PCR with the Qiagen system. Samples B-1, B-3, C-1 C-3 and D-2 were in addition amplified 
in parallel following Invitrogene and Stratagene protocols before sequencing. Samples C-3; CRF01-1; 
A-3; G-3; G-4; Cpx-1; CRF13-1; D-3; CRF14-1; J-1; CRF06-1 yielded non-interpretable sequences 
and required cloning prior to successful full-length sequencing.  
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Mean % nucleotide variation 
Sample Gag P17 P24 P7 P6 Region failing population sequencing 
C-3 2.1 3.01 0.05 0.70 3.30 P17, P6 
CRF01-1 1.97 0.4 0.08 2.45 0.08 P7 
A-3 2.03 0.47 0.12 2.50 0.08 P7 
G-3 1.38 1.44 0.14 2.37 1.61 P17, P7, P6 
G-4 1.87 0.34 0.13 1.18 5.96 P7,P6 
Cpx-1 3.12 1.32 0.05 8.51 2.57 P17, P7, P6 
CRF13-1 1.12 2.01 0.06 0.31 2.06 P17, P6 
D-3 1.87 0.98 0.13 2.11 4.33 P17, P7, P6 
CRF14-1 0.97 1.21 0.03 0.71 2.05 P17, P7, P6 
CRF06-1 1.04 0.96 0.05 2.01 1.13 P17, P7, P6 
J-1 1.63 2.55 0.05 1.94 1.98 P17, P7, P6 
Table 3.3 Nucleotide sequence variation of Gag gene.  
Variability across different Gag regions in 11 samples failing population sequencing was determined. 
Intra-clone distances were calculated using Mega software version 5.0.   
 
 
 Nucleotide (%) Amino acid (%) 
Qiagen 3.29 5.21 
                         Invitrogene 3.08 5.13 
Stratagene 2.98 5.02 
Table 3.4 Nucleotide and amino acid variability.  
The nucleotide variability among 20 clones obtained from one plasma sample was compared 
employing non-proofreading (Qiagen), proofreading (Stratagene) and a mix of proofreading/non-
proofreading (Invitrogene) enzymes. Inter-clone distances were calculated with Mega software 
version 5.0.    
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3.4 Discussion 
The present chapter describes the design, optimisation and validation of an assay for the 
amplification and sequencing of HIV-1 Gag and protease. Two main characteristics were to 
be taken into account when designing the assay:    
 
1) Heterogeneous target population: 
Group M HIV-1 viruses, which are further classified into nine subtypes (A-D, F-H, J and K) 
and at least 51 circulating recombinant forms (CRFs), are responsible for most HIV 
infections globally. The distribution of these viruses varies by geographical areas. In Western 
Europe, including the UK, subtype B predominates. However, the prevalence of non-B 
subtypes in Europe has progressively increased owing to the influx of immigrants from 
Africa and Asia (Deroo et al, 2002; Machuca et al, 2001; Lospistao et al, 2005; Op de Coul et 
al, 2001; Snoeck et al, 2004; Thomson and Najera, 2001). Because of historical and current 
connections with many countries across all six continents, subtypes other than B, namely A, 
C, D, E, F, G and H, were reported early in the UK (Clewley et al, 1996; Devereux et al, 
1999) and by 2001 it was estimated that up to 25% of HIV-1 infections were due to non-B 
subtypes and CRFs (Barlow et al, 2001). A study published in 2006 based on sequence 
analysis of the polymerase gene and representing approximately one-fifth of all UK HIV 
infections, showed that while B was the most common subtype, subtypes C and A were 
present at prevalence of 10% and 6%, respectively. In addition, all other subtypes as well as 
several CRFs and unclassified strains were also identified (Gifford et al, 2006).  
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Consistent with the increasingly diversity of the HIV-1 epidemic in the UK, a wide variety of 
subtypes are encountered among HIV-infected patients attending the Royal Free Hospital. 
Approximately half of the HIV-1 infected patients seen locally harbour subtypes other than 
B, most commonly subtype C followed by subtypes A, D and the recombinant form CRF02. 
However, all other subtypes as well as other recombinant forms and complex mosaic 
sequences are also detected (Booth et al, 2007). It should be emphasized that although 
subtypes other than B were historically linked to immigration (Barlow et al, 2001), more 
recently an increase has been observed in recent years in the number of UK indigenous 
population infected with non-B clade HIV-1(Fox et al, 2010). In line with these findings, 
non-B subtype infection among UK autochthonous population has also been observed within 
the Royal Free Hospital cohort, (Booth et al, 2007) possibly indicating a higher degree of 
mixture between UK native and non-native inhabitants.  As a consequence of the diversity of 
HIV strains in our study population, we aimed at developing an assay able to detect a wide 
range of HIV-1 subtypes and CRFs. 
 
2) Main purpose of the assay: 
The primary intended use of the assay was the detection of amino acids changes in HIV-1 
Gag and PR genes in patients failing a PI-based regimen, in order to identify markers of drug 
resistance associated with changes in these two genes. Genotypic resistance testing is the 
most convenient method to identify resistance to antiretrovirals as the cause of treatment 
failure and is recommended in patients experiencing failure of their current regimen and 
requiring a change in antiretroviral therapy (Hirsch et al, 2008).  
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Current guidelines for the treatment of HIV infection recommend durable and maximal 
plasma viral load suppression to <50 copies/ml as the desired outcome after starting 
antiretroviral treatment. They also indicate that therapy failure should be identified and 
managed promptly to achieve this outcome (Gazzard et al, 2008; Hammer et al, 2008 and US 
Department of Health and human services 2008). As a result, genotypic resistance testing is 
frequently performed early after the onset of treatment failure, on samples still displaying a 
low viral load. Therefore one key requirement for our assay was to have a high analytical 
sensitivity.   
 
A number of factors were considered in order to optimize the assay performance 
characteristics: 
1) Type of PCR 
Nested PCR was chosen over conventional PCR in order to achieve high analytical 
sensitivity, which would allow detection of the virus at a low viral load. This PCR strategy 
significantly improved not only the analytical sensitivity but also the analytical specificity of 
the amplification protocol.  
 
2) Primer design 
Due to the complex mixture of HIV-1 subtypes and CRFs in our study population, good 
primer design was a critical step to achieve a successful outcome. However, the design of 
suitable primers for the amplification of the HIV-1 Gag gene from different subtypes was 
more challenging than it would be for other genomic regions, such as pol, due to the higher 
- 130 - 
 
genetic variability present within this region (Albert et al, 1994). To address this problem, we 
proceeded as follows: Firstly, we selected the most conserved sites adjacent to the target 
sequence to ensure optimal primer binding. Secondly, multiple sets of primers were 
constructed in order to cover major sequence variations among different strains. Lastly, 
ambiguity positions were introduced in some primers in order to account for minor genomic 
diversity at primer binding sites within strains.  
 
3) Nucleic acid extraction methods 
Efficient recovery of high-quality intact HIV-1 RNA is fundamental for the success of any 
RT-PCR-based procedure. A plethora of nucleic acid extraction methods, both manual and 
automated, are currently available. As it has been reported that HIV genotypic resistance 
testing achieves higher rates of success when manual extraction techniques are employed 
(Perandin et al, 2009), we initially selected a manual extraction kit, the QiaAmp Viral RNA 
extraction minikit (Qiagen). However, because manual extraction methods are labour 
intensive and more susceptible to variations in operator performance, we evaluated in parallel 
a semi-automated extraction platform, the Nuclisens EasyMag (BioMerieux), which is an 
easy-to-use bench top instrument based on silica extraction technology.   
 
Consistent with previous studies, the success rate of amplification was higher when manual 
extraction was employed. However, the efficiency of the automated extraction procedure 
could be easily improved by including a high speed centrifugation step of the plasma sample 
prior to extraction. This additional step enabled us to amplify all samples with viral load 
around 1,000 copies/ml and 50% of samples with viral load around 500 copies/ml. Although, 
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the amplification success rate was slightly lower at viral load levels around 500 copies/ml 
when using the Nuclisens EasyMag platform compared to the QiaAmp Viral RNA minikit 
(100% vs. 50%), we considered it sufficient for the purpose of our assay. This performance is 
in line with that of commercial kits for HIV genotypic resistance testing of pol, which 
recommend a viral load of at least 1,000 copies/ml for reliable results. In addition,  the 
benefit of performing resistance testing below a threshold of 1,000 copies/ml is still focus of 
controversy, and although multiple studies have demonstrated that resistance testing below 
this threshold is informative (Mackie et al, 2004 and Mackie et al, 2010 ), the clinical utility 
remains unclear.  
 
In  light of our results, we can conclude that although HIV-1 RNA extraction using the 
manual QiaAmp Viral RNA extraction minikit (Qiagen) increases diagnostic sensitivity of 
the amplification of HIV-1 Gag and protease from diverse subtypes in comparison to the 
semi-automated platform Nuclisens EasyMag (Biomerieux), the latter performs to an 
acceptable level when slight modifications are introduced and offers a more suitable 
methodology in the diagnostic setting where high throughput and reduced  hands-on time are 
required.  
 
4) Types of reverse transcriptase and DNA polymerase enzymes 
The choice of enzymes involved in RT-PCR protocols represents another major parameter 
that influences a successful outcome.  
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There are currently a large number of reverse transcriptase and DNA polymerase enzymes to 
choose from, which differ among other characteristics in thermal stability, fidelity and 
processivity. Some manufacturers provide ready-to-use kits that incorporate both enzymes 
plus an optimized reaction buffer whereby reverse transcription and PCR reactions can be 
performed either in the same tube or independently in two tubes. Single-tube reverse 
transcription-PCR (RT-PCR) procedures are recommended in the diagnostic setting because 
they are simple to perform, allow high-throughput and reduce the risk of cross-contamination 
between samples.   
 
Initially, we selected the Qiagen one-step RT-PCR kit (Qiagen), which contains  a specially 
formulated enzyme blend for both reverse transcription (i.e., Omniscript / Sensiscript reverse  
transcriptases) and PCR (i.e., HotStarTaq DNA polymerase)  reactions and a proprietary 
reaction mix containing a buffer with optimised concentrations of Mg
2+
 cations and dNTPs. 
Omniscript and Sensiscript are non-MMLV/AMV-derived reverse transcriptases (RTs). 
These enzymes may be superior to other commercially-available enzymes due to their higher 
affinity for RNA, which facilitates transcription through secondary structures where other 
RTs may be inhibited. In addition, the special composition of the buffer provided allows 
these RTs to operate at high temperatures (50°C), thus further improving reaction efficiency 
by disrupting secondary structures. As a result of their different abilities to copy small 
amounts of template, this enzyme mixture provides highly efficient and sensitive reverse 
transcription of any RNA quantity from 1 pg to 2 µg.     
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HotStarTaq DNA polymerase is an engineered version of the native Taq DNA polymerase, 
which was isolated from Thermus aquaticus. While maintaining the robustness and low cost 
of the original Taq DNA polymerase, this enzyme features a hot start procedure where the 
enzyme is activated by a 15-minute incubation at 95°C; this activation pattern ensures that 
polymerase activity does not start until the sample has reached a temperature where all DNA 
is denatured, thus avoiding extension from non-specifically annealed primers and primer-
dimers that may have formed at lower temperatures. In addition, this enzyme, as all Taq DNA 
polymerases, has the capacity to incorporate adenosine overhangs at the 3’ end of the PCR 
products; this characteristic is very useful for clonation studies when using TOPO or TA 
vectors, as the presence of thymidine (T) overhangs in these vectors enables ligation using 
topoisomerase or DNA ligase. 
 
Using the Qiagen one-step RT-PCR kit (Qiagen) we achieved a high success rate for the 
amplification of gag and protease with a variety of group M HIV-1 subtypes. A success rate 
of 100% was achieved when samples with viral loads ranging from ≤ 1,000 to >100,000 
copies/ml were tested following the manufacturer’s recommendations. In addition, we carried 
out clonal analysis using TOPO/TA vectors on 11 samples that did not provide conclusive 
results by population sequencing. We successfully cloned all the 11 samples, using the TOPO 
TA cloning kit according to the manufacturer’s recommendation. No optimization was 
required as it is often necessary when traditional cloning methods involving restriction 
digestion are applied. Cloning of PCR product with proof-reading enzymes such as those 
included in Invitrogene and Stratagene systems required additional steps to introduce the A 
overhangs and was in general less efficient.  
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 Despite the advantages of Taq DNA polymerases, one of their main drawbacks is the lack of 
3’→5’ exonuclease activity (i.e., proof-reading activity), which removes a mispaired 
nucleotide from the 3’ end of the growing strand, thus improving the fidelity of 
polymerization. The error rate of DNA polymerases is commonly expressed as the number of 
mutations per nucleotide per cycle; it depends not only on the intrinsic properties of the 
enzyme but also on the nature of the target sequence and the PCR conditions. Some studies 
have suggested that mutation rates may be artificially increased when employing Taq DNA 
polymerases (Bracho et al, 1998) due to their lack of proof-reading activity. In one report, the 
use of Taq DNA polymerase overestimated the proportion of minor hepatitis C virus 
quasispecies variants detected (Mullan et al, 2001), and it has been documented that 
quasispecies diversity is in general lower when proof-reading enzymes are used (Polyak et al, 
2005). In another study the error rate of Taq DNA polymerase for the amplification of the 
HIV-1 Gag gene was estimated at about 1 in 83,000 nucleotides by cloning individual DNA 
molecules from the amplified population and determining the number of DNA sequences 
changes (Eckert and Kunkel, 1991).     
 
To investigate how the fidelity of reverse transcription and PCR reactions could affect the 
detection of Gag and protease mutations, we performed further studies with alternative 
commercial kits. After extensive literature revision, we selected the AccuScript® HF RT-
PCR system (Stratagene) and the SuperScript® one-step RT-PCR system with platinum Taq 
HF. AccuScript® HF RT-PCR system (Stratagene) contains  a specially formulated enzyme 
blend for both reverse transcription (i.e., AccuScript reverse transcriptase) and PCR (i.e., 
PfuUltra HF DNA polymerase)  reactions plus two proprietary reaction buffers containing 
optimized concentrations of Mg
2+
 cations and dNTPs; reverse transcription and PCR 
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reactions are performed independently in two separate tubes. AccuScript is a MMLV-derived 
reverse transcriptase, its main differential feature is the presence of 3’→5’ exonuclease 
activity which improves reverse transcription fidelity by more than three fold when compared 
to other commercially-available RTs (43).  PfuUltra HF DNA polymerase is an engineered 
version of the native Pfu DNA polymerase, which was isolated from Pyrococcus furiosus. Its 
accuracy has been documented to be 18 times higher than that of Taq DNA polymerases 
(Lundberg et al, 1991).  
 
Through the high fidelity (HF) of the enzymes included in the AccuScript® HF RT-PCR 
system (Stratagene, Netherlands), we expected to improve the accuracy of detection of 
mutations in HIV gag and protease genes. However, the Stratagene system had a series of 
disadvantages. Firstly, a series of extra requirements, such as the incorporation of RNAse 
inhibitors in the RT-PCR mix, the setting of the reverse transcription and PCR reactions on 
ice or the initiation of the PCR reaction in a pre-heated thermocycler immediately after the 
addition of the enzyme to avoid primer degradation. These additional steps increase hands-on 
time and the length and cost of the procedure. In addition, we observed a very low success 
rate for the amplification of our target sequence when following the manufacturer’s 
recommendations. To improve the performance of the assay, an increase in the Mg
2+
 cation 
concentration was required. It is known that while the lowest concentrations of Mg
2+
 favour 
specific priming and thus reduce non-specific amplification, the highest ones increase 
polymerization rates and as a result PCR sensitivity, but tend to facilitate non-specific primer 
binding, therefore diminishing PCR specificity. As a consequence, increasing Mg
2+
 
concentration may have led to a decrease in the fidelity of the Pfu DNA polymerase. After 
optimization of the [Mg
2+
], an amplification failure rate of 40% was observed compared to 
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0% with the Qiagen one-step RT-PCR kit. In addition, for those samples where amplification 
was successful, smaller amount of amplicons was produced by the Stratagene system than by 
the Qiagen kit, as demonstrated by the lower intensity of the PCR bands on agarose gel 
electrophoresis. This reduced yield can be due to primer degradation by the Pfu DNA 
polymerase as a result of its proof-reading activity and/or the stringent conditions of the PCR 
reaction (Takagi et al, 1997).  In conclusion, although the Stratagene system may be 
recommendable for techniques that require HF DNA synthesis, such as clonal analysis, it is 
not convenient for population sequencing purposes in a diagnostic setting as it may decrease 
the success rate of RT-PCR reactions and increase the length and cost of the procedure.      
 
Mixtures of proofreading and non-proofreading DNA polymerases have been reported to 
synthesize higher yields of PCR product (Barnes 1994) and fidelity comparisons with 
Pfu/Taq-containing polymerase blends have shown that the error rate of the mixtures appears 
to be intermediate between the error rate of Pfu and the non-proofreading enzyme (Cline et 
al, 1996) and is likely to depend on the ratio of non proof-reading to proof-reading enzyme. 
In order to obtain high reaction success rates and HF of template replication, we performed a 
one-step RT-PCR with SuperScript® III Platinum® one-step RT-PCR  system with Platinum 
® Taq DNA polymerase HF (Invitrogen, UK)  followed by amplification with Platinum ® 
Taq DNA polymerase HF (Invitrogen, UK).  SuperScript® III Platinum® one-step RT-PCR 
system with Platinum ® Taq DNA polymerase HF (Invitrogen, UK) combines SuperScript® 
III reverse transcriptase, Platinum® Taq DNA polymerase HF and a propietory reaction mix 
containing a buffer with optimised concentrations of Mg
2+
 cations and dNTPs. SuperScript® 
III is a version of MMLV RT that has been engineered to reduce RNAaseH activity providing 
more full-length cDNA than other RTs. Platinum ® Taq DNA polymerase HF (Invitrogen, 
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UK) is an enzyme mixture composed of Pyrococcus species GB-D polymerase, a 
recombinant enzyme that features 3’→5’ exonuclease activity, and a recombinant non proof-
reading enzyme, Platinum® Taq DNA polymerase. The reaction success rates obtained with 
the Invitrogene system were comparable to those obtained with Qiagen and the level of 
accuracy of mutation detection is likely to be between Qiagen and Stratagene.  
 
We performed a comparative study between the three enzymatic systems. A total of six 
samples underwent reverse transcription followed by a nested PCR reaction and the PCR 
products were subsequently analysed by population sequencing. We did not find significant 
differences between the three systems in the rate of mutations encountered. With regard to 
the type of mutations, transitions were much more frequently found than transversions  and 
were in order of decreasing frequency A-G (23.8%),G-A (16.5%),  T-C (15.4%) and C-T 
(13.9%) . These results suggest that a proof-reading polymerase is not advantageous over a 
DNA polymerase lacking 3’→5’ exonuclease activity for the purpose of population 
sequencing. The rate and type of mutations these enzymes produce is similar. Although the 
rate of mutations may be slightly higher with non-proofreading enzymes, it can be minimized 
by optimizing the PCR reaction conditions. In any case, the proportion of PCR product 
displaying enzyme-derived mutations represents only a minority of the quasispecies and as a 
consequence would go undetected by population sequencing (Alcorn and Faruki 2000). On 
the other hand reaction success rates were substantially higher when non-proofreading DNA 
polymerase was employed.   
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However, population sequence analysis was unsuccessful in 20% of the samples. These 
samples were further characterized by clonal analysis, an application that may be more 
affected by low fidelity of template replication. When we compared 20 individual clones 
derived from one sample, we could not found any significant differences in the rate of 
mutations observed.  Therefore, we concluded that despite lacking proof-reading activity, Taq 
polymerase can be used for some down-stream applications such as population sequencing 
and in our study clonal analysis, offering the advantages of high success rates, low cost, 
robustness and ease of use in cloning applications. We need to emphasize that our clonal 
analysis studies were not aimed at the detection of minority variants and therefore we only 
analyzed a reduced number of clones. In applications where variants that represent a minority 
in the quasispecies are of interest, requiring the analysis of a high number of clones, the use 
of more accurate enzymes, such as Pfu, is recommended.  
 
Another possible application of our clonal analysis was the study of linkage between 
mutations. Polymerising enzymes employed for this purpose must have the ability to 
complete strand synthesis and display HF of template replication. PCR-mediated 
recombination is a main concern when performing linkage analysis. Recombinants during 
PCR presumably arise due to the presence of incompletely extended primers annealing to a 
heterologous target (Meyerhans et al, 1989); this situation is avoided when complete rather 
than partial strand synthesis is achieved. Early studies demonstrated that the enzyme 
employed for DNA synthesis significantly affects the rate of artificial recombination (Fang et 
al, 1998). In general, proofreading enzymes facilitate complete strand synthesis and are the 
preferred enzymes in this setting. 
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The Invitrogen system may be best suited for this use as the reduced RNAase H activity if 
SuperScript® III reverse transcriptase maximises synthesis of complete cDNA strands and 
Platinum® Taq DNA polymerase HF contains a proofreading enzyme that ensures synthesis 
of HF complete DNA strands. However, adjustment of other parameters that may affect the 
rate of artificial recombination, such as the method of RNA isolation, reverse transcription 
time or number of cycles during PCR (Fang et al, 1998) may be required in order to optimise 
this application.   
 
The greatest challenge we faced to develop a protocol for the amplification and sequencing of 
HIV-1 gag and protease genes was the high degree of genetic variability present within the 
HIV-1 gag gene, which is not only observed between different subtypes, but also within 
subtypes and intra-patient quasispecies (Brown and Monaghan, 1988; Louwagie et al, 1993; 
Markham et al, 1995; Mulder-Kampinga et al, 1995 and Yoshimura et al, 1996).  Variability 
is not equally distributed across the gag gene. P17 and P7 were the most variable sites, 
whereas P24 is the most conserved region; Yoshimura and colleagues observed a variation of 
around 12% in P17 and P7 and 3% in P24 in a cohort of patients infected with the same HIV-
1 subtype. Similarly, when sequences of the gag clones within HIV-1 infected patients were 
compared, the greatest genetic diversity was located in P17 and P7 regions, while P24 had the 
lowest sequence variability (Yoshimura et al, 1996). 
 
 Due to the diversity seen in the gag gene, sequencing of this region posed a big challenge. 
Mismatches between sequencing primers and complementary sequences in the gag gene led 
to foreshortened sequences or to complete failure of the sequencing reaction in numerous 
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occasions. To overcome this problem, we developed multiple overlapping sequencing 
primers. A total of 18 sequencing primers were required to obtain a full-length gag sequence 
and were employed in different combinations according to the specific sample.  An additional 
challenge for gag sequencing is the intra-patient genetic variability, which according to 
previous reports is mainly concentrated in P17, P7 and P6 regions (Brown and Monaghan, 
1988). In our study, we obtained unreadable P17, P7 and/or P6 sequences due to 
heterogeneous sequencing signals in 11/27 (41%) of the samples analyzed. In addition, 
quasispecies displaying insertion and deletions of different length were also found in one 
patient (1/27, 4%), which resulted in a shift of the chromatogram and yielded a non-
interpretable population sequence. In order to circumvent these problems, we performed 
clonal analysis. Twenty clones per patient were analyzed to obtain full-length gag sequences 
of the independent dominant variants that constituted the patient’s quasispecies. Although 
this approach was cumbersome, it allowed us to accomplish full-length gag sequencing with 
all of the samples.         
 
In summary, we successfully developed an assay for the amplification and sequencing of 
HIV-1 gag and protease. The assay was validated by testing both manual and automated 
nucleic acid extraction techniques as well as different reverse transcriptase and DNA 
polymerase enzymes. The assay can be employed for different purposes, such as therapy 
monitoring or the study of linkage of mutations. The choice of manual or automated nucleic 
acid extraction methods, characteristics of RTs and DNA polymerases will depend on the 
goal of the study. The high variability present in the HIV-1 gag gene leads to a significant 
assay failure rate; the use of clonal analysis is required to characterize failed samples, 
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situation that makes the sequencing of Gag cumbersome in a high-throughput routine 
diagnostic setting.        
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4 Chapter four: cross-sectional comparison of 
prevalence and patterns of HIV-1 Gag mutations in 
PI-experienced and PI-naïve patients 
4.1 Introduction 
The HIV-1 protease (PR) plays a crucial role in the late phase of the HIV life cycle. It cleaves 
gag and Gag-Pro-Pol precursor polyproteins at particular sites thereby generating mature 
proteins, which are indispensable for the production of infectious virions. HIV-1 PR is a 
member of the aspartyl protease family. The functional enzyme exists as a symmetrical 
homodimer, each subunit comprising 99 amino acids and the two subunits interact non-
covalently to form a long tunnel where the active site is located. The active site consists of 
two Asp-Thr-Gly sequences, each sequence derived from a single monomer, and the aspartic 
residues play an essential role in the catalytic process. Access of substrates to the active 
centre is regulated by two flexible flaps located at the top of the tunnel, which undergo 
significant conformational changes to allow the substrate to enter and leave the tunnel.      .  
 
The gag precursor polyprotein is cleaved to generate structural proteins. Cleavage occurs in a 
controlled manner at 5 unique cleavage sites (CSs), comprising P17/P24, P24/P2, P2/P7, 
P7/P1 and P1/P6 (Krausslich et al, 1989; Pettit et al, 1994 and Wiegers et al, 1998). An 
important factor governing the order and rate of cleavage is the amino acid sequence at the 
specific CS (Pettit et al, 2002). Each CS consists of 10 amino acids; their positions relative to 
the cleaved peptide bond designated from N to C terminus as follows: N-P5-P4-P3-P2-
- 143 - 
 
P1/P1’-P2’-P3’-P4’-P5’-C, with cleavage occurring between P1and P1’ (Pettit et al, 2002). 
The amino acid sequence of the different CSs within Gag differs strikingly from one site to 
another. In addition, some sites, most notably P2/P7, show a high degree of polymorphism 
between HIV-1 strains (Bally et al, 2000; Feher et al, 2002; Gallego et al, 2003; Malet et al, 
2007 and De Oliveira et al, 2003). The difference in the amino acid sequence between these 
different CSs explains, at least in part, their differential rate of cleavage by the viral PR (Pettit 
et al, 2002 and Wiegers et al, 1998). Interestingly, in spite of the marked sequence diversity, 
these Gag sites show a strong similarity in their secondary structure (Bandaranayake et al, 
2008; Prabu-Jeyabalan et al, 2002), which explains why they all constitute strong and specific 
substrates for the viral PR, albeit with different rates of cleavage.  
 
The essential role that HIV-1 PR plays in the viral life cycle makes this enzyme an attractive 
target for antiretroviral drugs. There are currently nine protease inhibitors (PIs) licensed for 
the treatment of HIV-1 infection, namely Atazanavir (ATV), Darunavir (DRV), 
Fosamprenavir (FPV), Indinavir (IDV), Lopinavir (LPV), Nelfinavir (NFV), Ritonavir 
(RTV), Saquinavir (SQV) and Tipranavir (TPV). They act as competitive inhibitors that bind 
the active site of the viral PR blocking the entrance of the natural substrate. Unfortunately, 
resistance to all available PIs has been documented and represents a major obstacle for 
successful treatment of HIV-1 infected patients. The classic mechanism of PI resistance 
involves accumulation of substitutions in the viral PR (Croteau et al, 1997; Mammano et al, 
2000; Nijhuis et al, 1999). In general, the first mutations to be selected (i.e, primary or major 
resistance mutations) are located within or close to the substrate-binding domain, and can 
differ from one PI to another. Subsequently, secondary mutations are selected, which involve 
amino acids located away from the substrate-binding cleft. These secondary mutations, also 
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termed minor resistance mutations, are less drug-specific than primary mutations, but still 
essential for high-level resistance to PI and many of them play a key compensatory role, 
restoring viral fitness in strains with primary mutations.      
 
An alternative pathway of resistance to the PIs has been proposed, which is mediated by other 
genomic regions and focuses on cleavage sites of the viral PR (Nijhuis et al, 2007). The co-
evolution of PR and C-terminal gag CSs in PI-resistant viruses was reported soon after the 
introduction of PIs in antiretroviral regimens (Doyon et al, 1996; Zhang et al, 1997). The 
occurrence of CS mutations (CSMs) was originally attributed to compensatory effects similar 
to those described with secondary PR mutations (Doyon et al, 1996; Mammano et al, 
2000).However, growing evidence shows that CS mutations also confer PI resistance either in 
isolation or in combination with PR mutations (Dam et al, 2009; Maguire et al, 2002; Nijhuis 
et al, 2007; Prado et al, 2002; Zhang et al, 1997). Amino acids substitutions associated with 
PI resistance have been described at two gag CSs, namely P7/P1 and P1/P6. However, the 
role of amino acid changes at other gag CSs or outside CS regions of gag remains to be 
elucidated.  
 
The aim of the present chapter was to obtain full-length HIV-1 gag and PR sequences from 
PI-experienced patients employing the assay described in the previous chapter. These 
sequences were compared to HIV-1 gag and PR sequences from PI-naive individuals in order 
to identify mutations associated with PI-exposure. Furthermore the sequences were analysed 
with the aim of determining significant associations between PR mutations and gag mutations 
that may identify novel pathways of PI resistance.  
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4.2 Methods 
4.2.1 Sequences 
The gag and PR genes from 191 PI-experienced and 200 PI-naïve patients were analyzed 
retrospectively.  
 
Sequences from PI-experienced patients were obtained from different cohorts: patients 
recruited in the MaxCmin1, MaxCmin2 and COLATE trials, patients attending Cologne 
University Hospital and patients attending the Royal Free Hospital. The MaxCmin1 and 
MaxCmin2 were two open label, multicentre, phase IV trials that compared the safety and 
efficacy of ritonavir boosted Saquinavir (SQV/r), against ritonavir boosted Indinavir (IDV/r) 
and against ritonavir boosted Lopinavir (LPV/r). COLATE recruited patients failing a 
lamivudine-containing regimen, and assessed whether maintaining lamivudine in the 
subsequent regimen was of virological benefit. Patients from MaxCmin1, MaxCmin2 and 
COLATE whose regimens included one or more PIs and who showed major PR resistance 
mutations (n = 13) were included in the analysis. In order to maximize numbers, we also 
selected patients from Cologne University (n = 128) Hospital and Royal Free Hospital (n 
=50) who had been previously exposed to PIs, all of whom showed major PR resistance 
mutations.  
 
As a comparator group, we constructed a database of PI-naive sequences which included 
sequences obtained from RFH patients who had been previously exposed to antiretrovirals 
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(ARVs) other than PIs (n = 52) and sequences from ARV-naïve subjects from the Los 
Alamos database (n =148).    
 
Both PI-experienced (n= 191) and PI-naive (n = 200) sequences were retrieved from patients 
with long lasting (i.e.; 3-10 years of infection) subtype B HIV-1 infection.  
 
4.2.2 RNA extraction 
Prior to extraction, one millilitre of plasma was centrifuged at 25,000g for 1 hour at 4°C to 
concentrate the virus; the supernatant was then removed and the pellet re-suspended to a final 
volume of 280 µl. Samples with HIV-1 RNA load above 1,000 copies/ml underwent 
extraction employing the semi-automated extractor EasyMag (Nuclisens, France), whereas 
those with viral load below 1,000 copies/ml were extracted manually with the QIAamp Viral 
RNA MiniKit   (Qiagen, Germany). Finally, the RNA was eluted into 55µl of elution buffer 
and stored at -80°C until required.  
 
4.2.3 Amplification of the Gag-protease region 
A 2 Kb PCR product comprising full-length HIV-1 Gag and PR was amplified by nested 
PCR employing the Qiagen Gag-PR amplification protocol described in section 2.2.2.2.1 in 
chapter 2.    
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4.2.4 Purification of PCR products 
PCR products for population sequencing were purified using QIAQuick PCR purification Kit 
(Qiagen, Crawley, UK) according to the manufacturer’s instructions.  
 
4.2.5 Analysis of PCR products 
Five µl of PCR product mixed with five µl of loading buffer were loaded into a 1% agarose 
gel containing 0.5 µg/ml of ethidium bromide. Three µl of mass ladder was also loaded to use 
as a reference, and the gel was run for one hour at 80V. The gel was examined with UV light 
and the quantity and size of DNA was evaluated by comparing the intensity and position of 
the bands to those of the DNA mass ladder.  
 
4.2.6 Sequencing 
Purified PCR products of the right size were diluted to a final concentration of approximately 
10-20 ng/µl and population sequencing was performed using the ABI PRISM BigDye 
Terminator v3.1.ready reaction cycle sequencing Kit. Primers selected for PR and Gag 
sequences were those described in chapter 3 (Table 3.2).   
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4.2.7 Sequence analysis 
Sequences were analyzed using Sequence analysis version 5.0, Seqscape version 6.0 and 
Mega Molecular Evolutionary Genetic Analysis software version 4.0 programmes. 
 
4.2.8 Classification of protease mutations 
PR resistance mutations were assessed according to the last available list of mutations of the 
International AIDS Society (IAS, 2011) and classified into primary and secondary mutations 
according to the Stanford HIV Drug Resistance Database (Figure 4.1). 
 
4.2.9 Classification of Gag mutations 
We analysed mutations in the entire Gag protein. Gag sequences were aligned with the 
reference sequence HXB2 and subtyped by submitting the sequence to two different 
subtyping tools (NCBI and Rega). Mutations were defined as any change relative to the 
reference sequence. Mutations were divided into those seen in CSs (CSMs) and those seen 
outside CSs (Non-CSMs). Each CS consisted of the five amino acids on both sides of the 
cleavage bond. P5 to P1 and P5’ to P1’ were designated for residues on the N and C terminal 
sides of the target, respectively (Figure 4.2).  
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4.2.10 Gag and protease analysis 
PI-naive sequences were compared to the HXB2 reference sequence. The variability at each 
position in the Gag protein was given as a percentage, defined as the proportion of sequences 
with a non-wild type amino acid relative to the total number of sequences. We considered 
amino acid positions showing a variability ≤1 % as being conserved. The association between 
gag mutations and PI-exposure was analyzed by using the Fischer’s exact test. Gag CS 
positions (n =50) and Non-CS positions (n=450) were analyzed separately. A p value of less 
than 0.05 was considered to indicate a statistically significant different between groups in a 
preliminary analysis. Subsequently, the Bonferroni correction was applied in order to account 
for multiple comparisons. Therefore a p value of less than 0.05/50 = 0.001 for CSMs and 
0.05/450 = 0.0001 for Non-CSMs were considered as the threshold to show statistically 
significant differences. In addition, the association between presence of gag mutations and 
presence of PR mutations was also analyzed using the Fisher’s exact test after, again after 
applying the Bonferroni’s correction for multiple associations.  
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Figure 4.1 Protease inhibitor resistance mutations.  
The first row of letters indicates the reference (HXB2) amino acid sequence. All amino acids are indicated by their one letter code.  The position of the first 
and last amino acid of each series of 10 is indicated as well as positions where primary PR resistance mutations have been described which are also 
highlighted in bold. Letters below in bold red indicates primary resistance mutations and in black secondary mutations.      
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1
GARASVLSGG ELDRWEKIRL RPGGKKKYKL KHIVWASREL ERFAVNPGLL ETSEGCRQIL GQLQPSLQTG  
 
  SEELRSLYNT VATLYCVHQR IEIKDTKEAL DKIEEEQNKS KKKAQQAAAD TGHSNQVSQN YPIVQNIQGQ  
  MVHQAISPRT LNAWVKVVEE KAFSPEVIPM FSALSEGATP QDLNTMLNTV GGHQAAMQML KETINEEAAE  
  WDRVHPVHA            GPIAPG QMREP  RGSDIAGTTS TLQEQIGWMT NNPPIPVGEI YKRWIILGLN KIVRMYSPTS  
    ILDIRQGPKE PFRDYVDRFY KTLRAEQASQ EVKNWMTETL LVQNANPDCK TILKALGPAA TLEEMMTACQ  
  
 GVGGPGHKAR VLAEAMSQVT NSATIMMQRG NFRNQRKIVK CFNCGKEGHT ARNCRAPRKK GCWKCGKEGH  
  
 QMKDCTERQA NFLGKIWPSY KGRPGNFLQS RPEPTAPPEE SFRSGVETTT PPQKQEPIDK ELYPLTSLRS  
  LFGNDPSSQ
500
 
Figure 4.2 Gag HXB2 sequence.  
The letters indicate the reference (HXB2) Gag amino acid sequence. All amino acids are indicated by their one letter code. The number position of the first 
and last amino acid of the Gag polyprotein is indicated. The beginning and end of each individual protein is indicated by arrows. CSs sequence and positions 
are indicated in red.
P17 
128-137 
P24 
P2 
359-368 373-381 
P7 
428-437 
P1 
444-453 
P6 
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4.3 Results 
4.3.1 Patient characteristics 
PI experienced patients had been exposed to a median (range) of 2 PIs (1-4), 4 (2-5) NRTIs 
and 1 (0-2) NNRTIs. At the time of analysis, the most common PI individuals had previously 
been exposed to were: LPV/r (60/191, 31 %); SQV/r (42/191, 22%); IDV/r (30/191, 16%); 
APV/r (30/191; 16%); ATV/r (10/191, 5%); TPV/r (6/191, 3%) and DRV/r (4/191, 2%). All 
patients had major and minor protease resistance mutations. Similarly, 187/191 (98%) 
patients had NRTI-resistance-associated mutations and 125/191 (80%) had NNRTI-resistance 
associated mutations. The median (range) of major and minor PI resistance mutations at study 
entry were 3 (1-6) and 4 (0-8), respectively. The median (range) of NRTI and NNRTI-
resistance associated mutations were 5 (0-11) and 1 (0-4), respectively.  
 
PI-naïve patients were either completely treatment naïve (n = 148) or exposed to NRTIs and 
NNRTIs but not to PIs (n = 52). None of them had major PI resistance mutations and the 
median (range) number of minor PI resistance mutations was 1 (0 – 3). However, while none 
of the 148 treatment naïve sequences showed either NRTI nor NNRTI-resistance associated 
mutations, all of the 52 sequences ontained from patients previously exposed to ARVs other 
than PIs showed NRTI-resistance associated mutations, median 2, range (1-3) and 23/52 
(44%) showed in addition NNRTI-resistance associated mutations, median 2 (0-2).  
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4.3.2 Gag variability at non-cleavage site positions 
The 500 amino acid positions setting up the sequence of the Gag protein from 200 PI-naïve 
patients infected with subtype B HIV-1 were compared to the reference sequence HXB2. 
Non-cleavage site (Non-CS) amino acid positions (n=450) and CS amino positions (n=50) 
were examined separately. The latter comprised the 5 CSs (P17/P24; P24/P2; P2/P7; P7/P1 
and P1/P6), each consisting of 10 amino acids. Figures 4.3a to 4.3f show the variability of 
Non-CS amino acid positions in PI-naïve individuals, divided into the different Gag domains 
Matrix (P17), Capsid (P24), Nucleocapsid (P7), P6, P2 and P1, and excluding amino acid 
positions within the CSs. 
 
The analysis of the 450 Non-CS amino acid positions in the 200 PI-naïve individuals revealed 
the following: 
 P17:  
A total of 76/127 (60%) amino acid positions were conserved among subtype B HIV-1 
strains. Some conserved residues were scattered, such as K27, Y29, L50, Q63, S77, I92, 
K103 and Q116, while others were contiguous forming conserved motives of between 2 and 
10 amino acids. The remaining 51/127 (40%) positions showed a degree of variability 
ranging between 1% and 55% (Figure 4.3a).   
 P24:  
This region showed the highest degree of conservation. A total of 154/220 (70%) amino acid 
positions were conserved. Most conserved residues formed motives of between 2 and 11 
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amino acids, and only a few were individually scattered including 164F, 253N, 336A and 
347M. The remaining 66/220 amino acids (30%) showed a degree of variability ranging 
between 1% and 82% (Figure 4.3b).    
 P7:   
A total of 24/45 (53%) amino acid positions were conserved. Most conserved residues 
formed motives of between 2 and 6 amino acids except for one that was individually 
scattered (C426).  The remaining 21/45 amino acids (47%) showed a degree of variability 
ranging between 1% and 95% (Figure 4.3c).  
 P6:   
 This region showed the highest degree of variability. A total of 22/47 (47%) amino acid 
positions were conserved, six of them individually scattered (P455, V467, P472, Q474, P485 
and D496) and the remaining forming motives of between two and five amino acids. 
However, the majority of the amino acids (25/46, 54%) showed a degree of variability 
ranging between 1% and 75% (Figure 4.3c). 
 Spacer peptides P1  and P2 : 
The first spacer peptide encountered in the Gag polypeptide P2 was found to be highly 
polymorphic in the four Non-CS residues, with a degree of variability ranging between 8% 
and 22%. By contrast, the second spacer peptide P1 showed 3/6 (50%) conserved amino acids 
and 3/6 (50%) polymorphic residues (P439, S440, Y441H) with a degree of variability of 9%, 
1% and 48%, respectively (Figure 4.3c).  
 
- 155 - 
 
 
 
Figure 4.3a Polymorphisms of the HIV-1 P17 protein in subtype B strains from protease 
inhibitor-naïve patients.  
Cleavage site positions (amino acid: 128-132) were excluded from this analysis. Sequences from 200 
PI-naïve patients were compared to the HXB2 reference sequence (amino acid: 1-127). The letters 
specified on the bars indicate polymorphisms occurring at frequency ≥ 6%. HXB2 reference sequence 
and amino acid positions are shown.  
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Figure 4.3b Polymorphisms of the HIV-1 P24 protein in subtype B strains from protease 
inhibitor-naïve patients.  
Cleavage Site positions (amino acid: 133-138 and 359-362) were excluded. Sequences from 200 PI-
naïve patients were compared to the HXB2 reference sequence (amino acid: 138-358). The letters 
indicate polymorphisms occurring at frequencies ≥ 6%. HXB2 reference sequence and amino acid 
positions are shown.  
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Figure 4.3c Polymorphism of the P7, P6, P1 and P2 proteins in subtype B strains from protease 
inhibitor-naïve patients.  
Cleavage Site positions (amino acid: 377-381; 428-431; 448-453; 432-437; 444-447; 363-368 and 
373-376) were excluded. Sequences from 200 PI-naïve patients were compared to the HXB2 
reference sequence (amino acid 383-427; 454-500; 369-372 and 438-443 respectively).The letters 
indicate polymorphisms occurring at frequencies ≥ 6%. HXB2 reference sequence and amino acid 
positions are shown.  
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4.3.3 Gag variability at cleavage site positions 
The CS sequences from the 200 PI-naïve patients were examined and compared to the 
reference sequence HXB2. Each cleavage site consists of 10 amino acids designated as P5 to 
P1 and P1’ to P5’ for residues on the N and C terminal sites of the CS, respectively. 
Variability of CS differed considerably. Whereas three CSs (P17/P24; P24/P2 and P7/P1) 
were relatively conserved, P1/P6 and P2/P7 showed moderate and high variability 
respectively. Specifically, the P17/P24 CS showed only three mutations: V128A in 8/200 
(4%) patients, and V128S and Q130H in 2/200 (1%) patients each; the remaining eight 
positions were completely conserved.  The P24/P2 CS showed only two mutations: V362I in 
46/200 (23%) and R361K in 4/200 (2%) patients; the remaining eight positions were 
conserved.  Concerning the P7/P1 CS, only two mutations were encountered among the 200 
PI-naïve patients; these were E428D and K436R observed in 26/200 (13%) and 22/200 (11%) 
patients, respectively By contrast, at P2/P7 only two positions (Q379 and N382) were 
conserved, while all patients showed at least one mutation at the remaining eight positions 
and 144/200 (72%) showing more than one mutation (range 2-4mutations). Lastly, mutations 
at the P1/P6 CS were located at the C-terminal part, where four out of the five positions were 
variable; the most common mutations were L449P and L453P, found in 48/200 (24%) and 
46/200 (23%) patients, respectively. Mutations at positions Q450 (Q450E, 22/200, 11%) and 
S451 (S451N 22/200, 11%; S451A 10/200, 5%) were less frequent. The five amino acids 
forming the N-terminal part of the P1/P6 CS were completely conserved in the PI-naïve 
population.  Variability of the amino acids at the five Gag CSs is shown in figure 4.4.  
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Figure 4.4 Polymorphisms of the HIV-1 Gag CSs (P17/P24, P24/P2, P2/P7, P7/P1 and P1/P6) in subtype B strains from protease inhibitor-naïve 
patients.  
Sequences from 200 PI-naïve patients were compared to the HXB2 reference sequence. Letters indicate polymorphisms occurring at frequencies ≥ 6% 
HXB2 reference sequence and amino acid positions are shown.  
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4.3.4 Comparison of Gag non-cleavage site mutations according 
to history of exposure to protease inhibitors  
The comparison of full-length Gag and PR sequences from 191 PI-experienced and200 PI-
naïve individuals showed the following results: 
 P17:  
The 127 amino acids of the P17 protein were compared between sequences from PI-
experience and PI-naïve patients.  Overall 61 (48%) vs. 76 (60%) amino acids were 
conserved while 66 (52%) vs. 51 (40%) amino acids were variable, respectively. Among the 
66 variable positions seen in PI-experienced patients, we detected a total of 150 different 
mutations. Although 39 mutations out of the 150 found were associated with PI exposure 
when a cut-off  of 0.05 was considered, only 10 remained significantly associated when the 
Bonferroni’s correction for multiple associations was applied ( p = 0.05/450) (Table 4.1a).  
 P24:  
The 220 amino acids of the P24 protein were compared between sequences from PI-
experienced and PI-naïve patients. As described for the PI-naïve individuals in section 4.3.1, 
the CA-P24 protein also showed the highest degree of conservation in PI-experienced 
patients. Overall 149 (68%) vs. 154 (70%) residues were conserved and 71 (32%) vs. 66 
(30%) residues were variable in PI-experienced vs. PI-naïve individuals, respectively. Among 
the 71 variable positions seen in PI-experienced patients, we detected a total of 98 mutations. 
Although 17 out of the 98 mutations were associated with PI exposure when a cut- off of 0.05 
was considered, only five remained significantly associated when the Bonferroni’s correction 
for multiple associations was applied ( p = 0.05/450)  (Table 4.1b).  
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 P7:   
The 45 amino acids of the P7 protein were compared between sequences from PI-experienced 
and PI-naïve patients. We found the same number of conserved and variable residues in the 
two groups; these were 24 conserved residues and 21 variable residues. Among the 21 
variable amino acids in PI-experienced patients, we detected 42 mutations. Although seven 
out of the 42 mutations were significantly associated with PI-exposure when a cut-off of 0.05 
was considered, none remain significantly associated when the Bonferroni’s correction for 
multiple associations was applied (p= 0.05/450) (Table 4.1c).  
 P6:   
The 47 amino acids of the P6 protein was compared between sequences from PI-experienced 
and PI-naïve patients, overall 13 vs. 22 residues were conserved and 34 vs. 25 residues were 
variable in PI-experienced vs. PI-naïve individuals, respectively. We found 81 mutations 
distributed among the 34 variable residues seen in PI-experienced patients. Although, 19 out 
of the 34 mutations were associated with PI exposure when a cut-off of 0.05 was considered, 
only three remained significantly associated when the Bonferroni’s correction for multiple 
associations was applied (p = 0.05/450)   (Table 4.1d).  
 Spacer peptides P2: 
The four amino acids comprising the P2 peptide were compared between sequences from PI-
naïve and PI-experienced subjects. As I described for PI-naïve individuals in section 4.3.1, all 
P2 residues (n =4) were variable in PI-experienced individuals.  A total of 11 mutations were 
found distributed among the four variable residues in PI-experienced subjects. Although four 
out of the 11 mutations were significantly associated with PI exposure when a cut-off of 0.05 
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was considered, only one remained significantly associated when the Bonferroni’s correction 
for multiple associations was applied (p = 0.05/450) (Table 4.1e).  
 Spacer peptides P1: 
  Finally, the 6 amino acids comprising the P1 peptide were compared between sequences 
from PI-experienced and PI-naïve patients. Overall one vs. three residues was conserved and 
five vs. three were variable in PI-experience and PI-naïve patients, respectively. Among the 
five variable positions seen in PI-experienced subjects, we detected five mutations. Although 
one out of the five mutations was significantly associated with PI-exposure when a cut-off of 
0.05 was considered, it did not remain significantly associated when the Bonferroni’s 
correction for multiple associations was applied (p = 0.05/450) (Table 4.1e). 
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P17 
 
MUTATION 
PI-naïve (n= 200) PI-experienced (n= 191)  
n % n % P 
I34L 
Q59K 
L61I 
P66S 
T80A 
V82I 
T84V 
Y86W 
R91G 
I92V 
E93D 
I94V 
K103R 
E107I 
N109T 
N109S 
K113Q 
K113R 
K114R 
K114Q 
A115I 
Q117P 
Q117E 
A118T 
A119T 
A119E 
D121G 
D121A 
T122A 
T122K 
T122E 
G123K 
G123E 
H124K 
N126S 
N126G 
N126K 
Q127P 
Q127K 
16 
0 
2 
0 
0 
24 
60 
0 
0 
0 
62 
114 
0 
0 
2 
0 
0 
0 
0 
0 
0 
4 
0 
0 
0 
0 
0 
0 
24 
0 
0 
0 
6 
0 
16 
0 
0 
0 
0 
8 
0 
1 
0 
0 
12 
30 
0 
0 
0 
31 
57 
0 
0 
1 
0 
0 
0 
0 
0 
0 
2 
0 
0 
0 
0 
0 
0 
12 
0 
0 
0 
3 
0 
8 
0 
0 
0 
0 
32 
8 
20 
10 
10 
46 
86 
6 
6 
6 
92 
158 
16 
8 
10 
6 
22 
8 
22 
10 
6 
18 
6 
8 
6 
10 
16 
14 
48 
6 
18 
6 
18 
8 
130 
12 
6 
8 
24 
17 
4 
10 
5 
5 
24 
45 
3 
3 
3 
48 
83 
8 
4 
5 
3 
11 
4 
11 
5 
3 
9 
3 
4 
3 
5 
8 
7 
25 
3 
9 
3 
9 
4 
68 
6 
3 
4 
12 
0.02 
0.007 
<0.0001 
0.002 
0.002 
0.005 
0.009 
0.003 
0.03 
0.03 
0.003 
<0.0001 
<0.0001 
0.007 
0.04 
0.03 
<0.0001 
0.007 
<0.0001 
0.04 
0.03 
0.003 
0.03 
0.007 
0.03 
0.04 
<0.0001 
<0.0001 
0.003 
0.03 
<0.0001 
0.03 
0.02 
0.007 
<0.0001 
0.0004 
0.03 
0.007 
<0.0001 
Table 4.1a Non-cleavage site mutations in P17 significantly associated with PI-exposure.  
Mutations showing significant different between 200 PI-naïve (none of them showing major PI 
mutations, 52 showing NRTI-resistance associated mutations and 23 showing NNRTI-resistance 
associated mutations) and 191 PI-experienced individuals (all of them showing major protease 
resistance associated mutations, 187/191 (98%) showing NRTI-resistance associated mutations and 
125/191 (80%) showing NNRTI-resistance associated mutations) are presented. Total number f 
patients, percentage and p-values are shown. A p value of less than 0.05 was considered significant in 
a preliminary analysis. A Bonferroni’s correction was subsequently applied and a p of less than 
0.05/450 = 0.0001 was used instead. The mutations that remained significantly associated with PI 
exposure after the Bonferroni’s correction was applied are shown in bold.  
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P24 
MUTATION PI-naïve (n= 200) PI-experienced (n= 191)  
n % n % P 
I138A 
V143T 
V143I 
A146S 
S173A 
Q182H 
T186M 
T190I 
M200I 
A210S 
E211D 
V218A 
M228L 
L268M 
T280I 
S310T 
N315G 
2 
2 
0 
2 
2 
0 
0 
0 
0 
0 
0 
0 
0 
10 
0 
0 
0 
1 
1 
0 
1 
1 
0 
0 
0 
0 
0 
0 
0 
0 
5 
0 
0 
0 
14 
10 
6 
10 
12 
6 
16 
16 
12 
16 
16 
6 
6 
22 
10 
28 
6 
 
7 
5 
3 
5 
6 
3 
8 
8 
6 
8 
8 
3 
3 
11 
5 
14 
3 
0.003 
0.04 
0.03 
0.04 
0.01 
0.03 
<0.0001 
<0.0001 
0.0004 
<0.0001 
<0.0001 
0.03 
0.03 
0.04 
0.02 
<0.0001 
0.03 
 
Table 4.1b Non-cleavage site mutations in P24 significantly associated with PI-exposure.  
Mutations showing significant different between 200 PI-naïve (none of them showing major PI 
mutations, 52 showing NRTI-resistance associated mutations and 23 showing NNRTI-resistance 
associated mutations) and 191 PI-experienced individuals (all of them showing major protease 
resistance associated mutations, 187/191 (98%) showing NRTI-resistance associated mutations and 
125/191 (80%) showing NNRTI-resistance associated mutations) are presented. A p value of less 
than 0.05 was considered significant in a preliminary analysis. A Bonferroni’s correction was 
subsequently applied and a p of less than 0.05/450 = 0.0001 was used instead. The mutations that 
remained significantly associated with PI exposure after the Bonferroni’s correction was applied 
are shown in bold.  
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P7 
MUTATION PI-naïve (n= 200) PI-experienced (n= 191)  
n % n % P 
I389V 
V390A 
R403K 
K415R 
M423I 
T427S 
T427I 
0 
0 
52 
0 
0 
0 
0 
0 
0 
26 
0 
0 
0 
0 
6 
8 
74 
6 
6 
6 
10 
 
3 
4 
39 
3 
3 
3 
5 
 
0.03 
0.007 
0.02 
0.03 
0.03 
0.03 
0.002 
 
Table 4.1c Non-cleavage site mutations in P7 significantly associated with PI-exposure.  
Mutations showing significant different between 200 PI-naïve (none of them showing major PI 
mutations, 52 showing NRTI-resistance associated mutations and 23 showing NNRTI-resistance 
associated mutations) and 191 PI-experienced individuals (all of them showing major protease 
resistance associated mutations, 187/191 (98%) showing NRTI-resistance associated mutations and 
125/191 (80%) showing NNRTI-resistance associated mutations) are presentedTotal number of 
patients, percentage and p-values are shown. A p value of less than 0.05 was considered significant in 
a preliminary analysis. A Bonferroni’s correction was subsequently applied and a p of less than 
0.05/450 = 0.0001 was used instead. The mutations that remained significantly associated with PI 
exposure after the Bonferroni’s correction was applied are shown in bold.  
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P6 
MUTATION PI-naïve (n=200) PI-experienced (n= 191)  
n % n % P 
F463L 
F463V 
R464K 
R464G 
S465M 
G466R 
T469A 
T469I 
T470V 
T470A 
T471A 
T471S 
P472S 
Q474P 
E477G 
P478T 
P478Q 
I479V 
I479T 
0 
0 
0 
0 
0 
0 
0 
0 
0 
14 
4 
0 
0 
0 
0 
10 
0 
0 
6 
0 
0 
0 
0 
0 
0 
0 
0 
0 
7 
2 
0 
0 
0 
0 
5 
0 
0 
3 
22 
6 
12 
12 
8 
6 
6 
16 
6 
34 
18 
10 
10 
10 
10 
26 
22 
8 
22 
11 
3 
6 
6 
4 
3 
3 
8 
3 
18 
9 
5 
5 
5 
5 
14 
11 
4 
11 
<0.0001 
0.03 
0.0004 
0.0004 
0.007 
0.03 
0.03 
<0.0001 
0.003 
0.003 
0.03 
0.002 
0.002 
0.002 
0.002 
0.008 
<0.0001 
0.007 
0.003 
 
Table 4.1d Non-cleavage site mutations in P6 significantly associated with PI-exposure.  
Mutations showing significant different between 200 PI-naïve (none of them showing major PI 
mutations, 52 showing NRTI-resistance associated mutations and 23 showing NNRTI-resistance 
associated mutations) and 191 PI-experienced individuals (all of them showing major protease 
resistance associated mutations, 187/191 (98%) showing NRTI-resistance associated mutations and 
125/191 (80%) showing NNRTI-resistance associated mutations) are presented. A p value of less than 
0.05 was considered significant in a preliminary analysis. A Bonferroni’s correction was subsequently 
applied and a p of less than 0.05/450 = 0.0001 was used instead. The mutations that remained 
significantly associated with PI exposure after the Bonferroni’s correction was applied are shown in 
bold.  
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P1 
 
MUTATION 
PI-naïve  (n= 200) PI-experienced (n= 191)  
n % n % P 
K442R 0 0 8  4 0.007 
P2 V370M 
T371A 
T371Q 
N372P 
0 
0 
0 
0 
0 
0 
0 
0 
8 
8 
14 
6 
4 
4 
7 
3 
0.007 
0.007 
<0.0001 
0.03 
 
Table 4.1e Non-cleavage site mutations in P1 and P2 significantly associated with PI-exposure.  
Mutations showing significant different between 200 PI-naïve (none of them showing major PI 
mutations, 52 showing NRTI-resistance associated mutations and 23 showing NNRTI-resistance 
associated mutations) and 191 PI-experienced individuals (all of them showing major protease 
resistance associated mutations, 187/191 (98%) showing NRTI-resistance associated mutations and 
125/191 (80%) showing NNRTI-resistance associated mutations) are presented. A p value of less than 
0.05 was considered significant in a preliminary analysis. A Bonferroni’s correction was subsequently 
applied and a p of less than 0.05/450 = 0.0001 was used instead. The mutations that remained 
significantly associated with PI exposure after the Bonferroni’s correction was applied are shown in 
bold.  
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4.3.5 Comparison of Gag cleavage site mutations according to 
history of exposure to protease inhibitors  
At the five CSs, we detected 52 different mutations in PI-experienced individuals. The 
mutations were distributed as follow:  
 P17/P24. Six mutations were present at three positions: V128, Q130 and Y132. 
Variants at these residues were detected in 34/191 (18%), 16/191 (8%) and 2/191 (1%) PI-
experienced patients, respectively.  
 P24/P2. Three mutations were present at three positions A360, V362 and S368. 
Variants at these residues were detected in 2/191 (1%), 34/191 (18%) and 4/191 (2%) PI-
experienced patients, respectively. 
 P2/P7. 20 mutations were present at eight positions: S373, A374, T375, I376, M377, 
M378, R380 and G381. Variants at these residues were detected at a frequency ranging 
between 1% and 36% in the PI-experienced population.   
 P7/P1.Nine mutations were present at five positions: E428, R429, A431, K436, and 
I437. Variants at these residues were detected in 6/191 (3%), 2/191 (1%), 74/191 (39%), 
14/191 (7%), 28/191 (15%) and 4/191 (2%) PI-experienced patients, respectively. 
 P1/P6: 14 mutations were present at four positions: L449, S451, R452 and P453. 
Variants at these residues were detected at frequencies ranging between 1% and 21% in the 
PI-experienced population. 
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Overall, 17/52 CSMs were significantly associated with PI exposure when a cut-off of 0.05 
was considered. The majority of them 14/17 remained significantly associated with PI 
exposure after Bonferroni’s correction for multiple associations was applied (p= 0.05/50 = 
0.01). The 14 mutations associated with PI-exposure were: two in P17/P24 (V128I and 
Y132F), none in P24/P2, four in P2/P7 (S373T, A374S, T375A and T375N), three in P7/P1 
(A431V, K436R and I437V) and five in P1/P6 (L449F, S451T, S451R, R452S and P453T).  
 
Details of CSMs in PI-experienced and PI-naïve individuals are presented in table 4.1f.  
Comparison of the number of mutations detected on PI-naïve vs. PI-experienced sequences is 
depicted in figure 4.5.   
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 Mutation PI experienced 
patients (%) 
PI-naïve 
patients (%) 
p-value 
 
P17/P24 
Gag 128-137 
VSQNY/PIVQN 
V128I 
Y132F 
34 (18) 
16 (8) 
 
0 (0) 
0 (0) 
 
<0.0001 
< 0.0001 
 
P2/P7 
Gag 373-381 
SATIM/MQRGN 
S373A 
S373T 
A374S 
A374P 
T375A 
T375N 
G381S 
 
10 (5) 
16 (8) 
8 (4) 
6 (3) 
36 (19) 
36 (19) 
10 (5) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
15 (8) 
10 (5) 
2 (1) 
0.02 
<0.0001 
0.007 
0.03 
0.002 
<0.0001 
0.02 
 
P1/P7 
Gag 428-437 
ERQAN/FLGKI 
A431V 
K436R 
I437V 
74 (39) 
14 (7) 
28 (15) 
 
0 (0) 
2 (1) 
0 (0) 
 
<0.0001 
0.003 
<0.0001 
 
P1/P6 
Gag 444-453 
RPGNF/LQSRP 
L449F 
S451T 
S451R 
R452S 
P453T 
 
20 (10) 
16 (8) 
8 (4) 
10 (5) 
10 (5) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
<0.0001 
<0.0001 
0.007 
0.002 
0.002 
 
Table 4.1f Gag CSMs significantly associated with PI-exposure.  
Mutations showing significant different between 200 PI-naïve (none of them showing major PI 
mutations, 52 showing NRTI-resistance associated mutations and 23 showing NNRTI-resistance 
associated mutations) and 191 PI-experienced individuals (all of them showing major protease 
resistance associated mutations, 187/191 (98%) showing NRTI-resistance associated mutations and 
125/191 (80%) showing NNRTI-resistance associated mutations) are presented. Total number of 
patients, percentage and p-values are shown. A p value of less than 0.05 was considered significant in 
a preliminary analysis. A Bonferroni’s correction was subsequently applied and a p of less than 
0.05/50 = 0.001 was used instead. The mutations that remained significantly associated with PI 
exposure after the Bonferroni’s correction was applied are shown in bold.  
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Figure 4.5 Number of different mutations detected in PR and Gag functional domains and CSs 
in PI-naïve and PI-experienced patients.  
Sequences from 200 PI-naïve (none of them showing major PI mutations, 52 showing NRTI-
resistance associated mutations and 23 showing NNRTI-resistance associated mutations) and 191 PI-
experienced individuals (all of them showing major protease resistance associated mutations, 187/191 
(98%) showing NRTI-resistance associated mutations and 125/191 (80%) showing NNRTI-resistance 
associated mutations) were compared.  
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4.3.6 PROTEASE CONSENSUS SEQUENCES 
The reference sequence HXB2 for the 99 amino acids forming the HIV-1 protease and the two 
consensus sequences obtained from 200 PI-naive and 191 PI-experienced patients, respectively, are 
shown. Primary and secondary resistance positions are shown in red and blue, respectively. Dots 
denote identity with the reference sequence 
 
Amino acid 1 2 3 4 5 6 7 8 9 10 11 12 
HXB2 P Q V T L W Q R P L V T 
PI-naive . . . . . . . . . V . AINST 
PI-experienced . . . . . . . . . IFV I AINST 
 
 
 
Amino acid 13 14 15 16 17 18 19 20 21 22 23 24 
HXB2 I K I G G Q L K E A L L 
PI-naive AIV . IV AEG EG KQ ILT IK . . . . 
PI-experienced AIV . IV AEG EG KQ ILT IK . . IL IL 
 
 
 
Amino acid 25 26 27 28 29 30 31 32 33 34 35 36 
HXB2 D T G D D D T V L E E M 
PI-naive . . . . . . . . FLV . ED IM 
PI-experienced . . . . . DN . IV FLV . ED IM 
 
 
 
Amino acid 37 38 39 40 41 42 43 44 45 46 47 48 
HXB2 S L P G R W K P K M I G 
PI-naive ADES . KPQ . KR . KRT . KR . . . 
PI-experienced ADES . KPQ . KR . KRT . KR ILM IV AGMV 
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Amino acid 49 50 51 52 53 54 55 56 57 58 59 60 
HXB2 G I G G F I K V R Q Y D 
PI-naive . . . . . .  . . KR . . DE 
PI-experienced . ILV . . FL ILMT  .  . KR EQ . DE 
 
 
 
Amino acid 61 62 63 64 65 66 67 68 69 70 71 72 
HXB2 Q I L I E I C G H K A I 
PI-naive EQ IV AHLPVST IMV DE . CES . HQ KR . ITV 
PI-experienced EQ IV AHLPVST IMV DE . CES . HQ KR AILV ITV 
 
 
 
Amino acid 
 61 62 63 64 65 66 67 68 69 70 71 72 
HXB2 Q I L I E I C G H K A I 
PI-naive EQ IV AHLPVST IMV DE . CES . HQ KR . ITV 
PI-experienced EQ IV AHLPVST IMV DE . CES . HQ KR AILV ITV 
 
 
 
Amino acid 73 74 75 76 77 78 79 80 81 82 83 84 
HXB2 G T V L V G P T P V N I 
PI-naive . S . . IV . . . . I . . 
PI-experienced CGST PST . LV IV . . . . ACFSV . IV 
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Amino acid 85 86 87 88 89 90 91 92 93 94 95 96 
HXB2 I G R N L L T Q I G C T 
PI-naive . . . . LMV . . . IL . . . 
PI-experienced . . . DNS LMV LM . . IL . . . 
 
 
 
Amino acid 97 98 99 
HXB2 L N F 
PI-naive . . . 
PI-experienced . . . 
 
 
4.3.7 GAG CONSENSUS SEQUENCES 
The reference sequence HXB2 for the 500 amino acids forming the HIV-1 Gag polyprotein and the 
two consensus sequences obtained from 200 PI-naive and 191 PI-experienced patients, respectively, 
are shown below. CS positions are shown in red and the beginning of each domain is indicated. Dots 
denote identity with the reference sequence.  
 
 
Amino acid 1 2 3 4 5 6 7 8 9 10 11 12 13 
HXB2 M G A R A S V L S G G E L 
PI-naive . . . . . . IV IL . . AG EKQ . 
PI-experienced . . . . . . . . . . . . . 
 
 
 
P17 
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Amino acid 14 15 16 17 18 19 20 21 22 23 24 25 26 
HXB2 D R W E K I R L R P G G K 
PI-naive . AKQR . . KR . . . . . . GS KNRS 
PI-experienced . AKR . . KR . KQR . . . GM . KR 
 
 
 
Amino acid 27 28 29 30 31 32 33 34 35 36 37 38 39 40 
HXB2 K K Y K L K H I V W A S R E 
PI-naive . KMQR . KQR . . . ILV . . . . . . 
PI-experienced . HKMQRT . KMQR . . . ILV VL . . GS . . 
 
 
 
Amino acid 40 41 42 43 44 45 46 47 48 49 50 51 52 
HXB2 E L E R F A V N P G L L E 
PI-naive . . . . . ASV ILV . . GS . IL . 
PI-experienced . LM . . FY . ILV . . GS . . . 
 
 
 
Amino acid 53 54 55 56 57 58 59 60 61 62 63 64 65 
HXB2 T S E G C R Q I L G Q L Q 
PI-naive . ALS DEGN . . KR . . ILM AEGRTV . IL . 
PI-experienced . APST ADEG . . KQR KQR . ILM EGRSTV HQ . HQ 
 
 
 
Amino acid 66 67 68 69 70 71 72 73 74 75 76 77 78 
HXB2 P S L Q T G S E E L R S L 
PI-naive . AS IL KQ . . . . . FIL KR . LV 
PI-experienced PS AST . KQR AT . ST . . FLV KR . . 
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Amino acid 79 80 81 82 83 84 85 86 87 88 89 90 91 
HXB2 Y N T V A T L Y C V H Q R 
PI-naive FY . . IV AV TV . . . . . QR KNR 
PI-experienced FHY ANT . ILV AV TV . FWY CF . . EQR GKNQR 
              
 
 
 
Amino acid 92 93 94 95 96 97 98 99 100 101 102 103 104 
HXB2 I E I K D T K E A L D K I 
PI-naive . DEG IV KQR . . KR . . . DE . IV 
PI-experienced IV DEGN IV KR . . KNQ . . . DE KQR ILV 
 
 
 
Amino acid 105 106 107 108 109 110 111 112 113 114 115 116 117 
HXB2 E E E Q N K S K K K A Q Q 
PI-naive . . . QR NT EK CGRS EK . IKT AETV . PQ 
PI-experienced . . DEIQ . DKNST EKQRT CS EKQR EKQR AKQR AIKTV PQ EKNQPS 
 
 
 
Amino acid 118 119 120 121 122 123 124 125 126 127 128 129 
HXB2 A A A D T G H S N Q V S 
PI-naive . . . . AT EGR . . KNSQ NQS ASV . 
PI-experienced APTV AEPTV AENV ADEGS AEIKRTV AEGNRV ADHKNRS DKNQS EGNQRS HKNPQST AIV . 
 
 
 
Amino acid 130 
 
131 
 
 
132 133 134 135 136 137 138 139 140 141 
HXB2 Q N Y P I V Q N I Q G Q 
PI-naive QH . . . . . . . AILM . . . 
PI-experienced HQRS . FY . . . . . AILMPV PQ . . 
 
 
P24 
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Amino acid 142 143 144 145 146 147 148 149 150 151 152 153 
HXB2 M V H Q A I S P R T L N 
PI-naive . IV . . ANPS ILM ST AP . . . . 
PI-experienced AMW ITV . . APS ILMP . . . DT . . 
 
 
Amino acid 154 155 156 157 158 159 160 161 162 163 164 165 
HXB2 A W V K V V E E K A F S 
PI-naive . . . . . IV EK . . AGN . NS 
PI-experienced . . . . . INV . . . AS . NS 
 
 
 
Amino acid 166 167 168 169 170 171 172 173 174 175 176 177 
HXB2 P E V I P M F S A L S E 
PI-naive . . IV . . . . AST . . AS . 
PI-experienced . . . IN . . . AST . . AS DE 
 
 
 
Amino acid 178 179 180 181 182 183 184 185 186 187 188 189 
HXB2 G A T P Q D L N T M L N 
PI-naive . AC . . QS . . . ST . . . 
PI-experienced . . . . HQ . . . MTV . . . 
 
 
 
Amino acid 190 191 192 193 194 195 196 197 198 199 200 201 
HXB2 T V G G H Q A A M Q M L 
PI-naive AT . . . . . . . . . . . 
PI-experienced IT IV . . . . . . . . IM . 
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Amino acid 202 203 204 205 206 207 208 209 210 211 212 213 
HXB2 K E T I N E E A A E W D 
PI-naive . DE . . . DE . . . . . . 
PI-experienced . DE AT . . DE . . ASV DE . . 
 
 
 
Amino acid 214 215 216 217 218 219 220 221 222 223 224 225 
HXB2 R V H P V H A G P I A P 
PI-naive . ILMTV . . AV HQ . . . AINV APV . 
PI-experienced . AILMTV . . AV HQ . . . AIV APV . 
 
 
 
Amino acid 226 227 228 229 230 231 232 233 234 235 236 237 
HXB2 G Q M R E P R G S D I A 
PI-naive . . IM . DE . . . . . . . 
PI-experienced . . IKLM . DE . . . . . . AP 
 
 
 
Amino acid 238 239 240 241 242 243 244 245 246 247 248 249 
HXB2 G T T S T L Q E Q I G W 
PI-naive . ST . . NT . AQ . . IV AGNT . 
PI-experienced . ST PT . NST LP . DE . IV AGNT . 
 
 
 
Amino acid 250 251 252 253 254 255 256 257 258 259 260 261 
HXB2 M T N N P P I P V G E I 
PI-naive . . GNST . AP AP IV . . . DE . 
PI-experienced . . GHNS . . AP ITV . . . DE . 
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Amino acid 274 275 276 277 278 279 280 281 282 283 284 285 
HXB2 V R M Y S P T S I L D I 
PI-naive . KR . . . . STV . . . . . 
PI-experienced . KR . . . . ACITV . . . . . 
 
 
 
Amino acid 286 287 288 289 290 291 292 293 294 295 296 297 
HXB2 R Q G P K E P F R D Y V 
PI-naive EKR . . . . . PS . . . . . 
PI-experienced KR . . . . . PS . . . . . 
 
 
 
Amino acid 298 299 300 301 302 303 304 305 306 307 308 309 
HXB2 D R F Y K T L R A E Q A 
PI-naive . . . FY KRS TV . . . . . AS 
PI-experienced . . . FY . ATV IL . . . . . 
 
 
 
Amino acid 310 311 312 313 314 315 316 317 318 319 320 321 
HXB2 S Q E V K N W M T E T L 
PI-naive ST PQ DE . . HNST . . . DE . . 
PI-experienced ST . DE . . GN . . . DE ST . 
 
 
 
Amino acid 322 323 324 325 326 327 328 329 330 331 332 333 
HXB2 L V Q N A N P D C K T I 
PI-naive . IV . . AS . . . . KR NTS . 
PI-experienced . . . . AS . . . . . ST . 
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Amino acid 334 335 336 337 338 339 340 341 342 343 344 345 
HXB2 L K A L G P A A T L E E 
PI-naive . KR . LM EG PQ AG . ST . . DE 
PI-experienced . KR . . . PT AG AS ST LQ EK DE 
 
 
 
Amino acid 346 347 348 349 350 351 352 353 354 355 356 357 
HXB2 M M T A C Q G V G G P G 
PI-naive IM . AIT . . . . . . . . GS 
PI-experienced . . AST . . . . LV . . . GS 
 
 
 
Amino acid 358 359 360 361 362 363 364 365 366 367 368 369 
HXB2 H K A R V L A E A M S Q 
PI-naive . . . KR IV . . . . . GS HQ 
PI-experienced . . AS . IV . . . . . CS HQ 
 
 
 
Amino acid 370 371 372 373 374 375 376 377 378 379 380 381 
HXB2 V T N S A T I M M Q R G 
PI-naive AIV SNT GNQS APQST ASNPT AINSTV IMV LM IMV . KR GS 
PI-experienced AMV ANQST GNPQS ACPST ANPST AINSTV IMV LM IMV . KR GS 
 
 
 
Amino acid 382 383 384 385 386 387 388 389 390 391 392 393 
HXB2 N F R N Q R K I V K C F 
PI-naive NT FY KR NST PQ KR KR INMPST IV . . . 
PI-experienced . FY NKRS GKNRS PQ GKR . AINPRSTV AIV KR . . 
 
 
 
P2 
P7 
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Amino acid 394 395 396 397 398 399 400 401 402 403 404 405 
HXB2 N C G K E G H T A R N C 
PI-naive . . . KR DET . . ILT AS KR . . 
PI-experienced . . . KR DEQT . . ILTV . KR . . 
 
 
 
Amino acid 406 407 408 409 410 411 412 413 414 415 416 417 
HXB2 R A P R K K G C W K C G 
PI-naive KR . . . KR KR . . . . . . 
PI-experienced KR . . . KR KR . . . KR . . 
 
 
 
Amino acid 418 419 420 421 422 423 424 425 426 427 428 429 
HXB2 K E G H Q M K D C T E R 
PI-naive KQR . . . . IM KR DE . NT ED . 
PI-experienced KQR . . . . IM KR DE . AINST EDG GKR 
 
 
 
Amino acid 430 431 432 433 434 435 436 437 438 439 440 441 
HXB2 Q A N F L G K I W P S Y 
PI-naive . . . . . . KR . . PS PS HY 
PI-experienced . AV . . . . GKR ILV . PS PS HY 
 
 
 
Amino acid 442 443 444 445 446 447 448 449 450 451 452 453 
HXB2 K G R P G N F L Q S R P 
PI-naive . . . . . . . LP EQ ANS . LP 
PI-experienced KR EG . . . . . FHLPV . GNRST GRS ALPST 
 
 
 
P1 
P6 
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Amino acid 454 455 456 457 458 459 460 461 462 463 464 465 
HXB2 E P T A P P E E S F R S 
PI-naive ET . ST . . . AE . . . . . 
PI-experienced AEP . ST . . . AE EQ ILS FLV EGKLR CEFMS 
 
 
 
Amino acid 466 467 468 469 470 471 472 473 474 475 476 477 
HXB2 G V E T T T P P Q K Q E 
PI-naive GR . EG KT AT APT . PS . KR PQ DE 
PI-experienced GMQR EV EGK AIKT AITV APQST PS PS QP . . DEG 
 
 
 
Amino acid 478 479 480 481 482 483 484 485 486 487 488 489 
HXB2 P I D K E L Y P L T S L 
PI-naive LPST IKRT . . DEG KLMQ PY . LV AT . . 
PI-experienced AKPQST AEGIKLRTV DEGNSV EKNQR DEG KLMQP APY AP . ADSTV AS . 
 
 
 
Amino acid 490 491 492 493 494 495 496 497 498 499 500 
HXB2 R S L F G N D P S S Q 
PI-naive KR . . . . NS . PL LS LS KQ 
PI-experienced KR . . . . NS DS PQ LST . KQT 
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4.3.8 Association between protease and Gag mutations 
We analyzed the 191 sequences obtained from PI-experienced patients and explore the 
relationship between major resistance mutations in PR (22 mutations at 14 positions listed 
along the 99 amino acids) and Gag mutations identified in this study and described in section 
4.3.4 as being associated with PI-exposure, after Bonferroni’s correction for multiple 
comparisons was applied (19 mutations at 18 non-CS positions and 14 mutations at 12 CS 
positions). Therefore, PR mutations including in this analysis were: D30N, V32I, M46I, 
M46L, I47V, G48A, G48M, G48V, I50L, I50V, I54L, I54M, I54T, L76V, V82A, V82C, 
V82F, V82S, I84V, N88D, N88S and L90M. Gag Non-CSMs associated with PI-exposure 
included in the analysis were:  L61I, I94V, K103R, K113Q, K114R, D121G, D121A, T122E, 
N126S, Q127K, T186M, T190I, A210S, E211D, S310T, T371Q, F463L, T469I and P478Q. 
Finally, Gag CSMs associated with PI exposure included in the analyses were: V128I, 
Y132F, S373T, A374A, T375A, T375N, A431V, K436R, I437V, L449F, S451T, S451R, 
R452S and P453T. A total of 418 combinations of Non-CSMs and major PR resistance 
mutations were identified and analyzed with Fischer’s exact test. Only two associations were 
selected based upon the Bonferroni’s corrected p value cut-off (< 0.05/418 = 1.2 x 10-4).  
Similarly, we identified 308 combinations of major PR and CSMs and only one associations 
retained significance after applying the Bonferroni’s correction for multiple associations (p < 
0.05/308 = 1.6 x 10
-4
).   The association between the CSM A431V and the PR mutations 
M46I/L  as well as between CSM L449F and I84V that have been extensively described in 
the literature were close to the cut-off p value defined in the study ( p = 6 x 10
-4 
and 2 x 10
-4
, 
respectively) . Results are shown in table 4.2    
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P values for indicated Gag residues
a
 
Protease 
mutations 
P17 
N126S 
P17/P24 
Y132F 
P2/P7 
T375A    G381S 
P7/P1 
A431V
b
 
P1/P6 
L449F
b 
D30N  0.008    
M46I/L < 10
-5
 0.03 0.004 6 x 10
-4
  
I54V < 10
-5
   < 10
-4
  
V82A   0.02   
I84V     2 x 10
-4
 
L90M    0.01  
 
Table 4.2 Association between major protease resistance mutations and Gag mutations.  
The table shows the associations between Gag and major protease resistance mutations which were 
statistically significant when considered a p value = 0.05.  
a
p values in bold correspond to the 
associations retained using the Bonferroni’s correction method (p= 1.2 x 10-4 for NCSMs and 1.6 x 10-
4
 for CSMs, respectively). 
b
The association between A431V and M46I/L and between L449F and 
I84V showed  p values close to the Bonferroni’s corrected p value defined in the study p = 1.6 x 10-4. 
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4.4 Discussion 
In the present chapter, we performed a cross-sectional comparison of sequences from PI-
naïve and PI-experienced individuals in order to assess differences in the prevalence and 
patterns of mutations in the Gag protein. We identified key substitutions in both cleavage and 
non-cleavage site residues of Gag that were significantly associated with PI-exposure and the 
presence of major resistance mutations in the PR gene.  
 
Multiple pressures shape the evolution of Gag during long-term HIV-1 infection. Firstly, its 
key role in viral assembly and infectivity, which is mediated by the functional role of 
different gag cleavage products (Wang et al. 1993). Secondly, the immune system, as 
numerous CD8 epitopes are known to be located across the gag protein. Lastly, in those 
patients on suboptimal PI-based regimens who develop mutations on PR, Gag protein is 
likely to co-evolve in order to preserve the efficient cleavage of the polypeptide by the 
mutated PR. 
  
During or soon after the release of the immature virion from the plasma membrane, the gag 
polyprotein precursor (Pr55
gag
) is cleaved by the viral PR into four major Gag cleavage 
products, namely P17, P24, P7 and the C-terminal peptide P6. In addition, two small spacer 
peptides are generated - P2 which is closer to the N-terminus of Gag and P1. Polyprotein 
processing causes a dramatic transformation in viral structure. This process, known as 
maturation, gives rise to the condensed conical core, which is characteristic of fully infectious 
HIV viral particles. Each of the individual Gag proteins has multiple functions. The P17 
- 186 - 
 
protein plays a crucial role in targeting the Gag precursor to the site of assembly on the 
plasma membrane (Facke, et al. 1993; Spearman, et al. 1994; Wang et al, 1993; Yuan et al. 
1993); it is also essential for the stable association of the envelope glycoprotein with the viral 
capsid (Dorfman et al, 1994; Wang et al. 1993; Yu, et al. 1992) and its association with the 
pre-integration complex suggests that it might be important in directing this complex to the 
nucleus (Burkrinsky et al, 1993a; Burkrinsky et al, 1993b). The P24 protein is the major 
structural component of the virion, forming the capsid that encases the ribonucleoprotein 
complex. It influences both viral assembly and replication activities and determines the 
internal organization of the assembled and budded viral material (Cairns and Craven, 2001).  
The P7 protein contains sequences that are essential for the efficient encapsidation of the viral 
genomic RNA into the assembled viral particles (Aldovini and Young, 1990; Dorfman et al, 
1993; Gorelick, et al. 1988). The C-terminus proline-rich P6 peptide appears to be important 
in mediating viral budding (Gottlinger, et al. 1991). Little is known about the function of the 
two spacer peptides P1 and P2, which are present in all primate lentivirus.  Although poor 
conservation in sequence and length of these two peptides has been reported among different 
viruses (Henderson et al, 1988), their consistent presence suggests that they may have an 
important function in the retrovirus life-cycle. In fact, in the case of P2, early studies showed 
that this spacer peptide is essential for virus replication (Henderson et al, 1988).  
 
In agreement with the crucial roles that each functional Gag protein exerts in the life-cycle of 
HIV, we observed conserved amino acid motifs in each of them, including many known to be 
essential in the accomplishment of protein function during viral assembly. The first few 
amino acids located in the N-terminal of MA-P17 contain a myristilation signal that is 
essential for the formation of extracellular viral particles (Bryant et al. 1990; Gottlinger et al. 
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1989). In addition, a stretch of basic amino acids located between amino acid 17 and 31 is 
known to be responsible for the targeting of HIV-1 Gag to the plasma membrane during virus 
assembly by interacting with acidic phospholipids (Zhou et al, 1994). In an early mutagenesis 
analysis of the matrix protein performed by Freed and colleagues, mutations at some residues 
in this region, (i.e., R20, L21 and P23) were found to significantly decrease virus production 
(Freed et al, 1994). In the same study, several scattered residues in the C-terminus of matrix, 
such as A37, L50, E52, were also reported to decrease viral production and mutations at G56, 
C57 and I60 resulted in the complete absence of viral replication as well as mutations 
between positions L85 and H89.   
 
A high degree of conservation was observed in P24. The major homology region (MHR), 
which is located between amino acids I285 and L304, is known to be conserved across all 
lentivirus and has an important role in viral replication (Gorelick et al, 1990). Mutations in 
this region often interfere with particle assembly (Borsetti et al, 1998; Dorfman et al, 1994; 
Ebbets-Reed et al, 1996; Gamble et al, 1997; Mammano et al, 1994).Mutations at residues 
Q155, E159 and Y164 substantially reduce gag proteins release. In addition, numerous 
mutations scattered throughout the P24 protein have been found to block viral assembly and 
release (Chazal et al, 1994; Mammano et al 1994; Zhao et al 1994).  
 
The P7 protein contains the histidine box located between amino acids C392 and C405, 
which constitutes a metal-binding domain essential for effective RNA encapsidation, and 
mutations in this region yield viral particles with defective RNA encapsidation (Aldovini et al 
1990; Gorelick et al 1988; Gorelick et al 1990).  Three cysteines (C392, C395 and C405) and 
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one histidine (400H) are conserved. In addition, an aromatic amino acid at position Y393 and 
a basic amino acid at position K397 are also conserved.  
 
Consistent with these findings, the residues mentioned above were also highly conserved 
across our study population.  
 
P6 has been found to be the most variable protein in all primate lentiviruses including HIV 
(Accola et al, 2000). In agreement with this data, we observed some degree of variability in 
most of the amino acids of this protein in our population. However, even in this highly 
variable peptide we could recognise two highly conserved motifs. The first one was the 
PT/SAP motif located close to the amino terminus end of P6, from amino acids 455P to 
459P; this has been reported to be essential for viral release (Gottlinger et al, 1993; Huang et 
al, 1995). It has been demonstrated that mutations in this domain cause a defect in the 
budding process, which results in a larger number of immature particles tethering to the 
plasma membrane (Gottlinger et al 1991; Huang et al, 1995). The second conserved domain 
in the P6 protein was located towards the C-terminus and included amino acid L489 and 
491SLFG494. The conservation of this motif is less understood; the residues are known to be 
essential for the incorporation of the accessory protein Vpr into the assembling HIV-1 virion 
(Kondo et al, 1995; Kondo et al, 1996; Lu et al, 1995).  However, since this motif is 
dispensable for the incorporation of Vpr or the equivalent Vpx in certain simian 
immunodeficiency virus (Accola et al, 1999), it can be proposed that the interaction of the 
motif with other crucial factors during viral assembly must be in fact responsible for the 
striking conservation across HIV-1 strains. Apart from this constraint, the rest of the P6 
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protein seems to exhibit high plasticity with the exception of a few scattered conserved 
residues. 
 
With regard to the CSs, we observed a high degree of conservation in some of the amino 
acids that constitute the site of cleavage of HIV-1 PR, in particular those that directly 
constitute the cleavage bond (P1 and P1’). Sequential and ordered proteolytic processing of 
HIV-1 Gag is required to achieve fully infectious viral particles, and this process partially 
depends on the amino acid sequence within the processing site, thus explaining the necessity 
for some degree of conservation in the CS sequences. However, other determinants, such as 
the sequence of regions near the processing site that determines its accessibility are likely to 
contribute to effective processing. In addition, conservation across CSs is not equally 
distributed. Some of them, such as P2/P7, were highly variable, while others, such as P24/P2, 
were highly conserved. Amino acids at CSs are not only important for the concerted cleavage 
of the gag precursor polyprotein by the viral PR, but may in some cases be part of larger 
domains crucial for completion of the viral life-cycle. For example, amino acids located at the 
P24/P2 CS, and in particular those between amino acids L363 and S368, have been found to 
be part of a domain in P24 essential for viral replication. By contrast, those located in the 
P2/P7, and particularly those at the N terminus site between amino acids 373S and 378M, can 
be deleted without having a significant impact on viral replication, (Accola et al, 1998), 
which may at least partially explain the marked differences in variability in these two CSs.  
 
When we compared the PR and gag sequences obtained from PI-naïve and PI-experienced 
patients, we observed that PI-experienced patients had a higher variability not only in PR but 
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also throughout the Gag polyprotein. Importantly, certain mutations were significantly more 
prevalent in PI-experienced patients and others were completely absent across the PI-naïve 
population, suggesting that selective pressure with PIs leads to genetic evolution not only in 
PR but also in Gag. A role for Gag mutations in mediating PI resistance was proposed early 
after the introduction of PIs in antiretroviral therapy. In 1996, Doyon and colleagues 
demonstrated that HIV-1 variants highly resistant to PIs in vitro, showed mutations in the PR 
and also in the two gag CSs P1/P6 and P7/P1. In addition, they observed that CSMs improved 
polyprotein processing in viruses with PR mutations, providing the first evidence of a 
possible mechanism by which mutations in Gag can compensate for impaired PR activity. 
Furthermore, they observed that PR-mutated viral clones that contained CSMs grew much 
better in vitro than clones in which such mutations were removed by site-directed 
mutagenesis, highlighting a potential compensatory role for the CSMs (Doyon et al, 1996).  
Since then, numerous studies have demonstrated a role for Gag CSMs in failure to PIs, in 
particular for those located at the C-terminal P7/P1/P6. Although most studies agree on 
attributing a compensatory role to CSMs, the mechanism by which these mutations exert their 
function seems to differ. Thus, Gatanaga and colleagues observed that mutations in Gag were 
indeed essential for the efficient replication of APV-resistant variants. However, while the 
mutated gag was required for viral replication, the rate of cleavage was comparable to that 
exhibited by wild-type gag, suggesting that an alternative mechanism must be responsible for 
the compensatory role of Gag mutations towards improved polyprotein processing (Gatanaga 
et al, 2002).   
Most of the mutations at these two CSs (P7/P1 and P1/P6) that were associated with PI-
exposure in our study, such as A431V, I437V, K436R or L449F, have been previously 
described.  Thus, in line with previous studies (Verheyen et al, 2006), the A431V mutation 
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was found to be the most prevalent mutation in PI-experienced patients in our population. 
This mutation has been described before, both in vitro and in vivo (Mammano et al, 2000; 
Zhang et al, 1997; Maguire et al, 2002; Cote et al, 2001; Bally et al, 2000 and Dauber et al, 
2002). The residue is in direct contact with the substrate-binding pocket and the mutation 
results in an enhanced cleavage of P7/P1 by wild-type PR. Increased processing of A431V-
containing CS was also demonstrated in the background of primary PR resistance mutations 
at codons 46, 82, 84 and 90 (Feher et al, 2002).  Similarly, the L449F mutation, which on its 
own does not confer PI resistance, was associated with reduced PI susceptibility in the 
background of the major PR mutation I50V (Maguire et al, 2002; Prado et al, 2002). In 
addition, mutations such as I437V, which was also found to be associated with PI-exposure in 
our study, have been associated with enhanced proteolytic processing and direct contribution 
to PI resistance. Of note, the mutation was selected in the absence of any substitution in the 
PR during in vitro passages employing novel PIs (Nijhuis et al, 2007).  
 
In our study, we found mutations associated with PI-exposure not only at P7/P1/P6 CS but 
also at all other CS, except for P24/P2. This cleavage site, similarly to what we observed in 
PI-naïve individuals, was also highly conserved in PI-experienced patients and the rare 
mutations detected in this site did not show a significant different prevalence between PI-
naïve and PI-experienced patients. The P24/P2 sequence has been reported to be one of the 
best HIV-1 processing sites (Richards et al, 1990 and Tozser et al, 1991), an observation that 
may account for the high degree of conservation observed in both PI-naïve and PI-
experienced patients, as little improvement can be added by sequence modification. In 
addition, as mentioned above, this CS along with sequences located closely in P24 and P2 
constitutes a domain that plays a pivotal role in viral replication (Accola et al, 1998). 
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 We detected a number of mutations at P2/P7 and P17/P24 that were significantly associated 
with exposure to the PIs. The implication of mutations at these two CS in PI failure has been 
only briefly suggested in the literature. For example, the two mutations in P17/P24 associated 
with PI-exposure in our study, namely V128I and Y132F, have been previously reported. 
V128I was documented by Dierynck and colleagues as the only CS gag mutation emerging in 
patients whose viral load rebounded during DRV/r monotherapy (Dierynck et al, 2007). 
Similarly, the Y132F mutation was found to be linked to certain primary PR mutations and 
associated with improved rate of cleavage of P17/P24 (Myint et al, 2004; Ueda et al, 2005). 
Mutations at P2/P7 have also been briefly documented. Malet and colleagues reported an 
association between variants at codon 373 and impaired responses to ritonavir booster 
saquinavir (SQV/r)-based regimens. Nevertheless, a clear role for mutations at P17/P24 and 
P2/P7 in failure to PIs remains to be established, although it is worth mentioning that the 
number of studies looking at the P7/P1/P6 CS by far outnumbers that of studies looking at 
other CSs, explaining the substantial difference in information regarding mutations in PI-
experienced patients at this CS and the others.  
 
In the present chapter, we have seen that under PI-selective pressure mutations are likely to 
be selected not only in PR and its CSs but also in gag regions outside of the CSs. A role for 
Gag mutations outside cleavage site in PI failure has been previously suggested. Gatanaga 
and colleagues studied the effect of various substitutions on the development of HIV-1 
resistance to APV: L75R in the P17 protein, H219Q in the P24 protein, V390D/A and R403K 
in the P7 protein and E468K in the P6 protein, together with the P1/P6 CSM L449F. They 
concluded that both the CSMs and the mutations located outside CSs were essential for the 
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efficient replication of APV-resistant HIV-1. They also observed that while some non-CSMs 
were selected before major APV resistance-associated mutations, others only emerged after 
the selection of major PR mutations; both groups were shown to be required for efficient viral 
replication. However, they failed to demonstrate any differences in the mutated PR cleavage 
patterns between the wild-type and the gag mutated virus, suggesting once again that gag 
evolution under PI-selective pressure may facilitate certain functions such as assembly, 
packaging and budding functions and contribute to resistance to PIs by means other than 
recovery of polyprotein cleavage function (Gatanaga et al, 2002). Similarly, Myint and 
colleagues demonstrated that non-CSMs are as important as CSMs for the recovery of fitness 
in PI-resistant viruses. In addition, they saw that non-CSMs differed in different viral clones, 
suggesting that while PR and CS mutations implicated in PI-failure may be consistent across 
different patients, the pattern of non-CSMs may vary widely (Myint et al, 2004).  
 
In our study, we observed a trend towards a higher number of mutations in PI-experienced 
patients compared with PI-naïve patients at all gag domains. The effect was particularly 
noticeable in the P17 and the P6 proteins, suggesting a potentially more prominent role of the 
two proteins in PI failure compared with other gag regions. Recently, Parry and co-authors 
studied full-length Gag and PR genes from one multidrug resistant clinical isolate and 
showed that the P17 protein from the multidrug resistance virus was on its own able to rescue 
the replicative capacity (RC) of the mutated PR to the level observed in the WT virus. In 
addition, they also demonstrated that such mutated P17 protein could lead to a reduction in 
susceptibility to PIs in the absence of major PR resistance mutations, suggesting that major 
determinants of PI-resistance may be located in the HIV-1 P17 protein (Parry et al, 2009). 
They observed 12 mutations in the P17 protein from the clinical isolate when compared with 
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the HXB2 reference sequence; of these six (I34L, T84V, E93D, I94V, N124K and N126S) 
were found to be associated with PI selective pressure in our analysis. In particular two 
mutations (I94V and N126S) remained significant even after applying the Bonferroni’s 
correction. Similarly, other studies have suggested that the P6 protein inhibits HIV-1 PR 
function (Paulus et al, 1999) and therefore it is speculated that variations in its sequence may 
change PR activity, thereby affecting viral fitness and PI susceptibility. Kaufman and co-
workers explored this hypothesis by looking at mutations in the P7/P1/P6 CS and the P6 
protein in patients who experienced virological failure while on a SQV/r-based therapy. They 
observed that mutations emerged in the P6 region and were in general associated with major 
PR mutations which suggest a compensatory role for mutations in this region. They also 
reported an association between insertions in the P6-region and failure (Kauffman et al, 
2001). This observation has not been confirmed by other investigators, and in fact we did not 
find a higher prevalence of insertions in the P6 protein in PI-experienced patients compared 
with PI-naïve individuals in our study.  
 
 Several statistically significant associations between Gag and PR mutations were identified 
in the present analysis. The M46I/L mutation was associated with the CSM A431V as well as 
with the mutation N126S in P17. A431V was also associated with the I54V mutation in PR. 
The M46I/L and I54V mutations have been found to be associated in isolates obtained from 
patients receiving PI-based regimen (Wu, 2003) and may be selected in patients failing IDV/r 
(Condra et al, 1996). The relationship of the M46I/L and I54V cluster with the A431V 
mutation in Gag has been previously described (Bally et al, 2000; Koch et al 2001; Malet et 
al, 2007). In addition, we identified an association between the PR mutation I84V and the 
P1/P6 Gag CSM L449F. This association was also previously described by Verheyen and 
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colleagues (Verheyen et al; 2006). In addition, we observed an association between a non-
CSM located in the P17 protein N126S and two major PR mutations M46I/L and I54V, 
which has not been previously reported. However, as it has been previously pointed, studies 
addressing the impact of mutations beyond the Gag CSs NC-P7/P1/P6 are scarce. In the study 
performed by Parry and colleagues, a multi-protease resistant patient showed the M46I, 
L33F, I54V and V82A mutations in PR and full length gag sequencing identified the N126S 
mutation in the P17 protein along with other seven mutations. However, the study was based 
on the analysis of a single patient and therefore no statistical association between mutations 
could be confirmed. As discussed above, the study showed the important role that the P17 
protein plays in conferring resistance to PIs, but whether this can be attributed to specific 
residues or to the whole protein was not clarified in the study.  
 
It should be emphasized that all of the sequences analyzed in the present chapter were 
subtype B HIV-1 and consequently those mutations identified as associated with PI exposure 
in our population could be naturally occurring polymorphism in other HIV-1 subtypes what 
may have implications for susceptibility to PIs of such non-B subtype viruses. Studies 
addressing the variability of gag in both B and non-B subtypes are scarce. De Oliveira and 
colleagues reported a greater variability of Gag for subtype C HIV-1 compared to B subtype 
particularly at certain CSs such as P2/P7 and P17/P24 (De Oliveira et al, 2003). Similarly, 
Jinnopat reported a higher Gag variability in subtype CRF01 HIV-1 (Jinnopat et al, 2009) and 
in particular the mutations L61I and P66S in P17 were frequently detected in drug-naïve 
CRF01 viruses. Both L61I and P66S mutations were associated with PI-exposure in our study 
and in the case of L61I mutation the association remained significant once the Bonferroni’s 
correction for multiple associations was applied.  In addition, Gupta and co-authors detected 
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the T84V mutation frequently in subtype A (Gupta et al, 2010), which have also been 
associated with PI-exposure in our study.  Importantly, both Jinnopat and Gupta reported a 
decreased susceptibility of recombinant viruses containing CRF01 and A subtype Gag, 
respectively, compare to viruses containing subtype B Gag (Jinnopat et al, 2009 and Gupta et 
al, 2011). Overall, these findings suggest that indeed mutations selected under PI –selective 
pressure in subtype B HIV-1 can occur as natural polymorphism in non-B subtypes and may 
contribute to decrease susceptibility to PIs of non-B subtype HIV-1 viruses. However, further 
studies are required to confirm this hypothesis. In summary, in this chapter we have showed 
that several Gag mutations are more common in subtype B-infected PI-experienced patients 
than in those who have never been exposed to these drugs infected with the same subtype, 
and demonstrated that certain specific mutations were in fact statistically associated with PI-
exposure.  
 
In agreement with previous studies, we have found that mutations located at P2/P7/P1/P6 
including T375A, A431V, I437V and L449F were associated with PI exposure and with the 
presence of specific PR mutations namely M46IL, I54V and I84V. In addition, by addressing 
full-length Gag sequencing, we have expanded previous reports and have identified a number 
of mutations strongly associated with PI selective pressure namely, V128I, Y132F, S373T, 
A374S, T375N and S451T in Gag CS and L61I, I94V, K103R, K113Q, K114R, D121AG, 
N126S, T186M, A210S, E211D, T371Q, F463L, T469I and P478Q outside gag CS.   
 
 As a consequence full-length PR and gag sequencing may be of importance for the full 
assessment of failure to PIs. A longitudinal analysis of Gag and PR genes in patients with 
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ongoing viraemia while on PI-based regimen may be helpful to clarify the role of gag mutations 
in failure to PI inhibitors. Clonal analysis and phenotypic analysis could be also important to 
confirm linkage and effect of specific gag mutations. These points will be addressed in 
subsequent chapters.    
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5 Chapter five: genetic evolution of HIV-1 Gag and 
protease in patients failing a ritonavir-boosted 
protease inhibitor-based antiretroviral regimen  
5.1 Introduction 
Ritonavir-boosted protease inhibitors (PI/r) are among the most effective antiretroviral drugs 
(ARVs) currently employed for the treatment of HIV infection. These compounds inhibit the 
proteolytic activity of the viral protease enzyme and as a result they exert a powerful 
inhibitory action on HIV replication both “in vitro” and “in vivo”. In the large majority of 
treated patients, combination regimens containing PI/r result in effective and sustained 
suppression of HIV replication, dramatically reducing HIV-related morbidity and mortality. 
However, as with all other ARVs, failure to fully suppress HIV replication leads to the 
development of PI drug-resistance.  
 
HIV resistance to PIs is a stepwise process in which accumulation of amino acid substitutions 
in the viral protease causes a progressive increase in the level of resistance. (Condra et al, 
1996; Molla et al, 1996). The first mutations to be selected are generally those affecting 
amino acids that are in or close to the substrate-binding site of the enzyme: these mutations, 
which are termed primary mutations, often differ from one PI to another. Subsequently, 
secondary mutations develop, which involve amino acids located away from the substrate-
binding site: these mutations are generally less drug-specific than primary mutations. Primary 
and secondary mutations produce in conjunction an enlargement of the catalytic site of the 
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enzyme, which decreases the affinity of the viral protease for the inhibitor (Logsdon et al; 
2004; Prabu-Jeyabalan et al; 2006a; Prabu-Jeyabalan et al, 2006b). In general, primary 
mutations are accountable for the resistant phenotype displayed by the mutated virus. By 
contrast, secondary mutations often do not have a substantial resistance effects, but they 
restore, at least partially, the fitness impairment caused by primary mutations. As a 
consequence, secondary mutations are still critical for the development of high-level PI 
resistance (Mammano et al, 2000; Martinez-Picado et al, 1999; Zennou et al, 1998).  
As discussed in the previous chapter, a key feature of resistance to the PIs is that mutations 
implicated in drug resistance and viral fitness are located not only in the viral protease, but 
also in its natural substrate Gag. Similarly to secondary mutations in the HIV-1 protease, 
substitutions in Gag were initially described as compensatory mutations aimed at restoring 
the loss of viral fitness caused by primary mutations (Doyon et al, 1996; Zhang, et al. 1997). 
Following these  observations, several studies pointed to the importance of Gag mutations in 
the evolution of HIV resistance to the PIs (Brumme et al, 2003; Banke et al, 2009; Brann et 
al, 2006; Cote et al, 2001; Maguire et al, 2002; Malet et al, 2007; Robinson et al, 2000). Since 
then, evidence has been accumulating that Gag mutations can also directly affect HIV 
susceptibility to the PIs independently of their effect on viral fitness (Zhang et al, 1997;; 
Maguire, et al. 2002; Prado, et al. 2002). Two recent studies in particular, clearly 
demonstrated that Gag mutations should be considered as authentic PI resistance mutations 
(Dam et al, 2009; Nijhuis et al, 2007). Nevertheless, it should be emphasized that all of the 
above studies have exclusively investigated mutations affecting cleavage site (CS) sequences 
in the P7-NC/P1/P6 region of Gag. A more recent paper however suggested that domains in 
Gag beyond its CSs can have both resistance and fitness effects in viruses bearing primary 
mutations in the protease (Parry et al, 2009).  
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Despite this body of knowledge, the impact of Gag mutations on clinical responses to PI-
based regimens remains to be established. Several studies have demonstrated that patients 
experiencing viraemia during their first PI/r containing regimen infrequently show primary 
protease resistance mutations in routine testing (Kempf et al, 2004; Delaugerre et al, 2009; 
Gupta et al, 2008; Lathouwers et al, 2011). Suboptimal adherence and fast pharmacokinetics 
of PIs compared to other drug classes such as the non-nucleoside reverse transcriptase 
inhibitors (NNRTIs) (Bangsberg et al, 2004) have been suggested as determinants for the 
frequent lack of protease drug-resistance mutations at the time of PI/r failure. Rapid clearance 
in particular may explain both the more common occurrence of rebound low-level viraemia 
during PI/r therapy and the narrower window for effective drug-selective pressure (i.e., the 
optimal combination of sufficient levels of virus replication and sufficient drug levels) 
compared to the NNRTIs (Bangsberg et al, 2004; Geretti et al, 2008). However, emergence of 
protease mutations can be observed during prolonged failure of a PI/r based regimen, and is 
facilitated by pre-existing protease mutations (Bandaranayake et al, 2010). There are scarce 
longitudinal data addressing Gag evolution in this population.  
 
In the previous chapter, we demonstrated that Gag mutations are observed in patients exposed 
to PIs and that many of these mutations are infrequent or absent in PI-naïve individuals. 
Importantly, mutations associated with PI-exposure were detected throughout the entire HIV-
1 Gag protein and not exclusively in CSs. Based upon this observation; we proposed that full-
length Gag sequencing may be required for full assessment of PI resistance.   
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The objective of the present chapter was to extend the above cross-sectional observations and 
longitudinally assess the emergence of mutations in the HIV-1 Gag and PR genes during 
failure of a PI/r-based regimen. Specifically, this involved the selection of patients with 
matched pre-treatment and failure plasma samples, the amplification and sequencing of full-
length Gag and PR at the two time points and the comparison of the sequences obtained. In 
addition, we postulated that if Gag mutations compensate for the loss of viral replicative 
capacity caused by protease resistance mutations, Gag and protease mutations should be 
linked on the same viral genome. To assess this hypothesis, we performed clonal analysis in 
samples showing evolution of Gag and PR genes.  
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5. 2 Methods 
5.2.1 Patient population 
We examined two groups of patients. The first group (Group I) received PI/r-based therapy 
within the MaxCmin1, MaxCmin2 and COLATE trials, experienced virological failure (see 
below) and had a resistance test available at both study entry (baseline) and virological 
failure. Patient’s treatment histories were examined in detail in order to exclude those that 
stopped therapy due to toxicity or poor adherence. The second group (Group II) consisted of 
PI/r-treated patients attending the HIV services of the Royal Free Hospital who presented 
with ongoing viraemia and evidence of accumulating protease resistance-associated 
mutations.  
 
5.2.2 Definition of virological failure for trial population 
Since the definition of virological failure differed between the three trials, we applied the 
MaxCmin2 definition on the combined trial population. This is: 
 For patients entering the trial with a HIV-1 RNA load <200 copies/ml, a confirmed viral 
load ≥200 copies/ml at any time during the trial.  
 For patients entering the trial with a viral load ≥200 copies/ml: 
o Any confirmed rise in viral load of > 0.5log10 copies/ml and/or 
o ≤ 0.5 log reduction in viral load at week 4 
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o ≤ 1.0 log reduction in viral load at week 12 
o Viral load ≥ 200 copies/ml at week 24 
 
5.2.3 RNA extraction 
One milliliter of plasma was centrifuged at 25,000 g for 1 hour at 4ºC to concentrate the 
virus. The supernatant was then removed and the pellet re-suspended to a final volume of 280 
µl. The re-suspended pellet was used for nucleic acid extraction. Samples with viral load 
above 1,000 copies/ml were subsequently processed employing the automated extractor 
EasyMag (Nuclisens, France) and those with viral load lower than 1,000 copies/ml were 
processed manually with the QIAamp Viral RNA Minikit (Qiagen, Germany). The RNA was 
eluted into 55 µl of elution buffer and stored at - 80ºC until required.   
 
5.2.4 Amplification of Gag-protease region 
The 2 Kb PCR product comprising the HIV-1 Gag and PR was amplified by nested PCR 
employing the invitrogene amplification protocol described in section 2.2.2.2.2 in chapter 
two.   
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5.2.5 Sequencing of Gag-protease region 
Purified PCR products of the right size were diluted to a final concentration of approximately 
10-20 ng/µl and population sequencing was performed using the ABI PRISM BigDye 
Terminator v3.1.ready reaction cycle sequencing Kit. Primers selected for PR and Gag 
sequences were those described in chapter 3 (Table 3.2). Sequences obtained were 
subsequently analyzed using Sequence analysis version 5.0 and Seqscape version 6.0.  
 
5.2.6 Classification of Gag and protease mutations 
As explained in chapter 4 (sessions 4.2.9 and 4.2.10) PR and Gag sequences from patients 
were aligned against the HXB2 HIV-1 reference sequence. Mutations were considered as any 
change with respect to the reference sequence. PR resistance associated mutations were 
assessed according to the IAS-2011 list (Figure 5.1). Gag mutations were classified into 
cleavage site mutations (CSMs) and non-cleavage site mutations (non-CSMs) and stratified 
as those associated and not associated with PI-exposure according to the cross-sectional 
analysis performed in the previous chapter.  
 
5.2.7 Cloning of Gag and protease genes  
PCR products obtained from selected patients were purified and cloned into the commercial 
vector pCR 2.1-TOPO (Invitrogene). Positive clones, identified as those harbouring inserts of 
the correct size after a restriction digest were subsequently sequenced and analysed as 
described above.  
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Figure 5.1 Protease resistance associated mutations.  
 
The first row of letters indicate the wild-type amino acid, numbers indicate codon position and 
letter below indicate amino acid substitution conferring resistance. Codons in red represent major 
mutation associated with resistance to the corresponding drug. All amino acids are shown by their 
one letter code.     
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5.3 Results 
5.3.1 Study population 
5.3.1.1 Group I 
The first group of patients studied was selected from those experiencing virological failure in 
the MaxCmin1, MaxCmin2 and COLATE clinical trials. The three trials together included 
over 700 patients on ART treatment with regimens including SQV/r, IDV/r or LPV/r as either 
first-line or subsequent lines of therapy. After reviewing the patients’ treatment histories to 
exclude those who had stopped therapy due to toxicity or poor adherence, we selected 28 
patients as eligible for the study: 7 on IDV/r, 13 on SQV/r and 8 on LPV/r. Of these, five 
were receiving their first PI-based regimen, whereas the remaining 23 had been exposed to 
other PIs before entering the trial. Details of these patients are presented in table 5.1.  
 
5.3.1.2 Group II 
We selected this second group from a laboratory database of patients undergoing drug 
resistance testing at the Royal Free Hospital. The database contains the patients’ pol gene 
sequences, current and past treatment regimens, plasma HIV-1 RNA load at the time of 
resistance testing, and HIV-1 subtype. Upon examination of the database, three patients with 
ongoing viraemia while on a PI/r-based regimen and whose routine genotype showed 
evidence of accumulating PI resistance-associated mutations were selected for the study. 
Details of these patients are shown in table 5.2. 
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Table 5.1 Group I: Patients from MaxCmin1, MaxCmin2 and COLATE who experienced 
virological failure.   
Patient ID* *Baseline HIV-1 RNA 
load (Copies/ml) 
 
VF HIV-1 RNA load 
(Copies/ml) 
Treatment status 
At **baseline  
IDV/r, n=8 
Pt-1 6,025 32,359 PI-naïve 
Pt-2 17,783 151,359 PI-experienced 
Pt-3 2,399 10,715 PI-experienced 
Pt-4 2,041 32,379 PI-experienced 
Pt-5 9,772 346,737 PI-experienced 
Pt-6 26,915 25,527 PI-experienced 
Pt-7 4,786 4,169 PI-experienced 
Pt-8 251,188 128,824 PI-naïve 
SQV/r, n=13 
Pt-9 9,333 8,317 PI-experienced 
Pt-10 549,540 40,738 PI-naïve 
Pt-11 281,838 38,019 PI-experienced 
Pt-12 3,467 6,761 PI-experienced 
Pt-13 147,910 43,651 PI-experienced 
Pt-14 21,380 589 PI-experienced 
Pt-15 43,651 10,233 PI-naïve 
Pt-16 117 301 PI-experienced 
Pt-17 10,000 275 PI-experienced 
Pt-18 1,047 363 PI-experienced 
Pt-19 1,259 282 PI-experienced 
Pt-20 1,995 229 PI-experienced 
Pt-21 1,202 501 PI-experienced 
LPV/r, n =7 
Pt-22 380,189 813 PI-experienced 
Pt-23 1,549 1,122 PI-naïve 
Pt-24 407,380 331 PI-experienced 
Pt-25 15,488 1,778 PI-experienced 
Pt-26 479 589 PI-experienced 
Pt-27 5,248 380 PI-experienced 
Pt-28 95,499 43,651 PI-experienced 
PI regimen, HIV-1 RNA load at baseline and at VF, as well as treatment status at baseline is 
indicated. 
*All patients were infected with subtype B HIV-1.    
**Baseline is referred to the sample at study entry.  
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Table 5.2 Group II: Patients with ongoing viraemia while on PI/r-based therapy selected for studying the dynamics of emergence of PR and Gag 
mutations. 
Pt Date HIV-1 RNA 
load 
(copies/ml) 
HIV-1 subtype        Regimen Protease resistance mutations 
RFH-1 08-2002 100,000  
 
C 
D4T,  3TC, NVP None 
11-2002 3,500 TDF, APV, LPV/r M46I 
06-2004 1,300 TDF, APV, LPV/r M46I, I84V 
11-2005 800 TDF, APV, LPV/r M46I, I84V, L76V 
08-2007 74,642 TDF, APV, LPV/r M46I, I84V, L76V, F53L 
    
RFH-2 09-2006 428,688  
CRF02 
NONE None 
03-2007 1,368 3TC, LPV/r, TDF None 
07-2007 857 3TC, ABC, TDF, LPV/r L76V 
10-2007 961 3TC, ABC, TDF, LPV/r L76V, M46I 
    
RFH-3 06-2004 64,545  
CRF02 
ddI, TDF, EFV, LPV/r M46I, I50V 
07-2005 49,861 ddI, TDF, EFV, LPV/r I54V, V82A 
11-2007 102,504 ZDV, 3TC, ABC, LPV/r, SQV/r G48V, I54V, V82A 
      
Date of resistance testing, HIV-1 RNA load and ARV regimen at the time of testing, as well as major PR resistance mutations detected in routine genotypic 
HIV resistance testing are shown.  
Abbreviations: stavudine (D4T), Lamivudine (3TC), Tenofovir (TDF). Didadosine (ddI), zidovudine (ZDV), efavirenz (EFV) and nevirapine (NVP) 
and PIs: ritonavir boosted lopinavir (LPV/r), amprenavir (APV) and ritonavir boosted saquinavir (SQV/r).   
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5.3.2 Full-length Gag and protease sequencing results 
 5.3.2.1 Group I  
 Baseline:  
At baseline 13/28 (46%) patients had at least one primary PR resistance-associated mutation 
(median 3, range 1-5); 27/28 (96%) had secondary PI resistance-associated mutations 
(median 4, range 1-7); and 28/28 (100%) had protease polymorphisms which are not 
associated with PI resistance. All 13 patients with primary PR mutations had been exposed to 
PIs before commencing the trial. The primary PR mutations observed included: D30N (n = 
1), V32I (n = 1), L33F (n = 1), M46I (n = 8), I47V (n =1), G48V (n = 1), I54V (n = 7), V82A 
(n = 7), I84V (n = 2), N88D (n = 1) and L90M (n = 5). The secondary PI mutations detected 
included: L10F (n = 1), L10I (n = 10), L10V (n = 4), I13V (n = 7), K20R ( n = 4), K20T (n = 
2), L24I ( n = 2), M36I ( n = 11), F53L ( n = 1), D60E ( n = 2), I62V ( n = 9), L63P ( n = 16), 
L63Q (n = 1), I64V ( n = 4), H69K ( n = 2), H69Q ( n = 2), A71I (n =1), A71T ( n = 3), 
A71V ( n = 5), G73S ( n = 1), G73T ( n = 1), V77I ( n =9), and I93L (n = 10).   
 
Regarding Gag, at baseline, 28/28 (100%) patients had at least one mutation associated with 
PI-exposure in the P17 protein (median 4, range 1-9); 13/28 (46%) showed at least one 
mutation associated with PI-exposure in the P24 protein (median 1, range 1-2); 15/28 (54%) 
presented at least one mutation associated with PI-exposure in the P7 protein (median 1, 
range 1-3); 18/28 (64%) had at least one mutation associated with PI exposure in the P6 
protein (median 3, range 1-4); 3/28 (11%) had at least one mutation associated with PI-
exposure in the spacer peptide P2 (median 1, range 1-2); and 8/28 (28%) had the mutation 
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K442R associated with PI-exposure in the spacer peptide P1.  In addition, at baseline 17/28 
(60%) showed at least one mutation associated with PI-exposure in one of the CSs, 
distributed as follow: 3/28 (11%) had ≥1 mutations in MA-P17/CA-P24; 15/28 (53%) had ≥1 
mutations in P2/P7; 3/28 (11%) had 1 mutation in NC-P7/P1 and 1/28 (3%) had 1 mutation in 
P1/P6. Most patients (24/28, 86%) presented polymorphisms in the CSs not associated with 
PI exposure and located mainly in P2/P7 (22/28, 78%) but also in P17/P24 (2/28, 7%), 
P24/P2 (4/28, 14%) and P1/P6 (2/28, 7%). Protease, Gag non-CS and Gag CS mutations at 
baseline for the 28 patients are shown in tables 5.3, 5.4a to 5.4f and 5.5, respectively.  
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Patient Protease mutations at baseline 
 MAJOR MINOR OTHER 
Pt-1* NONE I13V, V77I S37N, I64V, L90LF 
Pt-2 NONE I13V, M36I, I62V, L63P V3I, I15V, S37DN, K43R 
Pt-3 M46I, L90M L63P, A71AT, V77I V3I, T12ATM S37N, V82L 
Pt-4 NONE L10LV, L63P, I93L V3I, T12A, K14KR, S37N, 
R41K 
Pt-5 NONE M36I, H69HQ, I72IV V3I, S37D, Q61H 
Pt-6 V32I, M46I, I47V, 
V82A 
L10IL, K20R, M36I, I62IV, L63P, 
I93L 
E35D, S37D, K55R, Q58E 
Pt-7 L33F, I54V, I84V, 
L90M 
L10I, I13V, I62V, L63P, A71V, 
G73SG 
V3I, L19I, E21DE, E35D, 
S37D, D60E, I72L 
Pt-8* NONE I13V, K20R, M36I, H69K, I93L I15V, S37N, R41K, L89M 
Pt-9 L90M I13V, K20T, M36I, D60E, I93L V3I, I15V, E35D, S37N, P39Q, 
R41K, R57K, Q61D, I61IV 
Pt-10* NONE L10LV, M36I, D60E, I62IV V3I, I15V, E35D, S37N, P39Q, 
R41K, R57K, Q61D 
Pt-11 M46IM, I84IV, 
L90LM 
L10FIL, K20KT, I62IV, L63P,  
A71AV, V77IV, I93L 
V3I, K14KR, I15IL, G16AG, 
S37N, I85IV 
Pt-12 NONE M36I, I93L E35D, S37N, R41K, K45R, 
R57K, Q61S 
Pt-13 NONE L63P, V77IV L19Q, D25DN, S37CS 
Pt-14 NONE I62IV, L63P V3I, S37N, K45R, K70R, I72E 
Pt-15* NONE NONE V3I, S37N, L63A, E65DE 
Pt-16 NONE V77I S37N 
Pt-17 V82A M36I, L63P, H69K, I93L V3I, T12S, I15V, L19T, S37N, 
R41K, Q61E, L89M 
Pt-18 I54V, V82A L10I, L24I, I62IV, L63P, A71AITV,  
V77I, I93L 
S37T, R41K 
Pt-19 M46I, I54V, L90M L10IV, L63P, G73T I15V, S37N, K55R, V82C 
Pt-20  D30N, M46I, N88D L10IV, L63PQ, I64V, A71AV, V77IV S37N, E65D, V75IV, 
Pt-21 M46IM, G48V, 
I54IV, V82AV, 
L90LM 
I64IV, V77IV S37N, T74AT 
Pt-22 I54IV, V82A L10I, K20R, M36I, L63LP V3I, I15V, E35D, S37N, R41K, 
R57K, Q61N, I72IT, T74AT 
Pt-23* NONE L10I, I13V, L63P, H69HQ, A71AT V3I, L19IL 
Pt-24 NONE L63P, V77I R41K, I64L 
Pt-25 M46I, I54V, V82A L10I, I13V, K20R, M36I, I62V, I64V V3I, S37N, R41K, L63T, E65D 
Pt-26 NONE L63P, A71AV, I93L V3I, T12I, E35D, R41K, I62M 
Pt-27 M46I, I54V, V82A L10I, L24I, F53FL, I62V, I64V V3I, I15IV, E35D, M36V, 
S37N, K43T, K55R, L63A 
Pt-28 NONE M36I, I93L E35D, S37N 
Table 5.3 Protease mutations observed at baseline.  
*These patients were treatment-naïve at baseline.  
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Pt P17 mutations at baseline 
PI –exposure associated Other mutations 
Pt-1* V82I, E93D, I94V, N126SG S54P, G62VL, R76K,R91Q, A118TAins 
Pt-2 V82I, T84V, A119T, N126S E55EG, G62KREG, Q69QR, R76K,K114I, AT117ins 
Pt-3 T84V, E93D, I94V,Q123K, N126S A83AV, D102E, H124N 
Pt-4 I34L, I94V, N109NT, T122KT, N126S K28Q, K30Q, E55D, T70TS, G71RG, S72PS, E74QE, 
R76K, Y79YF, S11G, H124N, S125N 
Pt-5 E93D, I94V, K114R, N126S K28M, S38G, S54A, S67A, R76K, Y79F, K95R 
Pt-6 T84V, I94V, A119T, N126S R15S, K26S, K30Q, S54A, Q69K, R76K, Y79F,K113N, 
A120K, H124N 
Pt-7 G123K, N126S K20Q, K28R, R76K, R91N, E93K, I104V,K110E, 
Q117K, H124N 
Pt-8* L61I, I94V,  H124K R15T, R20K, K28NT, K30M, G49D, R58K, T81A, 
Q90E, E93A, A115T 
Pt-9 Q59K, L61I, V82I, T84V, I92V, 
K113R, Q117P, A119EA, T122K 
G62, L75F, A83V, C87F, R91K, I104L, K112Q, 
A115T, GHSN123ins, Q127G. 
Pt-10* I34L, L61IL, V82IM, T84V, K103R, 
K113KR, N126S 
R43QR, F44L, K58KR, G62A, Q63R, R76K, R91K, 
H124N 
Pt-11 T84V, I94V, A119T, T122A, Q127P K30Q, R76K, T81A, D102E, A118V, H124N, S125N 
Pt-12 T84V, K113R, A119T, K26N, K30R, E55G, G62E, R76K, Y79F, R91K, K98R, 
A120T, D121N, TGH122del 
Pt-13 V82I, N126S Q90E, R91K, D102E, I104V, A119E, AA119ins, 
G123R, H124N 
Pt-14 V82IV, E93D, I94V,  G123E, N126S G62AV, R76K, Y79YF, I104V, H124N 
Pt-15* I94IV, N126S K28T, K30R, G62M, R76K, E93N, S111C, H124N, 
S125N, 
Pt-16 E93D, I94V, D121G, N126S D102E, AT117ins, H124N 
Pt-17 D93E K58R, M61I, K62KNRS, A67S, Q69KN, H79F, 
K123del 
Pt-18 I34L, V82I, K113Q, K30R, R76K, D102E, A115V, H124N 
Pt-19 T84V, I94V, N109S, K114Q, N126S K30R, Q59R, Q65H, R76K, E93N, S111C, K112R, 
A115T, H124N 
Pt-20 T84V, E93D, N126S L61M, H124N, N125S 
Pt-21 N126S K28T, R76K, H124S, S125C, Q127S 
Pt-22 Q59K, I92V, I94V, R30K, V35I, P54T, K58R, R62G, A83V, C87F, K91Q, 
E102DE, KSQQK109ins, K110T, G111S, K114N 
Pt-23* I34L, I94V, N126S K28Q, K30Q, E55D, T70TS, G71GR, S72PS, E74QE, 
R76K, Y79YF, N109NT, S111SG, H124N, Q125N 
Pt-24 T84V, E93D, I94V, N126S V46IV, G62S, P66S, Q69K, R76K, H124N, Q127S 
Pt-25 I34L, L61I, I94V, K114Q, D121A, 
N126S 
K30R, V46L, N47D, E52D, S54A, Q69K, R76K, Y79F, 
Q90R, R91N, D102E, H124N 
Pt-26 I94IV, Q117P, T122A, N126S G62V, R76K, T81A, D96G, S111A, H124S 
Pt-27 T84V, I94V, N109S, N126S K30R, Q59R, Q65H, R76K, E93N 
Pt-28 T84V, Q127P K30R, R76K 
Table 5.4a P17 mutations observed at baseline.  
Mutations are classified as those associated with PI-exposure (as determined in the analysis presented 
in chapter 4) and other mutations. In bold are shown mutations which remained associated after 
Bonferroni’s correction.  
  * These patients were treatment-naïve at baseline.  
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Pt P24 mutations at baseline 
PI –exposure associated Other mutations 
Pt-1* None I138L, V215L, I223A, G248N, N252S, L268M, G357S 
Pt-2 None I138M, V215LV, R286K 
Pt-3 M200I, E211D I138L, A146P, I147L, S173T, V215L, N252S, E312D 
Pt-4 None N137T, I138IL, Q139P, Q141K, A146P, S176A, V215L, I223IV, 
T242TS, E245D, G248N, N252G, T280S, E312D, G357S 
Pt-5 None I138L, I223V, P292S 
Pt-6 L268M I138L, I147L, V215L, N252H, A340G 
Pt-7 L268M I147L, V215L, H219Q, I223V, M228I, G248A, R257KR, A326S, 
A340G 
Pt-8* None A147P, V157I, L213V, M226I, V254I, K284R 
Pt-9 T280I, N315G I138L, A146P, E203D, T204A, V215L, H219Q, G221R, A224P, 
M228I, G248Q, M252G, I256V, Y301F, S310T,E319P, A340G 
Pt-10* None I138L, I147L, V215L, H219Q, M228ML, T242N, G248A, T280V, 
E312D 
Pt-11 S173A I138L, S173T, T239S, N252S, I256IV, E312D, G357S 
Pt-12 None I138L, I147L, V159I, E203D, V215L, A224P, G248Q, N252S, 
I256V, T280V, Y301F, S310T, E319D, A340G 
Pt-13 None I138M, A146P, V159I, M200L, V215L, G248A, M250T, G357S 
Pt-14 A146S, Q182H I138L V191I, V215M, I223V, N252S, N253T, R286K, A326S 
Pt-15* None I138L, V215L, M228L, G248A, N253T, P255S, A340G 
Pt-16 None V215L, N252H 
Pt-17 None P144A, A147P, V157I, V166I, H217Q, V211IV, M226IV, V254I, 
T301GVCF, S240T 
Pt-18 L268M, T280I V147l, V159I, V215L, H219Q, I223V, T242N, G248A, N252G, 
P255A, A340G, G357S 
Pt-19 None I138L, V215L, A340G, E345D 
Pt-20 T280I I138L, I147L, V215L, N252H, E312D, G357S 
Pt-21 L268M V215L, H219Q, I223V, N252S, P292S, A340G 
Pt-22 N315G P142S, I143L, A214V, L220P, S316T, S322A 
Pt-23* None I138L, V215L, I223IV, E312D, G357S 
Pt-24 T280I, N315G I138L, V159I, V215L, I223V, T242S, G248A, N252S, I256V, 
A340G 
Pt-25 T280I I138L, V147L, V159I, V215L, I223V, E312D 
Pt-26 None V215L, Q246P, E312D, A326S, A340G 
Pt-27 None I138IL, V215L, I223A, T239S, N252S 
Pt-28 L268M, T280I I138L, I147L, S173A, V215M, R264K, R286K 
Table 5.4b P24 mutations observed at baseline.  
Mutations are classified as those associated with PI-exposure (according to chapter 4) and other 
mutations.  In bold are shown mutations which remained associated after Bonferroni’s correction.  
*These patients were treatment-naive at baseline. 
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Table 5.4c P7 mutations observed at baseline.  
Mutations are classified as those associated with PI-exposure (according to chapter 4) and other 
mutations.   
*These patients were treatment-naïve at baseline. 
 
 
 
 
 
Pt P7 mutations at baseline 
PI –exposure associated Other mutations 
Pt-1* None V390C, A402S 
Pt-2 R403K, T427S T401I, N404H, R406KR, K410R 
Pt-3 None N385S, I389T, T401I 
Pt-4 I389V, R403K, T427S R387G, E398A, T401I 
Pt-5 None N385K, T401I 
Pt-6 I389V, R403K T401I 
Pt-7 I389V, R403K T401I 
Pt-8* None R384K, N385G 
Pt-9 R403K N385Q, Q386H, R387K, K388R, E419K 
Pt-10* R403K N385H, K397R, T401I 
Pt-11 I389V, R403K R384K, R387K, K388R, K397R, T401I 
Pt-12 V390A, R403K R384K, T401I 
Pt-13 I389V, V390A, R403K K411R 
Pt-14 None T401I, K411R, D425E 
Pt-15* None T401I, K411R 
Pt-16 T427S T401I 
Pt-17 None I387V, L398I, R400K, K415R, V420M 
Pt-18 R403K R384K, R387K, K388R, E398V, T401I 
Pt-19 None R384K, R387KR, T401I 
Pt-20 I389V T401I, K418R 
Pt-21 None R384K, I389P, N394I, T401I, N404I, K424E 
Pt-22 None R383K, K413T, H416Q 
Pt-23* None T401I, K411R, K418R 
Pt-24 R403K T401I, K418R 
Pt-25 None R387K, K388R, T401I 
Pt-26 None T401I 
Pt-27 I389V T401I 
Pt-28 I398V, R403K N385S, T401I, K418R 
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Pt P6 mutations at baseline 
PI-exposure associated Other mutations 
Pt-1* None T456S, E460A, S465F, V467E, P473S, E477DE, D480E, T487A, R490K 
Pt-2 R464KR, T471A, S465F, I479R, T487A, R490K 
Pt-3 None V467E, T470A, I479V, T487A, R490K 
Pt-4 None 454EPTAins, S462C, S465F, V467E, T487AY, R490K, P497Q 
Pt-5 T470A, T471A E460A, S465F, V467E, 483LMPTins, R490K, S498L 
Pt-6 F463L, E477G, P478T S465L, V467E, P473S, T487A 
Pt-7 S465M, T469A 460EPTAPPEins, V467E, P473S, T487A, R490K 
Pt-8* None E460A, E482K, L483P 
Pt-9 T469A, Q474P, P478T, I479T 454EPTAPPAEins, E460A, P473A, K481R, P485A, R490K, N495S, 
S498L 
Pt-10* F463V, T470A E454A, T456S, S465F, V467E, E482D, R490K 
Pt-11 T470A, I479V APS459ins, S465F, V467E 
Pt-12 F463L, E477G, P478T S465L, V467E, P473S, T487A 
Pt-13 S465M, T470A, I479T V467E, T487A, 496-500del 
Pt-14 F463L, R464K, T469I, Q474P E460A, 465PPAESFins,V467F, P473A, P478A, I479R, K481R, P485A, 
R490K, N495S, S498L 
Pt-15* None E454A, 460EPTAPPEins, V467E, R490K 
Pt-16 T470A E454A, S462IV, S465F, V467E, P478PL, E482D, T487A, R490K 
Pt-17 None E457D, T487A, R490K 
Pt-18 None P459PS, S465F, V467E, E482D, R490K 
Pt-19 None E460A, E482K, L483P 
Pt-20 G466R R464L, D480V, K481N, S488A, D496S 
Pt-21 T471S, E477G, P478T S465F, V467E, T487A, R490K 
Pt-22 P478Q, I479T E460A, S465F, V467E, P473S, E482D, S488A 
Pt-23* None 459APSins, S465F, V467E, I479R 
Pt-24 None T456S, S465F, V467S, E482D, R490K 
Pt-25 S465M, P478Q V367E, E482D, T487A, R490K 
Pt-26 F463L,S465M, T471A, E477G V467E, P478A, S488A, R490K 
Pt-27 T470V, T471A, I479V E460A, S465F, V467E, P478S, D480E, R490K, N495S 
Pt-28 F463L, G466R 454EPTAins, S462C, S465F, V467E, T487AY, R490K, P497Q 
Table 5.4d P6 mutations observed at baseline.  
Mutations are classified as those associated with PI-exposure (according to chapter 4) and other mutations. In bold are 
shown mutations which remained associated after Bonferroni’s correction.  
 *These patients were treatment-naïve at baseline. 
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Pt P2 (SP1) mutations at baseline 
PI-exposure associated Other mutations 
Pt-1* None T371N 
Pt-2 None V370A 
Pt-3 None None 
Pt-4 None None 
Pt-5 None T371N 
Pt-6 None Q369H 
Pt-7 None None 
Pt-8* None T371N 
Pt-9 None T371N 
Pt-10* None V370A, N372S 
Pt-11 None None 
Pt-12 None None 
Pt-13 None V370A 
Pt-14 None None 
Pt-15* None None 
Pt-16 None None 
Pt-17 None V370A 
Pt-18 T371A Q369H, V370A 
Pt-19 None None 
Pt-20 None V370A 
Pt-21 None V370A, N372K 
Pt-22 None Q369H, T371V 
Pt-23* None None 
Pt-24 None Q369H 
Pt-25 V370M T371del 
Pt-26 None T371S 
Pt-27 None V370A 
Pt-28 V370M, T371A None 
Table 5.4e P2 mutations observed at baseline.  
Mutations are classified as those associated with PI-exposure (according to chapter 4) and other mutations.   
*These patients were treatment-naïve at baseline. 
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Pt P1 (SP2) mutations at baseline 
PI exposure associated Other mutations 
Pt-1* None Y441H 
Pt-2 K442R None 
Pt-3 None Y441H 
Pt-4 K442R Y441H, G443D 
Pt-5 K442R None 
Pt-6 None Y441H 
Pt-7 K442R Y441H 
Pt-8* None None 
Pt-9 None None 
Pt-10* None Y441S 
Pt-11 None None 
Pt-12 None None 
Pt-13 K442R Y441H 
Pt-14 None None 
Pt-15* None Y441S 
Pt-16 None Y441H 
Pt-17 None R439K 
Pt-18 None Y441H 
Pt-19 None None 
Pt-20 None R439K 
Pt-21 K442R None 
Pt-22 K442R None 
Pt-23* None None 
Pt-24 None Y441H 
Pt-25 K442R Y441H 
Pt-26 None Y441H, G443E 
Pt-27 None Y441H 
Pt-28 None None 
Table 5.4f P1 mutations observed at baseline.  
Mutations are classified as those associated with PI-exposure (according to chapter 4) and other mutations.   
*These patients were treatment-naïve at baseline
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Table 5.5 Cleavage site mutations observed at baseline.  
Mutations are classified as those associated with PI-exposure (according to chapter 4) and other mutations. In bold are shown mutations which remained 
associated after Bonferroni’s correction. *These patients were treatment-naïve at baseline.  
Patient Gag CS Mutations 
 P333I-exposure associated Other CS mutations 
 P17/P24 P24/P2 P2/P7 P7/P1 P1/P6 P17/P24 P24/P2 P2/P7 P7/P1 P1/P6 
Pt-1* None None A374S None None None A360S T375Y None None 
Pt-2 None None None None None None None S373A, R380K None None 
Pt-3 None None None None None None None S373Q None None 
Pt-4 None None A374S, T375A None None None None None None None 
Pt-5 None None T375A None None None None None None None 
Pt-6 V128I, Y132F None None None None None None S373A, A374N None None 
Pt-7 None None S373T, T375N None None None None A374del None None 
Pt-8* None None G381S None None Q130H None I376V, R380K None None 
Pt-9 None None G381S A431V None None None A374T, M377L, R380K None None 
Pt-10* None None None None None None V362I S373A, A374N, I376V None None 
Pt-11 None None T375N A431V None None None S373A, A374T None None 
Pt-12 None None S373T, G381S None None None None T375del, I376V, M377L None None 
Pt-13 None None A374P None None None None S373P, R380K None None 
Pt-14 None None T375A None None Q130H None None None P453L 
Pt-15* None None None None None None None S373P, R380K None None 
Pt-16 None None T375A None None None None AT373-374ins None None 
Pt-17 None None None None None None None None None L445F, N448S 
Pt-18 None None None A431V None None None TSA374ins, R380K None None 
Pt-19 Y132F None T375N None None None None S373A None None 
Pt-20 Y132F None A374S None None None V362I S373A, M378I None None 
Pt-21 None None None None None None None None None None 
Pt-22 None None G381S None None None A366V M378V None None 
Pt-23* None None None None None None None A374N, T375V, R380K None None 
Pt-24 None None None None S451T None None R380K None None 
Pt-25 None None A374S, G381S None None None None S373P, I376V, R380K None None 
Pt-26 None None None None None None None I376V, R380K None None 
Pt-27 None None None None None None None None None None 
Pt-28 None None None None None None None R380K None None 
- 219 - 
 
 Virological failure: 
At the time of virological failure, 6/28 (21%) and 13/28 (46%) patients showed emergence of 
primary and secondary PR resistance-associated mutations, respectively. Regarding Gag 9/28 
patients (32%) had P17 emergent mutations, 8/28 (28%) had P24 emergent mutations, 7/28 
(25%) had P7 emergent mutations, 5/28 (18%) had P1 emergent mutations, 4/28 (14%) had 
P2 emergent mutations and 1/28 (3%) had P6 emergent mutations. In addition, 13/28 (46%) 
patients had treatment emergent Gag CSMs including four patients with one mutation at 
P2/P7, five patients with one mutation in P7/P1 and four patients with one mutation in P1/P6.  
 
We next examined the Gag emergent mutations and classified them as associated or not 
associated with PI exposure. Among the 18 patients with Gag mutations emerging outside 
CSs, seven (39%) showed one mutation associated with PI exposure, three (17%) showed 
two mutations, one (5%) showed three mutations, and two (11%) showed four mutations. 
Overall, 24 mutations associated with PI exposure emerged at the time of VF and of them the 
majority were located in P17 (15/24, 62%); the remaining were found in P24 (5/20, 25%), P7 
(2/24, 8%) and P1 (2/24, 8%). In addition a total of 24 polymorphisms not associated with PI 
exposure emerged in 15/28 (53%) patients and where located in P17 (2/24, 8%), P24 (4/24, 
17%), P7 (7/24, 29%), P6 (2/24, 8%), P2 (5/24, 21%) and P1 (4/24, 17%). Among the 13 
patients with Gag CSMs, ten had one emergent mutation associated with PI exposure located 
in P2/P7, n = 3; P7/P1, n =4 and P1/P6, n =3. Moreover, three patients showed polymorphism 
not associated with PI exposure emerging in P2/P7, n =1; P7/P1, n =1 and P1/P6, n= 1.  
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Details of mutations emerging at the time of virological failure are shown in table 5.6. The 
comparison of the number of mutations observed at baseline and at virological failure is 
displayed in figure 5.2.  
- 221 - 
 
Table 5.6 Mutations emerging at virological failure. 
*These patients were treatment-naïve before commencing the PI-base regimen.  
Treatment Emergence mutations 
Patient Protease mutations Gag Mutations 
        Primary                Secondary  Polymorphisms CS non-CS 
 PI-associated others PI-associated others 
Pt-1* None None None P7/P1: I437V None P17: N109T; P7: I389V P7: T401I; P2: V370A 
Pt-2 None None T12ST P2/P7: T375A None None P2: T371N 
Pt-3 None I13V, M36I, I62V I15V, K43R None None P17: Q59K P24: E167EK 
Pt-4 None None None None None None None 
Pt-5 None None I51IV None P2/P7: R380K P17: L61I, P66S, H124K; P7: I389V P24: A163AV 
Pt-6 None None None None None None P24: Q139QR 
Pt-7 None None None P2/P7: G381S None None None 
Pt-8 None None K70KR None None None None 
Pt-9 I84V A71V None None P1/P6: P453L None None 
Pt-10* None None T4NT P1/P6: P453T None P17: Q59K, P66S, E93D; P1: K442R None 
Pt-11 None G73S None None None P24: V218A None 
Pt-12 None None V3I None None None P7: R387K, K388R 
Pt-13 None None None P1/P6: L449F None None P7: N404D 
Pt-14 M46IM, I54V, 
V82A, L90M 
L10I, I13IV, A71V, G73S, 
V77IV 
L19IL, Q61KQR P7/P1: A431V None P17: Q117P P1: Y441H 
Pt-15* None I13ILPT P9PS P1/P6: P453T None P24: E211D P6: E454A, T476P 
Pt-16 None L10V, I62V, L63P K14R, I15V, E35D, None None P1: K442R None 
Pt-17 None None K45KR None None None None 
Pt-18 I84V F53FL None None None None None 
Pt-19 None F53L None None None None None 
Pt-20 I84V T74P None P7/P1: I437V None P17: V82I, A115I P17: A120V; P1: Y441H, 
G443E 
Pt-21 I84IV M36I, L10I None None None None None 
Pt-22 None None K43KR P7/P1: K436R None P17: D121G; P24: S310T P1: R439G, P440Q 
Pt-23* None None V3I, E35DE None None P17: K103R, T122K; P24: N315G P17: E105K, P7: G420R 
Pt-24 None L24IL, I93L None None None None None 
Pt-25 None None I19IL None None P17: I92V P7: Q422L; P2: V370del, 
T371M 
Pt-26 None K20R None None P7/P1: E428K P24: T280I P24: R286K, P7: K418R 
Pt-27  None None E34EK P2/P7: T375A None None P2: N372A 
Pt-28 None L10V, I62V, L63P K14R, I15V, E35D, None None None None 
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Figure 5.2 Total number of mutations observed at baseline and at the time of virological 
failure in 28 patients failing a PI/r based regimen with IDV/r, SQV/r or LPV/r.  
Only major PI resistance-associated mutations and Gag CS and non-CS mutations associated with 
PI-exposure are shown. 
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5.3.2.2 Group II  
We selected three patients with ongoing viraemia while on a PI/r-based regimen.  
 Patient 1 (RFH-1) 
The first patient first attended the Royal Free Hospital in August 2002. At the time he was 
receiving an NNRTI-based regimen consisting of stavudine (D4T), Lamivudine (3TC) and 
nevirapine (NVP) and had never been exposed to PIs. The plasma HIV-1 RNA load was 
100,000 copies/ml. Routine HIV-1 genotypic resistance testing revealed subtype C infection, 
the presence of two major NRTI resistance-associated mutations and three secondary protease 
mutations which are commonly seen in drug naïve individuals as natural polymorphism, and 
no major protease-resistance mutation. Analysis of the Gag gene at this time point showed 
three CSMs and numerous non-CSMs. Two of the three CS and most of the non-CS mutations 
were polymorphisms; one CS and four non-CS mutations (P17: I34L, V82I, E93D, N126S) 
were associated with PI exposure. The patient was switched to a double PI/r-based regimen 
containing tenofovir (TDF), ritonavir boosted amprenavir (APV/r) and ritonavir boosted 
lopinavir (LPV/r) and in November 2002 his viral load was 3,500 copies/ml.  Analysis of full-
length PR and Gag genes showed the emergence of a major resistance-associated mutation in 
the protease (M46I) and no changes in Gag. In June 2004, while still on the above regimen, 
the viral load remained detectable (1,300 copies/ml). At this time point sequencing showed the 
emergence of the major protease mutations L76V and I84V and of 21 non-CS mutations 
distributed as follow: 3 mutations in P17, 6 mutations in P24, 5 mutations in P7, and 7 
mutations in P6. Of these 21 non-CS mutations, 9 were associated with PI-exposure and were 
located in MA-P17 (n=3), CA-P24 (n=1) and P6 (n=5). The remaining 12 were 
polymorphisms found in P24 (n=5), P7 (n=5) and P6 (n=2). The patient continued the same 
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regimen and in November 2005 showed a viral load of 800 copies/ml.  While no major 
protease mutation emerged at this time, new mutations appeared in Gag: the P1/P6 CS 
mutation L449F, one PI-associated mutation in P17, and two polymorphisms in P24. In 
August 2007, while still on the same regimen, the viral load increased to 74,642 copies/ml. 
Full-length PR and Gag sequencing showed the emergence of the secondary protease mutation 
F53L, 5 mutations in P17 (3 of which associated with PI exposure: Q59K, K103R, and 
Q117P), the P17/P24 CS Y132F mutation (associated with PI exposure), 4 mutations in P6 (2 
of which associated with PI exposure; R469K, E477G), and 3 polymorphisms in P7.  
 
To summarize, overall, 37 mutations emerged in Gag over time in this patient, including two 
CS and 35 non-CS mutations. The two CS mutations and most mutations emerging at P17 and 
P6 (7/9 and 7/11, respectively) were indicative of PI selective pressure according to the 
analysis showed in chapter 4.  The HIV-1 RNA viral load and PR and Gag evolution over time 
are shown in figure 5.3  
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Figure 5.3 Dynamic of emergence of PR and Gag mutations during PI/r-based therapy with 
ongoing viraemia - patient RFH-1.  
PI treatment and viral load at each time point are indicated. The table below shows the PR and Gag 
mutations emerging at each time point. Major PR mutations and Gag mutations associated with PI 
exposure are shown in red.   
 
 
 Patient 2 (RFH-2) 
 The patient first attended the Royal Free Hospital in September 2006 when he was ART-naïve 
and his viral load was 4278,688 copies/ml.  Full length PR and Gag sequencing demonstrated 
infection by a CRF02_AG recombinant HIV-1 virus, no major protease resistance-associated 
mutations and several Gag CS and non-CS mutations. The latter were mainly polymorphisms 
except for four mutations in P17, one in P7 and two in P6. The patient was started on 
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Lamivudine (3TC), Tenofovir (TDF) and LPV/r and in March 2007 his viral load remained 
detectable (1,368 copies/ml). Sequencing of PR and Gag genes showed no emergent mutations 
in the protease, but 6 P17 mutations (3 of which associated with PI exposure), and two 
polymorphisms in P7 emerged at that time. The patient continued on this regimen and in July 
2007 the viral load was 857copies/ml. At this time, sequencing showed the emergence of the 
major protease mutation L76V and four polymorphisms in Gag (P24, n=3; P7, n=1). Therapy 
was intensified with the NRTI Abacavir (ABC) but in October 2007 low-level viraemia 
persisted. Sequencing showed the emergence of the major protease mutation M46I and one 
gag CS mutation (P7/P1 A431V).  The HIV-1 RNA viral load and PR and Gag evolution over 
time are shown in figure 5.4.  
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Figure 5.4 Dynamic of emergence of PR and Gag mutations during PI/r-based therapy with 
ongoing viraemia-patient RFH-2.  
PI treatment and viral load at each time point are indicated. The table below shows the PR and Gag 
mutations emerging at each time point. Major PR mutations and Gag mutations associated with PI 
exposure are shown in red.   
 
 Patient 3 (RFH-3) 
The patient first attended the Royal Free Hospital in June 2004 when he was already highly 
ART-experienced and failing an IDV/r-based regimen consisting of didadosine (ddI), 
tenofovir (TDF), efavirenz (EFV) and ritonavir boosted indinavir (IDV/r). PR and Gag 
Sequencing showed infection by a CRF02_AG recombinant HIV-1 strain, two major protease 
mutations (M46I, I50V) and several gag CS (2 associated with PI-exposure) and non-CS 
mutations (12 associated with PI-exposure). A ritonavir boosted lopinavir (LPV/r)-containing 
- 228 - 
 
regimen was started (ddI, TDF, EFV and LPV/r) and in July 2005 the patient had a viral load 
of 49,861 copies/ml. PR and Gag sequencing did not show the two previous major protease 
mutations but all previously seen Gag mutations were still detectable. Two new major 
protease mutations emerged at this time (I54V, V82A) as well as two polymorphic CS 
mutations (P2/P7), and 8 non-CS mutations: three in MA-P17 (all associated with PI-
exposure), three in P24 (none associated with PI-exposure) and two in P6 (one associated 
with PI-exposure).  The patient was switched to a new regimen consisting of zidovudine 
(ZDV), lamivudine (3TC), abacavir (ABC), LPV/r and saquinavir (SQV) and in November 
2007 his viral load was 102,504 copies/ml and the major protease mutation G48V as well as 
2 mutations in P17 associated with PI-exposure, 6 mutations in P24 of which only one was 
associated with PI-exposure, 5 mutations in P7 of which none was associated with PI-
exposure, 3 mutations in P6, two of which were associated with PI-exposure and one P1/P6 
CS mutation associated with PI-exposure had also emerged.  The HIV-1 RNA viral load and 
PR and Gag evolution over time are shown in figure 5.5.   
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Figure 5.5 Dynamic of emergence of PR and Gag during PI/r-based therapy with ongoing 
viraemia-patient RFH-3.  
PI treatment and viral load at each time point are indicated. The table below shows the PR and Gag 
mutations that emerged or were lost at each time point. Major PR mutations and Gag mutations 
associated with PI exposure are shown in red.   
* Primary protease mutations shown in braquets were lost with respect to the baseline sample.  
 
 
5.3.3 Clonal analysis 
We performed clonal analysis using plasma samples from the last available time point for the 
three patients within the group II (RFH-1, RFH-2 and RFH-3) and for patient Pt-20 from 
group I.  A total of 10 clones per patient were analysed. 
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5.3.3.1 Full-length protease and Gag clones from patient RFH-1  
At the last time point, population sequencing in this patient had shown three major, four 
minor and three polymorphic protease mutations, respectively. Regarding Gag, population 
sequencing revealed five Gag CS mutations and 58 non-CS mutations. Out of the five CSMs 
detected, three were associated with PI-exposure according to the analysis presented in the 
previous chapter located in P17/P24, P2/P7 and P1/P6, respectively. With regard to non-
CSMs, 20 out of the 58 mutations detected were associated with PI exposure, 11 in P17, 8 in 
P6 and 1 in P24.  The 10 clones analysed all showed the four major protease resistance 
mutations and Gag mutations associated with PI-exposure were observed in between 54% 
and 100% of the clones. In particular, all those Gag mutations strongly associated with PI-
exposure (the association remained after a most conservative cut-off was applied, 
Bonferroni’s correction) including CSMs: Y132F and L449F; non-CSMs in P17:  I94V, 
K103R, K114R, D121G, N126S and the non-CSMs in P6: F463L were observed in over 90% 
of the clones.   Results are shown in Figure 5.6.   
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Figure 5.6 Clonal analysis from patient RFH-1.  
Full-length protease and gag genes from patient RFH-1 were cloned and sequenced. The proportions (%) of clones (n = 10) with mutations are shown. 
Sequences were analyzed for the presence of mutations relative to HXB2 wild type. Protease mutations were classified according to the IAS 2011-list of 
mutations. Bars in red denote major protease mutations, bars in orange represents Gag CS mutations associated with PI exposure and bars in purple shows gag 
non-CS mutations associated with PI exposure. Bars in grey indicate secondary protease mutations and gag mutations not associated with PI exposure, 
respectively.    
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5.3.3.2 Full-length protease and Gag clones from patient RFH-2  
At the last time point, population sequencing for this patient revealed the presence of two major, 
three minor and four polymorphic protease mutations, respectively. In addition, 5 CS and 37 non-
CS mutations were also detected. Regarding Gag mutations, two out of the five CSMs were 
associated with PI-exposure located at P2/P7 and P7/P1, respectively and 11 out of the 37 non-
CSMs were also associated with PI-exposure, located at P17 ( n = 8), P6 ( n = 2) and P7 ( n = 1). 
Clonal analysis demonstrated a very homogeneous population and the major PR mutations as 
well as the Gag CS and non-CS mutations associated with PI-selective pressure were present in 
all the ten clones. Figure 5.7 shows the protease and Gag mutations present in the 10 clones for 
patient RFH-2.  
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Figure 5.7 Clonal analysis from patient RFH-2.  
Full-length protease and gag genes from patient RFH-2 were cloned and sequenced. The proportions (%) of clones (n = 10) with mutations are shown. 
Sequences were analyzed for the presence of mutations relative to HXB2 wild type. Protease mutations were classified according to the IAS 2011-list of 
mutations. Bars in red denote major protease mutations, bars in orange represents Gag CS mutations associated with PI exposure and bars in purple shows gag 
non-CS mutations associated with PI exposure. Bars in grey indicate secondary protease mutations and Gag mutations not associated with PI exposure, 
respectively.    
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5.3.3.3 Full-length protease and Gag clones from patient RFH-3  
At the last time point, population sequencing for this patient showed the presence of three 
major, two minor and eight polymorphic protease mutations, respectively. Moreover, seven 
Gag CS and 46 non-CS mutations were also detected. With regard to Gag mutations, three of 
the seven CSMs were associated with PI exposure and were located at P2/P7, P7/P1 and 
P1/P6, respectively. Similarly, 20 of the 46 non-CSMs were associated with PI-selective 
pressure and were located at P17 (n = 11), P24 (n = 2) and P6 (n = 7). Clonal analysis 
demonstrated a homogeneous population and major protease mutations and Gag mutations 
associated with PI-exposure were present in between 99% and100% of the clones analyzed.  
Results are presented in figure 5.8. 
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Figure 5.8 Clonal analysis from patient RFH-3.  
Full-length protease and gag genes from patient RFH-3 were cloned and sequenced. The proportions (%) of clones (n = 10) with mutations are shown. 
Sequences were analyzed for the presence of mutations relative to HXB2 wild type. Protease mutations were classified according to the IAS 2011-list 
of mutations. Bars in red denote major protease mutations, bars in orange represents Gag CS mutations associated with PI exposure and bars in purple 
shows gag non-CS mutations associated with PI exposure. Bars in grey indicate secondary protease mutations and gag mutations not associated with PI 
exposure, respectively. 
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5.3.3.4 Full-length protease and Gag clones from patient Pt-20  
At the time of VF, population sequencing had shown four major, six minor and three 
polymorphic protease mutations. In addition, six Gag CS and 26 Gag non-CS mutations were 
also detected. With regard to Gag, three of the six CSMs were associated with PI exposure 
and were located at P17/P24, P2/P7 and P7/P1, respectively. Furthermore, eight out of the 26 
non-CSMs were also associated with PI-selective pressure and were located at P17 (n = 5), 
P24 ( n =1), P7 (n =1) and P6 ( n = 1). Clonal analysis showed a homogeneous population 
and all major protease mutations and Gag mutations associated with PI exposure were 
detected in all of the ten clones analysed.  
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Figure 5.9 Clonal analysis from patient Pt-20.  
Full-length protease and gag genes from patient Pt-20 were cloned and sequenced. The proportions (%) of clones (n = 10) with mutations are shown. 
Sequences were analyzed for the presence of mutations relative to HXB2 wild type. Protease mutations were classified according to the IAS 2011-list 
of mutations. Bars in red denote major protease mutations, bars in orange represents Gag CS mutations associated with PI exposure and bars in purple 
shows gag non-CS mutations associated with PI exposure. Bars in grey indicate secondary protease mutations and Gag mutations not associated with 
Pi exposure, respectively.  
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5.4 Discussion 
Numerous studies have shown that patients failing ritonavir-boosted protease inhibitors often 
lack major resistance-associated mutations in the protease gene that may account for the clinical 
resistance observed (Kempf et al, 2004; Delaugerre et al, 2009; Gupta et al, 2008; Lathouwers et 
al, 2011). Growing evidence however indicates that complete assessment of PI resistance is a 
more complex process than revealed by the detection of mutations in the protease gene. Analysis 
of the protease substrate Gag may be required to obtain a more complete picture. In this respect, 
the involvement of certain gag regions located at the protease cleavage sites P7/P1/P6 has been 
clearly established (Brumme et al, 2003; Banke et al, 2009; Brann et al, 2006; Cote et al, 2001; 
Maguire et al, 2002; Malet et al, 2007 and Robinson et al; 2000). However, the role of changes 
occurring elsewhere in the full-length gag protein has only rarely been addressed. The few 
studies available suggest that determinant of PI resistance may be located beyond gag CSs (Parry 
et al, 2009).   
 
In the current chapter we performed a longitudinal analysis of full-length protease and gag genes 
in patient experiencing virological failure while on PI/r-based regimens. We selected two 
different groups of patients to perform the analysis. The first group consisted of 28 patients 
infected with subtype B HIV-1 who had been enrolled in clinical trials and started on IDV/r, 
SQV/r or LPV/r. All of these patients experienced virological failure during up to 24 weeks of 
follow-up. The majority of the patients were treatment-experienced before commencing on one 
of these three regimens and in fact all but five had been exposed to PIs previously. Consistent 
239 
 
with this, we observed a high prevalence of primary and secondary protease mutations at 
baseline. In addition, we also detected a high frequency of Gag mutations at both CSs and non-
CSs which, based upon the analysis shown in the previous chapter, were associated with PI 
exposure. A substantial number of these baseline mutations, markedly those detected at the CSs, 
occurred very uncommonly in PI-naïve patients suggesting that long term PI-selective pressure 
could account for the significant variability observed in Gag in these baseline samples. 
Consistent with this hypothesis, the five trial patients who were PI-naïve at baseline showed no 
major protease mutation and the mutations detected in Gag were predominantly polymorphisms 
not associated with PI-experience. This was the case for the CSs as well as most non-CS regions 
except for the matrix protein (P17). P17, showed a high degree of variability even in PI-naïve 
patients.  
 
At the time of virological failure, our population showed a high prevalence of emergent primary, 
secondary or polymorphic protease mutations (17% of patients and 46% of patients, 
respectively) consistent with true virological failure and pointing at emergence of resistance 
variants as the cause of detectable viraemia. In addition, 54% of patients showed emergent 
polymorphic protease mutations, which are not known to confer PI resistance. Interestingly, 
emergence of mutations during virological failure was not restricted to the protease gene and in 
fact occurred more frequently in the Gag gene both within CSs (46% of patients) and in regions 
outside the CSs (64% of patients). While the vast majority of emergent mutations in Gag CSs 
and in P17 were seen predominantly or exclusively in the context of PI-selective pressure (77% 
and 94%, respectively), a substantial number of mutations emerging at other non-CSs such P24, 
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P7 and P2 were polymorphisms which are also seen relatively commonly in PI-naïve patients. 
This observation suggests that PIs exert a greater selective pressure on CSs and the non-CS, P17 
protein. As a result, one may postulate that mutations in these regions play a key role in PI 
failure.  
 
The high number of polymorphisms that were seen both at baseline and emerging under PI-
selective pressure in Gag may also be explained by pressure exerted by the immune system. 
Indeed, early studies showed that cellular immune pressure represent a dominant selective force 
in viral evolution, accounting for up to half of the intra-host amino-acid sequence diversity 
selected over the course of infection in some cases (Allen et al, 2005; O’Connor et al, 2004 and 
Jones et al, 2004). Importantly, certain Gag mutations observed frequently in PI-naïve and PI-
experienced patients in our population, such as K28QR, I34L, V82I, T84V, Y79F located in P17 
and I138L, A146P, G357S and V362I located in P24, are present within well defined CD8+ T-
cell epitopes (Frahm et al, 2008) and early studies performed  by Philips and colleagues 
demonstrated that some of these variants found in HIV seropositive haemophilic donors, such as 
I34L,  led to loss of CD8+ T cell recognition (Phillips et al, 1991). Similarly, Yokomaku and co-
authors showed that certain Gag variants located in immunodominant CD8+ epitopes in P17, 
such as K28Q, I34L or Y79F, failed to be killed by CD8+ T cell (Yokomaku et al, 2004) due to 
an impaired antigen processing and presentation. Overall, these studies suggest that evolution of 
Gag is greatly influenced by the host immune response and specifically by adaptive CD8+ T-cell 
selective pressure.  
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With regard to Gag CSMs emerging at VF, we observed that mutations emerged in P7/P1, P1/P6 
and P2/P7. Thus, at the time of VF we observed mutations emerging at P7/P1 in five patients. 
The mutations detected were: I437V in a patient failing IDV/r who did not show major protease 
mutations either at baseline or at VF and in a patient failing SQV/r who by contrast, presented 
major PR mutations at baseline and emerging at VF; the A431V mutation emerged in a patient 
failing SQV/r who showed major PR mutations at baseline but not emerging at VF; the K436R 
mutation appeared in a patient failing LPV/r who showed major PR mutations at baseline, but no 
new major PR mutations emerged at VF and finally, the E428K emerged in a patient failing 
LPV/r in the absence of major PR mutation either at baseline or at VF.  All the mutations 
described above, except for E428K, have been identified in our study (see chapter four) and 
others as associated with PI selective pressure (Nijhuis et al, 2007; Verheyen et al, 2006; Bally et 
el, 2000; Koch et al, 2000; Malet et al, 2007 and Maguire et al, 2002) . The I437V mutation was 
described during in vitro selection experiment with an experimental PI (RO033-4649) and was 
shown to confer 5 to 8-fold resistance to multiple PIs in the absence of protease mutations 
(Nijhuis et al, 2007). The mutation was shown to enhance P7/P1 processing of the substrate by 
wild type protease. Similarly, The A431V mutation is one of the best-characterized CS mutations 
observed in the setting of PI failure. A number of studies have probed the association of A431V 
with protease resistance-associated mutations and demonstrated that the presence of this 
mutation increase the rate of Gag cleavage by a mutated protease  indicating a plausible 
compensatory role for A431V (Verheyen et al, 2006; Bally et al, 2000; Koch et al 2001; Malet et 
al, 2007). In line with these studies, in the cross-sectional analysis presented in chapter 4 we 
found a high prevalence of A431V in PI-experienced patients and its absence in PI-naïve 
individuals. Furthermore, there was a statistically significant association with several major 
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protease mutations including M46IL and I54V, both of which were present at baseline in the 
patient who acquired A431V. Finally, the K436R was identified in our cross-sectional analysis 
as associated with PI exposure in line with previous reports (Verheyen et al, 2006).  Overall, our 
results suggest that mutations emerging at this CS were indeed the result of PI-selective. The fact 
that patients in the three different regimens developed mutations associated with PI selective 
pressure at NC-P7/P1 suggests that this CS may broadly influence PI susceptibility and 
mutations selected at this CS may contribute to PI resistance by a common mechanism to the 
drug class. In the majority of cases major PR mutations were present either at baseline or 
emerging at VF along with CSMs suggesting that emergent of mutations at this site, in general, 
follow the appearance of PR resistance-associated mutations (RAMs) and may act as 
compensatory mutations in order to restore the impaired replication usually observed in viruses 
harbouring major PR mutations.  However, CSMs were also observed in a few cases emerging at 
VF in the absence of major PR mutations either at baseline or at VF indicating that mutations at 
this CS may occasionally precede the emergence of PR mutations and they may be the first 
signal of virological failure to PIs.  
 
Four patients developed mutations in P1/P6 including P453L in one patient failing SQV/r who 
showed the L90M and I84V major PR mutations at baseline and emerging at VF, respectively; 
the P453T mutations emerged in two patients failing SQV/r, in both cases in the absence of 
major PR mutations either at baseline or at the time of VF. Finally, the L449F mutation appeared 
in a patient failing SQV/r, once again in the absence of major PR mutations at baseline or at VF. 
The P453L mutation has been previously reported in the literature as a naturally occurring 
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polymorphism but has been also associated with major protease resistance mutations including 
I84V and V82A (Maguire et al, 2002). Similarly in the cross-sectional analysis previously 
presented we observed this mutation to occur frequently in both PI-naïve and PI-experienced 
patients and can be speculated that although natural polymorphism may favor the selection of 
protease resistance mutations by facilitating viral replication. Interestingly, the I84V mutation 
emerged concomitant with the P453L in our patient, confirming the association between both 
mutations that Maguire and co-authors (Maguire et al, 2002) reported. The L449F mutation has 
been previously documented and demonstrated to have in vitro effects on both viral fitness and 
phenotypic resistance to APV (Maguire et al, 2002). The P453T mutation has not been 
previously described. However, this mutation was found in our study (chapter four) as associated 
with PI exposure (p < 0.002). Overall, in our study mutations at this site occur in the absence of 
major PR mutations suggesting that they may precede the appearance of the latter and facilitate 
their selection. This finding contrast with the results observed by Maguire and colleagues who 
found that the L449F mutation was selected after the emergence of the major PR mutation I50V. 
However, agreed with those recently reported by Ghosn and colleagues who described that the 
L449F mutation detected at baseline in a patient on LPV/r led to the selection of the major PR 
mutation I50V at the time of VF (Ghosn et al, 2011). Our study and those conducted by Maguire 
and Ghosn differed on the PI failing which may account for the different encounters. In the study 
conducted by Maguire, the failing PI was APV, which is a second generation PI that was 
designed with greater resemblance to the natural substrate Gag and which interacts much tighter 
with the viral PR than earlier generation PIs and consequently displays a higher genetic barrier to 
resistance. Given these differences, it is not surprising that specific mutations may have a 
different impact on resistance to different PIs and that resistance pathways differed between both 
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of them. In fact, the order of accumulation of Gag and PR mutations is likely to depend on the 
failing PI and likely on the backbone viral sequence. This phenomenon has been clearly 
established for mutations in the PR. Bandaranayake and colleagues showed that PR sequence 
polymorphisms were capable of altering protease activity and inhibitor binding and consequently 
were able to alter the pathway of inhibitor resistance (Bandaranayake et al, 2010). Another 
interesting finding in our study is that all patients developing mutations at this site at the time of 
VF were failing SQV/r. This data may be indicative of a greater impact of P1/P6 mutations on 
this drug compared to other PIs.   However, the number of patients studied is low as to establish 
a definitive linked.  
 
Four additional patients developed mutation in P2/P7 at VF including T375A in a patient failing 
IDV/r who did not show major PR mutations at baseline or at VF and in another failing LPV/r 
who presented three major PR mutations at baseline, although did not develop any new major PR 
mutation at VF; the R380K mutation was seen emerging in a patient failing IDV/r who did not 
show major PR mutations at baseline or at VF and finally the G381S emerged in a patient failing 
IDV/r who showed four major PR mutation at baseline and none emerging at VF. Data on the 
role of mutations at this CS in PI resistance are scarce, since most studies have exclusively 
addressed the function of mutations at P7/P1/P6. A recent study conducted by Ghosn and 
colleagues showed that baseline mutations at this CS were predictive of virological failure of 
LPV/r monotherapy in patients enrolled on the monark trial (comparison of first line LPV/r and 
LPV/r + ZDV/3TC). However, they did not see emergence of mutations at this CS or others at 
the time of VF (Ghosn et al, 2011). The R380K mutation has been found in our study and others 
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to occur frequently as a polymorphism (Malet et al, 2007). The G381S mutation has been first 
time described in our study as associated with PI exposure (p < 0.02) (chapter four). Finally, the 
T375A mutation has been found to be associated with PI-experience both in our study (p < 
0.002) (chapter 4) and by other investigators (Malet et al, 2007).  
 
We did not observe emergence of mutations in the two remaining CSs P17/P24 and CA-P24/P2. 
We and others have indeed observed that these two CSs are highly conserved in both PI-naïve 
and PI-experienced patients (Malet et al, 2007). We also found in the previous chapter that only a 
limited number of mutations such as V128I and Y132F were detected in P17/P24 in PI-
experienced patients and these were indeed significantly associated with exposure to PIs (p < 
0.0001). TheY132F mutation was observed in 3 of our 28 patients at baseline, all of whom had 
been exposed to other PIs before entering the trial. One of the patients presented in addition the 
V128I mutation. All patients with mutations at this CS showed in adition to three to four major 
protease mutations, suggesting that the patients were heavily treated and therefore that evolution 
in this CS does occur, but probably requires prolonged PI-selective pressure. Overall, our 
findings suggest that while evolution of P17/P24 under PI pressure is possible, greater effects 
occur at CSs located in the C-terminal site - P7/P1, P1/P6 and P2/P7. In detail treatment history 
and length of exposure to PIs was unfortunately unavailable to confirm this judgment. 
 
We also observed frequent emergence of mutations in non-CS regions of Gag at the time of 
virological failure. The effect was most prominent in the P17 protein, but was also noticed in all 
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other domains of Gag. Interestingly, while most mutations emerging in P17 were associated with 
PI-exposure (94%), several emerging mutations in other non-CSs were polymorphisms. These 
findings point once again to a prominent role of P17 in PI failure.  
The role of the P17 protein in PI failure was discussed in the previous chapter. As mention there, 
the role of non-CS regions in PI resistance has been addressed in only a limited number of 
studies. One of them demonstrated that P17 plays a pivotal role in the rescue of the replicative 
capacity of multi-protease resistance virus. The same study also revealed that mutations in P17 
are sufficient to confer resistance to all PIs (Parry et al, 2009).  
 
In the previous chapter, we described a high prevalence of mutations associated with PI-exposure 
not only in P17 but also in P6. Although, no PI-associated mutations emerged in P6 at the time of 
virological failure, at baseline patients who had been previously exposed to PIs often presented 
PI-associated mutations at this site. By contrast, only one of the five PI-naïve patients showed 
PI-associated mutations in P6 before starting PI treatment. Therefore, we can speculate a 
situation similar to the one mentioned above for the P17/P24 site, in that P6 evolution can occur 
under PI-selective pressure, but effects are mainly observed in the P17 protein. As a 
consequence, the short period of time between baseline and VF for this patient may account for 
lack of emergence of mutations at the P6 protein. Once again, a formal analysis on the 
association of presence of specific mutations in particular regions of Gag with duration of PI 
treatment would be required to support this verdict. However, this information was unavailable 
for all of the patients.   
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It is worth mentioning that we also detected Gag mutations associated with PI-exposure at 
baseline even in the five patients who had never been exposed to PIs. The effect was more 
noticeable in MA-P17 but also to a lesser extend in other regions such as P7, P6 and the P2/P7 
CS. In fact, all patients showed mutations associated with PI selective pressure at MA-P17, one 
patient showed in addition one mutation associated with PI selective pressure at P7 and two at P6 
and two further patients presented a P2/P7 CSM at baseline. Conversely, mutations described as 
polymorphisms in our study and others such as R380K (Malet et al, 2007) and P453L (Maguire 
et al, 2002 and Verheyen et al, 2006) were seen emerging at VF in the absence or concomitantly 
with major PR mutations, respectively.  
 
The detection of mutations associated with PI-exposure among PI-naive patients is not unusual 
as naturally occurring polymorphisms can confer an advantage to strains growing under PI-
selective pressure and be enriched during therapy and play a role in virological responses. For 
example the secondary protease mutation L63P, which is frequently observed in untreated 
patients, does not confer resistance by itself but provides a significant replication benefit for 
certain viral mutants, particularly under drug pressure (Martinez-Picado, 1999; Sune et al, 2004), 
explaining its higher prevalence in PI-experienced patients. Similar considerations may apply to 
certain Gag mutations, explaining their presence in drug-naïve individuals and their increase in 
prevalence in the setting of PI-exposure. 
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In order to gather further insights into the evolution of Gag under prolonged PI selective 
pressure, we studied in detail three patients who had long-term viraemia while on a PI/r-based 
regimen. We observed that CS mutations frequently occurred at the same codons and often 
showed similar patterns in these patients. For example, the A431V CS mutation in P7/P1 was 
seen in two of the three patients. By contrast, mutations at non-CSs differed considerably among 
patients. As also seen with trial patients, the P17 protein showed a significant number of PI-
associated mutations emerging over time under PI-selective pressure. In addition, we observed a 
high number of non-polymorphic changes emerging at other sites of Gag, predominantly in P6s. 
These results provide further support to the hypothesis that prolonged viral replication under 
selective drug pressure may drive evolution outside the previously mentioned hotspots such as 
P17 and CS P2/P7/P1/P6. Furthermore, the wide variety of non-CS mutations encountered in 
different patients indicates that while CS mutations emerge in consistent patterns, the 
evolutionary pathways in non-CS are complex. This was also earlier suggested by Myint and 
colleagues, who found that while protease and CS mutations were consistent between different 
viral clones, non-CS mutations differed considerably (Myint et al, 2004).  
 
Finally, we performed clonal analysis to confirm co-occurrence of protease and Gag mutations in 
the same genome, which would strengthen a role for Gag mutations in PI failure. As the main 
aim of this clonal analysis was the identification of possible linkage between protease and Gag 
mutations, we were only interested in the dominant quasispecies and as a consequent we only 
examined 10 clones in each patient. We observed very homogenous population in all the three 
patients analysed and in most cases protease mutations and gag mutations associated with PI-
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exposure co-existed on the same viral genome. This observation supports a contribution of Gag 
mutations as compensatory mutations, true resistance mutations, or both. We frequently observed 
the association between the A431V and the I437V CS mutations in Gag with major protease 
mutations, particularly M46I and I84V respectively. We and others previously observed a 
significant statistical association between occurrence of A431V and detection of M46I and other 
protease mutations (Verheyen et al, 2006). Here we have shown that the statistical relationship 
correlates with a genetic linkage between these two mutations. 
 
In order to account for random mutations that may result as a consequence of PCR errors, we 
performed the clonal analysis from the PCR product obtained from five independent PCR 
reactions. The clones we obtained were rather homogenous in each of the patients examined. 
This is likely to reflect the fact that the dominant replicating quasispecies is also rather 
homogenous during prolonged replication under the same treatment regimen. A number of 
technical considerations should be made however. Firstly, two of the plasma sample selected for 
clonal analysis showed a low HIV-1 RNA load (961 and 229 copies/ml respectively). In 
addition, due to insufficient sample, two other samples were diluted to a final viral load of 750 
and 1000 copies/ml, respectively. The relatively low input of HIV-1 RNA may have reduced the 
variability of RNA templates used for cloning. However, it should be pointed out that the scope 
of our clonal analysis was not to address viral genetic diversity within each patient, but rather to 
assess the linkage of protease and gag mutations in the dominant quasispecies.  
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A further technical consideration is that it may be argued that nested PCR amplification may 
introduce errors through the incorporation of incorrect nucleotides, which can be subsequently 
cloned and lead to misleading results. However, all the mutations seen in the clones were 
previously detected by population (Sanger) sequencing, which can only identify variants that 
represent over 20% of the population (Alcorn and Faruki, 2000). If PCR errors are introduced in 
the early cycles the spurious quasispecies can reach such a threshold of representation. However, 
this scenario is unlikely when employing optimized PCR reactions and particularly when proof-
reading enzymes are used.   
 
Another consideration is the possibility of recombination occurring in vitro during the PCR 
reaction, leading to a false interpretation of linkage of mutations. Recombinants presumably arise 
during PCR reactions due to the presence of incompletely extended primers annealing to a 
heterologous target. Consequently to prevent artificial recombination it is necessary to achieve 
complete strand synthesis. One effective strategy is performing limiting dilutions of the cDNA so 
that a single template is employed in the PCR and sequencing reactions. In addition, this also 
minimizes errors in the PCR reaction, as even if an error is introduced during the early PCR 
stages, the error will not be present in more than 25% of the bases in the mixture and will not 
result in an erroneous base call during sequencing (Learn et al; 1996). Therefore, limiting 
dilution is considered the reference technique for the identification of linkage of mutations. 
However, it requires a high volume of sample which was not available in our study. 
Nevertheless, we introduced a number of steps in order to minimize the risk of artificial 
recombination. Firstly, we employed a proof-reading enzyme with reduced RNAse H activity 
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during PCR and we also employed long PCR extension times of up to 3 minutes. Both actions 
are known to promote complete strand synthesis and as a result minimize artificial 
recombination. In addition, we used a low input of HIV-1 RNA, which limits the number of 
initial templates in the PCR reaction, in turn reducing the possibility of artificial recombination. 
We are therefore confident that the risk of artificial recombination was small to negligible in our 
study, and that the mutations shown to co-exist were indeed linked on the same viral genome. 
We, however, also confirmed the relationship between different mutations by performing in vitro 
replicative capacity and drug susceptibility experiments, as shown in the subsequent chapter.    
 
To summarize, the results obtained in this chapter showed that under PI selective pressure 
evolution of Gag occurs primarily, although not exclusively, at CSs (P2/P7, P7/P1 and P1/P6) 
and at the P17 protein outside CSs. The fact that the majority of emergent mutations at Gag have 
been shown in our studies and others to be associated with PI exposure support a role for Gag 
mutations in failure of PI-based regimens. We should emphasize, however, that a high proportion 
of patients also showed emergent protease mutations which although are not known to confer PI 
resistance, we cannot exclude that such protease mutations may have led to PI failure in these 
particular patients. In the subsequent chapter we will focus on studying the contribution of the 
emergent Gag mutations on drug susceptibility and replicative capacity in order to clarify the 
potential role of Gag mutations in failure of PIs.     
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6 Chapter six: effect of Gag mutations on replicative 
capacity and susceptibility to protease inhibitors 
6.1 Introduction 
The results obtained in the previous chapters suggest that full-length Gag sequencing may be 
required for a complete assessment of resistance to protease inhibitors (PIs).  Mutations in the 
Gag polyprotein associated with exposure to PIs and rare or absent in PI-naïve individuals have 
been identified. Importantly, mutations were not restricted to cleavage sites (CSs) but were 
detected throughout the whole Gag protein. Furthermore, by performing longitudinal studies in 
patients failing ritonavir boosted protease inhibitors (PI/r), we described emergence during 
treatment failure of mutations both within CSs and outside. Interestingly emergence of Gag 
mutations occurred in same cases in the absence of major protease resistance mutations. In the 
present chapter I describe the “in vitro” phenotypic characterization of some of the virus strains 
identified in patients in terms of drug susceptibility and replicative capacity (RC). For this 
purpose, I employed a single cycle recombinant assay.   
 
There are two main methods for characterizing the viral phenotype using recombinant vectors, 
namely the single cycle system and the multiple cycle system.  Both assays employ recombinant 
viruses obtained by cloning patient-derived sequences into a defective molecular clone. The 
resulting recombinant virus is then incubated in the presence of increasing concentration of drug, 
and the drug concentration required to reduce replication of the test virus by 50% relative to the 
control virus (IC50) is calculated. Results are expressed as n-fold change (FC) in the IC50 
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compared to the wild-type (WT) reference virus. A FC greater than one indicates reduced 
susceptibility of the virus tested compared to the wild type. By contrast, hypersusceptibility is 
usually defined as a virus that has a FC ≤ 0.4 compared to the wild type virus (Clark et al, 2006). 
The main difference between multiple and single cycle systems is that the first generates an 
infectious molecular clone capable of multiple rounds of replication. By contrast, the single cycle 
assay employs a replication-deficient vector that undergoes only a single round of infection. 
While the multiple cycle assay are proposed to more closely mimic the conditions that the virus 
experiences “in vivo”, the single cycle assay offers the advantages of high sensitivity and greater 
reproducibility. Furthermore, a single cycle system may be especially appropriate when studying 
the effect of a specific mutation, as the format limits the opportunity for “in vitro” selection of 
genetically diverse virus subpopulations, which may not accurately reflect the effect of the 
mutation of interest. In the studies presented in this chapter, a single cycle assay was employed, 
which is based on the system previously described by Petropoulos (Petropoulos et al, 2000), to 
characterize drug susceptibility and RC of virus strains and mutations of interest identified in the 
previous chapters.  
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6.2 Methods 
6.2.1 Patient samples 
Sample for drug susceptibility testing was available for the three patients selected from the HIV 
services at Royal Free Hospital, these are patients identified in chapter five as RFH-1, RFH-2 
and RFH-3 as well as for 9 out of the 28 patients selected form the MaxCmin1, MxCmin2 and 
COLATE clinical trials, these ones include patients Pt-1, Pt-2, Pt-3, Pt-4, Pt-5, Pt-8, Pt-20, Pt-10 
and Pt-26 described in chapter five. We selected patients showing evolution on Gag and in 
particular at sites identified throughout this study as associated with PI selective pressure in order 
to further explore the role of this specific sites in resistance to PIs. We were interested in 
addressing the role of both CS and non-CS mutations and as a consequence we selected patients 
showing evolution at both CSs and beyond. In particular, regarding CS mutations we wished to 
address the effects of mutations firstly identified in our study, but we also wanted to evaluate 
how our phenotypic results compare to those previously published. Therefore, we selected some 
patients with novel mutations (Y132F and T375A) and others with mutations previously 
described (I437V and A431V). With regard to non-CS mutaions, we were particularly interested 
in addressing the effects of P17 mutations specially those associated with PI selective pressure in 
my study, as the results showed in chapter four and five suggest a most prominent role of P17 in 
PI failure. We, therefore, selected four patients for drug susceptibility and replicative capacity.  
 
  The two first patients were selected from the MaxCmin1, MaxCmin2 clinical trials. One of the 
patients was infected with a subtype B HIV-1virus and was failing a ritonavir boosted indinavir 
(IDV/r)-containing regimen with a viral load of 151,359 copies/ml. The other patient was 
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infected with a subtype B HIV-1 virus and was failing a ritonavir boosted saquinavir (SQV/r)-
containing regimen with a viral load of 229 copies/ml. These two patients were identified in 
chapter five as Pt-2 and Pt-20, respectively.  
 
  The third patient was selected from the HIV clinic at the Royal Free Hospital. The patient was 
infected with a subtype C HIV-1 virus and had longstanding ongoing viraemia while on a ritonavir 
boosted amprenavir (APV/r) plus ritonavir boosted lopinavir (LPV/r) containing regimen. The 
patient was identified in chapter five as RFH-1.  
 
 
 The fourth patient was infected with CRF02 HIV-1virus and had long lasting ongoing viraemia 
while on ritonavir boosted lopinavir (LPV/r)-containing therapy. The patient was identified in 
chapter five as RFH-2.  
 
We selected patients RFH-1 and RFH-2 as both showed siginificant evolution in Gag both at CSs 
and beyond. Therefore, the study of these two patients allowed us to explore the effect of such 
eveolution on PI susceptibility and differentlially assess the role of both Gag CS and non-CS 
mutations. In addition, while patient RFH-1 showed the Y132F CS mutation emerging, the patient 
RFH-2 demonstrated the A431V appearing. The Y132F mutation has been for the first time 
described in the present study as associated with PI-selective pressure. By contrast, A431V is well 
stablished in the literature as implicated on resistance to LPV. Consequently, by selecting these two 
patients we were able to further explore the effect of the novel Y132F mutation and also to evaluate 
how our result compare with those previously reported in the case of the A431V mutation.  
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In addition, we studied patients Pt-2 and Pt20. Patient Pt-2 has the P2/P7 CS mutation T375A 
emerging at the time of VF. One again, the T375A mutation has only been briefly reported in the 
literature as associated with PI-selective pressure (Malet et al, 2007). However, its effect on PI 
susceptibility has never been evaluated. In chapter five, we have also demonstrated an association 
of this mutation with PI exposure. As a result, we selected this patient in order to describe the effect 
of this newly described mutation in PI susceptibility and viral replication capacity. Finally, patient 
pt-20 has the P1/P7 CS mutation I437V together with mutations outside CS, in particular 3 P17 
mutations and 2 P1 mutations. The CS mutation I437V has been extensively described in the 
literature as implicated in PI resistance and in fact it was the first Gag CS mutation found to confer 
resistance to PIs independently of protease resistance mutations (Nijhuis et al, 2007). Most 
mutations in P17 emerging in this patient at VF has been found to be associated with PI selective 
pressure in my study (chapter 4). In addition, the results showed in both chapter four and five 
suggest that Gag evolution under PI selective pressure is most prominent in the P17 subdomain of 
Gag and consequently pointed to a main role of P17 in failure to PIs. Therefore, the selection of this 
patient allowed us not only to compare our results with those previously reported for the case of the 
I437V mutation, but also to explore the hypothesis of role of P17 in resistance to PIs.    
Overall, we considered these four patients representative of the studied population and sufficient to 
explore our hypothesis.   
 
 
6.2.2 Side-directed mutants  
In addition to using wild-type viruses of interest, we produced site-directed mutants clinical by 
introducing or reverting specific Gag mutations. Furthermore, we independently introduced the 
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mutations Y132F and T375A into a wild-type backbone. SDM was in all cases performed using 
the Quick Change Site-Directed Mutagenesis Kit (Stratagene) as described in section 2.2.2.11 
and employing primers described in table 2.3 in chapter 2. The resulting viruses were 
subsequently studied for the effect of the mutations on drug susceptibility and RC.     
 
 
6.2.3 Generation of resistance test vectors 
Appropriate restriction sites were introduced in patients’ samples by PCR employing modified 
nested PCR primers containing the corresponding restriction site in the 5’ end (primer sequences 
are detailed in table 2.5 in chapter 2). Patient-derived Gag, Protease or whole Gag-Protease 
regions were subsequently cloned into the Gag-pol expression vector P8.9NSX by employing 
suitable restriction sites.  
 
6.2.4 Drug susceptibility testing 
PI susceptibility testing was performed as indicated in section 2.2.4 and briefly summarized here.  
Pseudovirus stocks used for PI susceptibility testing were produced by co-transfecting confluent 
human embryonic kidney 293 (HEK293T) cells with a resistance test vector DNA plasmid 
containing patient-derived HIV sequences; PMDG encoding the vesicular stomatitis virus G 
protein; and pCSFLW, encoding the firefly luciferase and the HIV packaging sequence. Cells 
were harvested 16 hours after transfection and seeded in the presence of different PI 
concentrations. Pseudovirus stocks produced in the presence of PIs were harvested 
approximately 24 hours later and used to infect fresh target HEK293T cells. Replication was 
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monitored by measuring luciferase production in infected target cells 48 hours after infection and 
compared to a control in the absence of drug. The IC50 was calculated by plotting the percentage 
luciferase inhibition vs. log10 drug concentration and using GraphPad Prism v5.0 to fit the 
inhibition curve by nonlinear least-squares analysis. Results were expressed as FC in the IC50 
compared to the wild-type subtype B HIV-1 reference (P8.9NSX). Experiments were done in 
duplicate and the calculated IC50 represented the mean of at least two independent 
determinations. 
 
In this study, a technical cut-off has been obtained by repeat testing of the wild type virus used as 
a reference throughout the experiments (P8.9NSX). In addition, the results were compared with 
the BCO and/or the two CCO proposed by Virco where available. As described in the 
introduction, hypersusceptibility was considered a FC of ≤ 0.4 (Clark et al, 2006).  
 
 
6.2.5 Replicative capacity testing 
Replicative capacity was measured as described in section 2.2.4.4. Briefly, as described above, 
pseudovirus stocks were produced by transfecting HEK293T cells with the three plasmids 
(RTVs, PMDG, and pCSFLW) and the RC determined by titration of serial dilutions on 
HEK293T cells and quantification of luciferase activity 48 hours after infection. Luciferase 
activity was determined with SteadyGlo and a Glomax luminometer (both Promega) and a mean 
was calculated by using at least four values within the linear range. In order to control for 
transfection efficiency, the expression of luciferase activity was normalized for the amount of 
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P24 protein in pseudovirus supernatants and expressed relative to the P8.9NSX reference virus 
(relative light units, RLU).    
 
6.2.6 Statistical analysis 
Replication capacity and fold-changes in IC50   were compared using one-way ANOVA test (or 
unpaired t-test if only two constructs were compared). A p < 0.05 was considered to be 
statistically significant. When groups differed significantly, a Bonferroni’s multiple comparison 
post-test was performed to make two by two comparisons. 
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6.3 Results 
6.3.1 Patients 
We studied clinical samples from four patients. The first two patients (Pt-2 and Pt-20) were 
already PI-experienced before starting IDV/r and SQV/r, respectively. However, patient Pt-2 
showed no major protease resistance mutations at both baseline and the time of virological 
failure, while showing the emergence of Gag mutations at virological failure. By contrast, patient 
Pt-20 had pre-existing major protease resistance mutations at baseline and showed emergence of 
both additional major protease resistance mutations and Gag mutations at virological failure. The 
selection of these two patients allowed us to study the effect of gag mutations on drug 
susceptibility and RC both in the presence and absence of major PI resistance mutations. 
 
The other two patients (RFH-1 and RFH-2), were PI-naïve at baseline, although patient RFH-1 
had been exposed to other antiretrovirals. Neither showed major protease mutations at baseline. 
Patient RFH-1 was studied over a five-year period during which he showed persistent viraemia 
while on a regimen composed of LPV/r, APV/r and TDF. Over this period, longitudinal samples 
showed the emergence of a total of 4 major protease mutations, 35 Gag non-CS mutations and 2 
Gag CS mutations. Patient RFH-2 was studied over a one-year period of ongoing viraemia while 
receiving a LPV/r-based regimen. Over this time, longitudinal samples showed the emergence of 
2 major protease mutations, 13 gag non-CS mutations and 1 CS mutation. The selection of these 
two patients allowed us to assess the long-term evolution in the Gag gene and its impact on drug 
susceptibility and RC. 
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Further details on these four patients can be found in chapter five. To facilitate the interpretation 
of the phenotypic data, a summary of protease and Gag mutations at baseline and at virological 
failure is presented in figures 6.1 to 6.4.   
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Figure 6.1 Schematic representation of HIV Protease and Gag protein for patient Pt-2.  
Amino acid changes found in plasma virus of patient Pt-2 are illustrated. Protease and functional Gag matrix (P17), capsid (P24), P2, 
Nucleocapsid (P7), P1 and P6 are shown with protease cleavage sites indicated. Changes are numbered according to the HXB2 consensus 
sequence. Changes detected just before starting IDV/r therapy (baseline) are shown above and changes emerging at the time of IDV/r failure (VF) 
are presented below. Mutations in blue in the protease represent minor mutations and those in black other polymorphisms. In Gag, mutations in red 
are those associated with PI-exposure and those in black other polymorphisms. In addition, Gag cleavage sites mutations are presented in solid 
boxes. 
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Figure 6.2 Schematic representation of HIV Protease and Gag protein for patient Pt-20.  
Amino acid changes found in plasma virus of patient Pt-20 are indicated. Protease and functional Gag matrix (P17), capsid (P24), P2, 
Nucleocapsid (P7), P1 and P6 are shown with protease cleavage sites indicated. Changes are numbered according to the HXB2 consensus 
sequence. Changes detected just before starting IDV/r therapy (baseline) are shown above and changes emerging at the time of SQV/r failure (VF) 
are presented below. Mutations in red in the protease represent major resistance mutations, in blue minor mutations and in black other 
polymorphisms. In Gag, mutations in red are those associated with PI-exposure and those in black other polymorphisms. In addition, Gag cleavage 
sites mutations are presented in solid boxes. 
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Figure 6.3 Schematic representation of HIV Protease and Gag protein for patient RFH-1.  
Amino acid changes found in plasma virus of patient RFH-1 are indicated. Protease and functional Gag matrix (P17), capsid (P24), P2, Nucleocapsid (P7), P1 
and P6 are shown with protease cleavage sites indicated. Changes are numbered according to the HXB2 consensus sequence. Changes detected at baseline 
(RFH-1B) are shown above and changes emerging at different time points (RFH-11 to RFH-14) are presented below. Mutations in red in the protease represent 
major resistance mutations, in blue minor mutations and in black other polymorphisms. In Gag, mutations in red are those associated with PI-exposure and 
those in black other polymorphisms. In addition, Gag cleavage sites mutations are presented in solid boxes. 
 
265 
 
 
.  
 
 
  Figure 6.4 Schematic representation of HIV Protease and Gag protein for patient RFH-2.  
Amino acid changes found in plasma virus of patient RFH-2 are illustrated. Protease and functional Gag matrix (P17), capsid (P24), P2, Nucleocapsid (P7), 
P1 and P6 are shown with protease cleavage sites indicated. Changes are numbered according to the HXB2 consensus sequence. Changes detected at baseline 
(RFH-2B) are shown above and changes emerging at different time points (RFH-21 to RFH-23) are presented below. Mutations in red in the protease represent 
major resistance mutations, in blue minor mutations and in black other polymorphisms. In Gag, mutations in red are those associated with PI-exposure and 
those in black other polymorphisms. In addition, Gag cleavage sites mutations are presented in solid boxes. 
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6.3.2 Resistance test vectors 
A total of 20 RTVs were produced: 
1) 8.9Pt2Baseline: containing baseline PR and Gag genes from patient Pt-2. 
2) 8.9Pt2VF: containing virological failure PR and Gag genes from patient Pt-2. 
3) 8.9Pt2VF∆T375A: containing virological failure PR and a modified virological failure 
Gag gene. Modification of Gag consisted of reversion to WT of the T375A mutation by 
SDM, previous to cloning into P8.9NSX.   
4) 8.9Pt20Baseline: containing the baseline PR and Gag genes from patient Pt-20. 
5) 8.9Pt20 Baseline +Gag: containing the baseline PR and a modified baseline Gag gene 
from patient Pt-20. Modification of baseline Gag consisted of introduction of the Gag 
mutations emerging at virological failure by SDM, previous to cloning into P8.9NSX. 
6) 8.9Pt20Baseline+Gag+PR: containing modified baseline PR and Gag genes from patient 
Pt-20. Modification of PR and Gag consisted of introduction of PR and Gag mutations 
emerging at virological failure by SDM, previous to cloning into P8.9NSX.  
7) 8.9Pt20Baseline+P1: containing baseline PR and a modified baseline Gag genes from 
patient Pt-20. Modification of Gag consisted of introduction of the P1 mutations 
emerging at virological failure, previous to cloning into P8.9NSX. 
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8) 8.9Pt20Baseline+P17: containing baseline PR and a modified baseline Gag gene from 
patient Pt-20. Modification of Gag consisted of introduction of the P17 mutations 
emerging at virological failure by SDM, previous to cloning into P8.9NSX. 
9) 8.9Pt20Baseline+I437V: containing the baseline PR and a modified Gag gene from 
patient Pt-20. Modification of Gag consisted of introduction of I437V mutation by SDM 
previous to cloning into P8.9NSX.  
10) 8.9RFH-1PRBGagB: containing baseline PR and Gag genes from patient RFH-1. 
11) 8.9RFH-1PR4Gag4: containing the last time point PR and Gag from patient RFH-1. 
12) 8.9RFH-1PRBGag4: containing baseline PR and last time point Gag from patient RFH-1. 
13) 8.9RFH-1PR4GagB: containing last time point PR and baseline Gag from patient RFH-1.  
14) 8.9RFH-1PRBGag4∆Y132F: containing baseline PR and a modified last time point Gag 
from patient RFH-1. Modification of Gag consisted of reversion to WT of the Y132F 
mutation by SDM, previous to cloning into P8.9NSX.  
15) 8.9RFH-1PRBGAG4∆CS: containing baseline PR and a modified last time point Gag 
from patient RFH-1. Modification of Gag consisted of reversion to WT of the two CS 
mutations emerging over time (Y132F and L449F) by SDM, previous to cloning into 
P8.9NSX.   
16) 8.9RFH-2PRBGagB: containing baseline PR and Gag from patient RFH-2. 
17) 8.9RFH-2PR1Gag1: containing PR and Gag from the first time point after baseline from 
patient RFH-2. 
268 
 
18) 8.9RFH-2PR2Gag2: containing PR and Gag from the second time point after baseline for 
patient RFH-2. 
19) 8.9RFH-2PR3Gag3: containing PR and Gag from the third time point after baseline from 
patient RFH-2. 
20) 8.9RFH-2PR3Gag3∆A431V: containing 3rd time point PR and a modified third time 
point Gag. Modification of Gag consisted of reversion to WT of the A431V mutation by 
SDM, previous to cloning into P8.9NSX.  
 
6.3.3 Determination of IC50 for the wild-type reference virus 
(P8.9NSX)  
The PI susceptibility profile for the wild-type reference virus P8.9NSX was determined.  The 
mean IC50 for each drug was obtained by repeat testing (n =10). Differences between the IC50 
from replicate assays were consistently below 2 fold and as a result we established a 2-fold 
change in IC50 as the technical cut-off for this study. The mean IC50, standard deviation and 95% 
confidence interval calculated from 10 separate determinations in the presence of 6 different PIs 
are shown in table 6.1.  
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Virus and statistics PI IC50(nM)* 
P8.9NSX 
Mean IC50 
SD 
95% CI 
APV ATV DRV IDV LPV SQV 
1.86 6.17 1.57 6.18 1.26 3.35 
0.14 0.24 0.09 0.25 0.09 0.23 
(1.6-2.3) (5.6-6.8) (1.4-1.8) (5.6-6.7) (1.2-1.4) (2.9-3.8) 
 
Table 6.1 IC50 for the WT reference virus P8.9NSX.  
The mean IC50, standard deviation (SD) and 95% confidence interval (95% CI) derived from 10 
independent determinations are shown for the wild type virus (P8.9NSX) employed as a reference in the 
present study.  
* 10% FCS was employed throughout the experiments.  
Abbreviations: amprenavir (APV), atazanavir (ATV), darunavir (DRV), indinavir (IDV), lopinavir (LPV) 
and saquinavir (SQV).  
 
 
6.3.4 Effect of Gag mutations on susceptibility to protease inhibitors 
We tested the susceptibility to ATV, DRV, IDV, LPV and SQV of all the resistance test vectors 
produced from patient Pt-2 (8.9Pt-2Baseline, 8.9Pt-2VF and 8.9Pt-2VF∆T375A) with the 
following results: 
At baseline (8.9Pt2Baseline) the FC was 1.5 for ATV, 2 for DRV, 3 for IDV and SQV and 6 for 
LPV. At the time of virological failure (8.9Pt2VF), the FC significantly increased for all PI 
tested from 1.5 to 3-fold for ATV, from 2-fold to 9-fold for DRV, from 3 fold to 8 fold for IDV, 
from 6 fold to 13 fold for LPV and from 3 fold to 15 fold for SQV. Reversion to WT of the 
treatment emergent T375A mutation (8.9Pt20VF∆T375A) led to a decreased in the level of 
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resistance to all PIs respect to the virological failure sample and was comparable to the FC 
observed at baseline. 
 
Figure 6.5 shows the drug susceptibility profile for the three RTVs from patient Pt-2. 
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Figure 6.5 PI susceptibility profile for patient Pt-2.  
The PI susceptibility profiles at baseline (8.9Pt2Baseline), at VF (8.9Pt2VF) and after reversion to wild-type of the treatment emergent Gag 
cleavage site mutation T375A (8.9Pt2VF∆T375A) are shown. Susceptibility is shown as change in IC50 compared to that of the wild-type virus; 
thus a FC of 1 indicates same susceptibility as the wild-type P8.9NSX. Error bars represent the standard error of the mean of three separate 
experiments. Numbers are the mean of three experiments ± SD. Bold numbers indicate that the different FC respect to the baseline was found 
statistically significant using one way ANOVA followed by Bonferroni’s multiple comparison post-test.  
DRUG    WT  
(mean IC50 nM) 
8.9Pt-2Baseline 8.9Pt-2VF 8.9Pt-2ΔT375A 
Mean 
IC50 nM 
Mean 
FC ± SD 
Mean IC50 nM Mean 
FC ± SD 
Mean 
IC50 nM 
Mean FC ± SD 
ATV 6 9 1.5 ± 0.15 18 3 ± 0.08 10 1.6 ± 0.11 
DRV 1.6 3.4 2± 0.10 15 9 ± 0.5 3 2 ± 0.06 
IDV 6 18 3± 0.15 46 8 ± 0.29 15 2.5 ± 0.14 
LPV 1.2 7.2 6± 0.361 16 13 ± 0.34 7 6  ± 0.17 
SQV 3 9 3± 0.32 46 15 ± 0.32 10 3 ± 0.2 
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We tested the susceptibility to ATV, DRV, IDV, LPV and SQV of all the resistance test vectors  
Obtained from patient 20, these were: 8.9Pt20Baseline, 8.9Pt20Baseline+Gag, 
8.9Pt20Baseline+Gag+PR, 8.9Baseline+P1, 8.9Baseline+P17 and 8.9Baseline+I437V. 
 
At baseline (8.9Pt20Baseline), according to the Virco biological and clinical cut-offs, the 
baseline sample showed complete susceptibility to DRV (FC: 2.0) and LPV (FC: 2.8) and 
reduced activity for ATV (FC: 4.8), IDV (FC: 5.3) and SQV (FC: 5.2). Introduction of the 
treatment emergent Gag mutations into the baseline Gag by SDM (8.9Pt20Baseline+Gag) led to 
an significant increase in the level of resistance for all the PIs tested, from 4.8-fold to 12 fold for 
ATV, from 2 fold to 10.5 fold for DRV, from 5.3 fold to 10 fold for IDV, from 2.8 to 10 fold for 
LPV and from 5.2 fold to 15 fold for SQV. Introduction of both treatment emergent Gag and 
protease mutations into the baseline (8/9Pt20Baseline+Gag+PR) led to a more substantial 
increase in the level of resistance for all the PIs tested, from 4.8 fold to 32 fold for ATV, from 2 
fold to 22 fold for DRV, from 5.3 fold to 43 fold for IDV, from 2.8 fold to 31 fold for DRV and 
from 5.2 fold to 75 fold for ATV.  
 
Figure 6.6 shows the drug susceptibility profile of 8.9Pt20Baseline, 8.9Pt20Baseline+Gag, 
8.9Pt20Baseline+Gag+PR. 
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DRUG 
WT 
 
8.9Pt20Baseline 8.9Pt20Baseline +Gag 8.9Pt20Baseline+Gag+PR 
 
Mean IC50 nM 
 
Mean IC50 nm Mean FC ± SD Mean  IC50 nm Mean FC ± SD Mean IC50 nm Mean  
FC ± SD 
ATV 6 28.8 4.8 ± 0.85 72 12 ± 0.9 192 32 ± 2 
DRV 1.6 3.2 2 ± 0.5 16.8 10.5 ± 1.0 35.2 22 ± 1.4 
IDV 6 32 5.3 ± 0.4 60 10 ± 1.3 258 43± 0.7 
LPV 1.2 3.4 2.8 ± 0.28 12 10 ± 1.3 37.2 31 ± 4.2 
SQV 3 15.6 5.2 ± 0.28 45 15 ± 1.0 225 75 ± 1.4 
 
Figure 6.6 PI susceptibility profile of RTVs: 8.9Pt20Baseline, 8.9Pt20Baseline+Gag and 8.9Pt20Baseline+Gag+PR. The figure shows the PI 
susceptibility of the baseline sample, after introduction of emergent Gag mutations (P17-MA: V82I, A115I and A120S; P1: Y441H and G443E) 
and after introduction of emergent Gag and PR (T74P and I84V) mutations. Susceptibility is shown as the change in IC50 compared to that of the 
wild-type P8.9NSX; thus a FC of 1 indicates same susceptibility as the wild-type. Error bars represent the standard error of the mean from three 
separate experiments. Bold numbers indicate that the different FC respect to the baseline was found statistically significant using one way 
ANOVA followed by Bonferroni’s multiple comparison post-test.  
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The susceptibility testing of the resistance test vectors containing modified Gag genes consisting 
of step-wise introduction of Gag mutations (8.9Pt20Baseline+P1, 8.9Pt20Baseline+MA and 
8.9Pt20Baseline+I437V) showed the following: 
Introduction of the two treatment emergent P1 mutations (Y441, G443E) did not change 
significantly the susceptibility profile of any of the PI tested compared to the baseline sample. 
However, introduction of the 3 treatment emergent P17 mutations (V82I, A115I and A120S) led 
to a significant increase of resistance to SQV from 5.2 fold to 9 fold compared with the baseline 
and from 2.8 fold to 6.0 fold for ATV sample but had no discernible effect on susceptibility to 
the other PIs.  Finally, introduction of the I437V mutations led to a significant increase of 
resistance to all PIs. From 4.8 fold to 8 fold for ATV, from 2 to 10.6 fold for DRV, from 5.3 fold 
to 10 fold for IDV, from 2.8 fold to 10 fold for LPV and from 5.2 to 8 fold to SQV.   
 
Figure 6.7 shows the comparison of the drug susceptibility profile of 8.9Pt20Baseline, 
8.9Pt20Baseline+P1, 8.9Pt20Baseline+MA, 8.9Pt20Baseline+I437V and 8.9Pt20Baseline+Gag. 
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DRUG WT  
(mean IC50 nM) 
P8.9Baseline P8.9Baseline+P1 P8.9Baseline+P17 P8.9Baseline+I437V P8.9Baseline+Gag 
Mean  
IC50 nM 
Mean  
FC ± SD 
Mean 
 IC50 nM 
Mean  
FC ± SD 
Mean  
IC50 nM 
Mean  
FC ± SD 
Mean 
IC50 nM 
Mean FC 
± SD 
Mean 
IC50 nM 
Mean  
FC ± SD 
ATV 6 28.8 4.8 ± 0.7 30 5 ± 0.2 36 6 ± 0.2 48 8 ± 0.6 72 12 ± 0.1 
DRV 1.6 3.2 2 ± 0.4 3.7 2.3 ± 0.2 3.4 2.1 ± 0.2 17 10.6 ± 0.2 16.8 10.5 ± 0.7 
IDV 6 32 5.3 ± 0.3 34.2 5.7 ± 0.5 29.7 4.9 ± 0.1 60 10 ± 0.1 60 10 ± 0.9 
LPV 1.2 3.4 2.8 ± 0.2 3.5 2.9 ± 0.3 3.6 3 ± 0.2 12 10 ± 0.4 12 10 ± 1.1 
SQV 3 15.6 5.2 ± 0.3 18.1 6 ± 0.5 27 9 ± 0.8 24 8 ± 0.4 45 15 ± 0.5 
 
Figure 6.7 Individual effects of treatment emergent Gag mutations on PI susceptibility. Susceptibility profile of the baseline sample 
(8.9Pt20Baseline), after introduction of P1 mutations (8.9Pt20Baseline+P1), after introduction of matrix mutations (8.9Pt20 Baseline+P17), after 
introduction of the I437V mutation (8.9Pt20Baseline+I437V) and after introduction of all Gag mutations simultaneously (8.9Pt20Baseline+Gag). 
Susceptibility is shown as the change in IC50 compared to that of the wild-type P8.9NSX; thus a FC of 1 indicates the same susceptibility as the 
wild-type. Error bars represent the standard error of the mean from three separate experiments. Bold numbers indicate that the different FC respect 
to the baseline was found statistically significant using one way ANOVA followed by Bonferroni’s multiple comparison post-test.  
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Next, it was compared the susceptibility to APV, ATV, DRV, IDV, LPV and SQV of patient 
RFH-1’s resistance test vectors including 8.9RFH-1PRBGagB, 8.9RFH-1PRBGag4, 8.9RFH-
1PRBGag4∆Y132F and 8.9RFH-1PRBGag4∆CS. The drug susceptibility results were as follow:  
At baseline (8.9RFH-1PRBGagB) it was found around 2-fold resistance to APV, DRV and LPV, 
a 3-fold resistance to ATV, a 5-fold resistance to IDV and a 7-fold resistance to SQV. When the 
Gag baseline was replaced by the last time point Gag in the baseline sample (8.9RFH-
1PRBGag4), a significant increase in resistance relative to the baseline sample was found. Thus, 
the FC for APV increased from 2.0 to 20, from 3 to 24 for ATV, from 2.2 to 23 for DRV, from 5 
to 28 fold for IDV, from 2 to 12 for LPV and from 7 to 22 for SQV. The reversion to WT of the 
Y132F mutation in Gag4 (8.9RFH-1PRBGag4∆Y132F) showed a decrease in the level of 
resistance for all PIs except SQV/r relative to the resistance test vectors containing intact Gag4 
but the level of resistance still  remained significantly above that seen with baseline Gag (GagB). 
Thus, the FC for 8.9RFH-1PRBGag4∆Y132F changed to 12-fold for APV, 19-fold for ATV and 
DRV, 22-fold for IDV, 10-fold for LPV and 21-fold for SQV. Finally, both Y132F and L449F 
mutations were reverted to wild-type in Gag4 (9RFH-1PRBGag4∆CS) to evaluate the effect that 
treatment emergent Gag CS mutations had on PI susceptibility. A further decrease in the level of 
resistance relative to that seen when only Y132F was reverted to wild-type was found. However, 
the FC still remained significantly higher than those seen with GagB for all PIs except for APV. 
Thus, FC with RFH-1PRBGag4∆CS was 4.3-fold for APV and IDV, 10-fold for ATV and DRV, 
6-fold for LPV and 14-fold for SQV. 
 
The contribution of Gag4 to PI susceptibility is depicted in figure 6.8 and figure 6.9.    
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Figure 6.8 Contribution of emergent Gag mutations to PI resistance. The PI susceptibility of the 
RTVs containing baseline protease and last time point Gag (8.9RFH-1PRBGag4) is shown. 
Susceptibility is shown as change in IC50 compared to that of the WT virus; thus a FC of 1 
indicates same susceptibility as the WT P8.9NSX. Error bars represent the standard error of the 
mean of two separate experiments.  
DRUG            WT  
(mean IC50 nM) 
8.9RFH-1PRBGagB 8.9RFH-1PRBGag4 
Mean  
IC50 nM 
Mean  
   FC ± SD 
Mean  
IC50 nM 
  Mean  
     FC ± SD 
APV 1.8 3.1 2 ± 0.3 36 20 ± 1 
ATV 6 18 3 ± 1.0 144 24 ± 1.4 
DRV 1.6 3.5 2.2 ± 0.4 37 23 ± 1.3 
IDV 6 29.4 5 ± 1.3 168 28 ± 0 
LPV 1.2 2.2 2 ± 0.3 15 12 ± 1.3 
SQV 3 13.5 7 ± 1.1 66 22 ± 1.3 
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DRUG WT  
(mean IC50 
nM) 
8.9RFH-1PRBGagB 8.9RFH-1PRBGag4ΔCS 8.9RFH-1PRBGag4ΔY132F 8.9RFH-1PRBGag4 
Mean 
IC50 nM 
Mean 
FC ± SD 
Mean 
IC50 nM 
Mean 
FC  ± SD 
Mean 
IC50 nM 
Mean 
FC ± SD 
Mean 
IC50 nM 
Mean 
FC ± SD 
APV 1.8 3.1 2 ± 0.3 15 4.3 ± 0.4 37 12 ± 0.4 36 20 ± 1.4 
ATV 6 18 3 ± 1 60 10 ± 0.7 72 19 ± 0.7 144 24 ± 1.6 
DRV 1.6 3.5 3 ± 0.4 16 10 ± 1.4 22 19 ± 0.7 37 23 ± 1.0 
IDV 6 29.4 5 ± 1.3 48 8 ± 1.2 60 22 ± 1.0 168 28 ± 1.2 
LPV 1.2 2.2 2 ± 0.3 7 6 ± 0.8 16 10 ± 0.3 15 12 ± 0 
SQV 3 13.5 7 ± 1.1 42 14 ± 0.1 51 21 ±0.6 66 22 ± 1.0 
 
Figure 6.9 Contribution of Gag CSMs to PI resistance.  The PI susceptibility of the RTVs containing baseline protease and last time point Gag 
after sequential reversion to WT of the emergent CSMs (8.9RFH-1PRBGag4∆Y132F and 8.9RFH-1PRBGag4∆CS) compared to the baseline and 
last time point (8.9RFH-1PRBGagB and 8.9RFH-1PR4Gag4) is shown. Susceptibility is shown as change in IC50 compared to that of the WT virus; 
thus a FC of 1 indicates same susceptibility as the WT P8.9NSX. Error bars represent the standard error of two different experiments. Bold 
numbers indicate that the different FC respect to the baseline was found statistically significant using one way ANOVA followed by Bonferroni’s 
multiple comparison post-test.  
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Finally, it was evaluated the susceptibility to ATV, DRV, IDV, LPV and SQV of the resistance 
test vectors obtained by cloning the PR and Gag sequences from patient RFH-2. These are 
8.9RFH-2PRBGagB, 8.9RFH-2PR1Gag1, 8.9RFH-2PR3Gag3 and 8.9RFH-2PR3Gag3∆A431V.  
The results of the PI susceptibility for the construct tested were as follow: 
At baseline (8.9RFH-2PRBGagB) a 4-fold resistance to LPV and below 2 fold change for all 
other PIs was observed.  At the first time point after the baseline (8.9RFH-2PR1Gag1), it was 
found that the level of resistance to ATV increased from 1 to 2.8 fold, to LPV from 4 to 6.7 fold 
and for SQV from 1.6 to 4 fold and no change was observed for DRV and IDV. The FC 
difference was only significant for SQV.  
When the last time point (8.9RFH-2PR3Gag3) was analysed, it was seen that the level of 
resistance further increased to a 12 fold change for LPV, 4 FC for DRV and 2 FC for IDV but 
hypersusceptibility for ATV and SQV (FC: 0.28 and 0.32, respectively) was detected. Applying 
the one-way ANOVA test followed by Bonferroni’s multiple comparison tests showed that in 
this case, the difference FC respect to the baseline was significant for LPV and DRV but not for 
other PIs. Reversion to WT of the A431V mutation in the above construct (8.9RFH-
2PR3Gag3∆A431V) led to a modest decrease in the LPV FC from 12 to 10 fold and no change in 
the other PIs. The difference fold change respect to the baseline still remained significance for 
LPV.  
PI susceptibility profiles for the RTVs obtained from patient RFH-2 are shown in figures 6.10 
and 6.11.   
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DRUG            WT  
(mean IC50 nM) 
8.9RFH-2PRBGagB 8.9RFH-2PR1Gag1 
Mean  
IC50 nM 
    Mean  
   FC ± SD 
   Mean  
IC50 nM 
     Mean  
   FC ± SD 
ATV 6 7 1 ± 0.8 17 2.8 ± 0.4 
DRV 1.6 2 1.2 ± 0.3 2.1 1.3 ± 0.1 
IDV 6 8 1.3 ± 0.2 10 1.7 ± 0.3 
LPV 1.2 5  4 ± 0.6 8 6.7 ± 0.7 
SQV 3 5 1.7 ± 0.3 13 4.3 ± 0.4 
 
Figure 6.10 PI susceptibility profiles at baseline and 1
st
 follow-up time for patient RFH-2. 
The PI susceptibility of the RTVs containing baseline sample and 1
st
 time point after the baseline is 
shown. Susceptibility is shown as change in IC50 compared to that of the wild-type virus; thus a FC of 1 
indicates same susceptibility as the wild-type P8.9NSX. Error bars represent the standard error of two 
different experiments.  Bold numbers indicate that the different FC respect to the baseline was found 
statistically significant using one way ANOVA followed by Bonferroni’s multiple comparison post-test.  
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Figure 6.11 Contribution of emergent Gag CSMs to PI resistance. The PI susceptibility of the RTVs 
containing the last time point Gag after reversion to WT of the emergent A431V mutation (8.9RFH-
2PR3Gag3∆A431V) is shown. Susceptibility is shown as change in IC50 compared to that of the WT virus; 
thus a FC of 1 indicates same susceptibility as the WT P8.9NSX. Error bars represent the standard error 
of the mean of two separate experiments. Bold numbers indicate that the different FC respect to the 
baseline was found statistically significant using one way ANOVA followed by Bonferroni’s multiple 
comparison post-test. Virco Biological cut off (BCO), lower and upper clinical cut-offs (CCO1 and 
CCO2) are shown.  
DRUG            WT  
(mean IC50 nM) 
RFH-23 RFH-23ΔA431V 
Mean  
IC50 nM 
Mean  
   FC ± SD 
Mean  
IC50 nM 
    Mean  
 FC ± SD 
ATV 6 3 0.4 ± 0.1 3 0.28 ± 0.1 
DRV 1.6 6 4 ± 0.5 6 4 ± 0.1 
IDV 6 14 2 ± 0.1 12 2 ± 0.1 
LPV 1.2 15 12.5 ± 0.7 12 10 ± 0.1 
SQV 3 2 0.2 ± 0.6 2 0.32 ± 0.1 
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6.3.5 Effect of Gag mutations on replicative capacity 
The replicative capacity (RC) of the 20 resistance test vectors generated was determined and 
compared to that of the wild type reference 8.9PNSX virus. The results were as follows: 
 Comparison of the RC of the resistance test vectors obtained from patient Pt-2 
demonstrated that the baseline virus 8.9Pt-2Baseline showed 80% ± 1.4 RC relative to wild-type 
virus. At the time of virological failure, the virus replicated more efficiently than the WT virus 
(RC 146% ± 5.7) (P < 0.0004). However, if the T375A mutation was reverted to WT in the latter 
virus (8.9Pt2VF∆T375A), the RC returned to levels observed at baseline (from 146% ± 5.7 to 
73% ± 7.8). Results are shown in the figure below (Figure 6. 12).  
WT
8.9Pt2Baseline
8.9Pt2VF
T375A8.9Pt2VF
Replication capacity (% of WT by rlu/ng P24)
0 25 50 75 100
 
Figure 6.12 Replication capacity of RTVs from patient Pt-2.Recombinant resistance test vectors were prepared containing 
patient’s derived PR and Gag genes: 8.9Pt2Baseline contained baseline PR and Gag, 8.9Pt2VF contained virological failure PR 
and Gag and 8.9Pt2VF∆T375A contained virological failure PR and a modified virological failure Gag in which the T375A 
mutation have been reverted to WT by SDM. RTVs were produced encoding luciferase and titrated. Luciferase activity was 
determined with SteadyGlo and a Glomax luminometer (both Promega); a mean was obtained using at least four values within 
the linear range and is expressed as the luciferase activity of the sample relative to the 8.9PNSX reference virus (relative light 
units, rlu). Virus titres were previously normalized for the amount of P24 protein produced in supernatants to correct for 
transfection efficiency. Results are shown as a percentage RC relative to the wild-type control virus.  
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 Comparison of the RC of the RTVs obtained from patient Pt-20 showed that the baseline 
virus (8.9Pt20Baseline) replicated around 50% less efficiently than the WT reference virus RC: 
(56% ± 2.82, P < 0.0001). Introduction of the treatment emergent PR mutations 
(8.9Pt20Baseline+PR) led to a significant decreased in viral RC from 56% ±2.82 to 32.5% ± 
3.54). However, introduction of treatment emergent Gag mutations (8.9Pt20Baseline+Gag) 
rescued the RC from 32.5 % ± 3.54 to 69% ± 1.4 (P < 0.0001) relative to the wild-type reference 
virus. Step-wise introduction of the Gag emergent mutations demonstrated that introduction of 
the MA-P17 mutations led to a recovery in RC comparable to that obtained when all Gag 
mutations were introduced (69% ± 1.4 vs. 68% ± 0). However, when either P1 mutations or the 
I437V mutation were introduced, no significance changed on RC was found: 32.5 ± 3.54 vs. 33.5 
± 2.12 and 32.5 ± 3.54 vs. 38 ± 2.83, respectively.  Results are shown in figure 6.13.  
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Figure 6.13 Replication capacity of RTVs from patient Pt-20. 
Recombinant resistance test vectors were prepared containing patient’s derived protease and Gag genes: 
8.9Pt20Baseline contained baseline PR and Gag, 8.9Pt20Baseline+PR contained baseline Gag and 
mutated PR in which all treatment emergent PR mutations (I84V + T74P) were introduced by SDM. 
8.9Pt20Baseline+PR+P1 contained the mutated PR and mutated Gag in which all treatment emergent P1 
mutations were introduced by SDM. 8.9Pt20Baseline+PR+ I437V contained the mutated PR and a 
mutated Gag in which the I437V mutation was introduced by SDM. 8.9Baseline+PR+P17 contained 
baseline PR and a mutated Gag in which treatment emergent P17 mutations were introduced by SDM and 
finally 8.9Pt20Baseline+PR+Gag contained the mutated PR and a mutated Gag in which all treatment 
emergent Gag mutations were introduced simultaneously by SDM. RTVs were produced encoding 
luciferase and titrated. Luciferase activity was determined with SteadyGlo and a Glomax luminometer 
(both Promega); a mean was obtained using at least four values within the linear range and is expressed as 
the luciferase activity of the sample relative to the 8.9PNSX reference virus (relative light units, rlu). 
Virus titres were previously normalized for the amount of P24 protein produced in supernatants to correct 
for transfection efficiency. Results are shown as a percentage RC relative to the wild-type control virus.  
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 Comparison of the RC of the RTVs obtained from patient RFH-1 showed that the 
baseline virus (8.9RFH-1PRBGagB) had a RC comparable to that of the WT virus (98.5 ± 2.12 vs. 
99 ± 0.71). At the last time point tested (8.9RFH-1PR4Gag4), the virus showed an increase in RC 
(131.5% ± 9.2, P < 0.0001) respect to the wild-type virus. In order to assess the role that Gag 
evolution played in this increased in RC, the Gag from the two time points were exchanged. It 
was found that the virus containing baseline PR and last time point Gag (8.9RFH-1PRBGag4) had 
a RC relative to WT virus of 159.5% ± 10.6. This difference respect to the baseline virus reached 
statistical significance (P < 0.0001). By contrast, the virus containing last time point PR and 
baseline Gag (8.9RFH-1PR4GagB) decreased significantly its RC respect to the baseline virus 
98.5 ± 2.12 vs. 10% ± 2.83 (P< 0.0001). Furthermore, the effect that treatment emergent Gag CS 
mutations had on RC was assessed by step-wise reversion to WT of the two emergent mutations 
Y132F and L449F in the last time point Gag. It was observed that reversion of Y132F (8.9RFH-
1PRBGag4∆Y132F) led to a non-significance decrease in RC from 159% ±1 0.6 to 150% ± 2.8 
and further reversion of  L449F (8.99RFH-1PRBGag4∆CS) led to a significant decrease from 
159%  ± 10.6 to 129 ± 3.0% ( P < 0.0001).  Results are shown in figure 6.14.  
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  Figure 6.14 Replication capacity of RTVs from patient RFH-1. 
Recombinant resistance test vectors were prepared containing patient’s derived PR and Gag genes: 8.9RFH-
1PRBGagB contained baseline PR and Gag, 8.9RFH-1PR4Gag4 contained last time point PR and Gag, 8.9RFH-
1PRBGag4 contained baseline protease and last time point Gag, 8.9RFH-1PR4GagB contained last time point PR and 
baseline Gag, 8.9RFH-1PRBGag4∆Y132F contained baseline PR and a modified last time point Gag in which the 
Y132F mutation have been reverted to WT by SDM and 8.9RFH-1PRBGag4∆CS contained baseline PR and a 
modified last time point Gag in which both Y132F and L449F mutations have been reverted to WT by SDM.  
Luciferase activity was determined with SteadyGlo and a Glomax luminometer (both Promega); a mean was 
obtained using at least four values within the linear range and is expressed as the luciferase activity of the sample 
relative to the 8.9PNSX reference virus (relative light units, rlu). Virus titres were previously normalized for the 
amount of P24 protein produced in supernatants to correct for transfection efficiency. Results are shown as a 
percentage RC relative to the wild-type control virus.  
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 Comparison of the RC of the RTVs obtained from patient RFH-2 showed that the 
baseline virus (8.9RFH-2PRBGagB) had a 97% ± 0.71 RC respect to the WT virus. At the first 
time point after the baseline (8.9RFH-2PR1Gag1) the RC increased to130% ± 1.41. The 
difference in RC between baseline and first time point reached statistical significance (P, 
0.0001). At the second time point after the baseline (8.9RFH-2PR2Gag2) the replicative capacity 
was significantly reduced from 97% ± 0.71 to 24 ± 4.24 ( P < 0.0001). However, the RC was 
rescued at the third time point after the baseline (8.9RFH-2PR3Gag3) from 24 ± 4.24 to 74.5 ± 
6.36, P < 0.0001. Reversion to WT of the treatment emergent Gag CS mutation A431V in the 
third time point (8.9RFH-2PR3GAG3∆A431V) led to a significant reduction in RC from 74.5% ± 
6.36 to 55% ± 4.24, P < 0.0001.  Results are depicted in the figure below (Figure 6.15).               
 
  Figure 6.15 Replication capacity of RTVs from patient RFH-2. 
Recombinant resistance test vectors were prepared containing patient’s derived PR and Gag genes: 
8.9RFH-2PRBGagB contained baseline PR and Gag, 8.9RFH-2PR1Gag1 contained first time point after 
baseline PR and Gag, 8.9RFH-2PR2Gag2 contained second time point after baseline PR and Gag, 
8.9RFH-2PR3Gag3 contained third time point after baseline PR and Gag, 8.9RFH-2PR3Gag3∆A431V 
contained third time point PR and a modified third time point Gag in which the A431V mutation have 
been reverted to WT by SDM.  Luciferase activity was determined with SteadyGlo and a Glomax 
luminometer (both Promega); a mean was obtained using at least four values within the linear range and 
is expressed as the luciferase activity of the sample relative to the 8.9PNSX reference virus (relative light 
units, rlu). Virus titres were previously normalized for the amount of P24 protein produced in 
supernatants to correct for transfection efficiency. Results are shown as a percentage RC relative to the 
wild-type control virus. 
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6.3.6 Characterization of Y132F and T375A mutations 
Y132F and T375A are CS mutations that were found to emerge during PI failure in our study, 
and which appeared to have effects on PI susceptibility and RC. In order to confirm the effect of 
these mutations we introduced each mutation in the P8.9NSX WT backbone by SDM and 
studied the phenotype of the resulting mutated viruses (P8.9NSX-T375A and P8.9NSX-Y132F). 
 
The results were as follows: 
Introduction of the P2/NC-P7 CS mutation T375A into the wild-type backbone by SDM led to a 
significant increase in resistance to all PIs. The FC in IC50 of the mutated virus compared to the 
wild-type virus was: 5 for ATV, DRV and LPV and 10 for DRV and SQV. The mutated T375A 
virus showed an RC of 161.5% ± 4.95, which was significantly higher compared to the WT virus 
(P = 0.003).  
Introduction of the MA-P17/CA-P24 CS mutation Y132F into the wild-type backbone by SDM 
also produced around a 10-fold increase in resistance to all PIs. However, it negatively affected 
RC as this declined to 61.5% ± 3.5, P = 0.009.  
Drug susceptibility and RC profiles for the P8.9NSX-T375A are shown in figures 6.16 and 6.17, 
respectively. Drug susceptibility and RC profiles for P8.9NSX-Y32F are shown in figures 6.18 
and 6.19, respectively.  
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DRUG WTP8.9NSX 
(mean IC50 nM) 
WTP8.9NSX-T375A 
Mean  IC50 nM Mean FC ± SD 
ATV 6.1 33 5.4 ± 0.3 
DRV 1.14 11.6 10 ± 1.4 
IDV 6.1 32.6 5 ± 0.7 
LPV 1.2 6.2 5.2 ± 0.6 
SQV 3.3 33 10 ± 0.7 
  
Figure 6.16 Phenotypic PI susceptibility profile of SDM containing T375A.  
Phenotypic drug susceptibility testing was performed with the wild-type reference virus 
P8.9NSX and a mutated wild-type virus (P8.9NSX-T375A) which contained the same 
HIV backbone as the reference virus except for the Gag CS mutation T375A which had 
been introduced by SDM. Green curves represent the reference virus and red curves 
represent the mutated virus. Inhibition curves shifted to the right (higher drug 
concentration) indicates reduced susceptibility.  The fold change was calculated by 
comparing the IC50 of the reference virus to the IC50 for the mutated virus.  
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  Figure 6.17 Replication capacity of SDM containing T375A.  
Recombinant resistance test vectors were prepared containing either the WT reference virus (P8.9NSX) or 
a mutated virus (P8.9NSX-T375A) in which the T375A Gag CS mutation was introduced by SDM.  
Luciferase activity was determined with SteadyGlo and a Glomax luminometer (both Promega); a mean 
was obtained using at least four values within the linear range and is expressed as the luciferase activity of 
the sample relative to the 8.9PNSX reference virus (relative light units, rlu). Virus titres were previously 
normalized for the amount of P24 protein produced in supernatants to correct for transfection efficiency. 
Results are shown as a percentage RC relative to the wild-type virus control.   
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Figure 6.18 Phenotypic PI susceptibility profile of SDM containing Y132F.  
Phenotypic drug susceptibility testing was performed with the WT reference virus P8.9NSX and 
a mutated WT virus (P8.9NSX-Y132F) which contained the same HIV backbone as the 
reference virus except for the Gag CS mutation Y132F which had been introduced by SDM. 
Green curves represent the reference virus and red curves represent the mutated virus. Inhibition 
curves shifted to the right (higher drug concentration) indicates reduced susceptibility.  The fold 
change was calculated by comparing the IC50 of the reference virus to the IC50 for the mutated 
virus..  
 
DRUG         
WTP8.9NSX  
(mean IC50 nM) 
WTP8.9NSX-Y132F 
Mean  IC50 nM Mean  FC ± SD 
ATV 6.1 61 10 ± 0.7 
DRV 1.63 16 9.8 ± 1.8 
IDV 6.2 60.6 9.8 ± 0.2 
LPV 1.2 12 10 ± 0.8 
SQV 3.3 33 10 ± 1.6 
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P8.9NSX VS. P8.9NSX-Y132F
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Figure 6.19 Replication capacity of SDM containing Y132F.  
Recombinant resistance test vectors were prepared containing either the WT reference virus 
(P8.9NSX) or a mutated virus (P8.9NSX-Y132F) in which the Y132F Gag CS mutation was 
introduced by SDM.  Luciferase activity was determined with SteadyGlo and a Glomax 
luminometer (both Promega); a mean was obtained using at least four values within the linear 
range and is expressed as the luciferase activity of the sample relative to the 8.9PNSX reference 
virus (relative light units, rlu). Virus titers were previously normalized for the amount of P24 
protein produced in supernatants to correct for transfection efficiency. Results are shown as a 
percentage RC relative to the wild-type virus control.  
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6.4 Discussion 
In the present chapter we have evaluated the impact of HIV-1 Gag mutations on PI susceptibility 
and viral replication capacity.  
Overall our results showed that cleavage site mutations affect viral replicative capacity and 
resistance to protease inhibitors.  While all CS mutations evaluated in this study increased to 
some extend the level of resistance to one or more PIs, the impact on RC differed among 
mutations and among viral constructs. These results suggest that CS mutations may be selected 
as truly resistance mutation independent of their role as compensatory mutations.  In addition, we 
observed that non-CS mutations also increased the levels of PI resistance and in fact confer PI 
resistance on their own. By contrast with CS mutations, non-CS mutations had in all cases a 
positive effect on viral RC.  
 
We employed a single cycle assay for the assessment of drug susceptibility and RC. The system 
incorporates a self-inactivating vector capable of a single round of infection and was initially 
developed by Petropoulos and colleagues (Petropoulos et al, 2000).  Versions of this assay such 
as Phenosense are currently licensed for diagnostic purposes.  The ability of single cycle assays 
to predict drug susceptibility “in vivo” has been debated. It has been stated that multiple cycle 
assays may be more appropriate as they more closely reproduced “in vivo” conditions. However, 
a few studies have shown comparable drug susceptibility results with both formats (Maguire et 
al, 2002). In addition, we should emphasize that our primarily objective was to address the effect 
of specific Gag mutations detected at the time of virological failure. In this respect, single cycle 
assays may be more suitable as the restriction to a single round makes virtually impossible the 
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selection of virus subpopulations that may not accurately reflect the initial viral population.  The 
ability of our system to generate reproducible measurements of PI susceptibility was evaluated 
by repeatedly testing the drug susceptible reference strain P8.9NSX which derived from the 
NL4-3 molecular clone. The assay rendered highly reproducible measurements of PI 
susceptibility and the IC50 were within the range observed in published studies (Petropoulos et al, 
2000). 
 
We were interested in evaluating the contribution to PI resistance and RC of the emergent Gag 
mutations both at CSs and beyond. The I437V CS mutation located in P7/P1 emerged in patient 
Pt-20 together with one major (I84V) and one minor (T74P) protease resistance mutations as 
well as three non-CS mutations located in P17 and two in P1. Maximum levels of PI resistance 
for the recombinant construct containing patient derived Gag and PR sequences were observed 
when all PR, Gag CS and Gag non-CS mutations were incorporated. The stepwise introduction 
of Gag mutations demonstrated that the maximum effect on PI resistance was attributed to the 
I437V CS mutation. Thus the introduction of this mutation in the baseline sample led to a 
different in FC of between 2.8 and 8.6 depending on the PI and it was in all cases statistically 
significance. While P1 have no effect on resistance to PIs, a 3.8 FC difference for SQV and 1.2 
for ATV were found after introduction of the P17 mutations in the baseline sample. These 
differences were statistically significant when applying the one-way ANOVA with the 
Bonferroni’s correction for multiple comparisons. The fact that two of the three emergent P17 
mutations were found to be associated with PI selective pressure in our study (chapter 4), that the 
patient was failing a SQV-based regimen and that the introduction of the mutations led to an 
increase resistance mainly to this drug suggest that the selection of the mutations was driven but 
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SQV-selective pressure and contribute to therapy failure. With regard to the RC experiments, we 
saw that emerging Gag mutations improved the replication of the PR-mutated-containing virus 
and in this case most of the replicative benefit was conferred by the P17 emerging mutations 
while I437V and P1 mutations had no discernible effect. This result suggest that the CS 
mutation, I437V, was selected as a truly resistance mutation rather than as a compensatory 
mutation. These findings are consistent with those obtained by other authors. For instance, 
Nijhuis and colleagues (Nijhuis et al, 2007) reported the selection of I437V mutation in P7/P1 
without any preceding PR mutation during in vitro passages with an experimental PI (RO033-
4649); after introduction of the I437V mutation in a reference strain they observed between 2-5 
fold increase in IC50 to all PIs in a multiple cycle drug resistance assay and 2-3 fold increase in a 
single cycle assay. They demonstrated that incorporation of the mutation enhanced Gag 
polyprotein processing by the WT protease and propose this as a possible mechanism of PI 
resistance. Similarly, Dam and co-investigators (Dam et al, 2009) evaluated the effect of Gag on 
phenotypic PI resistance and observed the I437V in two patients infected with viruses containing 
several major protease resistance mutations. They observed that incorporation of the I437V 
mutation in the recombinant construct led to a 1.6 to 5 fold increase in resistance to all PIs in a 
single cycle assay while very little effect on resistance was attributed to other Gag regions (Dam 
et al 2009). Also consistent with our results, they reported that while reversion to WT of the 
I437V mutation clearly impacted the level of PI resistance, it did had very little effect on RC, 
strengthening the hypothesis that I473V has a role as a resistance mutation.  By contrast, the RC 
benefit mainly lied on the non-CS mutations and in particular on those located in the P17 region. 
In agreement with our results, Parry and co-authors reported that the P17 protein was sufficient 
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to recover the otherwise compromised RC of a multi-PI resistant virus to levels observed in the 
wild-type virus (Parry et al, 2009).  
 
We also observed the emergence of the T375A mutation at P2/P7 in patient Pt-2. Interestingly 
this patient had no major protease mutations either at baseline or emerging at VF. In fact the 
emergence of T375A along with T371N located in the spacer peptide P2 were the only changes 
observed at the time of virological failure in this patient. When we compared the level of PI 
resistance of the construct containing patient’s PR and Gag at baseline and at virological failure, 
we observed a significance difference in FC of between 1.5 and 12 depending on the PI. In order 
to assess the contribution of T375A to this increased level of resistance, we reverted the mutation 
to WT in the virological failure sample and observed that the level of resistance returned to the 
levels found at baseline. We also evaluated the RC of the different viral constructs and observed 
that in this case the T375A mutation not only increased PI resistance but also the RC of the virus. 
Thus, at baseline the patient virus showed 80% RC compared to the wild-type reference virus 
and this was increased to 146% at the time of VF. Importantly, the increased in RC correlated 
with a one log increased in the patient’s viral load.  While we and others have reported a 
significantly higher prevalence of T375A mutation in PI-experienced than in PI naïve subjects 
(Malet et al, 2007) a role for this mutation in resistance to PIs had never been evaluated. Our 
results suggest that the selection of T375A mutation at the time of VF was not a random event, 
but was indeed driven by PI selective pressure. Due to the novelty of the T375A mutation, we 
employed SDM to introduce the mutation in the wild-type reference strain in order to address the 
independent impact of the mutation on PI resistance and viral RC. We found that the T375A 
mutation led to a 5 to 10 fold increase in the IC50 for all PIs and increased significantly the RC of 
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the wild-type reference strain (100% to 146%).  These results further support a role of T375A 
mutation in PI resistance. The mechanism by which the T375A mutation exerts its effect on PI 
susceptibility and RC has not been addressed in this study. However, a role similar to the one 
documented for the well characterized A431V mutation can be postulated. A431V is located in 
the P7/P1 CS and it has been demonstrated to be selected in the presence of major protease 
resistance mutations. The A431V mutation increases the rate of processing of the CS 
compensating for the catalytic deficiency displayed by the mutated protease (Zhang et al, 1997 
and Zennou et al, 1998). We propose that the T375A mutation may also lead to better substrates 
for protease thereby facilitating Gag processing. The processing of Gag is a coordinated process 
in which every site is cleaved in a specific order and a specific rate. T375A is located in P2/P7 
CS, which in this study, and others, have found to be highly polymorphic (Malet et al, 2007). 
The extreme variation in this CS compared to others is probably related to the fact that this is the 
first site to be cleaved and its cleavage takes place rapidly. As a consequence, it is anticipated 
that variations in the rate of cleavage of this site may not be as crucial as those affecting other 
intermediate and rate limiting steps.  Therefore, it is possible that the presence of the T375A 
mutation leads to an increase rate of cleavage of P2/P7 and as consequence to an overall 
improvement of Gag processing and viral replication. Maximum benefit of the mutation will be 
however achieved in the context of impaired protease activity, explaining its preferential 
selection in PI-exposed subjects. A similar mechanism has been also demonstrated for 
compensatory mutations in the PR, such as L63P which is a common polymorphism in pre-
treatment isolates but is even more frequently selected during PI failure and it is known to 
improve the catalytic activity of the viral PR (Martinez-Picado et al, 1999).       
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Over a one year period on unsuccessful LPV/r therapy, patient RFH-2 developed the two major 
protease resistance mutations M46I and L76V, the CS mutation A431V in P7/P1 and several 
Gag non-CS mutations mainly located in the P17 protein. The emergence of P17 mutations 
preceded the appearance of both protease resistance mutations and the A431V mutation and was 
accompanied by a significance increase in viral replication capacity from 97% to 140% respect 
to the WT reference virus. In addition, an increased in the fold change for ATV (from 1 to 2.8 
FC), LPV (from 4 to 6.7 FC) and SQV (from1.7 to 4.3 FC) was also seen, which only reached 
statistical significance for SQV.  The appearance of the L76V resistance mutation led to a 
significant decrease in viral replication (from 140% to around 24% respect to the wild type 
reference virus) and finally the RC was rescued to 74% following the emergence of the M46I 
mutation in the PR and the A431V at P7/P1 CS. At this time the level of resistance to LPV also 
increased from 4 to 12 fold, while hypersusceptibility, defined as a fold change ≤0.4 (Clark et al, 
2006), to ATV and SQV was also seen. Reversion to wild type of the A431V mutation led to a 
significance decrease in RC from 74% to 55% and slight decrease in the IC50 for LPV from 12 to 
10 fold change, which was not statistically significance. The LPV/r resistance pathway 
consisting of emergence of L76V and M46I mutations in the protease was first time observed in 
patients failing LPV/r monotherapy in the MONARK trial (Delaugerre et al, 2009) and it was 
later confirmed by Nijhuis and colleagues. Consistent with our results, Nijhuis reported the 
concomitant occurrence of the two protease mutations with the A431V CS mutation and this 
mutation conferred a replicative benefit to the otherwise severely impaired replication of the 
L76V-containing virus.   However, they observed that the triple mutant containing M46I and 
L76V in the PR and A431V in Gag conferred 12 fold LPV resistance, while the single mutant 
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A431V conferred 3 fold resistance to LPV.  In addition, they also found that the A431V was the 
most frequent single mutant and proposed that the A431V may precede and facilitate the 
selection of the L76V protease resistance mutation. By contrast, our result showed that the 
A431V was selected after the emergence of the L76V protease resistance mutation and increased 
the RC of the virus while having no significance effect on resistance.  Differences in viral 
subtype and the format of the assay employed for drug susceptibility testing may be accountable 
for these discrepancies. Nijhuis and colleagues employed a multiple cycle assay and studied a 
subtype B HIV-1 virus, while we employed a single cycle assay and evaluated a CRF02 HIV-1 
virus.  Different viral subtypes may differ in the pathway and order of accumulation of mutations 
(Wainberg et al, 2011). Also, subtle differences in fold change may be observed in different 
phenotypic assays.   
 
Patient RFH-3 was followed over a five year period on unsuccessful LPV/r + APV/r therapy. 
During this time, the patient developed four major protease mutations (M46I, I84V, L76V and 
F53L), 35 non-CS mutations and 2 CS mutations (P17/P24: Y132F and P1/P6:  L449F).  
Interestingly, we observed that despite the presence of 4 major protease resistance mutations, 
which are known to have a negative effect on RC (Martinez-Picado et al, 1999; Nijhuis et al, 
1999), the patient’s last time point virus replicated significantly more efficiently than the 
baseline virus which did not contain major protease resistance mutations (97% vs. 160%). In 
order to assess the contribution of Gag evolution to the efficient replication, we exchanged the 
Gag from baseline and last time point. We observed that the resistance test vector containing the 
last time point PR combined with the baseline Gag displayed a significantly impaired RC of 4% 
compared to the 160% observed when both last time PR and Gag were incorporated. This result 
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illustrated that Gag evolution was required for effective replication of the virus containing 
multiple major protease resistance mutations. We next stepwise reverted to wild type the two 
emergent CS mutations so that we could determine their effect on viral replication. We found 
that reversion of both mutations led to a non-significance decrease in RC from 159% to 150% 
when Y132 was reverted to wild-type and the RC was further decreased if also L449F mutation 
was reverted to wild type (159% to 129%) and in this case the difference in replication reached 
statistical significance. This result indicates that although emergent Gag CS mutations slightly 
contributed to the efficient replication of the multi-PI-resistant virus, most of the replicative 
benefit exhibited by the virus is likely to lie on the non-CS mutations. The importance of non-CS 
Gag mutations for the full recovery of viral fitness of multi-PI resistant viruses has been 
previously reported. We have already mentioned that Parry and co-authors described the 
importance of the P17 Gag domain for the efficient replication of multi-PI resistant viruses 
(Parry et al 2009). In the same line, Gatanaga and colleagues studied the effect of various non-
CS substitutions on the development of HIV-1 resistance to APV and concluded that both the CS 
and non-CS mutations were essential for the efficient replication of APV-resistant HIV-1 
(Gatanaga et al, 2002).  
 
We also evaluated the PI susceptibility of the construct containing baseline Gag and PR and 
baseline PR with last time point Gag with and without emergent CS mutations in order to assess 
the effect of both CS and non-CS emergent mutations on PI susceptibility. Interestingly, we 
observed a significant increase in the level of resistance to all PIs when the baseline Gag was 
replaced with last time point Gag. The difference in FC was between 9 and 33 fold depending on 
the PI. If applying the Virco clinical cut-off to these data, this result means that Gag alone was 
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sufficient to elevate the level of resistance well above the lower clinical cut-off for all PIs and 
even above the upper clinical cut-off for APV. A further consideration of clinical relevance is the 
importance of addressing treatment failure early to avoid continuous viral replication and virus 
evolution which importantly, can occur not only in the PR but also in its substrate, the protein 
Gag and therefore be missed by routine genotypic testing.  In this line, studies have reported that 
patients are most likely to fail a PI regimen if they were previously PI experienced even if the 
level of cross-resistance predicted by genotypic analysis of the PR is low (Dronda et al, 2001). 
Our results suggest that continuous evolution of the Gag gene under unsuccessful PI therapy may 
be at least in part be accountable for this finding.  Although the stepwise reversion to wild type 
of the two emergent CS mutations (Y132F and L449F) led to a slight decreased in the level of PI 
resistance, the changes in IC50 were still significantly above those observed in the resistance test 
vector containing baseline Gag indicating that determinant of PI resistance were in this patient 
located in Gag both at CS and beyond. Importantly, at CSs we found the mutation L449F at 
P1/P6 and its reversion to wild type decreased the FC for all PI tested. Consistent with this 
finding Maguire and colleagues reported a 5-fold increase in APV resistance caused by this 
mutation (Maguire et al, 2002). Interestingly, we observed the mutation Y132F at P17/P24. The 
involvement of mutations at this CS on PI resistance has not been previously reported as we have 
already mentioned that studies have primarily focused on addressing the effect of mutations in 
P7/P1/P6. This focus reflects the fact that cleavage at these sites is the rate-limiting step in Gag 
processing and therefore it was anticipated that its cleavage would be severely affected by the 
loss of catalytic activity displayed by viral PR containing major PR resistance mutations. As a 
result, these CS were expected to rapidly evolve in order to maintain the efficient processing 
(Croteau et al, 1997; Zenou et al, 1998 and Martinez-Picado et al, 1999). However, it should be 
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noted that Maguire and colleagues showed that mutations in protease reduced cleaving efficiency 
for all known wild type CS substrates suggesting potential selective pressure on CS others than 
P7/P1/P6. In fact, in our study we have seen that mutations associated with PI exposure were 
seen in all CS except for P24/P2. In fact, we have found that the Y132F mutation was strongly 
associated with PI selective pressure (chapter four) and we and others have seen the Y132F 
mutation emerging in patients who developed PI resistance (Mammano et al, 1994). The fact that 
the reversion to wild type of the treatment emergent CS mutation Y132F led to an increase on PI 
susceptibility further support a role for the mutation in PI resistance.  
 
Due to the scarce information available on the phenotypic impact of Y132F, we employed SDM 
to introduce the mutation in a drug susceptible reference strain. It was observed that the Y132F 
mutation led to a 10 fold reduction on PI susceptibility while also having a detrimental effect on 
RC. The negative impact on RC is consistent with the observation that Y132F occurs exclusively 
in PI–experienced patients (chapter four). The mechanism by which Y132F reduce PI 
susceptibility have not been addressed. It can be postulated that as other CS mutations may 
render the CS better substrate and facilitate its cleavage. To support this hypothesis, early studies 
demonstrated that the Y132F mutation caused an increase in the rate of P17/P24 processing 
(Tritch et al, 1991). It may be envisaged that in the context of a wild-type protease displaying 
unimpaired catalytic activity Y132F may lead to premature cleavage and production of aberrant 
viral particles.  
 
It should be noticed that the effect of Y132F mutation on PI susceptibility was higher in the 
wild-type subtype B reference strain than it was on the CRF02 subtype patient’s virus 
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highlighting the importance of including the whole virus backbone in the phenotypic assay. 
Thus, it has been documented that polymorphism and secondary protease resistance mutations 
may have different PI resistance effects on different viral contexts (Wainberg et al, 2011 and 
Martinez-Cajas et al, 2012).  
 
Overall, our results showed that both CS and non-CS mutations are involved in modulating both 
PI susceptibility and RC. While most studies have agreed on the importance of Gag non-CS 
substitutions for the full recovery of virus RC of multi-PI resistant viruses (Gatanaga et al, 2002; 
Myint et al, 2004; Parry et al, 2009), the role of non-CS mutations in PI resistance have been 
debated. In line with our findings Parry and co-investigators reported that Gag alone was able to 
confer 10-15 fold resistance to all PIs. By contrast Dam and colleagues documented that no Gag 
region other than P7/P1/P6 was accountable for PI resistance. Several factors may account for 
the discrepancy such as the format of the phenotypic assay employed for drug susceptibility 
testing. In the present study and the one performed by Parry, a single cycle incorporating 
luciferase as reported gene was used. Dam and co-authors employed also a single cycle but 
galactosidase activity was in this case the indicator what may be less sensitive for the detection 
of subtle fold changes. In addition, as previously mentioned the backbone and subtype of the 
virus tested my also affect the results.  
 
In summary, we have shown that Gag CS and non-CS mutations modulate PI susceptibility and 
RC. Gag alone was sufficient to reduced PI susceptibility and in some cases the fold change in PI 
resistance was above the upper clinical cut-off reported by some commercial assays. In 
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conclusion, our results indicated that exclusion of the Gag gene in phenotypic resistance testing 
may overestimate PI susceptibility.   
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7 Chapter seven: general discussion 
The development of protease inhibitors (PIs) in the early 1990s was a landmark breakthrough in 
the treatment of HIV-1 infection. PIs made possible the dual-class triple combination therapy 
that became known as highly active antiretroviral therapy (HAART) and that has since 
constituted the standard of care of HIV-1 infected patients worldwide.  However, first-generation 
PIs, such as saquinavir (SQV), ritonavir (RTV) indinavir (IDV) and nelfinavir (NFV) showed 
significant pharmacokinetic limitations. Poor oral absorption, high serum-protein binding, and 
rapid liver enzyme metabolism resulted in PIs needing to be ingested often and in large 
quantities to maintain effective antiviral concentrations in blood, with significant food intake 
requirements. Consequently, first generation PI-based HAART often led to suboptimal 
adherence and limited long-term viral inhibition. Moreover, when therapy failure occurred, 
frequently multiple protease resistance mutations were present which were capable of producing 
significant cross-resistance, since all first- generation PIs occupied the same cavity within the 
HIV-1 protease (PR) enzyme.  A major advance in the use of PIs came with the discovery that 
ritonavir (RTV) was a potent inhibitor of the hepatic cytochrome P450 isoenzyme CYP3A4 
which, in turn, is the main enzyme responsible for PI metabolism. Concomitant administration of 
low-dose RTV with a PI (PI/r) led to “boosting” of the most important pharmacokinetic 
parameters of most PIs, which ultimately simplified otherwise complex regimens by reducing the 
frequency and number of pills to be administered and often obviating to complex food intake 
requirements. In addition, by elevating drug plasma levels, boosted PIs became les prone to 
select for drug resistance and more effective against PI-resistant HIV-1 variants. Subsequently, 
novel PIs were licensed for the treatment of HIV-1 infection which displayed improved 
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pharmacokinetic profiles and genetic barrier to resistance. Lopinavir (LPV) was the first and 
currently remains the only PI co-formulated with a low dose RTV. LPV/RTV was also the first 
boosted PI to be compared head-to-head with a non-nucleoside/nucleotide reverse transcriptase 
inhibitor (NNRTI) for the initial treatment of HIV-1 infection and is still currently one of the 
most frequently prescribed PI for HIV-1 treatment, especially in the developing world. Another 
approach to overcoming PI resistance consisted of the development of PIs with greater 
resemblance to the PR substrate, the protein Gag. This resulted mutational profiles different from 
those observed for previously developed PIs. Amprenavir (APV) and Darunavir (DRV) were the 
the first and last second-generation PI respectively designed with this approach. DRV shows a 
particularly high binding affinity for HIV-1 PR what further increases the genetic barrier 
compared to all previous PIs. DRV was initially introduced for the treatment of patient infected 
with multi-PI resistant viruses. However, its antiviral potency, good adverse event profile and 
high genetic barrier to resistance led to the drug being evaluated and approved for the treatment 
of antiretroviral naïve patients. Furthermore, boosted PIs, including atazanavir (ATV), LPV and 
DRV, have also been tested in clinical trials as monotherapy with results ranging from 
suboptimal (ATV) to good (DRV) relative to standard triple therapy.  As a result of all the 
progress made with PI-based therapy, since the introduction of the first PI nearly 20 year ago, 
these drugs continue today to be a cornerstone in the treatment of HIV-1 infection.  
 
Despite the extraordinary improvement in PI therapy, the life-long nature of HIV treatment, 
together with the enormous genetic plasticity of the virus, make the development of PI resistance 
and the subsequent loss of efficacy unavoidable. While failure of first generation PI-based 
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treatment strategies was generally characterised by the presence of multiple PR resistance 
mutations, treatment failure of combination therapy including newer PIs, such as LPV/RTV or 
DRV/RTV in subjects previously antiretroviral-naïve rarely showed the emergence of resistance 
mutations (Kempf et al, 2004 and Gupta et al, 2008). In contrast, it has been observed that their 
genetic barrier to resistance can be lowered by mutations selected during previous PI-based 
regimens (Mo et al, 2005). The main determinants for failure of PI/r in the absence of detectable 
PR resistance mutations remain poorly understood. Incomplete adherence or altered absorption 
and metabolism of PIs may be possible explanations in some patients. However, unexplored 
pathways of resistance involving the Gag protein have also been considered. Along this line, 
numerous studies have demonstrated an association between the selection of protease mutations 
and the emergence of mutations in Gag, predominantly in the cleavage sites (CS) P7/P1 and 
P1/P6 (Maguire et al, 2002; Prado et al, 2002; Nijhuis et al, 2007 and Dam et al, 2009). A study 
performed by Maguire and colleagues (Maguire et al, 2002) demonstrated that mutations in 
P1/P6 CS (L449F and P453L), which individually did not confer PI resistance, reduced APV 
sensitivity in the context of the major protease mutation I50V, thus providing evidence that PR 
and Gag mutations can interact to increase PI resistance.  Nijhuis and co-authors showed that 
variants in the Gag CS P7/P1 (A431V, K436E and/or I437V/T) were selected by PIs in vitro, in 
the absence of any substitution in the viral PR. The introduction of these Gag mutations in a 
reference strain led to low-level resistance to all PIs (Nijhuis et al, 2007). A more recent analysis 
of clinical isolates of patients on PI therapy carried out by Dam and colleagues (Dam et al, 2009) 
reported that mutations in P7/P1 (A431V and I437V) strongly and directly contributed to PI 
resistance in addition to compensating for the loss fitness caused by major PI resistance 
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mutations. Overall, these findings showed that selection of P7/P1 cleavage site mutations 
(CSMs) may represent an alternative pathway of PI resistance.  
 
 The role of mutations at other gag CS or even beyond CS regions has been poorly evaluated. A 
few studies suggest that determinants of PI resistance may be present at CS other than NC-P7/P1 
and P1/P6 as well as at non-cleavage sites (non-CS). Malet and colleagues showed that 
mutations at amino acid 373 in the P2/P7 CS were predictive of impaired virological responses 
to SQV/r (Malet et al, 2007). Recently, Ghosn and colleagues evaluated the impact of amino acid 
variability in the five Gag CSs on failure to LPV/r monotherapy within the MONARK trial. The 
study compared the efficacy of LPV/r monotherapy to that of triple therapy with LPV/r, 
zidovudine (ZDV) and lamivudine (3TC) for treatment of antiretroviral-naïve HIV-1 infected 
patients. They showed that having more than two mutations in P2/P7, especially if involving 
position 374, at baseline was predictive of virological failure of LPV/r monotherapy. Similarly, 
Parry and colleagues showed that determinants of PI resistance are likely to be located outside 
PR and its CSs, and that Gag conferred low-level resistance to all PIs in the context of a wild-
type PR (Parry et al, 2009). 
        
Despite this body of knowledge, the clinical management of PI failure remains based on the 
sequencing of the PR gene, in search for recognised protease resistance mutations. Similarly, the 
phenotypic evaluation of PI resistance involves the use of recombinant viruses containing 
patient’s derived PR and, in some cases, NC-P7/P1/P6 CS sequences. However, the contribution 
of full-length gag to PI resistance remains unaddressed. 
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In the course of my PhD studies, I developed and optimised an assay for amplification of full-
length HIV-1 PR and gag genes. This was made challenging by the considerable variability 
occurring in gag. Using this assay, I was able to amplify and sequence full-length PR and gag 
from a variety of HIV-1 subtypes and circulating recombinant forms (CRFs) at viral loads of 
around 500 to 1,000 copies/ml. Consequently, the assay sensitivity was regarded satisfactory for 
monitoring patients experiencing PI failure. However, due to the intra-patient variability of the 
gag gene, non-interpretable population sequencing was not unusual and clonal analysis was 
required to circumvent the problem in some samples. This represents an important limitation to 
the implementation of full-length gag sequencing in a high-throughput routine diagnostic setting.   
 
By applying the assay to the study of full-length Gag and PR genes from PI-naïve and PI-
experienced patients, we obtained sequences from 200 PI-naïve .and 191 PI-experienced patient 
samples. Comparison of the two groups demonstrated that PI-experienced subjects showed 
greater variability than PI-naïve individuals not only in PR, but also throughout the Gag protein. 
Importantly, there were significant differences in the prevalence of certain Gag mutations in the 
two groups, suggesting that HIV-1 genetic evolution under PI-selective pressure is not restricted 
to the PR gene but occurs in its natural substrate, the Gag protein.  Consistent with previous 
reports, we found that mutations in P7/P1 and P1/P6 CSs, such as A431V, K436R, I437V and 
L449F, were associated with PI selective pressure and occurred concomitantly with specific 
major PR resistance mutations, namely M46IL, I54V and I84V (Mammano et al, 2000; Zhang et 
al, 1997; Maguire et al, 2002; Cote et al, 2001; Bally et al, 2000 and Dauber et al, 2002, 
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Verheyen et al, 2006, Feher et al, 2002, Prado et al, 2002 and Nijhuis et al, 2007). However, by 
analysing full-length Gag, we significantly expanded previous knowledge and have identified a 
number of novel Gag mutations strongly associated with PI-experience. In the present study, 
mutations associated with PI-selective pressure were found in all CS except for CA-P24/P2. 
Mutations strongly associated with PI-experience included V128I and Y132F in P17/P24, and 
S373T, A374S and T375N in P7/P2.  
 
Interesting, in our study, we found that mutations associated with PI exposure were also present 
outside the CSs. Thus, we observed a trend towards a higher number of mutations in PI-
experienced patients compared with PI-naïve patients in all Gag domains. The effect was 
particularly noticeable in the MA-P17 and the P6 proteins, suggesting the two may play a 
prominent role in PI failure compared with other Gag regions. Consistent with this hypothesis, 
Parry and colleagues (Parry et al, 2009) reported that the P17 protein from a multidrug PI-
resistant virus was on its own able to rescue the otherwise impaired replicative capacity (RC) of 
the mutated PR to the level observed in the wild-type virus. In addition, they demonstrated that 
the mutated P17 reduced PI susceptibility in the absence of major PR resistance mutations, 
suggesting that major determinants of PI-resistance may be located in this protein. Interestingly, 
the clinical isolate they studied showed 12 mutations in MA-P17 (compared with the HXB2 
reference sequence) including six (I34L, T84V, E93D, I94V, N124K and N126S) that were 
found to be associated with PI selective pressure in our analysis. Two of these mutations in 
particular (I94V and N126S) showed a strong association with PI experience remaining 
significantly associated even after applying the Bonferroni’s correction.     
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In order to gather more insight into the role of Gag mutations in patient experiencing PI failure 
we performed longitudinal analyses of patients that were failing a PI-based treatment regimen. A 
group of 28 patients receiving IDV/r, SQV/r or LPV/r were followed for up to 24 weeks and 
their Gag and protease sequences obtained pre-treatment (baseline) and at the time of virological 
failure were compared. In addition, I was able to follow three patients for up to 5 years and 
obtain Gag and protease sequences at multiple time points (3-5) during treatment failure of 
.LPV/r for two patients and LPV/r plus APV/r for one patient. As expected, we observed a high 
prevalence of treatment-emergent major and minor protease resistance mutations. Interestingly, 
we observed an even higher prevalence of emergent Gag mutations both in and outside its CSs. 
In the first group of patients, we detected treatment- emergent mutations in three CSs:  P2/P7, 
P7/P1 and P1/P6. In total we observed nine different mutations emerging in these three CSs 
during failure. The majority of these mutations (6/9) had been found to be associated with PI 
selective pressure in both our study and studies by others (Verheyen et al, 2006; Malet et al, 
2006).  The role of most mutations occurring in P7/P1 (A431V and I437V), and in P1/P6 
(L449F) has been described in the literature (Mammano et al, 2000; Zhang et al, 1997; Maguire 
et al, 2002; Cote et al, 2001; Bally et al, 2000 and Dauber et al, 2002, 2002 and Nijhuis et al, 
2007). Emergence of CS mutations was observed both in the absence and presence of major 
protease mutations. Furthermore, the mutations did not appear to depend generally on the 
specific PI in the failing regimen, although P1/P6 mutations were more common in patients 
failing SQV/r and mutations in P2/P7 were seen mainly in patients failing IDV/r.  Nevertheless, 
the number of patients studied longitudinally was limited and did not allow a formal analysis in 
the association between specific regimen and the presence of certain Gag mutations.  
312 
 
 
Emergent mutations outside the CSs, and predominantly in P17, were also detected, that had 
been found to be associated with PI exposure, thus strengthening the hypothesis that in addition 
to gag CSs, P17 plays a significant role in PI failure.  
 
Although the cross-sectional analysis found several mutations associated with PI exposure in 
P17/P24 and P6, in our longitudinal analysis we did not observe emergence of mutations in these 
regions. However, we did observed the P17/P24 mutations Y132F and V128I in the baseline 
samples of three patients who had been previously exposed to PIs and showed several major 
protease resistance mutations. In addition, 18 patients had one or more mutations associated with 
PI selective pressure in P6, all of whom had been previously exposed to PIs. These findings 
suggest that that PI initially exert selective pressure mainly on the CSs P2/P7, P7/P1 and P1/P6 
(which are located in the gag terminal site) and on the P17 protein outside the CSs. Long-term 
selective pressure in contrast may trigger evolution in other CSs (such as P1/C-P24) and in P6 
outside the CSs. This concept was further supported by the observations made in the three 
patients who were followed by a longer period of time, and in whom we saw emergent mutations 
at these sites. Thus, the Y132F mutation in P17/P24 emerged in one patient after five years of 
ongoing viral replication while on APV/r and LPV/r, and P6 mutations also emerged in two 
patients overtime. Unfortunately, for most patients, we did not have access to data on the length 
of PI exposure at baseline. Therefore we could not formally analyse the association between 
duration of PI exposure and presence of specific Gag mutations.   
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An important observation is that while emergent Gag CS mutations were common among 
patients and consistent with previous reports, the emergent non-CSMs were highly heterogenous 
and did not show consistent patterns. This indicates that evolution outside CS is complex and 
likely to be driven by different pressures including virological factors (genetic make-up, level 
and duration of virus replication, emerging mutations in protease and CSs), pharmacology 
factors (drug type and drug exposure), and host-related factors (immune response).  
 
In the final chapter we applied a single cycle assay for the phenotypic measurement of PI 
susceptibility and viral RC. We studied samples collected from four patients at the time of 
virological failure and assessed the impact of several CSMs (Y132F, T375A, A431V, I437V and 
L449F) on drug susceptibility and RC. Overall, we observed that CSMs contributed to PI 
resistance. Thus, the reversion to wild-type of Y132F, T375A or L449F led in all cases to a 3-5 
fold reduction in PI susceptibility. Similarly, the introduction by side-directed mutagenesis of the 
I437V mutation in the patient’s baseline sample produced a 2-5 fold increase in PI resistance.  In 
addition, most CSMs led to an improvement in viral RC, with the exception of I437V which did 
not have a discernible effect. We confirmed the independent effect of mutations Y132F and 
T375A on PI susceptibility and RC by introducing the mutations in a wild type backbone. We 
found that Y132F conferred around 10 fold resistance to all PIs while decreasing RC, while 
T375A produced 5-10 fold resistance to all PIs but increased RC. In addition, in line with 
previous studies (Gatanaga et al, 2002; Myint et al, 2004; Dam et al, 2009 and Parry et al, 2009), 
we found that non-CS mutations, in addition to contributing to PI resistance, were also required 
for efficient replication of multi-PI resistance viruses. Importantly, we found that emergent Gag 
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mutations were not generally associated with a specific PI regimen but rather the same mutations 
were seen emerging under different PI regimens. This finding, combined with the observation 
that the Gag mutations conferred a degree of cross-resistance to most PIs in the phenotypic 
assay, suggests a common mechanism for conferring resistance.  
 
PIs, with the exception of IDV, are more than 90% protein bound in vivo (Bilello et al, 1996). 
Our phenotypic drug susceptibilities studies have been performed in HEK T293 cells grown and 
maintained in cell culture media supplemented with 10% FCS. As the calculation of the IC50 
relies on the presence of unbound drug concentrations, it will be highly dependent on  the 
composition of the incubation media. As a result, caution should be applied when comparing the 
results obtained in the present studies with those obtained under different tissue culture 
conditions and also before extrapolating the IC50 in this study to in vivo conditions.  
 
Overall, our results clearly indicate that continuous viral replication under PI selective pressure 
leads to evolution of the viral PR as well as its substrate, the Gag protein. Consequently, 
analyzing PR alone after PI failure may underestimate the level of PI resistance. Given our result 
and in general the expanding body of evidence indicating that Gag mutations contribute to PI 
resistance in treated patients, full-length Gag sequences should be incorporated in phenotypic 
assays to determine PI susceptibility of clinical isolates.  
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Expansion of full-length Gag sequencing in patients failing PI-based regimens would be also of 
interest to populate the relevant databases employed for the clinical assessment of HIV drug 
resistance and to assist in the identification of specific Gag determinants of PI susceptibility. 
Only then, the importance of Gag genotypic determination to guide patient care could be 
evaluated.    
 
In addition, the findings of my PhD studies could also have important implications for drug 
development and as a result I propose that when novel PIs are being developed, it should be 
checked whether Gag evolution provides an alternative mechanism of escape for the virus.  
 
It should be emphasised that all patients studied were failing PIs as part of triple combination 
therapies. However, due to financial constraints, the interest on PI-monotherapy regimens is 
increasing in many countries around the world. Nevertheles, it shold be emphasized that the 
analysis of patients failing LPV/r monotherapy in the MONARK trial demonstrated a lower 
genetic barrier to resistance compared with triple therapy. Therefore, it can be proposed that the 
effect of Gag mutations may be more prominent in the context of PI/r monotherapy. Consistent 
with this concept, the analysis of baseline Gag sequences from patients assigned to receive 
LPV/r monotherapy in MONARK showed that patients with at least two mutations in the gag CS 
P2/P7 were more likely to experience virological failure of LPV/r than those who did not show 
mutations at this CS (Ghosn et al, 2011).  Consequently, it would be of interest to address the 
evolution of the Gag in patients starting PI/r monotherapy and its effect of drug susceptibilty. 
Currently, PI/r monotherapy is only established as a treatment switch in patients with stable 
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undetectable viraemia while on HAART. Consquently, performing such analysis may be 
hampered by the potential lack of access to the baseline samples for the patients.   
 
It should be also noticed that most of my PhD work has been performed with subtype B HIV-1 
viruses.  By the end of 2007, nearly three million people were on HAART worldwide as a 
consequence of the therapy roll-out in developing countries. NNRTI-based regimens are 
recommended by the World Health Organisation (WHO) as first-line therapy in low-income 
countries. For second line therapy, the WHO advises initiation of a PI-based regimen, currently 
LPV/r or ATV/r, plus two NRTIs. As the number of patients having access to antiretroviral 
therapy increase in developing countries so does the number of patients needing to move to 
second line PI-based therapy. However, some of the Gag mutations that we have described as 
associated with PI exposure and that indeed we have found to decrease PI susceptibility “in 
vitro” may occur as natural polymorphisms in non-B subtypes thus potentially affecting 
responses to second-line therapy. This is especially important when considering that patients in 
these regions commonly start second-line therapy having already accumulated significant 
resistance to the NRTI component of the regimen. A few studies have shown that Gag variability 
is greater in non-B subtypes than in B subtype HIV-1 (Jinnopat et al, 2009 and Ghosn et al, 
2011). For instance, Jinnopat reported a higher Gag variability in subtype CRF01 (Jinnopat et al, 
2009), and in particular the mutations L61I and P66S in P17 were frequently detected in drug-
naïve patients. Both L61I and P66S were associated with PI-exposure in our study and in the 
case of L61I the association remained significant after the Bonferroni’s correction for multiple 
associations was applied. In addition, Gupta and co-authors frequently detected the T84V 
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mutation in subtype A (Gupta et al, 2010), which have also been associated with PI-exposure in 
our study.  Importantly, Gupta and colleagues reported that in the context of wild-type subtype B 
PR, replacing the subtype B Gag with subtype A Gag decreased PI susceptibility. Similarly, 
Ghosn and colleagues showed that the risk of virological failure of LPV/r monotherapy was 
significantly higher in patients with polymorphisms at P2/P7 CS and polymorphism at this CS 
were in turn more common in non-B subtypes compared to subtype B HIV-1 viruses.  
Considering that resistance testing is not routinely perfomed in developing countries and the 
important implications that Gag mutations in non-B subtypes and their correnponding effects on 
PI susceptibility may have for the public health approach to antiretroviral treatment, in future 
work, we would like to expand the full-length Gag sequencing to patients infected with non-B 
subtypes who are due to start a PI-based regimen and to evaluate the prevalence of subtype-B 
mutations associated with PI exposure in non-B subtypes at baseline as well as the impact of 
such polymorphisms on virological responses to PIs.  
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